11058428
D008775_D013119 NONE <e1>methylprednisolone</e1> do harm <e2>injury</e2>
D008775_D013119 NONE <e1>methylprednisolone</e1> became studies <e2>injury</e2>
D008775_D013119 NONE <e1>methylprednisolone</e1> became <e2>injury</e2>
D008775_D013119 NONE <e1>methylprednisolone</e1> offers <e2>injury</e2>
D000305_D009135 NONE <e1>corticosteroid</e1> <e2>myopathy</e2>
D000305_D009135 NONE <e1>corticosteroid</e1> <e2>myopathy</e2>
D008775_D009135 CID <e1>methylprednisolone</e1> cause <e2>myopathy</e2>
D008775_D009135 CID <e1>methylprednisolone</e1> offers protection recording recovers <e2>myopathy</e2>
D008775_D009135 CID <e1>methylprednisolone</e1> offers protection recording recovery <e2>myopathy</e2>
D008775_D009135 CID <e1>methylprednisolone</e1> cause <e2>myopathy</e2>
D013256_D009135 NONE <e1>steroid</e1> <e2>myopathy</e2>
D013256_D009135 NONE <e1>steroid</e1> myopathy recovers recording recovery <e2>myopathy</e2>
D013256_D009135 NONE <e1>steroid</e1> myopathy recovery recording recovers <e2>myopathy</e2>
D013256_D009135 NONE <e1>steroid</e1> <e2>myopathy</e2>
D013256_D013119 NONE <e1>steroid</e1> myopathy recovers recording protection offers <e2>injury</e2>
D013256_D013119 NONE <e1>steroid</e1> myopathy recovery recording protection offers <e2>injury</e2>
7785794
D014700_D012770 NONE <e1>verapamil</e1> treatment complete <e2>shock</e2>
D014700_D006327 CID <e1>verapamil</e1> treatment complete <e2>block</e2>
D014700_D006327 CID <e1>verapamil</e1> woman presented <e2>block</e2>
D008790_D012770 NONE <e1>metoprolol</e1> sr treatment complete <e2>shock</e2>
D008790_D006327 CID <e1>metoprolol</e1> sr treatment complete <e2>block</e2>
D008790_D006327 CID <e1>metoprolol</e1> use verapamil woman presented <e2>block</e2>
D014700_D007022 CID <e1>verapamil</e1> woman presented block <e2>hypotension</e2>
D008790_D007022 CID <e1>metoprolol</e1> use verapamil woman presented block <e2>hypotension</e2>
D001285_D007022 NONE <e1>atropine</e1> uses continued remain <e2>hypotensive</e2>
D001285_D006327 NONE <e1>atropine</e1> uses continued remain hypotensive <e2>block</e2>
D004298_D007022 NONE <e1>dopamine</e1> agents doses atropine uses continued remain <e2>hypotensive</e2>
D004298_D006327 NONE <e1>dopamine</e1> agents doses atropine uses continued remain hypotensive <e2>block</e2>
D004280_D007022 NONE <e1>dobutamine</e1> dopamine agents doses atropine uses continued remain <e2>hypotensive</e2>
D004280_D006327 NONE <e1>dobutamine</e1> dopamine agents doses atropine uses continued remain hypotensive <e2>block</e2>
D002122_D007022 NONE <e1>chloride</e1> use <e2>hypotension</e2>
D002122_D006327 NONE <e1>chloride</e1> use hypotension <e2>block</e2>
3057041
C020976_D006255 NONE <e1>azelastine</e1> chlorpheniramine placebo treatment <e2>rhinitis</e2>
C020976_D006255 NONE <e1>azelastine</e1> compared maleate placebo treatment <e2>rhinitis</e2>
C020976_D006255 NONE <e1>azelastine</e1> appears medication <e2>rhinitis</e2>
D002744_D006255 NONE <e1>chlorpheniramine</e1> placebo treatment <e2>rhinitis</e2>
D002744_D006255 NONE <e1>maleate</e1> placebo treatment <e2>rhinitis</e2>
C020976_D006970 CID <e1>azelastine</e1> group increased <e2>drowsiness</e2>
C020976_D013651 CID <e1>azelastine</e1> group increased drowsiness <e2>perception</e2>
9214597
D004967_D010911 NONE <e1>estrogen-induced</e1> <e2>tumors</e2>
D004967_D010911 NONE <e1>estrogen-initiated</e1> angiogenesis mediate expression factor receptor development <e2>tumors</e2>
D004967_D009369 NONE <e1>estrogen-induced</e1> tumors development receptor factor expression mediate angiogenesis <e2>tumor</e2>
D004967_D009369 NONE <e1>estrogen-initiated</e1> angiogenesis <e2>tumor</e2>
D004967_D009369 NONE <e1>estrogens</e1> associated types <e2>cancers</e2>
D004967_D009369 NONE <e1>estrogens</e1> induce angiogenesis <e2>tumor</e2>
D004967_D009369 NONE <e1>estrogen</e1> carcinogenesis details induction <e2>tumor</e2>
D004967_D009369 NONE <e1>estrogen</e1> role regulation angiogenesis <e2>tumor</e2>
D004967_D009369 NONE <e1>estrogen</e1> induced angiogenesis <e2>tumor</e2>
D004967_D063646 NONE <e1>estrogen</e1> <e2>carcinogenesis</e2>
D004958_D009369 NONE <e1>e2</e1> pituitary expression associated potential <e2>tumor</e2>
15893386
D013390_D014313 CID <e1>succinylcholine-induced</e1> <e2>rigidity</e2>
D013390_D014313 CID <e1>succinylcholine</e1> administration case <e2>rigidity</e2>
D013390_D014313 CID <e1>succinylcholine</e1> administration case jaw <e2>steel</e2>
D013390_D014313 CID <e1>sch</e1> administration case <e2>rigidity</e2>
D013390_D014313 CID <e1>sch</e1> administration case jaw <e2>steel</e2>
D015742_D008305 NONE <e1>propofol</e1> infusion continued available detect <e2>hyperthermia</e2>
3461217
D008770_D011471 CID <e1>n-nitroso-n-methylurea</e1> treatments production <e2>cancer</e2>
D008770_D011471 CID <e1>n-nitroso-n-methylurea</e1> treatments <e2>adenocarcinomas</e2>
D008770_D011471 CID <e1>n-nitroso-n-methylurea</e1> treatments adenocarcinomas <e2>pas</e2>
D013739_D011471 NONE <e1>testosterone</e1> n-nitroso-n-methylurea treatments production <e2>cancer</e2>
D008770_D009369 NONE <e1>n-nitroso-n-methylurea</e1> treatments adenocarcinomas most rats <e2>tumor-bearing</e2>
D043343_D011471 CID <e1>propionate</e1> <e2>adenocarcinomas</e2>
D043343_D011471 CID <e1>propionate</e1> adenocarcinomas <e2>pas</e2>
D043343_D011471 CID <e1>tp</e1> propionate <e2>adenocarcinomas</e2>
D043343_D011471 CID <e1>tp</e1> propionate adenocarcinomas <e2>pas</e2>
D043343_D011471 CID <e1>tp</e1> treated developed <e2>pa</e2>
D043343_D011471 CID <e1>tp</e1> acted emphasis development <e2>cancer</e2>
D043343_D009369 NONE <e1>propionate</e1> adenocarcinomas most rats <e2>tumor-bearing</e2>
D043343_D009369 NONE <e1>tp</e1> propionate adenocarcinomas most rats <e2>tumor-bearing</e2>
D043343_D009369 NONE <e1>tp</e1> acted agent <e2>tumor</e2>
8251368
D009543_D013684 CID <e1>nifedipine-induced</e1> <e2>telangiectasia</e2>
D009543_D013684 CID <e1>nifedipine</e1> starting months developed <e2>telangiectasia</e2>
D009543_D013684 CID <e1>adalat</e1> nifedipine starting months developed <e2>telangiectasia</e2>
D017311_D013684 CID <e1>amlodipine</e1> commenced recurrence <e2>telangiectasia</e2>
17019386
D008353_D005910 NONE <e1>mannitol</e1> passage <e2>gliomas</e2>
D008353_D005910 NONE <e1>mannitol</e1> administered bolus patients <e2>glioma</e2>
D008353_D005910 NONE <e1>mannitol</e1> concentrations measured higher patients <e2>glioma</e2>
D008353_D005910 NONE <e1>mannitol</e1> concentrations patients <e2>glioma</e2>
D008353_D005910 NONE <e1>mannitol</e1> leak <e2>gliomas</e2>
D008353_D001929 NONE <e1>mannitol</e1> use reduce <e2>edema</e2>
D008353_D019586 CID <e1>mannitol</e1> use reduce edema <e2>icp</e2>
D008353_D001932 NONE <e1>mannitol</e1> use reduce patients <e2>tumor</e2>
D008353_D001932 NONE <e1>mannitol</e1> passage research administration patients <e2>tumor</e2>
D008353_D009362 NONE <e1>mannitol</e1> administered bolus patients glioma <e2>metastases</e2>
D008353_D009362 NONE <e1>mannitol</e1> concentrations higher meningioma <e2>metastases</e2>
D008353_D008579 NONE <e1>mannitol</e1> administered bolus patients glioma <e2>meningioma</e2>
D008353_D008579 NONE <e1>mannitol</e1> concentrations higher <e2>meningioma</e2>
D008353_D004487 NONE <e1>mannitol</e1> leak reversing gradient <e2>edema</e2>
9209318
D015215_D009190 CID <e1>azidothymidine</e1> mice treatment produces <e2>myelodysplasia</e2>
D015215_D009190 CID <e1>azt</e1> azidothymidine mice treatment produces <e2>myelodysplasia</e2>
D015215_D009190 CID <e1>azt</e1> incorporation induced hemopoiesis cells known seen <e2>syndrome</e2>
D015215_D000748 CID <e1>azt</e1> induced <e2>anemia</e2>
D015215_D000748 CID <e1>azt</e1> therapy induced <e2>anemia</e2>
D015215_D000163 NONE <e1>azt</e1> induced anemia patients <e2>aids</e2>
D015215_D000163 NONE <e1>azt</e1> therapy induced anemia patients <e2>aids</e2>
8514073
D008874_D014652 CID <e1>midazolam</e1> <e2>complications</e2>
D008874_D014652 CID <e1>midazolam</e1> associated <e2>complications</e2>
D008874_D014652 CID <e1>midazolam</e1> diazepam injection incidence <e2>complications</e2>
D008874_D014652 CID <e1>midazolam</e1> frequent <e2>complications</e2>
D003975_D014652 CID <e1>diazepam</e1> <e2>complications</e2>
D003975_D014652 CID <e1>diazepam</e1> associated <e2>complications</e2>
D003975_D014652 CID <e1>diazepam</e1> injection incidence <e2>complications</e2>
D003975_D014652 CID <e1>diazepam</e1> frequent <e2>complications</e2>
D003975_D010146 NONE <e1>diazepam</e1> group patients occurred <e2>pain</e2>
D008874_D010146 NONE <e1>midazolam</e1> group % compared occurred <e2>pain</e2>
D000431_D010146 NONE <e1>alcohol</e1> use needle <e2>pain</e2>
D000431_D014652 NONE <e1>alcohol</e1> use needle time smoking had incidence <e2>complications</e2>
6892185
D002122_D015878 NONE <e1>chloride</e1> effect <e2>mydriasis</e2>
D002122_D015878 NONE <e1>chloride</e1> changed hand <e2>mydriasis</e2>
D002122_D015878 NONE <e1>chloride</e1> dissociate vocalization fighting phenomena <e2>mydriasis</e2>
D002122_D014202 NONE <e1>chloride</e1> effect <e2>tremor</e2>
D002122_D014202 NONE <e1>chloride</e1> changed hand mydriasis <e2>tremor</e2>
D002122_D014202 NONE <e1>chloride</e1> dissociate vocalization fighting phenomena mydriasis <e2>tremor</e2>
D002122_D004830 NONE <e1>chloride</e1> effect tremor <e2>convulsions</e2>
D002122_D004830 NONE <e1>chloride</e1> changed hand mydriasis <e2>convulsions</e2>
D002122_D004830 NONE <e1>chloride</e1> dissociate vocalization fighting phenomena mydriasis <e2>convulsions</e2>
D002217_D015878 CID <e1>carbachol</e1> produced convulsions tremor effect <e2>mydriasis</e2>
D002217_D015878 CID <e1>carbachol</e1> evoked convulsions <e2>mydriasis</e2>
D002217_D015878 CID <e1>carbachol</e1> caused vocalization fighting phenomena <e2>mydriasis</e2>
D002217_D014202 CID <e1>carbachol</e1> produced convulsions <e2>tremor</e2>
D002217_D014202 CID <e1>carbachol</e1> evoked convulsions mydriasis <e2>tremor</e2>
D002217_D014202 CID <e1>carbachol</e1> caused vocalization fighting phenomena mydriasis <e2>tremor</e2>
D002217_D004830 CID <e1>carbachol</e1> produced <e2>convulsions</e2>
D002217_D004830 CID <e1>carbachol</e1> evoked <e2>convulsions</e2>
D002217_D004830 CID <e1>carbachol</e1> caused vocalization fighting phenomena mydriasis <e2>convulsions</e2>
D010830_D015878 CID <e1>eserine</e1> carbachol produced convulsions tremor effect <e2>mydriasis</e2>
D010830_D015878 CID <e1>eserine</e1> carbachol evoked convulsions <e2>mydriasis</e2>
D010830_D015878 CID <e1>eserine</e1> carbachol caused vocalization fighting phenomena <e2>mydriasis</e2>
D010830_D014202 CID <e1>eserine</e1> carbachol produced convulsions <e2>tremor</e2>
D010830_D014202 CID <e1>eserine</e1> carbachol evoked convulsions mydriasis <e2>tremor</e2>
D010830_D014202 CID <e1>eserine</e1> carbachol caused vocalization fighting phenomena mydriasis <e2>tremor</e2>
D010830_D004830 CID <e1>eserine</e1> carbachol produced <e2>convulsions</e2>
D010830_D004830 CID <e1>eserine</e1> carbachol evoked <e2>convulsions</e2>
D010830_D004830 CID <e1>eserine</e1> carbachol caused vocalization fighting phenomena mydriasis <e2>convulsions</e2>
11337188
D010068_D018366 CID <e1>oxacillin</e1> associated <e2>vasculitis</e2>
D010068_D018366 CID <e1>oxacillin</e1> included drugs cause <e2>vasculitis</e2>
D010068_D013203 NONE <e1>oxacillin</e1> treated <e2>bacteremia</e2>
D010068_D016470 NONE <e1>oxacillin</e1> treated <e2>bacteremia</e2>
D010068_D051437 CID <e1>oxacillin</e1> treated man developed <e2>failure</e2>
D010068_D011693 NONE <e1>oxacillin</e1> treated man developed failure <e2>lesions</e2>
6111982
D011433_D001145 NONE <e1>propranolol</e1> that surpasses inhibiting <e2>arrhythmia</e2>
D010869_D001145 NONE <e1>pindolol</e1> propranolol that surpasses inhibiting <e2>arrhythmia</e2>
D010042_D001145 CID <e1>ouabain</e1> <e2>arrhythmia</e2>
10533019
D004110_D013746 CID <e1>diltiazem-induced</e1> <e2>tetany</e2>
D004110_D013746 CID <e1>diltiazem</e1> infusion developed <e2>tetany</e2>
D004110_D013746 CID <e1>diltiazem</e1> administration accompany <e2>tetany</e2>
D002122_D013746 NONE <e1>chloride</e1> reversal <e2>tetany</e2>
D002122_D013746 NONE <e1>chloride</e1> administration resolved <e2>tetany</e2>
D002122_D013746 NONE <e1>chloride</e1> remedy accompany <e2>tetany</e2>
D004110_D012131 NONE <e1>diltiazem</e1> infusion developed <e2>arrest</e2>
14982270
D008713_D041781 CID <e1>methimazole-induced</e1> <e2>jaundice</e2>
D008713_D007565 NONE <e1>methimazole</e1> receiving itching had <e2>jaundice</e2>
D008713_D011537 CID <e1>methimazole</e1> receiving <e2>itching</e2>
D008713_D006980 NONE <e1>methimazole</e1> receiving treatment <e2>hyperthyroidism</e2>
D011433_D007565 NONE <e1>propranolol</e1> receiving itching had <e2>jaundice</e2>
D011433_D011537 NONE <e1>propranolol</e1> receiving <e2>itching</e2>
D011433_D006980 NONE <e1>propranolol</e1> receiving treatment <e2>hyperthyroidism</e2>
D008713_D002779 NONE <e1>methimazole-induced</e1> <e2>cholestasis</e2>
D011433_D002779 NONE <e1>propranolol</e1> therapy resumed diagnosed <e2>cholestasis</e2>
8638876
D011374_D006261 NONE <e1>progesterone</e1> use seizure left developed <e2>headache</e2>
D011374_D009325 NONE <e1>progesterone</e1> use seizure left developed headache <e2>nausea</e2>
D011374_D014839 NONE <e1>progesterone</e1> use seizure left developed headache nausea <e2>vomiting</e2>
D011374_D010291 NONE <e1>progesterone</e1> use seizure left <e2>hemiparesis</e2>
D011374_D012640 NONE <e1>progesterone</e1> use <e2>seizure</e2>
D004958_D006261 NONE <e1>estradiol</e1> progesterone use seizure left developed <e2>headache</e2>
D004958_D009325 NONE <e1>estradiol</e1> progesterone use seizure left developed headache <e2>nausea</e2>
D004958_D014839 NONE <e1>estradiol</e1> progesterone use seizure left developed headache nausea <e2>vomiting</e2>
D004958_D010291 NONE <e1>estradiol</e1> progesterone use seizure left <e2>hemiparesis</e2>
D004958_D012640 NONE <e1>estradiol</e1> progesterone use <e2>seizure</e2>
D004958_D003920 NONE <e1>estradiol</e1> <e2>dm</e2>
D004958_D002341 CID <e1>estradiol</e1> use increased postulate provided denominator thrombosis ica <e2>sinus</e2>
D004958_D012851 CID <e1>estradiol</e1> use increased postulate provided denominator thrombosis ica <e2>sinus</e2>
D011374_D003920 NONE <e1>progesterone</e1> estradiol <e2>dm</e2>
D011374_D002341 CID <e1>progesterone</e1> estradiol use increased postulate provided denominator thrombosis ica <e2>sinus</e2>
D011374_D012851 CID <e1>progesterone</e1> estradiol use increased postulate provided denominator thrombosis ica <e2>sinus</e2>
6732043
D000728_D020181 CID <e1>androgen</e1> administration induction <e2>syndrome</e2>
D000728_D020181 CID <e1>androgens</e1> administered developed changes syndrome <e2>apnea</e2>
D000728_D020181 CID <e1>androgen</e1> rechallenge produced symptoms <e2>apnea</e2>
D000728_D020181 CID <e1>androgen</e1> therapy effect considered development <e2>syndrome</e2>
D000728_D012891 NONE <e1>androgens</e1> role pathogenesis <e2>apnea</e2>
15814210
D003907_D009422 CID <e1>dexamethasone</e1> treatment <e2>dysfunction</e2>
D003907_D009422 CID <e1>dexamethasone</e1> therapy <e2>dysfunction</e2>
D003907_D009422 CID <e1>dexamethasone</e1> treatment showed rate <e2>dysfunctions</e2>
6153967
D004737_D012640 CID <e1>enflurane</e1> patient resulted <e2>seizures</e2>
D004737_D012640 CID <e1>enflurane</e1> activated delineated ablated <e2>seizure-free</e2>
D004737_D004827 NONE <e1>enflurane</e1> activated delineated foci <e2>epileptic</e2>
D004737_D004827 NONE <e1>enflurane</e1> prove activator foci <e2>epileptic</e2>
17574447
D010634_-1 NONE <e1>phenobarbital</e1> therapy related <e2>hepatonecrosis</e2>
D010634_D002761 CID <e1>phenobarbital</e1> therapy related hepatonecrosis <e2>cholangitis</e2>
D010634_D008107 CID <e1>phenobarbital</e1> has believed indicate predict development <e2>disease</e2>
D010634_D008107 CID <e1>pb</e1> phenobarbital has believed indicate predict development <e2>disease</e2>
D010634_D008107 CID <e1>pb-related</e1> increases indicate predict development <e2>disease</e2>
D010634_D008107 CID <e1>pb</e1> associated <e2>damage</e2>
D010634_D004827 NONE <e1>pb</e1> treated <e2>epilepsy</e2>
D010634_D006323 NONE <e1>pb</e1> treated epilepsy history patients report one consequence <e2>arrest</e2>
D010634_D001996 NONE <e1>pb</e1> treated epilepsy history patients report one other <e2>bronchopneumonia</e2>
D010634_D056487 NONE <e1>pb-related</e1> <e2>dysfunction</e2>
2220369
C015173_D020246 CID <e1>epinephrine</e1> <e2>thrombosis</e2>
C015173_D020246 CID <e1>epinephrine</e1> medication started acquired <e2>thrombosis</e2>
C015173_D005901 NONE <e1>epinephrine</e1> <e2>glaucoma</e2>
17366349
C092292_D009459 CID <e1>ziprasidone</e1> induced <e2>syndrome</e2>
C092292_D009459 CID <e1>ziprasidone</e1> use associated <e2>syndrome</e2>
C092292_D009459 CID <e1>ziprasidone</e1> use associated syndrome <e2>nms</e2>
C092292_D009459 CID <e1>ziprasidone</e1> drugs cause associated <e2>nms</e2>
C092292_D009459 CID <e1>ziprasidone</e1> dose treatment days developed signs <e2>nms</e2>
C092292_D009459 CID <e1>ziprasidone</e1> <e2>nms</e2>
C092292_D012559 NONE <e1>ziprasidone</e1> dose treatment days developed history <e2>schizophrenia</e2>
19370593
D004967_D054556 CID <e1>oestrogen-only</e1> ht increased risk <e2>thrombo-embolism</e2>
D004967_D020521 CID <e1>oestrogen-only</e1> ht increased risk thrombo-embolism disease <e2>stroke</e2>
D004967_D005705 CID <e1>oestrogen-only</e1> ht increased risk thrombo-embolism <e2>disease</e2>
D004967_D001943 NONE <e1>oestrogen-only</e1> ht increased increase risk <e2>cancer</e2>
2466960
D005472_D066126 NONE <e1>fluorouracil</e1> associated <e2>toxicity</e2>
D005472_D066126 NONE <e1>5-fu</e1> therapy associated <e2>toxicity</e2>
D005472_D009369 NONE <e1>5-fu</e1> infusion treatment <e2>tumors</e2>
D005472_D007511 CID <e1>5-fu</e1> infusion undergoing patients monitoring performed order assess incidence changes <e2>ischemic</e2>
D005472_D007511 CID <e1>5-fu</e1> infusion prior 0.05 incidence episodes <e2>ischemic</e2>
D005472_D007511 CID <e1>5-fu</e1> infusion 0.05 incidence episodes <e2>ischemic</e2>
D005472_D007511 CID <e1>5-fu</e1> minutes 0.05 incidence episodes <e2>ischemic</e2>
D005472_D007511 CID <e1>5-fu</e1> minutes 0.05 incidence episodes <e2>ischemic</e2>
D005472_D007511 CID <e1>5-fu</e1> infusion associated increase deviation suggestive <e2>ischemia</e2>
D005472_D000787 CID <e1>5-fu</e1> infusion had rare episodes <e2>anginal</e2>
D005472_D000787 CID <e1>5-fu</e1> infusion had <e2>angina</e2>
D005472_D003324 NONE <e1>5-fu</e1> infusion associated increase patients <e2>disease</e2>
12448656
D013792_D002292 NONE <e1>thalidomide</e1> <e2>carcinoma</e2>
D013792_D002292 NONE <e1>thalidomide</e1> toxicity patients <e2>cancer</e2>
D013792_D002292 NONE <e1>thalidomide</e1> activity <e2>carcinoma</e2>
D013792_D002292 NONE <e1>thalidomide</e1> <e2>carcinoma</e2>
D013792_D064420 NONE <e1>thalidomide</e1> <e2>toxicity</e2>
6942642
D049971_D007008 NONE <e1>thiazide</e1> diuretics arrhythmias <e2>hypokalemia</e2>
D049971_D007008 NONE <e1>thiazide</e1> therapy consequence <e2>hypokalemia</e2>
D049971_D007008 NONE <e1>thiazide</e1> diuretics cause <e2>hypokalemia</e2>
D049971_D001145 NONE <e1>thiazide</e1> diuretics <e2>arrhythmias</e2>
D006852_C563897 NONE <e1>hydrochlorothiazide</e1> hctc <e2>hypertension</e2>
D006852_C563897 NONE <e1>hctc</e1> <e2>hypertension</e2>
D011188_D007008 NONE <e1>potassium</e1> <e2>hypokalemia</e2>
2598570
D013496_D021501 CID <e1>suprofen</e1> syndrome <e2>pain</e2>
D000431_D006255 NONE <e1>alcohol</e1> use likely suffer <e2>fever</e2>
D000431_D001249 NONE <e1>alcohol</e1> use likely suffer fever <e2>asthma</e2>
D007052_D007674 NONE <e1>ibuprofen</e1> agents use <e2>disease</e2>
D007052_D007669 NONE <e1>ibuprofen</e1> agents use disease history <e2>stones</e2>
D007052_D006073 NONE <e1>ibuprofen</e1> agents use disease history stones history <e2>gout</e2>
458486
D063325_D004409 NONE <e1>tiapride</e1> <e2>movements</e2>
D063325_D004409 NONE <e1>tiapride</e1> reduced <e2>movements</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>movements</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>movements</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D063325_D010300 NONE <e1>tiapride</e1> reduced patients <e2>disease</e2>
C037689_D004409 NONE <e1>benzamide</e1> tiapride reduced <e2>movements</e2>
C037689_D010300 NONE <e1>benzamide</e1> tiapride reduced patients <e2>disease</e2>
D008787_D004409 NONE <e1>metoclopramide</e1> related tiapride reduced <e2>movements</e2>
D008787_D010300 NONE <e1>metoclopramide</e1> related tiapride reduced patients <e2>disease</e2>
D007980_D010300 NONE <e1>levodopa-induced</e1> movements reduced patients <e2>disease</e2>
D063325_D004421 NONE <e1>tiapride</e1> had morning <e2>dystonia</e2>
D007980_D004421 NONE <e1>levodopa-induced</e1> morning <e2>dystonia</e2>
D004298_D004409 NONE <e1>dopamine</e1> receptors group overstimulation caused <e2>dyskinesias</e2>
17786501
D004221_D009901 NONE <e1>disulfiram-induced</e1> optic <e2>neuropathy</e2>
D004221_D009901 NONE <e1>disulfiram</e1> use <e2>neuropathy</e2>
D004221_D010523 NONE <e1>disulfiram-induced</e1> optic <e2>neuropathy</e2>
D004221_D010523 NONE <e1>disulfiram</e1> use <e2>neuropathy</e2>
D004221_D000437 NONE <e1>disulfiram</e1> use management <e2>dependence</e2>
D004221_D000437 NONE <e1>disulfiram</e1> <e2>dependence</e2>
3961813
D003345_D009422 NONE <e1>corticosterone</e1> effects <e2>neuropathy</e2>
D003345_D009422 NONE <e1>corticosterone</e1> concentrations had <e2>neuropathy</e2>
D010755_D009422 NONE <e1>organophosphorus-induced</e1> <e2>neuropathy</e2>
C025541_D009422 CID <e1>totp-induced</e1> <e2>neuropathy</e2>
C025541_D009422 CID <e1>totp</e1> had <e2>neuropathy</e2>
D007531_D009422 CID <e1>dfp</e1> totp had <e2>neuropathy</e2>
C025541_D020258 NONE <e1>totp</e1> hr activities esterase <e2>neurotoxic</e2>
D007531_D020258 NONE <e1>dfp</e1> totp hr activities esterase <e2>neurotoxic</e2>
D010755_D020258 NONE <e1>organophosphorous</e1> compounds given activities esterase <e2>neurotoxic</e2>
C025541_D009410 CID <e1>totp</e1> levels evident <e2>fibers</e2>
D007531_D009410 CID <e1>dfp</e1> totp levels evident <e2>fibers</e2>
1504402
D007741_D004342 CID <e1>dilevalol-associated</e1> hepatitis mechanism reaction <e2>hypersensitivity</e2>
D007741_D056486 CID <e1>dilevalol-associated</e1> <e2>hepatitis</e2>
D007741_D056486 CID <e1>dilevalol</e1> reactivity assess case <e2>injury</e2>
D007741_D056486 CID <e1>dilevalol</e1> antigens containing serum dilevalol reactivity assess case <e2>injury</e2>
D007741_D056486 CID <e1>dilevalol-induced</e1> <e2>injury</e2>
D007741_D056486 CID <e1>dilevalol-induced</e1> <e2>injury</e2>
D007741_D056486 CID <e1>dilevalol</e1> antigens containing sera sensitization detection allowed suggesting involvement mechanism <e2>injury</e2>
D007741_D056486 CID <e1>dilevalol-induced</e1> <e2>injury</e2>
12760988
D013390_D010149 CID <e1>succinylcholine</e1> <e2>myalgia</e2>
D013390_D010149 CID <e1>succinylcholine</e1> associated effect <e2>myalgia</e2>
D013390_D010149 CID <e1>succinylcholine</e1> administration effective decreasing incidence severity <e2>myalgia</e2>
D013390_D010149 CID <e1>succinylcholine-induced</e1> <e2>myalgia</e2>
D013390_D010149 CID <e1>succinylcholine</e1> prevent <e2>myalgia</e2>
D013390_D063806 CID <e1>succinylcholine-associated</e1> <e2>myalgia</e2>
D013390_D063806 CID <e1>succinylcholine</e1> pretreated patients determined incidence <e2>myalgia</e2>
D013390_D063806 CID <e1>succinylcholine-associated</e1> <e2>myalgia</e2>
D003907_D063806 NONE <e1>dexamethasone</e1> saline pretreated patients determined incidence <e2>myalgia</e2>
D003907_D063806 NONE <e1>dexamethasone</e1> group patients groups differ incidence severity <e2>myalgia</e2>
D003907_D063806 NONE <e1>dexamethasone</e1> group patients complained <e2>myalgia</e2>
D003907_D063806 NONE <e1>dexamethasone</e1> group patients <e2>myalgia</e2>
D003907_D010149 NONE <e1>dexamethasone</e1> administration effective decreasing incidence severity <e2>myalgia</e2>
D003907_D010149 NONE <e1>dexamethasone</e1> pretreatment justified prevent <e2>myalgia</e2>
11827497
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin</e1> exposure days presents <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin</e1> exposure included hospitalizations went <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin</e1> anticoagulants therapy consider <e2>thrombocytopenia</e2>
D006493_D001157 CID <e1>heparin-induced</e1> thrombocytopenia presents with arterial <e2>thromboemboli</e2>
D006493_D001157 CID <e1>heparin</e1> exposure days presents with arterial <e2>thromboemboli</e2>
D006493_D054556 CID <e1>heparin-induced</e1> thrombocytopenia presents with arterial <e2>thromboemboli</e2>
D006493_D054556 CID <e1>heparin</e1> exposure days presents with arterial <e2>thromboemboli</e2>
D006493_D013923 NONE <e1>heparin-induced</e1> thrombocytopenia became apparent presentation complications <e2>thromboembolic</e2>
D006493_D013923 NONE <e1>heparin-induced</e1> tests results counts onset <e2>thromboembolism</e2>
D006493_D013923 NONE <e1>heparin</e1> exposure included hospitalizations went return complications <e2>thromboembolic</e2>
D006493_D013923 NONE <e1>heparin-induced</e1> thrombocytopenia consider returns <e2>thromboembolism</e2>
D006493_D013923 NONE <e1>heparin</e1> anticoagulants therapy consider returns <e2>thromboembolism</e2>
1355091
D011224_D007024 CID <e1>prazosin-pretreated</e1> rats blockade occurs <e2>hypotension</e2>
D011224_D007024 CID <e1>prazosin</e1> treated shr <e2>hypotension</e2>
D011224_D007024 CID <e1>prazosin</e1> dosing performed produce <e2>hypotension</e2>
D011224_D006973 NONE <e1>prazosin-pretreated</e1> rats <e2>hypertensive</e2>
D011224_D006973 NONE <e1>prazosin</e1> treatment alters function control pressure rats <e2>hypertensive</e2>
D015016_D007024 NONE <e1>rauwolscine</e1> treated shr prazosin treated shr <e2>hypotension</e2>
C014282_D001919 CID <e1>cirazoline</e1> <e2>bradycardia</e2>
C014282_D001919 CID <e1>cirazoline</e1> pressor <e2>bradycardia</e2>
C056299_D001919 CID <e1>abbott-53693</e1> cirazoline <e2>bradycardia</e2>
C056299_D001919 CID <e1>abbott-53693</e1> effects similar greater <e2>bradycardia</e2>
D009638_D001919 CID <e1>noradrenaline</e1> responses <e2>bradycardia</e2>
D009638_D001919 CID <e1>noradrenaline-induced</e1> effect accompanied <e2>bradycardia</e2>
D011224_D001919 NONE <e1>prazosin</e1> pretreatment determined responses <e2>bradycardia</e2>
D011224_D001919 NONE <e1>prazosin</e1> treated shr abolished pressor <e2>bradycardia</e2>
D011224_D001919 NONE <e1>prazosin</e1> treatment greater <e2>bradycardia</e2>
D011224_D001919 NONE <e1>prazosin</e1> treatment similar <e2>bradycardia</e2>
15579441
D011692_D000860 CID <e1>aminonucleoside-induced</e1> syndrome <e2>hypoxia</e2>
D011692_D000860 CID <e1>aminonucleoside-induced</e1> syndrome <e2>hypoxia</e2>
D011692_D000860 CID <e1>aminonucleoside</e1> model reaching increased expression transgene <e2>hypoxia-responsive</e2>
D011692_D009404 CID <e1>aminonucleoside-induced</e1> <e2>syndrome</e2>
8988571
D003042_D003693 CID <e1>cocaine</e1> use <e2>delirium</e2>
D003042_D003693 CID <e1>cocaine</e1> toxicity mechanisms evidence provide <e2>delirium</e2>
D003042_D003693 CID <e1>cocaine-induced</e1> <e2>delirium</e2>
D003042_D003693 CID <e1>cocaine-induced</e1> delirium <e2>edds</e2>
D003042_D003693 CID <e1>cocaine-related</e1> deaths registry compared <e2>edds</e2>
D003042_D003693 CID <e1>cocaine-related</e1> deaths registry compared victims <e2>delirium</e2>
D003042_D003693 CID <e1>cocaine</e1> overdose victims compared <e2>edds</e2>
D003042_D003693 CID <e1>cocaine</e1> overdose victims <e2>delirium</e2>
D003042_D003693 CID <e1>cocaine</e1> concentrations had <e2>edds</e2>
D003042_D003693 CID <e1>cocaine</e1> use disrupts hypothesis consistent precipitate agitation <e2>delirium</e2>
D003042_D003693 CID <e1>cocaine</e1> use coupled precipitate agitation <e2>delirium</e2>
D003042_D064420 NONE <e1>cocaine</e1> use delirium provide evidence mechanisms <e2>toxicity</e2>
D003042_D064420 NONE <e1>cocaine</e1> <e2>toxicity</e2>
D003042_D062787 NONE <e1>cocaine-related</e1> deaths registry compared victims <e2>overdose</e2>
D003042_D062787 NONE <e1>cocaine</e1> <e2>overdose</e2>
C005618_D003693 NONE <e1>benzoylecgonine</e1> cocaine concentrations had <e2>edds</e2>
D003042_D011595 NONE <e1>cocaine</e1> use disrupts hypothesis consistent precipitate <e2>agitation</e2>
D003042_D011595 NONE <e1>cocaine</e1> use coupled precipitate <e2>agitation</e2>
D003042_D012206 CID <e1>cocaine</e1> use disrupts hypothesis consistent precipitate agitation <e2>rhabdomyolysis</e2>
D003042_D012206 CID <e1>cocaine</e1> use coupled precipitate agitation <e2>rhabdomyolysis</e2>
D003042_D003645 CID <e1>cocaine</e1> use disrupts hypothesis consistent precipitate agitation <e2>death</e2>
D003042_D003645 CID <e1>cocaine</e1> use coupled precipitate agitation <e2>death</e2>
3934126
D014640_D007239 NONE <e1>vancomycin</e1> curative % patients <e2>infection</e2>
D014640_D007239 NONE <e1>vancomycin</e1> constitutes therapy <e2>infections</e2>
D000617_D013924 NONE <e1>aminoglycoside</e1> receiving patients confined occurred <e2>thrombophlebitis</e2>
D000617_D007674 NONE <e1>aminoglycoside</e1> receiving patients confined occurred infusion <e2>nephrotoxicity</e2>
D000617_D006311 NONE <e1>aminoglycoside</e1> receiving patients confined occurred infusion nephrotoxicity <e2>ototoxicity</e2>
D014640_D013924 CID <e1>vancomycin</e1> aminoglycoside receiving patients confined occurred <e2>thrombophlebitis</e2>
D014640_D007674 NONE <e1>vancomycin</e1> aminoglycoside receiving patients confined occurred infusion <e2>nephrotoxicity</e2>
D014640_D006311 CID <e1>vancomycin</e1> aminoglycoside receiving patients confined occurred infusion nephrotoxicity <e2>ototoxicity</e2>
16844102
D024502_D020258 NONE <e1>alpha-tocopherol</e1> effect deferoxamine <e2>neurotoxicity</e2>
D024502_D020258 NONE <e1>alpha-tocopherol</e1> effect deferoxamine <e2>neurotoxicity</e2>
D024502_D020258 NONE <e1>alpha-tc</e1> alpha-tocopherol effect deferoxamine <e2>neurotoxicity</e2>
D003676_D020258 NONE <e1>deferoxamine</e1> <e2>neurotoxicity</e2>
D003676_D020258 NONE <e1>deferoxamine</e1> <e2>neurotoxicity</e2>
D003676_D020258 NONE <e1>dfo</e1> deferoxamine <e2>neurotoxicity</e2>
D008694_D020258 NONE <e1>methamphetamine-induced</e1> <e2>neurotoxicity</e2>
D008694_D020258 NONE <e1>methamphetamine</e1> <e2>neurotoxicity</e2>
D008694_D020258 NONE <e1>(ma)-induced</e1> <e2>neurotoxicity</e2>
D008694_D020258 NONE <e1>ma-induced</e1> <e2>neurotoxicity</e2>
D010100_D020258 NONE <e1>oxygen</e1> species scavenger alpha-tocopherol effect deferoxamine <e2>neurotoxicity</e2>
D007501_D020258 NONE <e1>iron</e1> chelator deferoxamine <e2>neurotoxicity</e2>
D024502_D005334 NONE <e1>alpha-tc</e1> attenuated <e2>hyperthermia</e2>
D003676_D005334 NONE <e1>dfo</e1> alpha-tc attenuated <e2>hyperthermia</e2>
D008694_D005334 CID <e1>ma-induced</e1> <e2>hyperthermia</e2>
D024502_D009422 NONE <e1>alpha-tc</e1> ameliorate <e2>damage</e2>
D003676_D009422 NONE <e1>dfo</e1> alpha-tc ameliorate <e2>damage</e2>
D008694_D009422 CID <e1>ma-induced</e1> <e2>damage</e2>
15867025
D006514_D006509 CID <e1>antigen-positive</e1> mothers born infants done screening <e2>b</e2>
D006514_D006509 CID <e1>antigen-positive</e1> mothers born infants done dose birth administration vaccine <e2>b</e2>
D006514_D006509 CID <e1>antigen-positive</e1> mothers born infants done infants administration globulin <e2>b</e2>
D006514_D006509 CID <e1>antigen-positive</e1> mothers born infants received globulin <e2>b</e2>
D006514_D012409 NONE <e1>antigen-positive</e1> mothers born infants done screening b <e2>rubella</e2>
D006514_D012409 NONE <e1>antigen-positive</e1> mothers immunity <e2>rubella</e2>
D006514_D012409 NONE <e1>antigen-positive</e1> mothers born infants done administration vaccine <e2>rubella</e2>
D006514_D012409 NONE <e1>antigen-positive</e1> mothers born infants done women <e2>rubella</e2>
16471092
C099041_D053201 NONE <e1>tolterodine</e1> treatment symptoms changes women <e2>bladder</e2>
C099041_D053201 NONE <e1>tolterodine</e1> treatment study symptoms quality changes women <e2>bladder</e2>
C099041_D053201 NONE <e1>tolterodine</e1> treatment study symptoms quality <e2>oab</e2>
C099041_D053201 NONE <e1>tolterodine</e1> tolerated improved quality women <e2>oab</e2>
15974569
D007608_D010146 NONE <e1>kainate</e1> receptor antagonists prodrugs actives models <e2>pain</e2>
D005557_D010146 NONE <e1>formalin-induced</e1> licking reversal active models <e2>pain</e2>
D005557_D006930 NONE <e1>formalin-induced</e1> licking <e2>hyperalgesia</e2>
D005557_D006930 NONE <e1>formalin-induced</e1> licking reversal active <e2>hyperalgesia</e2>
D002351_D010146 NONE <e1>carrageenan-induced</e1> hyperalgesia licking reversal active models <e2>pain</e2>
D002351_D006930 CID <e1>carrageenan-induced</e1> <e2>hyperalgesia</e2>
D002351_D006930 CID <e1>carrageenan-induced</e1> hyperalgesia licking reversal active <e2>hyperalgesia</e2>
D002211_D010146 NONE <e1>capsaicin-induced</e1> hyperalgesia active models <e2>pain</e2>
D002211_D006930 CID <e1>capsaicin-induced</e1> hyperalgesia active reversal licking <e2>hyperalgesia</e2>
D002211_D006930 CID <e1>capsaicin-induced</e1> <e2>hyperalgesia</e2>
6504332
D010634_D004409 CID <e1>phenobarbital-induced</e1> <e2>dyskinesia</e2>
D010634_D004409 CID <e1>phenobarbital</e1> therapy starting developed <e2>dyskinesia</e2>
D010634_D004409 CID <e1>phenobarbital</e1> challenge recurred <e2>dyskinesia</e2>
D010634_D009422 NONE <e1>phenobarbital-induced</e1> dyskinesia child <e2>neurologically-impaired</e2>
D010634_D009422 NONE <e1>phenobarbital</e1> therapy starting developed child <e2>impairment</e2>
D010634_D012640 NONE <e1>phenobarbital</e1> therapy <e2>seizures</e2>
D010634_D009069 NONE <e1>phenobarbital</e1> added list drugs cause <e2>disorders</e2>
18356633
D000583_D007674 CID <e1>amikacin</e1> <e2>nephrotoxicity</e2>
D000583_D007674 CID <e1>amikacin-associated</e1> <e2>nephrotoxicity</e2>
D000583_D007674 CID <e1>amikacin</e1> concentrations evaluation increase means occurrence <e2>nephrotoxicity</e2>
D000583_D009503 NONE <e1>amikacin</e1> aminoglycoside used provide treatment <e2>neutropenia</e2>
D000583_D007239 NONE <e1>amikacin</e1> aminoglycoside used provide treatment neutropenia <e2>infections</e2>
D000617_D009503 NONE <e1>aminoglycoside</e1> used provide treatment <e2>neutropenia</e2>
D000617_D007239 NONE <e1>aminoglycoside</e1> used provide treatment neutropenia <e2>infections</e2>
D000617_D006402 NONE <e1>aminoglycoside</e1> treatment required <e2>disorder</e2>
D000617_D009369 NONE <e1>aminoglycoside</e1> treatment required <e2>disorder</e2>
D000583_D006402 NONE <e1>amikacin</e1> conventional randomized patients diagnosis consistent <e2>disorder</e2>
D000583_D009369 NONE <e1>amikacin</e1> conventional randomized patients diagnosis consistent <e2>disorder</e2>
D003404_D007674 NONE <e1>creatinine</e1> increase means occurrence <e2>nephrotoxicity</e2>
1564236
D013793_D023921 NONE <e1>thallium-201</e1> tomography correlation relation defects observed echocardiography severity <e2>stenosis</e2>
D004176_D006940 CID <e1>dipyridamole-induced</e1> <e2>hyperemia</e2>
D004176_D006940 CID <e1>dipyridamole-induced</e1> <e2>hyperemia</e2>
D004176_D006940 CID <e1>dipyridamole-induced</e1> <e2>hyperemia</e2>
D004176_D023921 NONE <e1>dipyridamole-induced</e1> hyperemia had 12 dogs <e2>stenosis</e2>
D013793_D006940 NONE <e1>thallium-201</e1> spect demonstrated defect dogs analyzed <e2>hyperemia</e2>
9305828
D010862_D004833 CID <e1>pilocarpine</e1> model <e2>epilepsy</e2>
D010862_D004833 CID <e1>pilo</e1> model <e2>tle</e2>
D010862_D004827 NONE <e1>pilocarpine</e1> model <e2>epilepsy</e2>
D010862_D004827 NONE <e1>pilo</e1> pilocarpine model <e2>epilepsy</e2>
D010862_D013226 NONE <e1>pilocarpine</e1> model characterized period <e2>epilepticus</e2>
D010862_D013226 NONE <e1>pilo</e1> pilocarpine model characterized period <e2>epilepticus</e2>
D010862_D012640 NONE <e1>pilocarpine</e1> model characterized period epilepticus followed <e2>seizures</e2>
D010862_D012640 NONE <e1>pilo</e1> pilocarpine model characterized period epilepticus followed <e2>seizures</e2>
D010862_D001930 NONE <e1>pilocarpine</e1> model characterized period epilepticus followed seizures <e2>damage</e2>
D010862_D001930 NONE <e1>pilo</e1> pilocarpine model characterized period epilepticus followed seizures <e2>damage</e2>
7791169
D016595_D007674 NONE <e1>misoprostol</e1> effect <e2>dysfunction</e2>
D016595_D007674 NONE <e1>misoprostol</e1> addition minimize <e2>impairment</e2>
D007213_D007674 CID <e1>indomethacin</e1> <e2>dysfunction</e2>
D007213_D007674 CID <e1>indomethacin</e1> <e2>dysfunction</e2>
D016595_D010146 NONE <e1>misoprostol</e1> addition minimize affecting control <e2>pain</e2>
2021202
D007530_D007022 CID <e1>isoflurane-induced</e1> <e2>hypotension</e2>
D007530_D007022 CID <e1>isoflurane-induced</e1> <e2>hypotension</e2>
D007530_D007022 CID <e1>isoflurane</e1> inspired concentration increasing induced <e2>hypotension</e2>
D007530_D007022 CID <e1>isoflurane-induced</e1> <e2>hypotension</e2>
17285209
D017311_D006973 NONE <e1>amlodipine/benazapril</e1> 10/5 pill started <e2>hypertension</e2>
D017311_D015746 NONE <e1>amlodipine/benazapril</e1> 10/5 pill started hypertension female report presented room <e2>pain</e2>
D017311_D009325 NONE <e1>amlodipine/benazapril</e1> 10/5 pill started hypertension female report presented room pain <e2>nausea</e2>
D017311_D014839 NONE <e1>amlodipine/benazapril</e1> 10/5 pill started hypertension female report presented room pain nausea <e2>vomiting</e2>
C044946_D006973 NONE <e1>amlodipine/benazapril</e1> 10/5 pill started <e2>hypertension</e2>
C044946_D015746 NONE <e1>amlodipine/benazapril</e1> 10/5 pill started hypertension female report presented room <e2>pain</e2>
C044946_D009325 NONE <e1>amlodipine/benazapril</e1> 10/5 pill started hypertension female report presented room pain <e2>nausea</e2>
C044946_D014839 NONE <e1>amlodipine/benazapril</e1> 10/5 pill started hypertension female report presented room pain nausea <e2>vomiting</e2>
D000809_D007410 NONE <e1>angiotensin-converting</e1> enzyme recognition <e2>angioedema</e2>
D000809_D007410 NONE <e1>angiotensin</e1> blocker enzyme recognition <e2>angioedema</e2>
D000809_D000799 NONE <e1>angiotensin-converting</e1> enzyme recognition <e2>angioedema</e2>
D000809_D000799 NONE <e1>angiotensin</e1> blocker enzyme recognition <e2>angioedema</e2>
7752389
D015232_D053201 CID <e1>e2-induced</e1> <e2>hyperactivity</e2>
D015320_D053201 NONE <e1>tachykinins</e1> involvement <e2>hyperactivity</e2>
D015320_D053201 NONE <e1>tachykinins</e1> release prostanoids contribute urge <e2>hyperactivity</e2>
D011453_D053201 NONE <e1>prostanoids</e1> contribute urge <e2>hyperactivity</e2>
12907924
D008774_D009771 CID <e1>methylphenidate-induced</e1> <e2>symptoms</e2>
D008774_D009771 CID <e1>methylphenidate</e1> replaced <e2>behavior</e2>
D008774_D061218 NONE <e1>methylphenidate</e1> started man <e2>depression</e2>
D008774_D000544 NONE <e1>methylphenidate</e1> started man depression <e2>disease</e2>
D016666_D009771 NONE <e1>fluvoxamine</e1> replaced <e2>behavior</e2>
8643973
D017239_D010051 NONE <e1>paclitaxel</e1> combined carboplatin treatment <e2>cancer</e2>
D017239_D010051 NONE <e1>paclitaxel</e1> dose given infusion combination carboplatin administered days women <e2>cancer</e2>
D017239_D010051 NONE <e1>taxol</e1> company dose given infusion combination carboplatin administered days women <e2>cancer</e2>
D017239_D010051 NONE <e1>paclitaxel</e1> doses escalated study determine dose given infusion combination carboplatin administered days women <e2>cancer</e2>
D016190_D010051 NONE <e1>carboplatin</e1> treatment <e2>cancer</e2>
D016190_D010051 NONE <e1>carboplatin</e1> administered days women <e2>cancer</e2>
11912119
D007980_D004409 CID <e1>levodopa-induced</e1> overflow <e2>dyskinesias</e2>
D007980_D004409 CID <e1>levodopa</e1> therapy complications relationship coordination assessed <e2>dyskinesias</e2>
D007980_D004409 CID <e1>levodopa</e1> therapy complications relationship coordination assessed dyskinesias <e2>lid</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> dyskinesias <e2>lid</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> dyskinesias disease <e2>lid</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> dyskinesias disease <e2>lid</e2>
D007980_D004409 CID <e1>levodopa</e1> on assessed score score <e2>dyskinesia</e2>
D007980_D004409 CID <e1>levodopa</e1> increased disease <e2>lid</e2>
D007980_D010300 NONE <e1>levodopa-induced</e1> overflow dyskinesias <e2>disease</e2>
D007980_D010300 NONE <e1>levodopa</e1> therapy complications relationship coordination <e2>disease</e2>
D007980_D010300 NONE <e1>levodopa-induced</e1> dyskinesias assessed coordination <e2>disease</e2>
D007980_D010300 NONE <e1>levodopa-induced</e1> dyskinesias disease studied groups patients <e2>disease</e2>
D007980_D010300 NONE <e1>levodopa-induced</e1> dyskinesias <e2>disease</e2>
D007980_D010300 NONE <e1>levodopa-induced</e1> dyskinesias disease lid <e2>disease</e2>
D007980_D010300 NONE <e1>levodopa</e1> on assessed score scale <e2>disease</e2>
D007980_D010300 NONE <e1>levodopa</e1> increased <e2>disease</e2>
3108839
D016685_D006463 CID <e1>c</e1> associated <e2>syndrome</e2>
D016685_D006463 CID <e1>c</e1> associated <e2>syndrome</e2>
D016685_D006463 CID <e1>c</e1> associated syndrome <e2>hus</e2>
D016685_D000743 NONE <e1>c</e1> treatment associated <e2>anemia</e2>
D016685_D013921 NONE <e1>c</e1> treatment associated anemia <e2>thrombocytopenia</e2>
D016685_D013921 NONE <e1>c</e1> treatment describe findings man developed failure <e2>thrombocytopenia</e2>
D016685_D051437 CID <e1>c</e1> treatment associated anemia <e2>failure</e2>
D016685_D051437 CID <e1>c</e1> treatment start develops <e2>failure</e2>
D016685_D051437 CID <e1>c</e1> treatment start develops % <e2>failure</e2>
D016685_D051437 CID <e1>c</e1> treatment describe findings man developed <e2>failure</e2>
D016685_D011654 NONE <e1>c</e1> treatment start develops % failure <e2>edema</e2>
D016685_D011654 NONE <e1>c</e1> treatment describe died <e2>edema</e2>
D016685_D013274 NONE <e1>c</e1> treatment describe findings man <e2>adenocarcinoma</e2>
17682013
D008727_D056784 CID <e1>methotrexate</e1> recipients commonly described <e2>leukoencephalopathy</e2>
D008727_D056784 CID <e1>methotrexate</e1> treated patients <e2>leukoencephalopathy</e2>
D008727_D002544 NONE <e1>methotrexate</e1> recipients commonly described leukoencephalopathy mimicking <e2>accident</e2>
D008727_D007938 NONE <e1>methotrexate</e1> <e2>leukaemia</e2>
D005472_D056784 CID <e1>5-fluorouracil</e1> methotrexate treated patients <e2>leukoencephalopathy</e2>
C017367_D056784 CID <e1>carmofur</e1> <e2>leukoencephalopathy</e2>
C110904_D056784 CID <e1>capecitabine</e1> identified reports <e2>leukoencephalopathy</e2>
6216862
D010396_D001172 NONE <e1>penicillamine</e1> therapy effects patient <e2>arthritis</e2>
D010396_D001172 NONE <e1>penicillamine</e1> therapy patients <e2>arthritis</e2>
D010396_D001172 NONE <e1>penicillamine</e1> treated <e2>arthritis</e2>
D010396_D005076 CID <e1>penicillamine</e1> therapy complications recorded <e2>rashes</e2>
D010396_D011507 CID <e1>penicillamine</e1> therapy complications recorded rashes <e2>proteinuria</e2>
D010396_D008180 CID <e1>penicillamine</e1> therapy complications recorded rashes <e2>erythematosus</e2>
D010396_D017285 CID <e1>penicillamine</e1> therapy complications recorded rashes erythematosus <e2>polymyositis</e2>
D010396_D009157 CID <e1>penicillamine</e1> therapy complications recorded rashes erythematosus <e2>gravis</e2>
D010396_D012871 NONE <e1>penicillamine</e1> treated arthritis patients patients effect reported resembled <e2>lesion</e2>
D010396_C536202 NONE <e1>penicillamine</e1> treated arthritis patients patients effect reported resembled <e2>serpiginosa</e2>
D010396_D006527 NONE <e1>penicillamine</e1> treated arthritis patients patients <e2>disease</e2>
9636837
D016190_D020258 NONE <e1>carboplatin</e1> advantages striking rate effects <e2>neurotoxic</e2>
D016190_D020258 NONE <e1>cbdca</e1> advantages striking rate effects <e2>neurotoxic</e2>
D016190_D020258 NONE <e1>cbdca</e1> schedules use association drugs <e2>neurotoxic</e2>
D016190_D020258 NONE <e1>cbdca</e1> <e2>neurotoxic</e2>
D016190_D020258 NONE <e1>cbdca</e1> neurotoxic similar those caused cddp probable induced <e2>neurotoxicity</e2>
D002945_D020258 NONE <e1>cisplatin</e1> advantages striking rate effects <e2>neurotoxic</e2>
D002945_D020258 NONE <e1>cddp</e1> cisplatin advantages striking rate effects <e2>neurotoxic</e2>
D002945_D020258 NONE <e1>cddp</e1> caused those similar <e2>neurotoxic</e2>
D002945_D020258 NONE <e1>cddp</e1> probable induced <e2>neurotoxicity</e2>
D016190_D010523 CID <e1>cbdca</e1> schedules use cause concern safety respect <e2>damage</e2>
D016190_D010523 CID <e1>cbdca</e1> administration induced <e2>neurotoxicity</e2>
1728915
D002220_D006331 NONE <e1>carbamazepine-induced</e1> <e2>dysfunction</e2>
D002220_D006331 NONE <e1>carbamazepine-associated</e1> <e2>dysfunction</e2>
D002220_D001919 CID <e1>carbamazepine</e1> induced patient <e2>bradycardia</e2>
D002220_D001919 CID <e1>carbamazepine</e1> levels associated consisted exclusively women developed <e2>bradyarrhythmias</e2>
D002220_D054537 CID <e1>carbamazepine</e1> induced patient bradycardia <e2>block</e2>
D002220_D054537 CID <e1>carbamazepine</e1> levels associated consisted exclusively women developed bradyarrhythmias <e2>delay</e2>
D002220_D013616 CID <e1>carbamazepine</e1> overdose setting developed <e2>tachycardias</e2>
D002220_D062787 NONE <e1>carbamazepine</e1> <e2>overdose</e2>
D002220_D001523 NONE <e1>carbamazepine</e1> used treatment conditions neurologic <e2>psychiatric</e2>
6323692
C018824_D001259 CID <e1>acetate</e1> pretreatment doubled remained increased <e2>incoordination</e2>
C018824_D001259 CID <e1>nh4ac</e1> acetate pretreatment doubled remained increased <e2>incoordination</e2>
C018824_D001259 CID <e1>nh4ac</e1> treatment had remained increased <e2>incoordination</e2>
C018824_D001259 CID <e1>nh4ac</e1> pretreatment enhanced analgesia- <e2>incoordination</e2>
C018824_D001259 CID <e1>nh4ac</e1> verapamil affected enhanced analgesia- <e2>incoordination</e2>
D009020_D001259 NONE <e1>morphine-treated</e1> mice remained increased <e2>incoordination</e2>
D009020_D001259 NONE <e1>morphine</e1> analgesia- <e2>incoordination</e2>
D003975_D001259 CID <e1>diazepam</e1> <e2>incoordination</e2>
D003975_D001259 CID <e1>diazepam-induced</e1> <e2>incoordination</e2>
D002118_D003866 NONE <e1>calcium</e1> addition reversed <e2>depression</e2>
D002118_D003866 NONE <e1>calcium-independent</e1> release blocked reversed <e2>depression</e2>
D002395_D003866 NONE <e1>catecholamine</e1> release blocked reversed <e2>depression</e2>
D000079_D003866 NONE <e1>acetaldehyde</e1> release blocked reversed <e2>depression</e2>
C018824_D003866 NONE <e1>nh4ac</e1> blocked reversed <e2>depression</e2>
D014700_D000699 NONE <e1>verapamil</e1> enhanced <e2>analgesia-</e2>
D014700_D000699 NONE <e1>verapamil</e1> affected enhanced <e2>analgesia-</e2>
D014700_D001259 NONE <e1>verapamil</e1> enhanced analgesia- <e2>incoordination</e2>
D014700_D001259 NONE <e1>verapamil</e1> affected enhanced analgesia- <e2>incoordination</e2>
C018824_D000699 NONE <e1>nh4ac</e1> pretreatment enhanced <e2>analgesia-</e2>
C018824_D000699 NONE <e1>nh4ac</e1> verapamil affected enhanced <e2>analgesia-</e2>
D009020_D000699 NONE <e1>morphine</e1> <e2>analgesia-</e2>
D003975_D000699 NONE <e1>diazepam-induced</e1> incoordination <e2>analgesia-</e2>
D000661_D000699 NONE <e1>amphetamine-induced</e1> activity antagonized enhanced <e2>analgesia-</e2>
D000661_D001259 NONE <e1>amphetamine-induced</e1> activity antagonized enhanced analgesia- <e2>incoordination</e2>
D010433_D000699 NONE <e1>metrazol</e1> action affected enhanced <e2>analgesia-</e2>
D010433_D001259 NONE <e1>metrazol</e1> action affected enhanced analgesia- <e2>incoordination</e2>
D002118_D022124 NONE <e1>calcium</e1> channel action exerts <e2>hyperammonemia</e2>
7072798
D002701_D000741 CID <e1>chloramphenicol</e1> administration <e2>anemia</e2>
D002701_D000741 CID <e1>chloramphenicol</e1> therapy beginning extraction undergoing died <e2>anemia</e2>
D002701_D000741 CID <e1>chloramphenicol</e1> response associated pattern <e2>anemia</e2>
D002701_D000741 CID <e1>chloramphenicol</e1> treatment report <e2>anemia</e2>
D002701_D002386 NONE <e1>chloramphenicol</e1> therapy beginning extraction <e2>cataract</e2>
D002701_D001855 NONE <e1>chloramphenicol</e1> treatment report reported cases <e2>hypoplasia</e2>
D002701_D005128 NONE <e1>chloramphenicol</e1> associated <e2>toxicity</e2>
8441146
D006046_D000741 CID <e1>gold</e1> caused <e2>anemia</e2>
D010396_D000741 CID <e1>d-penicillamine</e1> case caused <e2>anemia</e2>
8911359
D003520_D001749 CID <e1>cyclophosphamide</e1> <e2>cancer</e2>
D003520_D001749 CID <e1>cyclophosphamide</e1> <e2>cancer</e2>
D003520_D001749 CID <e1>cyclophosphamide</e1> <e2>tumor</e2>
D003520_D014523 NONE <e1>cyclophosphamide</e1> <e2>cancer</e2>
10193809
D011692_D011507 CID <e1>aminonucleoside</e1> administered rats induce <e2>proteinuria</e2>
D011692_D011507 CID <e1>pan</e1> aminonucleoside administered rats induce <e2>proteinuria</e2>
3780814
D010634_D063646 NONE <e1>phenobarbital</e1> action <e2>anti-carcinogenic</e2>
D010634_D063646 NONE <e1>phenobarbital</e1> mg effect <e2>carcinogenesis</e2>
D010634_D063646 NONE <e1>pb</e1> mg effect <e2>carcinogenesis</e2>
D010634_D063646 NONE <e1>pb</e1> den den treated schedule <e2>hepatocarcinogenesis</e2>
D010634_D063646 NONE <e1>pb</e1> promotes <e2>carcinogenesis</e2>
D004052_D063646 NONE <e1>diethylnitrosamine</e1> action <e2>anti-carcinogenic</e2>
D004052_D063646 NONE <e1>diethylnitrosamine</e1> administered planned order elucidate effect <e2>carcinogenesis</e2>
D004052_D063646 NONE <e1>den</e1> diethylnitrosamine administered planned order elucidate effect <e2>carcinogenesis</e2>
D004052_D063646 NONE <e1>den</e1> treated schedule <e2>hepatocarcinogenesis</e2>
D004052_D063646 NONE <e1>den</e1> den treated schedule <e2>hepatocarcinogenesis</e2>
D004052_D063646 NONE <e1>den</e1> treatment administered promotes <e2>carcinogenesis</e2>
D004052_D063646 NONE <e1>den</e1> given reduces pb promotes <e2>carcinogenesis</e2>
D010634_D011230 NONE <e1>pb</e1> given reduced number size <e2>foci</e2>
D004052_D011230 CID <e1>den</e1> given reduced number size <e2>foci</e2>
D004052_D009369 NONE <e1>den</e1> prolonged decreased incidence <e2>tumor</e2>
D004052_D009369 NONE <e1>den</e1> obtained results compared decreased incidence <e2>tumor</e2>
D010634_D009369 NONE <e1>pb</e1> treated rats den prolonged decreased incidence <e2>tumor</e2>
20683499
C029036_D000544 NONE <e1>crocin</e1> effects model <e2>disease</e2>
C029036_D000544 NONE <e1>crocins</e1> <e2>disease</e2>
C029036_D000544 NONE <e1>crocin</e1> effectiveness antagonizing deficits potential treatment diseases <e2>disease</e2>
D013311_D000544 CID <e1>streptozocin-induced</e1> model <e2>disease</e2>
D013311_D000544 CID <e1>streptozocin</e1> induced <e2>disease</e2>
D013311_D000544 CID <e1>stz</e1> streptozocin induced <e2>disease</e2>
D013311_D000544 CID <e1>stz-icv</e1> injected groups <e2>disease</e2>
D013311_D000544 CID <e1>stz-icv</e1> application repeated injected groups <e2>disease</e2>
D013311_D000544 CID <e1>stz-icv</e1> caused deficits potential treatment diseases <e2>disease</e2>
C029036_D007859 NONE <e1>crocin</e1> attenuated learning <e2>impairment</e2>
C029036_D008569 NONE <e1>crocin</e1> attenuated learning <e2>impairment</e2>
D013311_D007859 NONE <e1>stz-injected</e1> group learning <e2>impairment</e2>
D013311_D008569 NONE <e1>stz-injected</e1> group learning <e2>impairment</e2>
C029036_D003072 NONE <e1>crocin</e1> effectiveness antagonizing <e2>deficits</e2>
C029036_D019636 NONE <e1>crocin</e1> effectiveness antagonizing deficits potential treatment <e2>diseases</e2>
D013311_D003072 CID <e1>stz-icv</e1> caused <e2>deficits</e2>
D013311_D019636 NONE <e1>stz-icv</e1> caused deficits potential treatment <e2>diseases</e2>
19674115
D011718_D000857 CID <e1>pyrazinamide</e1> induced <e2>dysosmia</e2>
D011718_D000857 CID <e1>pyrazinamide</e1> related <e2>disorder</e2>
D011718_D000857 CID <e1>pyrazinamide</e1> withdrawal disappeared <e2>dysosmia</e2>
D011718_D056486 NONE <e1>pyrazinamide</e1> have effects <e2>toxicity</e2>
D011718_D033461 NONE <e1>pyrazinamide</e1> have effects toxicity <e2>hyperuricemia</e2>
19944736
D013619_D012640 CID <e1>tacrine</e1> induces <e2>seizures</e2>
D013619_D001930 CID <e1>tacrine</e1> induces delayed <e2>damage</e2>
D013619_D001930 CID <e1>tacrine-loaded</e1> nanoparticles administration induced damage <e2>cells</e2>
D013619_D001930 CID <e1>tacrine</e1> solution induced damage <e2>cells</e2>
D018021_D012640 CID <e1>licl</e1> pre-treated rats administered tacrine induces <e2>seizures</e2>
D018021_D001930 CID <e1>licl</e1> pre-treated rats administered tacrine induces delayed <e2>damage</e2>
D013619_D004827 NONE <e1>tacrine-loaded</e1> nanoparticles treated animals showed outcome symptoms onset <e2>epileptic</e2>
D013619_D004827 NONE <e1>tacrine-lithium</e1> model <e2>epilepsy</e2>
D008094_D004827 NONE <e1>tacrine-lithium</e1> model <e2>epilepsy</e2>
1141447
D008094_D003919 CID <e1>lithium-induced</e1> <e2>insipidus</e2>
D008094_D003919 CID <e1>lithium-induced</e1> <e2>insipidus</e2>
8686832
D008012_D001416 CID <e1>lignocaine</e1> involving anaesthesia leg <e2>pain</e2>
D008012_D001416 CID <e1>lignocaine</e1> use associated <e2>pain</e2>
D000431_D010146 NONE <e1>alcohol</e1> intake admitted pain five <e2>pain</e2>
D000431_D010146 NONE <e1>alcohol</e1> intake admitted <e2>pain</e2>
11185967
D003042_D012640 NONE <e1>cocaine</e1> screening prevalence patients <e2>seizure</e2>
D003042_D012640 NONE <e1>cocaine</e1> screening patients <e2>seizure</e2>
D000661_D012640 NONE <e1>amphetamine</e1> cocaine screening prevalence patients <e2>seizure</e2>
D000431_D012640 NONE <e1>alcohol-related</e1> disorder <e2>seizure</e2>
D000431_D012640 NONE <e1>alcohol-related</e1> disorder drug demographics time <e2>seizure</e2>
D000431_D019970 NONE <e1>alcohol-related</e1> disorder drug demographics time seizure collection history <e2>abuse</e2>
D000431_D019969 NONE <e1>alcohol-related</e1> disorder drug demographics time seizure collection history <e2>abuse</e2>
D000662_D012640 NONE <e1>amphetamines</e1> cocaine screening patients <e2>seizure</e2>
9564988
D064704_D012852 NONE <e1>levofloxacin</e1> assessment treatment <e2>sinusitis</e2>
D064704_D012852 NONE <e1>levofloxacin</e1> efficacy evaluate treating outpatients <e2>sinusitis</e2>
D064704_D012852 NONE <e1>levofloxacin</e1> mg treatment <e2>sinusitis</e2>
10565806
C076029_D001714 CID <e1>olanzapine</e1> induced syndrome <e2>hypomania-like</e2>
C076029_D001714 CID <e1>olanzapine</e1> treatment introduction developed <e2>hypomania</e2>
C076029_D011618 NONE <e1>olanzapine</e1> treatment introduction developed <e2>disorder</e2>
9672273
D013629_D001943 NONE <e1>tamoxifen</e1> prevention <e2>cancer</e2>
D013629_D001943 NONE <e1>tamoxifen</e1> agent <e2>cancer</e2>
D013629_D001943 NONE <e1>tamoxifen</e1> trial have <e2>cancer</e2>
D013629_D001943 NONE <e1>tamoxifen</e1> placebo frequency <e2>breast-cancer</e2>
D013629_D001943 NONE <e1>tamoxifen</e1> receiving women reduction <e2>cancer</e2>
D013629_D001943 NONE <e1>tamoxifen</e1> receiving women reduction is found cases <e2>cancer</e2>
D013629_D001943 NONE <e1>tamoxifen</e1> allocated women case cases found is reduction <e2>cancer</e2>
D013629_D001943 NONE <e1>tamoxifen</e1> allocated women case cases <e2>cancer</e2>
D013629_D001943 NONE <e1>tamoxifen</e1> effects apparent cohort women risk <e2>cancer</e2>
D013629_D016889 NONE <e1>tamoxifen</e1> agent associated development <e2>cancer</e2>
D013629_D014652 CID <e1>tamoxifen</e1> women hypertriglyceridaemia <e2>events</e2>
D013629_D015228 CID <e1>tamoxifen</e1> women <e2>hypertriglyceridaemia</e2>
11077455
D020888_D014786 CID <e1>vigabatrin-attributed</e1> <e2>constriction</e2>
D020888_D014786 CID <e1>vigabatrin</e1> associated thought <e2>constriction</e2>
D020888_D014786 CID <e1>vigabatrin-attributed</e1> <e2>loss</e2>
D020888_D014786 CID <e1>vigabatrin</e1> therapy associated appears <e2>constriction</e2>
1423339
D011433_D000647 CID <e1>propranolol</e1> toxicity associated <e2>syndrome</e2>
D011433_D064420 NONE <e1>propranolol</e1> <e2>toxicity</e2>
D011433_D064420 NONE <e1>propranolol</e1> <e2>toxicity</e2>
D011433_D000544 NONE <e1>propranolol</e1> toxicity result developed dementia subacute <e2>alzheimer-like</e2>
D011433_D003704 NONE <e1>propranolol</e1> toxicity result developed <e2>dementia</e2>
7710775
D008315_D002545 CID <e1>malondialdehyde</e1> dependence nucleosides <e2>ischemia</e2>
-1_D002545 NONE <e1>oxypurines</e1> malondialdehyde dependence nucleosides <e2>ischemia</e2>
D009705_D002545 NONE <e1>nucleosides</e1> <e2>ischemia</e2>
-1_D007511 NONE <e1>oxypurines</e1> increase <e2>ischemia</e2>
-1_D007511 NONE <e1>oxypurines</e1> malondialdehyde determination used monitor alterations occurring phenomena <e2>ischemic</e2>
D009705_D007511 NONE <e1>nucleosides</e1> increase <e2>ischemia</e2>
D009705_D007511 NONE <e1>nucleosides</e1> malondialdehyde determination used monitor alterations occurring phenomena <e2>ischemic</e2>
D008315_D007511 NONE <e1>malondialdehyde</e1> increased min <e2>ischemia</e2>
D008315_D007511 NONE <e1>malondialdehyde</e1> recorded <e2>ischemia</e2>
D008315_D007511 NONE <e1>malondialdehyde</e1> recorded <e2>ischemia</e2>
D008315_D007511 NONE <e1>malondialdehyde</e1> higher recorded <e2>ischemia</e2>
D008315_D007511 NONE <e1>malondialdehyde</e1> higher recorded <e2>ischemia</e2>
D008315_D007511 NONE <e1>malondialdehyde</e1> determination used monitor alterations occurring phenomena <e2>ischemic</e2>
D008315_D007022 NONE <e1>malondialdehyde</e1> recorded nitroprusside <e2>hypotensive</e2>
D008315_D007022 NONE <e1>malondialdehyde</e1> higher recorded nitroprusside <e2>hypotensive</e2>
D001241_D007511 NONE <e1>acetylsalicylate</e1> recorded <e2>ischemia</e2>
D001241_D007511 NONE <e1>acetylsalicylate</e1> recorded <e2>ischemia</e2>
D001241_D007022 NONE <e1>acetylsalicylate</e1> recorded nitroprusside <e2>hypotensive</e2>
D009599_D007511 NONE <e1>nitroprusside</e1> recorded <e2>ischemia</e2>
D009599_D007511 NONE <e1>nitroprusside</e1> recorded <e2>ischemia</e2>
D009599_D007022 NONE <e1>nitroprusside</e1> <e2>hypotensive</e2>
8888541
C047426_D020230 CID <e1>venlafaxine-tranylcypromine</e1> interaction <e2>syndrome</e2>
C047426_D020230 CID <e1>venlafaxine-maoi</e1> interaction resulted <e2>syndrome</e2>
D014191_D020230 CID <e1>venlafaxine-tranylcypromine</e1> interaction <e2>syndrome</e2>
D014191_D020230 CID <e1>tranylcypromine</e1> taking male resulted <e2>syndrome</e2>
D012701_D009127 NONE <e1>serotonin</e1> receptors stimulation causes syndrome excess consists shivering <e2>rigidity</e2>
D012701_D009127 NONE <e1>serotonin</e1> excess consists shivering <e2>rigidity</e2>
D012701_D012798 NONE <e1>serotonin</e1> receptors stimulation causes syndrome excess consists shivering <e2>salivation</e2>
D012701_D012798 NONE <e1>serotonin</e1> excess consists shivering <e2>salivation</e2>
D012701_D003221 NONE <e1>serotonin</e1> receptors stimulation causes syndrome excess consists shivering salivation <e2>confusion</e2>
D012701_D003221 NONE <e1>serotonin</e1> excess consists shivering salivation <e2>confusion</e2>
D012701_D011595 NONE <e1>serotonin</e1> receptors stimulation causes syndrome excess consists shivering salivation <e2>agitation</e2>
D012701_D011595 NONE <e1>serotonin</e1> excess consists shivering salivation <e2>agitation</e2>
D012701_D005334 NONE <e1>serotonin</e1> receptors stimulation causes syndrome excess consists shivering salivation agitation <e2>hyperthermia</e2>
D012701_D005334 NONE <e1>serotonin</e1> excess consists shivering salivation agitation <e2>hyperthermia</e2>
C047426_D003866 NONE <e1>venlafaxine-maoi</e1> interaction resulted male taking <e2>depression</e2>
D014191_D003866 NONE <e1>tranylcypromine</e1> taking <e2>depression</e2>
D003975_D009127 NONE <e1>diazepam</e1> mg temperature rate remained tremulous <e2>rigidity</e2>
7282516
D004317_D009202 CID <e1>doxorubicin</e1> relationships <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>doxorubicin</e1> produced <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>doxorubicin</e1> produced cardiomyopathy <e2>cm</e2>
D004317_D009202 CID <e1>doxorubicin</e1> produced cardiomyopathy provides opportunity analyze relationships development <e2>disease</e2>
D004317_D009202 CID <e1>dxr</e1> doxorubicin produced <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>dxr</e1> doxorubicin produced cardiomyopathy <e2>cm</e2>
D004317_D009202 CID <e1>dxr</e1> doxorubicin produced cardiomyopathy provides opportunity analyze relationships development <e2>disease</e2>
D004317_D009202 CID <e1>adriamycin</e1> <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>adriamycin</e1> cardiomyopathy <e2>cm</e2>
D004317_D009202 CID <e1>adriamycin</e1> cardiomyopathy provides opportunity analyze relationships development <e2>disease</e2>
D004317_D009202 CID <e2><e1>dxr-cm</e1></e2>
D004317_D009202 CID <e1>dxr-cm</e1> <e2>damage</e2>
D004317_D009202 CID <e1>dxr</e1> dose insult degree proportional damage <e2>dxr-cm</e2>
D004317_D009202 CID <e1>dxr</e1> dose insult degree proportional <e2>damage</e2>
11838826
D018967_D006966 CID <e1>risperidone-induced</e1> <e2>hyperprolactinemia</e2>
D018967_D006966 CID <e1>risperidone</e1> associated <e2>hyperprolactinemia</e2>
D018967_D006966 CID <e1>risperidone-induced</e1> <e2>hyperprolactinemia</e2>
D018967_D006966 CID <e1>risperidone-induced</e1> <e2>hyperprolactinemia</e2>
D018967_D006966 CID <e1>risperidone-induced</e1> <e2>hyperprolactinemia</e2>
D004298_D006966 NONE <e1>dopamine</e1> agonist treatment <e2>hyperprolactinemia</e2>
C047047_D006966 NONE <e1>cabergoline</e1> treatment <e2>hyperprolactinemia</e2>
C047047_D006966 NONE <e1>cabergoline</e1> treated <e2>hyperprolactinemia</e2>
C047047_D006966 NONE <e1>cabergoline</e1> useful treatment <e2>hyperprolactinemia</e2>
D018967_D001523 NONE <e1>risperidone-induced</e1> elevations males diagnostic <e2>disorders</e2>
D018967_D001714 NONE <e1>risperidone-induced</e1> elevations males <e2>disorder</e2>
D018967_D011605 NONE <e1>risperidone-induced</e1> elevations males disorder <e2>psychoses</e2>
C047047_D001523 NONE <e1>cabergoline</e1> treated males diagnostic <e2>disorders</e2>
C047047_D001714 NONE <e1>cabergoline</e1> treated males <e2>disorder</e2>
C047047_D011605 NONE <e1>cabergoline</e1> treated males disorder <e2>psychoses</e2>
16192988
D008694_D001523 CID <e1>methamphetamine</e1> causes alterations pathways brains mice display <e2>aggressiveness</e2>
D008694_D001523 CID <e1>methamphetamine</e1> abusers common reported <e2>behaviors</e2>
D008694_D001523 CID <e1>methamphetamine</e1> abusers common reported patients suffer <e2>disorders</e2>
D008694_D001523 CID <e1>meth</e1> methamphetamine abusers common reported <e2>behaviors</e2>
D008694_D001523 CID <e1>meth</e1> methamphetamine abusers common reported patients suffer <e2>disorders</e2>
D008694_D001523 CID <e1>meth</e1> injections increased <e2>aggressiveness</e2>
D008694_D001523 CID <e1>meth-induced</e1> hyperactivity secondary increase <e2>aggressiveness</e2>
D008694_D006948 NONE <e1>meth-induced</e1> <e2>hyperactivity</e2>
1732442
D004317_D009202 CID <e1>adriamycin-induced</e1> <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>adriamycin-induced</e1> <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>adriamycin-induced</e1> cardiomyopathy model using tested hypothesis appear exacerbated adriamycin <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>adriamycin</e1> exacerbated appear hypothesis tested using model <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>adriamycin</e1> <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>adriamycin-induced</e1> cardiomyopathy detection method indicates appearance presence <e2>impairment</e2>
D004317_D009202 CID <e1>adriamycin-induced</e1> <e2>cardiomyopathy</e2>
D019797_D009202 NONE <e1>iodine-125-metaiodobenzylguanidine</e1> detection activity <e2>cardiomyopathy</e2>
D019797_D009202 NONE <e1>mibg</e1> scintigraphy method indicates appearance presence <e2>impairment</e2>
D019797_D009202 NONE <e1>mibg</e1> scintigraphy method detection <e2>cardiomyopathy</e2>
D004317_C536522 NONE <e1>adriamycin</e1> treatment duration relation analyzed degree degeneration <e2>cells</e2>
D004317_C536522 NONE <e1>adriamycin-induced</e1> cardiomyopathy detection method indicates appearance presence impairment scattered <e2>degeneration</e2>
D019797_C536522 NONE <e1>mibg</e1> scintigraphy method indicates appearance presence impairment scattered <e2>degeneration</e2>
11890511
33969
C084820_D010302 NONE <e1>ethopropazine</e1> <e2>parkinsonism</e2>
C084820_D010302 NONE <e1>ethopropazine</e1> compared benztropine treatment <e2>parkinsonism</e2>
C084820_D010302 NONE <e1>ethopropazine</e1> found effective controlling <e2>symptoms</e2>
D001590_D010302 NONE <e1>benztropine</e1> ethopropazine <e2>parkinsonism</e2>
D001590_D010302 NONE <e1>benztropine</e1> treatment <e2>parkinsonism</e2>
D001590_D010302 NONE <e1>benztropine</e1> ethopropazine found effective controlling <e2>symptoms</e2>
D001590_D010302 NONE <e1>benztropine</e1> drug treatment <e2>symptoms</e2>
C084820_D012559 NONE <e1>ethopropazine</e1> compared benztropine treatment parkinsonism induced outpatients <e2>schizophrenic</e2>
D001590_D012559 NONE <e1>benztropine</e1> treatment parkinsonism induced outpatients <e2>schizophrenic</e2>
C017610_D010302 CID <e1>enanthate</e1> induced <e2>parkinsonism</e2>
C017610_D012559 NONE <e1>enanthate</e1> induced outpatients <e2>schizophrenic</e2>
D011352_D010302 NONE <e1>procyclidine</e1> efficacious effective controlling <e2>symptoms</e2>
D001590_D004409 CID <e1>benztropine</e1> treated patients had increase <e2>dyskinesia</e2>
D001590_D001008 CID <e1>benztropine</e1> treated patients had <e2>anxiety</e2>
D001590_D003866 CID <e1>benztropine</e1> treated patients had anxiety <e2>depression</e2>
D011352_D004409 NONE <e1>procyclindine</e1> treatment condition had increase <e2>dyskinesia</e2>
D011352_D001008 NONE <e1>procyclindine</e1> treatment condition had <e2>anxiety</e2>
D011352_D003866 NONE <e1>procyclindine</e1> treatment condition had anxiety <e2>depression</e2>
C084820_D004409 NONE <e1>ethopropazine</e1> treated patients anxiety had increase <e2>dyskinesia</e2>
C084820_D001008 NONE <e1>ethopropazine</e1> treated patients <e2>anxiety</e2>
C084820_D003866 NONE <e1>ethopropazine</e1> treated patients anxiety <e2>depression</e2>
591536
D006493_D013923 NONE <e1>heparin</e1> therapy receiving patients <e2>thromboembolism</e2>
D006493_D013923 NONE <e1>heparin-induced</e1> thrombocytopenia associated complication <e2>thromboembolism</e2>
D006493_D013923 NONE <e1>heparin</e1> therapy complication <e2>thromboembolism</e2>
D006493_D013923 NONE <e1>heparin-induced</e1> aggregation factor <e2>thromboembolism</e2>
D006493_D013921 CID <e1>heparin</e1> therapy receiving patients thromboembolism complication associated <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin</e1> therapy initiation occurring occlusion preceded <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-induced</e1> aggregation factor thromboembolism <e2>thrombocytopenia</e2>
D006493_D001157 CID <e1>heparin</e1> therapy initiation occurring <e2>occlusion</e2>
D006493_D013927 NONE <e1>heparin</e1> therapy initiation occurring occlusion <e2>thrombi</e2>
D006493_D007511 NONE <e1>heparin</e1> therapy initiation occurring occlusion thrombi <e2>ischemia</e2>
D006493_D001791 NONE <e1>heparin-induced</e1> <e2>aggregation</e2>
133615
D003276_D013923 NONE <e1>contraceptive</e1> therapy complications <e2>thromboembolic</e2>
D003276_D001778 CID <e1>contraceptive</e1> therapy complications thromboembolic relationship levels factors <e2>coagulation</e2>
19944333
C471405_D009203 NONE <e1>sorafenib-induced</e1> <e2>infarction</e2>
C471405_D003329 CID <e1>sorafenib-induced</e1> infarction <e2>spasm</e2>
C471405_D003329 CID <e1>sorafenib-induced</e1> <e2>spasm</e2>
D020108_D060050 NONE <e1>nicorandil</e1> addition reduced maintained status <e2>angina</e2>
16174948
D003042_D013345 CID <e1>cocaine-associated</e1> <e2>hemorrhage</e2>
D003042_D013345 CID <e1>cocaine-associated</e1> <e2>hemorrhage</e2>
D003042_D013345 CID <e1>cocaine-associated</e1> hemorrhage <e2>sah</e2>
D003042_D013345 CID <e1>cocaine</e1> use underwent patients <e2>hemorrhage</e2>
D003042_D013345 CID <e1>cocaine</e1> use underwent patients hemorrhage <e2>sah</e2>
D003042_D013345 CID <e1>cocaine</e1> toxicology those identified screened patients <e2>sah</e2>
D003042_D013345 CID <e1>cocaine</e1> use associated <e2>sah</e2>
D003042_D013901 NONE <e1>cocaine</e1> use associated <e2>complications</e2>
D003042_D014657 NONE <e1>cocaine</e1> use associated complications vasoconstriction <e2>vasculitis</e2>
D003042_D014657 NONE <e1>cocaine</e1> use associated sah underwent patients found evidence narrowing arteries evidence narrowing <e2>vasculitis</e2>
D003042_D017542 CID <e1>cocaine</e1> use associated sah <e2>aneurysmal</e2>
8267029
D010396_D005921 CID <e1>penicillamine-induced</e1> <e2>glomerulonephritis</e2>
D010396_D005921 CID <e1>d-penicillamine</e1> months presented <e2>glomerulonephritis</e2>
D010396_D005921 CID <e1>d-penicillamine</e1> months presented glomerulonephritis <e2>rpgn</e2>
D010396_D005921 CID <e1>d-penicillamine</e1> treatment course case <e2>rpgn</e2>
D010396_D001172 NONE <e1>penicillamine-induced</e1> glomerulonephritis patient <e2>arthritis</e2>
D010396_D001172 NONE <e1>d-penicillamine</e1> months presented woman <e2>arthritis</e2>
D010396_D011507 NONE <e1>d-penicillamine</e1> treatment course case emphasizes need monitoring function evaluation sediment <e2>proteinuria</e2>
2435991
C032151_D001145 NONE <e1>cibenzoline</e1> concentrations <e2>arrhythmias</e2>
C032151_D001145 NONE <e1>cibenzoline</e1> effects ligation- <e2>arrhythmias</e2>
C032151_D001145 NONE <e1>cibenzoline</e1> effects ligation- using examined concentration model <e2>arrhythmia</e2>
C032151_D001145 NONE <e1>cibenzoline</e1> suppressed <e2>arrhythmias</e2>
C032151_D001145 NONE <e1>cibenzoline</e1> suppressed 1.9 concentrations <e2>arrhythmias</e2>
C032151_D001145 NONE <e1>cibenzoline</e1> had found active given dogs <e2>arrhythmia</e2>
D004071_D001145 CID <e1>digitalis-</e1> ligation- <e2>arrhythmias</e2>
D004071_D001145 CID <e1>digitalis-</e1> ligation- using examined concentration model <e2>arrhythmia</e2>
D004071_D001145 CID <e1>digitalis</e1> ligation concentrations 1.9 suppressed <e2>arrhythmias</e2>
D004071_D001145 CID <e1>digitalis</e1> ligation concentrations <e2>arrhythmias</e2>
D004837_D001145 CID <e1>adrenaline-induced</e1> ventricular ligation- <e2>arrhythmias</e2>
D004837_D001145 CID <e1>adrenaline-induced</e1> ventricular ligation- using examined concentration model <e2>arrhythmia</e2>
D004837_D001145 CID <e1>adrenaline</e1> concentrations 1.9 suppressed <e2>arrhythmias</e2>
D004837_D001145 CID <e1>adrenaline</e1> concentrations <e2>arrhythmias</e2>
D004837_D001145 CID <e1>adrenaline-induced</e1> <e2>arrhythmia</e2>
D004837_D001145 CID <e1>adrenaline-induced</e1> arrhythmia concentration higher those types <e2>arrhythmias</e2>
C032151_D007022 NONE <e1>cibenzoline</e1> had <e2>hypotensive</e2>
C032151_D003866 NONE <e1>cibenzoline</e1> had effects <e2>depressive</e2>
7102237
D012601_D001049 NONE <e1>scopolamine</e1> premedicated patients slower found occurred <e2>apnoea</e2>
D009020_D001049 NONE <e1>morphine</e1> scopolamine premedicated patients slower found occurred <e2>apnoea</e2>
D009567_D001049 NONE <e1>nitrazepam</e1> mg patients slower found occurred <e2>apnoea</e2>
D008874_D001049 CID <e1>midazolam</e1> mg/kg effect slower found occurred <e2>apnoea</e2>
D008874_D001049 CID <e1>midazolam</e1> group found occurred <e2>apnoea</e2>
D008874_D001049 CID <e1>midazolam</e1> group occurred <e2>apnoea</e2>
D013874_D001049 CID <e1>thiopentone</e1> mg/kg that slower found occurred <e2>apnoea</e2>
2051906
D001379_D002779 CID <e1>azathioprine</e1> therapy injury <e2>cholestasis</e2>
D001379_D002779 CID <e1>azathioprine</e1> therapy <e2>injury</e2>
D001379_D002779 CID <e1>azathioprine</e1> therapy initiation months developed clinical features <e2>cholestasis</e2>
D001379_D002779 CID <e1>azathioprine-induced</e1> reversible <e2>cholestasis</e2>
D001379_D002779 CID <e1>azathioprine-induced</e1> reversible cholestasis associated evidence <e2>injury</e2>
D001379_D017285 NONE <e1>azathioprine</e1> therapy initiation months developed patient <e2>polymyositis</e2>
D001379_D008107 NONE <e1>azathioprine</e1> therapy initiation months developed patient polymyositis evidence <e2>disease</e2>
803783
D010121_D014869 CID <e1>oxytocin</e1> administration associated <e2>intoxication</e2>
D010121_D014869 CID <e1>oxytocin</e1> administration connection <e2>intoxication</e2>
D010121_D014869 CID <e1>oxytocin</e1> administration advocated carried aware symptoms <e2>intoxication</e2>
D010121_D000031 NONE <e1>oxytocin</e1> administration associated <e2>abortion</e2>
D010121_D000031 NONE <e1>oxytocin</e1> administration connection intoxication cases <e2>abortions</e2>
D010121_D000031 NONE <e1>oxytocin</e1> administration <e2>abortions</e2>
D010121_D001247 NONE <e1>oxytocin</e1> administration advocated carried instructed watch report <e2>asthenia</e2>
D010121_D001523 NONE <e1>oxytocin</e1> administration advocated carried instructed watch report <e2>irritability</e2>
D010121_D006261 NONE <e1>oxytocin</e1> administration advocated carried instructed watch report irritability <e2>headaches</e2>
3001299
D008094_D018500 NONE <e1>lithium</e1> treatment important development <e2>insipidus</e2>
D008094_D007037 CID <e1>lithium</e1> treatment important development insipidus <e2>hypothyroidism</e2>
D008094_D007037 CID <e1>lithium</e1> taking developed <e2>hypothyroidism</e2>
1711760
D007530_D006973 NONE <e1>isoflurane</e1> anesthesia occluded mca rats <e2>hypertensive</e2>
C009591_D009410 NONE <e1>2,3,5-triphenyltetrazolium</e1> staining determined extent <e2>injury</e2>
D010656_D006973 CID <e1>phenylephrine-induced</e1> <e2>hypertension</e2>
D010656_D020244 NONE <e1>phenylephrine-induced</e1> hypertension instituted edema <e2>mcao</e2>
D010656_D004487 NONE <e1>phenylephrine-induced</e1> hypertension instituted <e2>edema</e2>
D010656_D004487 NONE <e1>phenylephrine-induced</e1> hypertension instituted improves <e2>edema</e2>
D010656_D007511 NONE <e1>phenylephrine-induced</e1> hypertension instituted edema core <e2>ischemic</e2>
D010656_D007511 NONE <e1>phenylephrine-induced</e1> hypertension instituted improves edema periphery territory <e2>ischemic</e2>
D010656_D009410 NONE <e1>phenylephrine-induced</e1> hypertension instituted reduces area <e2>dysfunction</e2>
20735774
D000082_D017114 CID <e1>paracetamol-induced</e1> <e2>failure</e2>
D000082_D017114 CID <e1>paracetamol-induced</e1> <e2>failure</e2>
D000082_D017114 CID <e1>paracetamol-induced</e1> <e2>failure</e2>
D000082_D017114 CID <e1>paracetamol-induced</e1> injury caused <e2>failure</e2>
D000082_D017114 CID <e1>paracetamol-induced</e1> injury caused patients higher age-dependent died survivors <e2>failure</e2>
D000082_D017114 CID <e1>paracetamol-induced</e1> <e2>failure</e2>
D000082_D056486 NONE <e1>paracetamol-induced</e1> <e2>injury</e2>
D000082_D056486 NONE <e1>paracetamol-induced</e1> <e2>injury</e2>
D000082_D008107 NONE <e1>paracetamol-induced</e1> injury caused patients higher age-dependent died <e2>disease</e2>
20705401
D012701_D011605 NONE <e1>serotonin</e1> gene associated <e2>psychosis</e2>
D012701_D011605 NONE <e1>5-ht6</e1> receptors involved pathophysiology <e2>disorders</e2>
D012701_D011605 NONE <e1>5-ht6</e1> gene association <e2>psychosis</e2>
D008694_D011605 CID <e1>methamphetamine-induced</e1> <e2>psychosis</e2>
D008694_D011605 CID <e1>methamphetamine</e1> (meth)-induced <e2>psychosis</e2>
D008694_D011605 CID <e1>(meth)-induced</e1> <e2>psychosis</e2>
D008694_D011605 CID <e1>meth-induced</e1> <e2>psychosis</e2>
D008694_D011605 CID <e1>meth-induced</e1> patients <e2>psychosis</e2>
D008694_D011605 CID <e1>meth-induced</e1> patients <e2>psychosis</e2>
D008694_D011605 CID <e1>meth-induced</e1> patients <e2>psychosis</e2>
D008694_D011605 CID <e1>meth-induced</e1> <e2>psychosis</e2>
D012701_D006948 NONE <e1>serotonin</e1> receptor targeted corrected <e2>hyperactivity</e2>
D012701_D006948 NONE <e1>5-ht6</e1> receptor targeted corrected <e2>hyperactivity</e2>
D012701_D006948 NONE <e1>5-ht6</e1> antagonist use corrected <e2>hyperactivity</e2>
D003024_D006948 NONE <e1>clozapine</e1> antipsychotics targeted corrected <e2>hyperactivity</e2>
C076029_D006948 NONE <e1>olanzapine</e1> clozapine antipsychotics targeted corrected <e2>hyperactivity</e2>
D003913_D006948 NONE <e1>d-amphetamine-induced</e1> <e2>hyperactivity</e2>
D012701_D012559 NONE <e1>5-ht6</e1> receptors involved suggests considered reflect symptoms <e2>schizophrenia</e2>
D008694_D012563 NONE <e1>methamphetamine</e1> (meth)-induced psychosis symptoms similar those <e2>schizophrenia</e2>
D008694_D012563 NONE <e1>(meth)-induced</e1> psychosis symptoms similar those <e2>schizophrenia</e2>
14704468
C066440_D012640 NONE <e1>loreclezole</e1> exerted reducing durations <e2>seizure</e2>
18006530
D015742_D010146 CID <e1>propofol</e1> induction reduction <e2>pain</e2>
D015742_D010146 CID <e1>propofol</e1> injection <e2>pain</e2>
D015742_D010146 CID <e1>propofol</e1> infusion <e2>pain</e2>
D015742_D010146 CID <e1>propofol</e1> infusion starting infusing prevented <e2>pain</e2>
D015742_D010146 CID <e1>propofol</e1> caused <e2>pain</e2>
D015742_D010146 CID <e1>propofol</e1> infusion using evaluated <e2>pain</e2>
D015742_D010146 CID <e1>propofol</e1> tci reduction <e2>pain</e2>
D015742_D010146 CID <e1>propofol</e1> <e2>pain</e2>
C071741_D010146 NONE <e1>remifentanil</e1> propofol induction reduction <e2>pain</e2>
C071741_D010146 NONE <e1>remifentanil</e1> infusing prevented <e2>pain</e2>
C071741_D010146 NONE <e1>remifentanil</e1> concentration determine prevent <e2>pain</e2>
C071741_D010146 NONE <e1>remifentanil-related</e1> complications assessed evaluated <e2>pain</e2>
C071741_D010146 NONE <e1>remifentanil</e1> infusion assessed evaluated <e2>pain</e2>
C071741_D010146 NONE <e1>remifentanil</e1> propofol tci reduction <e2>pain</e2>
C071741_D010146 NONE <e1>remifentanil</e1> administration complications achieved induction tci reduction <e2>pain</e2>
8045270
C081198_D002375 NONE <e1>kf17837</e1> administration ameliorated responses <e2>cataleptic</e2>
C081198_D002375 NONE <e1>kf17837</e1> reduced <e2>catalepsy</e2>
D000241_D002375 NONE <e1>adenosine</e1> agonist administration induced responses <e2>cataleptic</e2>
C061282_D002375 CID <e1>21680</e1> cgs responses <e2>cataleptic</e2>
D006220_D002375 CID <e1>haloperidol</e1> induced <e2>catalepsy</e2>
D012110_D002375 CID <e1>reserpine</e1> reduced <e2>catalepsy</e2>
C081198_D010302 NONE <e1>kf17837</e1> drug treatment <e2>parkinsonism</e2>
17344330
D008691_D013575 CID <e1>methadone</e1> treated patients prolongation <e2>syncope</e2>
D008691_D013575 CID <e1>methadone</e1> effect caused attribute episodes <e2>syncope</e2>
D008691_D013575 CID <e1>methadone</e1> dose reporting <e2>syncope</e2>
D008691_D013575 CID <e1>methadone</e1> dose associated odds <e2>syncope</e2>
D008691_D013575 CID <e1>methadone</e1> associated prolongation reporting <e2>syncope</e2>
D008691_D008133 CID <e1>methadone</e1> treated patients <e2>prolongation</e2>
D008691_D008133 CID <e1>methadone</e1> treated subjects had <e2>interval</e2>
D008691_D008133 CID <e1>methadone</e1> associated <e2>prolongation</e2>
D003932_D013575 NONE <e1>heroin</e1> dependence methadone treated patients prolongation <e2>syncope</e2>
D003932_D013575 NONE <e1>heroin</e1> addicts faint attribute episodes <e2>syncope</e2>
D003932_D013575 NONE <e1>heroin</e1> addicts population prolongation reporting <e2>syncope</e2>
D003932_D008133 NONE <e1>heroin</e1> dependence methadone treated patients <e2>prolongation</e2>
D003932_D008133 NONE <e1>heroin</e1> addicts population <e2>prolongation</e2>
D008691_D016171 NONE <e1>methadone</e1> users reported prolongation interval ecg patients torsade <e2>pointes</e2>
D008691_D016171 NONE <e1>methadone</e1> users reported prolongation interval ecg patients torsade <e2>tdp</e2>
D008691_D016171 NONE <e1>methadone</e1> effect caused attribute illicit underestimate incidence <e2>tdp</e2>
D003932_D016171 NONE <e1>heroin</e1> addicts faint attribute illicit underestimate incidence <e2>tdp</e2>
9799166
D003042_D020521 CID <e1>cocaine</e1> <e2>stroke</e2>
D003042_D020521 CID <e1>cocaine</e1> use association <e2>stroke</e2>
D003042_D020521 CID <e1>cocaine</e1> <e2>stroke</e2>
D003042_D020521 CID <e1>cocaine</e1> using admitted women <e2>stroke</e2>
D003042_D020521 CID <e1>cocaine</e1> use factor <e2>stroke</e2>
D000661_D020521 CID <e1>amphetamine</e1> <e2>stroke</e2>
D000661_D020521 CID <e1>amphetamine</e1> cocaine use association <e2>stroke</e2>
D000661_D020521 CID <e1>amphetamine</e1> cocaine <e2>stroke</e2>
D000661_D020521 CID <e1>amphetamine</e1> cocaine using admitted women <e2>stroke</e2>
D000661_D020521 CID <e1>amphetamine</e1> cocaine use factor <e2>stroke</e2>
D003042_D007511 NONE <e1>cocaine</e1> use association stroke hemorrhagic <e2>ischemic</e2>
D000661_D007511 NONE <e1>amphetamine</e1> cocaine use association stroke hemorrhagic <e2>ischemic</e2>
11226639
D008550_D053608 CID <e1>melatonin</e1> effects <e2>narcosis</e2>
D008550_D053608 CID <e1>melatonin</e1> affects clear influence <e2>narcosis</e2>
D008550_D053608 CID <e1>melatonin</e1> pre-treatment affected <e2>narcosis</e2>
D008550_D053608 CID <e1>melatonin</e1> dose caused produced reduction duration <e2>narcosis</e2>
D008550_D053608 CID <e1>melatonin</e1> influenced duration latency ketamine- <e2>narcosis</e2>
D008550_D053608 CID <e1>melatonin</e1> action <e2>narcosis</e2>
C032232_D053608 NONE <e1>barbiturate-induced</e1> <e2>narcosis</e2>
C032232_D053608 NONE <e1>barbiturate</e1> <e2>narcosis</e2>
C032232_D053608 NONE <e1>barbiturate</e1> <e2>narcosis</e2>
C032232_D053608 NONE <e1>barbiturate</e1> mechanism specific seems action <e2>narcosis</e2>
D007649_D053608 CID <e1>ketamine-</e1> <e2>narcosis</e2>
D003975_D053608 CID <e1>diazepam-induced</e1> ketamine- <e2>narcosis</e2>
2894433
D003975_D001919 CID <e1>diazepam</e1> facilitates <e2>bradycardia</e2>
D003975_D001919 CID <e1>diazepam</e1> rats pretreatment enhance <e2>bradycardia</e2>
D003975_D001919 CID <e1>diazepam</e1> enhancement <e2>bradycardia</e2>
D003975_D001919 CID <e1>diazepam</e1> acts facilitate <e2>bradycardia</e2>
D004837_D001919 CID <e1>adrenaline</e1> infusion rats produced <e2>bradycardia</e2>
D004837_D001919 CID <e1>adrenaline-induced</e1> effect change causing pretreatment enhance <e2>bradycardia</e2>
D004837_D001919 CID <e1>adrenaline-induced</e1> <e2>bradycardia</e2>
D004837_D001919 CID <e1>adrenaline-induced</e1> <e2>bradycardia</e2>
D010852_D001919 NONE <e1>picrotoxin</e1> dose rats pretreatment antagonized enhancement <e2>bradycardia</e2>
D002712_D001919 NONE <e1>chloride</e1> channels blocks antagonized enhancement <e2>bradycardia</e2>
D002712_D001919 NONE <e1>benzodiazepine-gaba-chloride</e1> channel complex associated sites binding blocks antagonized enhancement <e2>bradycardia</e2>
D002712_D001919 NONE <e1>benzodiazepine-gaba-chloride</e1> channel complex acts facilitate <e2>bradycardia</e2>
D001569_D001919 NONE <e1>benzodiazepine-gaba-chloride</e1> channel complex associated sites binding blocks antagonized enhancement <e2>bradycardia</e2>
D001569_D001919 NONE <e1>benzodiazepine-gaba-chloride</e1> channel complex acts facilitate <e2>bradycardia</e2>
D005680_D001919 NONE <e1>benzodiazepine-gaba-chloride</e1> channel complex associated sites binding blocks antagonized enhancement <e2>bradycardia</e2>
D005680_D001919 NONE <e1>benzodiazepine-gaba-chloride</e1> channel complex acts facilitate <e2>bradycardia</e2>
7905523
C059896_D015658 NONE <e1>n-butyl-deoxynojirimycin</e1> safety patients <e2>infection</e2>
C059896_D015658 NONE <e1>sc-48334</e1> n-butyl-deoxynojirimycin safety patients <e2>infection</e2>
D015215_D015658 NONE <e1>zidovudine</e1> n-butyl-deoxynojirimycin safety patients <e2>infection</e2>
C059896_D007153 NONE <e1>sc-48334</e1> level concentration virus <e2>immunodeficiency</e2>
19289093
D006493_D007022 NONE <e1>heparin</e1> products lots number found contaminated derivative elicit response <e2>hypotensive</e2>
D006493_D007022 NONE <e1>heparin</e1> products using showed produces <e2>hypotension</e2>
D002809_D007022 CID <e1>sulfate</e1> derivative elicit response <e2>hypotensive</e2>
12231232
D006220_D010300 NONE <e1>haloperidol</e1> rigidity <e2>parkinsonian-like</e2>
D006220_D009127 CID <e1>haloperidol</e1> <e2>rigidity</e2>
D006220_D009127 CID <e1>haloperidol-induced</e1> <e2>rigidity</e2>
C095756_D009127 NONE <e1>aida</e1> diminished <e2>rigidity</e2>
871943
D013390_D001049 CID <e1>succinylcholine</e1> <e2>apnoea</e2>
D013390_D001049 CID <e1>succinylcholine</e1> demonstrating <e2>apnoea</e2>
D013390_D001049 CID <e1>succinylcholine</e1> <e2>apnoea</e2>
19692487
D008094_D011141 NONE <e1>lithium-induced</e1> <e2>polyuria</e2>
D008094_D011141 NONE <e1>lithium-induced</e1> <e2>polyuria</e2>
D008094_D011141 NONE <e1>lithium-induced</e1> <e2>polyuria</e2>
D008094_D011141 NONE <e1>lithium-induced</e1> <e2>polyuria</e2>
D008094_D011141 NONE <e1>lithium-induced</e1> <e2>polyuria</e2>
D011458_D011141 NONE <e1>e</e1> synthase-1 deficient mice <e2>polyuria</e2>
D018021_D011141 CID <e1>licl</e1> administration led <e2>polyuria</e2>
D015232_D011141 NONE <e1>)</e1> pge(2 blockade accompanied resistant <e2>polyuria</e2>
D015232_D011141 NONE <e1>)</e1> pge(2 conclude mediates <e2>polyuria</e2>
2907585
-1_D002375 NONE <e1>aryl-piperazine</e1> drugs reversal <e2>catalepsy</e2>
-1_D002375 NONE <e1>aryl-piperazine</e1> analogues series tested ability reverse <e2>catalepsy</e2>
D002065_D002375 NONE <e1>buspirone</e1> drug reverses <e2>catalepsy</e2>
D002065_D002375 NONE <e1>buspirone</e1> analogues series tested ability reverse <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol</e1> induced <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol</e1> <e2>catalepsy</e2>
D058825_D002375 NONE <e1>agonists</e1> analogues series tested ability reverse <e2>catalepsy</e2>
D012701_D002375 NONE <e1>5-hydroxytryptamine1a</e1> receptors affinity drugs able reverse <e2>catalepsy</e2>
D012701_D002375 NONE <e1>5-ht</e1> receptors inhibition inhibited reversal <e2>catalepsy</e2>
9098464
D005473_D062788 CID <e1>hydrochloride</e1> induced hyperprolactinemia effects model <e2>adenomyosis</e2>
D005473_D062788 CID <e1>hydrochloride</e1> induced hyperprolactinemia effects induction <e2>adenomyosis</e2>
D005473_D062788 CID <e1>fluoxetine</e1> caused hyperprolactinemia effects respect <e2>adenomyosis</e2>
D005473_D062788 CID <e1>fluoxetine</e1> receiving group revealed cases <e2>adenomyosis</e2>
D005473_D006966 CID <e1>hydrochloride</e1> induced <e2>hyperprolactinemia</e2>
D005473_D006966 CID <e1>fluoxetine</e1> caused <e2>hyperprolactinemia</e2>
D005473_D006966 CID <e1>fluoxetine</e1> given days produce <e2>hyperprolactinemia</e2>
D012701_D062788 NONE <e1>serotonin</e1> inhibitor hydrochloride induced hyperprolactinemia effects model <e2>adenomyosis</e2>
D012701_D062788 NONE <e1>serotonin</e1> inhibitor hydrochloride induced hyperprolactinemia effects induction <e2>adenomyosis</e2>
D012701_D006966 NONE <e1>serotonin</e1> inhibitor hydrochloride induced <e2>hyperprolactinemia</e2>
D012701_D006966 NONE <e1>serotonin</e1> inhibitor fluoxetine given days produce <e2>hyperprolactinemia</e2>
28952
D011188_D007008 NONE <e1>potassium</e1> loss <e2>hypokalaemia</e2>
D011188_D007008 NONE <e1>potassium</e1> loss development <e2>hypokalaemia</e2>
D011188_D007008 NONE <e1>potassium</e1> loss investigate performed patients hypertension shown <e2>hypokalaemia</e2>
D011188_D006973 NONE <e1>potassium</e1> loss administration patients <e2>hypertension</e2>
D011188_D006973 NONE <e1>potassium</e1> loss investigate performed patients <e2>hypertension</e2>
D002752_D007008 CID <e1>chlorthalidone</e1> administration loss <e2>hypokalaemia</e2>
D002752_D006973 NONE <e1>chlorthalidone</e1> administration patients <e2>hypertension</e2>
D012964_D007008 NONE <e1>sodium</e1> restriction influence loss <e2>hypokalaemia</e2>
D012964_D006973 NONE <e1>sodium</e1> restriction influence loss administration patients <e2>hypertension</e2>
12042105
C052342_D053040 CID <e1>topiramate-induced</e1> <e2>nephrolithiasis</e2>
C052342_D053040 CID <e1>topiramate-induced</e1> <e2>nephrolithiasis</e2>
C052342_D004827 NONE <e1>topiramate</e1> medication prescribed efficacy treating <e2>seizures</e2>
C020243_D053040 NONE <e1>phosphate</e1> <e2>nephrolithiasis</e2>
15858223
D014635_D056486 CID <e1>acid</e1> i course <e2>toxicity</e2>
D014635_D056486 CID <e1>acid</e1> levels <e2>toxicity</e2>
D014635_D056486 CID <e1>vpa-associated</e1> stress <e2>hepatotoxicity</e2>
D014635_D056486 CID <e1>vpa</e1> treated determine was relationship stress <e2>hepatotoxicity</e2>
D005978_D056486 NONE <e1>alpha-glutathione</e1> s-transferase levels evaluated <e2>toxicity</e2>
D014635_D009336 CID <e1>vpa</e1> treatment results measured levels precedes onset <e2>necrosis</e2>
D014635_D005234 CID <e1>vpa</e1> treatment results measured levels precedes onset necrosis <e2>steatosis</e2>
C075750_D009336 NONE <e1>15-f(2t)-isop</e1> levels precedes onset <e2>necrosis</e2>
C075750_D005234 NONE <e1>15-f(2t)-isop</e1> levels precedes onset necrosis <e2>steatosis</e2>
16820346
C065179_D006973 NONE <e1>atorvastatin</e1> prevented reversed <e2>hypertension</e2>
C065179_D006973 NONE <e1>atorvastatin</e1> effects assess <e2>hypertension</e2>
C065179_D006973 NONE <e1>atorva</e1> atorvastatin effects assess <e2>hypertension</e2>
C065179_D006973 NONE <e1>atorva</e1> treated assess <e2>hypertension</e2>
C065179_D006973 NONE <e1>atorva</e1> reversed <e2>hypertension</e2>
C065179_D006973 NONE <e1>atorva</e1> dex superoxide decreased reversed <e2>hypertension</e2>
C065179_D006973 NONE <e1>atorvastatin</e1> prevented reversed <e2>hypertension</e2>
D003907_D006973 CID <e1>dexamethasone-induced</e1> <e2>hypertension</e2>
D003907_D006973 CID <e1>dexamethasone</e1> effects assess <e2>hypertension</e2>
D003907_D006973 CID <e1>(dex)-induced</e1> <e2>hypertension</e2>
D003907_D006973 CID <e1>dex-induced</e1> <e2>hypertension</e2>
D003907_D006973 CID <e1>dex</e1> superoxide decreased reversed <e2>hypertension</e2>
D003907_D006973 CID <e1>dex</e1> atorva dex superoxide decreased reversed <e2>hypertension</e2>
D003907_D006973 CID <e1>dexamethasone-induced</e1> <e2>hypertension</e2>
D013481_D006973 NONE <e1>superoxide</e1> decreased reversed <e2>hypertension</e2>
18674790
D004041_D009765 CID <e1>fat</e1> rats <e2>obese</e2>
D004041_D009765 CID <e1>fat</e1> diet induces <e2>obesity</e2>
D004041_D066126 NONE <e1>fat</e1> rats sensitive <e2>cardiotoxicity</e2>
D004041_D066126 NONE <e1>fat</e1> diet feeding intervention sensitizes <e2>cardiotoxicity</e2>
D004317_D009765 NONE <e1>doxorubicin-induced</e1> cardiotoxicity sensitive rats <e2>obese</e2>
D004317_D009765 NONE <e1>doxorubicin-induced</e1> cardiotoxicity sensitizes intervention feeding diet induces <e2>obesity</e2>
D004317_D009765 NONE <e1>doxorubicin/kg</e1> dose led cardiotoxicity mortality rats <e2>obese</e2>
D004317_D009765 NONE <e1>doxorubicin/kg</e1> dose led cardiotoxicity mortality rats obese <e2>ob</e2>
D004317_D009765 NONE <e1>doxorubicin</e1> studies revealed diet-fed hearts <e2>ob</e2>
D004317_D009765 NONE <e1>doxorubicin</e1> accumulation change revealed diet-fed hearts <e2>ob</e2>
D004317_D009765 NONE <e1>doxorubicin</e1> administration ratio accompanied levels drop revealed sensitized rats <e2>ob</e2>
D004317_D009765 NONE <e1>doxorubicin</e1> administration ratio accompanied levels drop revealed oxidation <e2>ob</e2>
D004317_D009765 NONE <e1>doxorubicin-induced</e1> cardiotoxicity sensitized rats <e2>obese</e2>
D004317_D066126 NONE <e1>doxorubicin-induced</e1> <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>doxorubicin</e1> chemotherapy limited life threatening <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>adriamycin</e1> doxorubicin chemotherapy limited life threatening <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>doxorubicin-induced</e1> <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>doxorubicin-induced</e1> <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>doxorubicin/kg</e1> dose led <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>doxorubicin-induced</e1> <e2>cardiotoxicity</e2>
D004317_D006331 CID <e1>doxorubicin/kg</e1> dose led cardiotoxicity <e2>dysfunction</e2>
D004317_D007674 NONE <e1>doxorubicin/kg</e1> dose led absence <e2>toxicity</e2>
D004317_D056486 NONE <e1>doxorubicin/kg</e1> dose led absence <e2>toxicity</e2>
C010013_D009765 NONE <e1>doxorubicinol</e1> doxorubicin accumulation change revealed diet-fed hearts <e2>ob</e2>
D000249_D009765 NONE <e1>amp-alpha2</e1> kinase decreased revealed sensitized rats <e2>ob</e2>
D000249_D009765 NONE <e1>amp-alpha2</e1> kinase decreased revealed oxidation <e2>ob</e2>
D000255_D009765 NONE <e1>atp</e1> levels drop revealed sensitized rats <e2>ob</e2>
D000255_D009765 NONE <e1>atp</e1> levels drop revealed oxidation <e2>ob</e2>
D000255_D009765 NONE <e1>atp/adp</e1> ratio accompanied levels drop revealed sensitized rats <e2>ob</e2>
D000255_D009765 NONE <e1>atp/adp</e1> ratio accompanied levels drop revealed oxidation <e2>ob</e2>
D000255_D009765 NONE <e1>atp</e1> generation sensitized rats <e2>obese</e2>
D000244_D009765 NONE <e1>atp/adp</e1> ratio accompanied levels drop revealed sensitized rats <e2>ob</e2>
D000244_D009765 NONE <e1>atp/adp</e1> ratio accompanied levels drop revealed oxidation <e2>ob</e2>
D000255_D066126 NONE <e1>atp</e1> generation sensitized <e2>cardiotoxicity</e2>
8424298
D007741_D007022 CID <e1>labetalol</e1> induced <e2>hypotension</e2>
D007741_D007022 CID <e1>labetalol</e1> induced <e2>hypotension</e2>
D007741_D007022 CID <e1>labetalol</e1> isoflurane group <e2>hypotensive</e2>
D007741_D007022 CID <e1>labetalol</e1> induced <e2>hypotension</e2>
D007530_D007022 CID <e1>isoflurane</e1> labetalol induced <e2>hypotension</e2>
D007530_D007022 CID <e1>isoflurane</e1> labetalol induced <e2>hypotension</e2>
D007530_D007022 CID <e1>isoflurane</e1> group <e2>hypotensive</e2>
D007530_D007022 CID <e1>isoflurane</e1> labetalol induced <e2>hypotension</e2>
9758264
D005492_D008180 CID <e1>acid</e1> activity induces <e2>sle</e2>
D005492_D008180 CID <e1>acid</e1> <e2>sle</e2>
D005492_D008180 CID <e1>acid</e1> dose triggered conclusions damage disease <e2>lupus</e2>
D005492_D004827 NONE <e1>acid</e1> activity induces sle acid <e2>epilepsy</e2>
D005492_D004827 NONE <e1>acid</e1> <e2>epilepsy</e2>
D005492_D004827 NONE <e1>acid-containing</e1> multivitamin supplementation women <e2>epileptic</e2>
D005492_D004827 NONE <e1>acid-containing</e1> multivitamin supplementation effect study order determine rate defects effects <e2>epilepsy-related</e2>
D005492_D004827 NONE <e1>acid</e1> women <e2>epileptic</e2>
D005492_D004827 NONE <e1>acid</e1> women results developed effects <e2>epilepsy-related</e2>
D005492_D004827 NONE <e1>acid</e1> carbamazepine treated woman <e2>epileptic</e2>
D005492_D004827 NONE <e1>acid</e1> dose triggered conclusions damage disease patient <e2>epileptic</e2>
D005492_D004827 NONE <e1>acid</e1> dose healthy women <e2>epileptic</e2>
D005492_D004827 NONE <e1>acid</e1> dose increase risk <e2>seizures</e2>
D005492_D000014 NONE <e1>acid-containing</e1> multivitamin supplementation effect study order determine rate <e2>defects</e2>
D002220_D004827 NONE <e1>carbamazepine</e1> treated woman <e2>epileptic</e2>
D005492_D001327 NONE <e1>acid</e1> dose triggered conclusions damage <e2>disease</e2>
D005492_D001327 NONE <e1>acid</e1> dose <e2>disease</e2>
D005492_D012640 CID <e1>acid</e1> dose triggered cluster <e2>seizures</e2>
9875685
D014031_D064420 NONE <e1>tobramicyn</e1> concentrations <e2>toxicity</e2>
D003404_D007674 NONE <e1>creatinine</e1> observed evidence <e2>nephrotoxicity</e2>
20331935
D018967_D006966 CID <e1>risperidone-induced</e1> <e2>hyperprolactinemia</e2>
D018967_D006966 CID <e1>risperidone</e1> treated n present <e2>hyperprolactinemia</e2>
D018967_D006966 CID <e1>risperidone</e1> occurred occurred patients <e2>hyperprolactinemia</e2>
D018967_D006966 CID <e1>risperidone-induced</e1> <e2>hyperprolactinemia</e2>
D013739_D006966 NONE <e1>testosterone</e1> concentration increased affected <e2>hyperprolactinemia</e2>
D018967_D050723 NONE <e1>risperidone</e1> occurred <e2>fractures</e2>
16225977
C012052_D013981 CID <e1>amisulpride</e1> <e2>symptoms</e2>
C012052_D013981 CID <e1>amisulpride</e1> dose reduced resolved <e2>symptoms</e2>
C012052_D013981 CID <e1>amisulpride</e1> quetiapine antipsychotics treatment occur <e2>symptoms</e2>
C012052_D012559 NONE <e1>amisulpride</e1> symptoms <e2>schizophrenic</e2>
C012052_D012559 NONE <e1>amisulpride</e1> treatment months developed <e2>schizophrenic</e2>
D018967_D013981 NONE <e1>risperidone</e1> antipsychotics treated <e2>disorders</e2>
C076029_D013981 NONE <e1>olanzapine</e1> risperidone antipsychotics treated <e2>disorders</e2>
C092292_D013981 NONE <e1>ziprasidone</e1> olanzapine risperidone antipsychotics treated <e2>disorders</e2>
C069541_D013981 NONE <e1>quetiapine</e1> treatment occurring show <e2>symptoms</e2>
C069541_D013981 NONE <e1>quetiapine</e1> antipsychotics treatment occur <e2>symptoms</e2>
D003024_D013981 NONE <e1>clozapine</e1> quetiapine treatment occurring show <e2>symptoms</e2>
D003024_D013981 NONE <e1>clozapine</e1> quetiapine antipsychotics treatment occur <e2>symptoms</e2>
C012052_D020820 NONE <e1>amisulpride</e1> treatment months developed <e2>movements</e2>
6540303
D000588_D002389 NONE <e1>amine</e1> pretreatment <e2>catatonia</e2>
D007649_D002389 CID <e1>ketamine</e1> <e2>catatonia</e2>
D007649_D002389 CID <e1>ketamine-induced</e1> <e2>catatonia</e2>
D007649_D002389 CID <e1>ketamine</e1> duration <e2>catatonia</e2>
D007649_D002389 CID <e1>ketamine</e1> <e2>catatonia</e2>
D002395_D002389 NONE <e1>catecholamines</e1> role clarify pineal idolamines <e2>catatonia</e2>
D004298_D002389 CID <e1>dopamine</e1> pretreatment increased duration <e2>catatonia</e2>
D004298_D002389 CID <e1>dopamine</e1> appeared act systems involved induction <e2>catatonia</e2>
D009638_D002389 NONE <e1>norepinephrine</e1> pretreatment did increased duration <e2>catatonia</e2>
6292680
D004317_D009202 CID <e1>doxorubicin</e1> <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>doxorubicin</e1> dosage bed irradiation experienced <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>doxorubicin</e1> interaction portion include fact attributed <e2>cardiomyopathy</e2>
D004317_D009396 NONE <e1>doxorubicin</e1> cardiomyopathy children <e2>tumor</e2>
D004317_D009396 NONE <e1>doxorubicin</e1> dosage bed irradiation experienced children <e2>tumor</e2>
D004317_D009396 NONE <e1>doxorubicin</e1> interaction portion include fields <e2>tumor</e2>
D004317_D009396 NONE <e1>doxorubicin</e1> dosage restricted children <e2>tumor</e2>
D018943_D009396 NONE <e1>anthracycline</e1> experienced children <e2>tumor</e2>
D018943_D009202 NONE <e1>anthracycline</e1> experienced <e2>cardiomyopathy</e2>
D018943_D009369 NONE <e1>anthracycline</e1> experienced irradiation bed <e2>tumor</e2>
D004317_D009369 NONE <e1>doxorubicin</e1> dosage bed <e2>tumor</e2>
2826064
D010096_D007008 NONE <e1>oxprenolol</e1> abolishment <e2>hypokalemia</e2>
D010096_D007008 NONE <e1>oxprenolol</e1> efficacy investigated antagonizing <e2>hypokalemia</e2>
D010096_D007008 NONE <e1>oxprenolol</e1> pretreatment concentrations spite antagonized <e2>hypokalemia</e2>
D013726_D007008 CID <e1>terbutaline-induced</e1> <e2>hypokalemia</e2>
D013726_D007008 CID <e1>terbutaline</e1> concentrations spite antagonized <e2>hypokalemia</e2>
9915601
D007538_D001919 CID <e1>isoniazid</e1> pretreated rats antagonists induced <e2>bradycardia</e2>
D007538_D001919 CID <e1>isoniazid</e1> doses increase change <e2>bradycardia</e2>
D007538_D001919 CID <e1>isoniazid</e1> <e2>bradycardia</e2>
D007538_D001919 CID <e1>isoniazid</e1> increased <e2>bradycardia</e2>
D007538_D007022 CID <e1>isoniazid</e1> doses increase <e2>hypotension</e2>
D007538_D013610 NONE <e1>isoniazid</e1> doses increase change <e2>tachycardia</e2>
D005680_D007022 NONE <e1>acid</e1> synthesis attributed interaction increase <e2>hypotension</e2>
D005680_D007022 NONE <e1>gaba</e1> acid synthesis attributed interaction increase <e2>hypotension</e2>
D005680_D013610 NONE <e1>acid</e1> synthesis attributed interaction increase change <e2>tachycardia</e2>
D005680_D013610 NONE <e1>gaba</e1> acid synthesis attributed interaction increase change <e2>tachycardia</e2>
D005680_D001919 NONE <e1>acid</e1> synthesis attributed interaction increase change <e2>bradycardia</e2>
D005680_D001919 NONE <e1>gaba</e1> acid synthesis attributed interaction increase change <e2>bradycardia</e2>
D002698_D001919 NONE <e1>chloralose-urethane</e1> anaesthetised rats determined enhancement isoniazid <e2>bradycardia</e2>
D014520_D001919 NONE <e1>chloralose-urethane</e1> anaesthetised rats determined enhancement isoniazid <e2>bradycardia</e2>
D011433_D001919 NONE <e1>propranolol</e1> <e2>bradycardia</e2>
D010869_D001919 NONE <e1>pindolol</e1> propranolol <e2>bradycardia</e2>
D007741_D001919 NONE <e1>labetalol</e1> pindolol propranolol <e2>bradycardia</e2>
D001262_D001919 NONE <e1>atenolol</e1> labetalol pindolol propranolol <e2>bradycardia</e2>
D003000_D001919 NONE <e1>clonidine</e1> increased <e2>bradycardia</e2>
D018738_D001919 NONE <e1>hexamethonium</e1> increased <e2>bradycardia</e2>
D002217_D001919 NONE <e1>carbachol</e1> hexamethonium increased <e2>bradycardia</e2>
6496797
D014196_D006327 CID <e1>trazodone</e1> dose <e2>block</e2>
D014196_D006327 CID <e1>trazodone</e1> dose receiving minutes developed <e2>block</e2>
7604176
D017035_D009135 NONE <e1>pravastatin-associated</e1> <e2>myopathy</e2>
D017035_D009135 NONE <e1>pravastatin</e1> discontinuation resolved <e2>myopathy</e2>
D017035_D009135 NONE <e1>pravastatin-associated</e1> myopathy represent associated <e2>myopathy</e2>
D017035_D009135 NONE <e1>pravastatin-associated</e1> <e2>myopathy</e2>
D017035_D009220 CID <e1>pravastatin</e1> use associated <e2>myopathy</e2>
D017035_D006937 NONE <e1>pravastatin</e1> assumed <e2>hypercholesterolemia</e2>
D008148_D009135 NONE <e1>lovastatin</e1> associated <e2>myopathy</e2>
D008148_D009135 NONE <e1>lovastatin</e1> associated represent <e2>myopathy</e2>
D019821_D009135 NONE <e1>simvastatin</e1> lovastatin associated <e2>myopathy</e2>
D019821_D009135 NONE <e1>simvastatin</e1> lovastatin associated represent <e2>myopathy</e2>
20466178
D016559_D003872 NONE <e1>tacrolimus</e1> treatment associated <e2>dermatitis</e2>
D016559_D003872 NONE <e1>tacrolimus</e1> ointment % using developed eruptions <e2>dermatitis</e2>
D016559_D003872 NONE <e1>tacrolimus</e1> immunomodulators use regarded cause <e2>dermatitis</e2>
D016559_D012393 NONE <e1>tacrolimus</e1> ointment % using developed eruptions <e2>rosacea-like</e2>
D016559_D003875 NONE <e1>tacrolimus</e1> ointment % using developed <e2>eruptions</e2>
D016559_D005148 NONE <e1>tacrolimus</e1> ointment <e2>dermatitis</e2>
C117268_D003872 CID <e1>pimecrolimus</e1> tacrolimus immunomodulators use regarded cause <e2>dermatitis</e2>
663266
D003973_D014693 NONE <e1>diatrizoate</e1> <e2>fibrillation</e2>
C027278_D064420 NONE <e1>%</e1> compared <e2>toxicity</e2>
C027278_D064420 NONE <e1>%</e1> that compared <e2>toxicity</e2>
D003974_D014693 NONE <e1>renografin</e1> often occurred <e2>fibrillation</e2>
D003974_D064420 NONE <e1>renografin</e1> often occurred suggesting contribute <e2>toxicity</e2>
15638391
D006220_D006966 CID <e1>haloperidol</e1> induced <e2>hyperprolactinemia</e2>
D006220_D006966 CID <e1>haloperidol</e1> induced examine influence <e2>hyperprolactinemia</e2>
D006220_D006966 CID <e1>hal</e1> haloperidol induced examine influence <e2>hyperprolactinemia</e2>
15266362
D004280_D002312 NONE <e1>dobutamine</e1> infusion managed admitted patient known have <e2>cardiomyopathy</e2>
D004280_D018754 NONE <e1>dobutamine</e1> infusion managed admitted <e2>failure</e2>
D004280_D004342 CID <e1>dobutamine</e1> therapy related myocarditis <e2>hypersensitivity</e2>
D004280_D004802 CID <e1>dobutamine</e1> therapy related myocarditis <e2>eosinophilic</e2>
D004280_D009205 CID <e1>dobutamine</e1> therapy related <e2>myocarditis</e2>
2004015
D015215_C565469 NONE <e1>azidothymidine</e1> treated mice <e2>immunodeficient</e2>
D015215_D000740 CID <e1>3'-azido-3'dideoxythymidine</e1> induced <e2>anaemia</e2>
D015215_D000740 CID <e1>azt</e1> 3'-azido-3'dideoxythymidine induced <e2>anaemia</e2>
D015215_D000740 CID <e1>azt-induced</e1> <e2>anaemia</e2>
D015215_D000740 CID <e1>azt</e1> produced <e2>anaemia</e2>
D015215_D000740 CID <e1>azt</e1> mice number increased <e2>anaemia</e2>
D015215_D000740 CID <e1>azt</e1> mice observed levels appropriate degree <e2>anaemia</e2>
D015215_D000740 CID <e1>azt</e1> comparable degrees <e2>anaemia</e2>
D015215_D000740 CID <e1>azt</e1> mice observed <e2>anaemia</e2>
D015215_D000740 CID <e1>azt-induced</e1> <e2>anaemia</e2>
D015215_D000163 NONE <e1>azt-induced</e1> anaemia due determine used model <e2>aids</e2>
D015215_D007239 NONE <e1>azt-induced</e1> anaemia due determine used model <e2>infection</e2>
D015215_D007938 NONE <e1>azt-induced</e1> anaemia due determine used model infection virus <e2>leukaemia</e2>
C030299_D000740 NONE <e1>phenylhydrazine</e1> compared observed <e2>anaemia</e2>
C030299_D000740 NONE <e1>phz</e1> phenylhydrazine compared observed <e2>anaemia</e2>
C030299_D000740 NONE <e1>phz</e1> treated mice azt comparable degrees <e2>anaemia</e2>
D015215_D045262 NONE <e1>azt</e1> mice observed anaemia degree inappropriate <e2>reticulocytosis</e2>
188339
D003276_D008113 CID <e1>contraceptives</e1> associated <e2>tumors</e2>
D003276_D008113 CID <e1>contraceptive</e1> steroids using seen <e2>tumors</e2>
D003276_D008113 CID <e1>contraceptives</e1> associated <e2>tumors</e2>
D013256_D008113 NONE <e1>steroids</e1> using seen <e2>tumors</e2>
6293644
D006220_D002375 CID <e1>haloperidol-induced</e1> <e2>catalepsy</e2>
D006220_D006948 NONE <e1>haloperidol-induced</e1> catalepsy potentiation prevention <e2>hyperactivity</e2>
D001058_D002375 NONE <e1>apomorphine-induced</e1> hyperactivity prevention potentiation <e2>catalepsy</e2>
D001058_D006948 CID <e1>apomorphine-induced</e1> <e2>hyperactivity</e2>
11243580
D008012_D012640 CID <e1>lidocaine-induced</e1> <e2>convulsion</e2>
D008012_D012640 CID <e1>lidocaine-induced</e1> <e2>convulsions</e2>
D008012_D012640 CID <e1>lidocaine</e1> incidence <e2>convulsions</e2>
D008012_D012640 CID <e1>lidocaine</e1> mg/kg <e2>convulsions</e2>
D008012_D012640 CID <e1>lidocaine-induced</e1> <e2>convulsions</e2>
D019331_D012640 NONE <e1>ester</e1> effects investigated <e2>convulsions</e2>
D019331_D012640 NONE <e1>l-name</e1> ester effects investigated <e2>convulsions</e2>
D019331_D012640 NONE <e1>l-name</e1> decreased incidence <e2>convulsions</e2>
D009569_D012640 NONE <e1>oxide</e1> inhibitor effects investigated <e2>convulsions</e2>
D009569_D012640 NONE <e1>no</e1> inhibitor effects investigated <e2>convulsions</e2>
D009569_D012640 NONE <e1>no</e1> precursor inhibitor effects investigated <e2>convulsions</e2>
D009569_D012640 NONE <e1>no</e1> mediator <e2>convulsions</e2>
D001120_D012640 NONE <e1>l-arginine</e1> inhibitor effects investigated <e2>convulsions</e2>
D001120_D012640 NONE <e1>l-arginine</e1> treatment increased incidence lidocaine mg/kg <e2>convulsions</e2>
D003975_D012640 NONE <e1>diazepam</e1> l-name decreased incidence <e2>convulsions</e2>
326460
D001539_D007008 CID <e1>bendrofluazide-induced</e1> <e2>hypokalemia</e2>
D001539_D007008 CID <e1>bendrofluazide</e1> treatment <e2>hypokalemia</e2>
D013999_D007008 NONE <e1>timolol</e1> amelioration <e2>hypokalemia</e2>
D013999_D007008 NONE <e1>timolol</e1> drug tended correct <e2>hypokalemia</e2>
17923537
D005446_D014605 NONE <e1>acetonide</e1> implants treated <e2>uveitis</e2>
D005446_D014605 NONE <e1>acetonide</e1> treated <e2>uveitis</e2>
D005446_D014605 NONE <e1>fa</e1> acetonide treated <e2>uveitis</e2>
D005446_D009798 CID <e1>acetonide</e1> treated uveitis patients incidence <e2>pressure</e2>
D005446_D009798 CID <e1>fa</e1> acetonide treated uveitis patients incidence <e2>pressure</e2>
14736955
D004317_D009401 CID <e1>doxorubicin</e1> <e2>nephrosis</e2>
D004317_D007674 NONE <e1>doxorubicin</e1> induces <e2>nephropathy</e2>
D004317_D007674 NONE <e1>doxorubicin</e1> induces nephropathy characterized glomerular <e2>lesions</e2>
D004317_D007674 NONE <e1>doxorubicin-induced</e1> <e2>lesions</e2>
C102006_D007674 NONE <e1>citrate</e1> synthase activity dehydrogenase activities had glomerular <e2>lesions</e2>
D013481_D007674 NONE <e1>superoxide</e1> production correlated correlated <e2>injury</e2>
D013481_D007674 NONE <e1>superoxide</e1> induction reduction <e2>lesions</e2>
20727411
-1_D011605 NONE <e1>s-ketamine</e1> <e2>psychosis</e2>
D016202_D012559 NONE <e1>n-methyl-d-aspartate</e1> receptor implicated pathophysiology <e2>schizophrenia</e2>
D016202_D012559 NONE <e1>nmda</e1> receptor implicated pathophysiology <e2>schizophrenia</e2>
D016202_D012559 NONE <e1>nmda</e1> ketamine dose volunteers administered leads symptoms similar those observed <e2>schizophrenia</e2>
D016202_D012559 NONE <e1>nmda</e1> dysfunction pathophysiology <e2>schizophrenia</e2>
D007649_D012559 NONE <e1>ketamine</e1> dose volunteers administered leads symptoms similar those observed <e2>schizophrenia</e2>
D007649_D012559 NONE <e1>ketamine</e1> exacerbates patients <e2>schizophrenia</e2>
D007649_D012559 NONE <e1>ketamine</e1> induces changes subjects similar those observed patients <e2>schizophrenia</e2>
D007649_D018754 NONE <e1>ketamine</e1> exacerbates supporting hypothesis <e2>dysfunction</e2>
D007649_D011605 CID <e1>ketamine</e1> elicited <e2>psychosis</e2>
3969369
D013739_D063646 NONE <e1>testosterone</e1> effects <e2>carcinogenesis</e2>
D013739_D011471 CID <e1>testosterone</e1> implanted developed incidence <e2>cancer</e2>
D013739_D011471 CID <e1>testosterone-treated</e1> rats developed <e2>cancer</e2>
D013739_D009369 NONE <e1>testosterone</e1> implanted developed <e2>tumors</e2>
D013739_D009369 NONE <e1>testosterone</e1> implanted developed included <e2>tumors</e2>
D013739_D011472 CID <e1>testosterone</e1> treated fed developed <e2>prostatitis</e2>
2339463
D015119_D020225 NONE <e1>acid</e1> therapy associated <e2>thrombosis</e2>
D015119_D020227 NONE <e1>acid</e1> therapy associated <e2>thrombosis</e2>
D015119_D008595 NONE <e1>acid</e1> therapy <e2>menorrhagia</e2>
D015119_D013923 NONE <e1>acid</e1> treatment reported risk <e2>disease</e2>
D015119_D012851 NONE <e1>acid</e1> treatment reported described <e2>thrombosis</e2>
8268147
D010396_D017285 CID <e1>d-penicillamine</e1> treated cirrhosis patient case <e2>polymyositis</e2>
D010396_D017285 CID <e1>d-penicillamine</e1> treatment complications one develop <e2>polymyositis/dermatomyositis</e2>
D010396_D017285 CID <e1>d-penicillamine</e1> therapy receiving developed <e2>polymyositis</e2>
D010396_D017285 CID <e1>d-penicillamine</e1> therapy receiving patients followed development complications <e2>polymyositis/dermatomyositis</e2>
D010396_D008105 NONE <e1>d-penicillamine</e1> treated <e2>cirrhosis</e2>
D010396_D008105 NONE <e1>d-penicillamine</e1> therapy receiving developed patient <e2>cirrhosis</e2>
D010396_D012216 NONE <e1>d-penicillamine</e1> used <e2>diseases</e2>
D010396_D064420 NONE <e1>d-penicillamine</e1> used limits <e2>toxicity</e2>
D010396_D003882 NONE <e1>d-penicillamine</e1> treatment complications one develop <e2>polymyositis/dermatomyositis</e2>
D010396_D003882 NONE <e1>d-penicillamine</e1> therapy receiving patients followed development complications <e2>polymyositis/dermatomyositis</e2>
9165568
D018967_D009459 CID <e1>risperidone</e1> <e2>syndrome</e2>
D018967_D009459 CID <e1>risperidone</e1> monotherapy developed <e2>syndrome</e2>
D018967_D009459 CID <e1>risperidone</e1> observed effects protection ensure protection <e2>syndrome</e2>
D004298_D009459 NONE <e1>dopamine</e1> blockade result thought <e2>syndrome</e2>
D018967_D001480 NONE <e1>risperidone</e1> <e2>symptoms</e2>
20164825
D008687_D007674 NONE <e1>metformin</e1> prevents <e2>nephropathy</e2>
D008687_D007674 NONE <e1>metformin</e1> correction markers <e2>dysfunction</e2>
D008687_D007674 NONE <e1>metformin</e1> effects <e2>nephrotoxicity</e2>
D005839_D007674 NONE <e1>gentamicin-induced</e1> <e2>nephropathy</e2>
D005839_D007674 NONE <e1>gentamicin</e1> <e2>nephrotoxicity</e2>
D008687_D014652 NONE <e1>metformin</e1> diminish prevent <e2>dysfunction</e2>
D005839_D064420 NONE <e1>gentamicin</e1> <e2>toxicity</e2>
D008687_D058186 NONE <e1>metformin</e1> treatment blocked <e2>failure</e2>
D005839_D058186 CID <e1>gentamicin-mediated</e1> <e2>failure</e2>
6728084
D000617_D007674 NONE <e1>aminoglycoside</e1> treatment effects <e2>nephrotoxic</e2>
D000617_D007674 NONE <e1>aminoglycosides</e1> act level inducing impairment <e2>reabsorption</e2>
625456
D002119_D006934 CID <e1>carbon-ate-sodium</e1> powders amounts consumed patients reported case <e2>hypercalcaemia</e2>
D002119_D053040 CID <e1>carbon-ate-sodium</e1> powders amounts consumed patients reported case two <e2>nephrolithiasis</e2>
D017693_D006934 CID <e1>bicarbonate</e1> powders amounts consumed patients reported case <e2>hypercalcaemia</e2>
D017693_D053040 CID <e1>bicarbonate</e1> powders amounts consumed patients reported case two <e2>nephrolithiasis</e2>
18363626
D020927_D001919 CID <e1>dexmedetomidine</e1> sedation associated incidence <e2>bradycardia</e2>
D010100_D001919 NONE <e1>oxygen</e1> saturations range % associated incidence <e2>bradycardia</e2>
1286498
D005442_D009325 CID <e1>flumazenil</e1> group <e2>nausea</e2>
D005442_D009325 CID <e1>flumazenil</e1> group <e2>nausea</e2>
D005442_D014839 CID <e1>flumazenil</e1> group nausea <e2>vomiting</e2>
D005442_D010146 NONE <e1>flumazenil</e1> group <e2>pain</e2>
8599504
D004329_D000799 CID <e1>droperidol</e1> administration associated <e2>angioedema</e2>
D004329_D000799 CID <e1>droperidol</e1> dose administration minutes developed report case swelling <e2>angioedema</e2>
D004329_D004342 NONE <e1>droperidol</e1> dose administration minutes developed report case man <e2>allergies</e2>
D004329_D014060 NONE <e1>droperidol</e1> dose administration minutes developed report case <e2>swelling</e2>
D004329_D004487 NONE <e1>droperidol</e1> dose administration minutes developed report case <e2>swelling</e2>
9514561
D002211_D010146 CID <e1>capsaicin</e1> elicited <e2>pain</e2>
D002211_D010146 CID <e1>capsaicin</e1> amount administered evoke sensation <e2>painful</e2>
9848575
D018943_D009202 NONE <e1>anthracycline</e1> derivative effects <e2>cardiomyopathy</e2>
C055866_D009202 NONE <e1>sm-5887</e1> derivative effects <e2>cardiomyopathy</e2>
C055866_D009202 NONE <e1>sm-5887</e1> administration show sacrificed animals demonstrated changes decrease <e2>cardiomyopathy</e2>
C055866_D009202 NONE <e1>sm-5887</e1> effect examine induced <e2>cardiomyopathy</e2>
C055866_D009202 NONE <e1>sm-5887</e1> treatment progress grade <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>doxorubicin-induced</e1> heart effects <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>doxorubicin</e1> courses received animals demonstrated changes decrease <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>doxorubicin</e1> courses induced <e2>cardiomyopathy</e2>
C055866_D066126 NONE <e1>sm-5887</e1> potential <e2>cardiotoxic</e2>
C055866_D066126 NONE <e1>sm-5887</e1> potential effect <e2>cardiotoxicity</e2>
C055866_D066126 NONE <e1>sm-5887</e1> effect potential <e2>cardiotoxic</e2>
C055866_D066126 NONE <e1>sm-5887</e1> effect <e2>cardiotoxicity</e2>
C055866_D066126 NONE <e1>sm-5887</e1> effect <e2>cardiotoxic</e2>
C055866_D066126 NONE <e1>sm-5887</e1> have potential <e2>cardiotoxicity</e2>
C055866_D066126 NONE <e1>sm-5887</e1> have potential cardiotoxicity <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>doxorubicin</e1> pre-induced cardiotoxicity effect potential <e2>cardiotoxic</e2>
D004317_D066126 NONE <e1>doxorubicin</e1> pre-induced <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>doxorubicin</e1> courses induced examine effect <e2>cardiotoxic</e2>
D004317_D066126 NONE <e1>doxorubicin</e1> treatment enhanced changes <e2>cardiotoxic</e2>
D004317_D066126 NONE <e1>doxorubicin-induced</e1> cardiotoxicity <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>doxorubicin-induced</e1> <e2>cardiotoxicity</e2>
11573852
D000666_D012640 CID <e1>b-induced</e1> <e2>seizures</e2>
D000666_D012640 CID <e1>b</e1> infusion case episodes activity <e2>seizure</e2>
D000666_D012640 CID <e1>b</e1> infusion experienced summary stopped <e2>seizures</e2>
D000666_D012640 CID <e1>b</e1> administration occurred persisted <e2>seizures</e2>
D000666_D012640 CID <e1>b</e1> cause <e2>seizures</e2>
D000666_D012640 CID <e1>b</e1> seems cause <e2>seizures</e2>
D000666_D012640 CID <e1>b</e1> associated <e2>seizures</e2>
D000666_D000163 NONE <e1>b-induced</e1> seizures patient <e2>aids</e2>
D000666_D000163 NONE <e1>b</e1> infusion case episodes activity patent <e2>aids</e2>
D000666_D000163 NONE <e1>b</e1> cause patient <e2>aids</e2>
D000666_D004830 NONE <e1>b</e1> infusion experienced <e2>seizures</e2>
D010672_D012640 NONE <e1>phenytoin</e1> administration persisted <e2>seizures</e2>
D008140_D012640 NONE <e1>lorazepam</e1> phenytoin administration persisted <e2>seizures</e2>
D000431_D000437 NONE <e1>alcohol</e1> intake had history <e2>abuse</e2>
D000431_D012640 NONE <e1>alcohol</e1> intake cause <e2>seizures</e2>
D016049_D012640 NONE <e1>didanosine</e1> has potential inducing <e2>seizures</e2>
8012887
D006493_D013927 CID <e1>heparin-induced</e1> <e2>thrombosis</e2>
D006493_D013927 CID <e1>heparin-induced</e1> <e2>thrombosis</e2>
D006493_D013927 CID <e1>heparin</e1> patients <e2>thrombosis</e2>
D006493_D013927 CID <e1>heparin</e1> patients thrombosis development prophylaxis used defined syndrome <e2>thrombosis</e2>
D006493_D013927 CID <e1>heparin</e1> require prophylaxis development <e2>thrombosis</e2>
D006493_D013927 CID <e1>heparin</e1> require prophylaxis used defined syndrome <e2>thrombosis</e2>
D006493_D013927 CID <e1>heparin-induced</e1> <e2>thrombosis</e2>
D006493_D001791 NONE <e1>heparin</e1> patients thrombosis development prophylaxis <e2>aggregation</e2>
D006493_D001791 NONE <e1>heparin</e1> require prophylaxis <e2>aggregation</e2>
8766220
D014147_D006212 CID <e1>tramadol</e1> intake nightmares <e2>hallucinations</e2>
D014147_D006212 CID <e1>tramadol</e1> drugs withdrawal stopped <e2>hallucinations</e2>
D014147_D009369 NONE <e1>tramadol</e1> opioid effects used treat pain <e2>cancer</e2>
D014147_D010146 NONE <e1>tramadol</e1> opioid effects used treat <e2>pain</e2>
D014147_D010146 NONE <e1>tramadol</e1> opioid effects used treat pain <e2>pain</e2>
D017374_-1 NONE <e1>paroxetine</e1> association patient <e2>tetraparetic</e2>
D017374_D059350 NONE <e1>paroxetine</e1> association patient <e2>pain</e2>
D004308_-1 NONE <e1>hydrochloride</e1> dosulepine paroxetine association patient <e2>tetraparetic</e2>
D004308_D059350 NONE <e1>hydrochloride</e1> dosulepine paroxetine association patient <e2>pain</e2>
3088349
D000661_D009069 CID <e1>amphetamine</e1> exhaustion susceptibility reflects <e2>rotation</e2>
D000661_D009069 CID <e1>amphetamine-induced</e1> behavior effect examined order clarify nature <e2>rotation</e2>
D000661_D009069 CID <e1>amphetamine-induced</e1> <e2>behavior</e2>
D000661_D009069 CID <e1>amphetamine</e1> administered evident indicating involvement <e2>rotation</e2>
D000661_D009069 CID <e1>amphetamine</e1> dose volume regardless tended <e2>rotation</e2>
D000661_D009069 CID <e1>amphetamine-induced</e1> <e2>rotation</e2>
D000661_D009069 CID <e1>amphetamine</e1> injections response lesion circled tended <e2>rotation</e2>
D000661_D009069 CID <e1>amphetamine</e1> has effect contributing <e2>rotation</e2>
D000661_-1 NONE <e1>amphetamine</e1> exhaustion susceptibility reflects rotation <e2>lesion</e2>
D016627_-1 NONE <e1>6-ohda</e1> <e2>lesion</e2>
D016627_D009069 NONE <e1>6-ohda</e1> lesion period <e2>rotation</e2>
D016627_D009069 NONE <e1>6-ohda</e1> lesion reported precede <e2>circling</e2>
12739036
D003401_D008180 NONE <e1>creatine</e1> kinase levels diagnosis <e2>erythematosus</e2>
D002738_D009135 NONE <e1>chloroquine-induced</e1> <e2>myopathy</e2>
D002738_D009135 NONE <e1>chloroquine-induced</e1> <e2>myopathy</e2>
D001379_D008180 NONE <e1>azathioprine</e1> treatment periods involvement suffering <e2>erythematosus</e2>
D001379_D008180 NONE <e1>azathioprine</e1> treatment periods involvement suffering erythematosus <e2>sle</e2>
D001379_D007674 NONE <e1>azathioprine</e1> treatment periods <e2>involvement</e2>
D003520_D008180 NONE <e1>cyclophosphamide</e1> azathioprine treatment periods involvement suffering <e2>erythematosus</e2>
D003520_D008180 NONE <e1>cyclophosphamide</e1> azathioprine treatment periods involvement suffering erythematosus <e2>sle</e2>
D003520_D007674 NONE <e1>cyclophosphamide</e1> azathioprine treatment periods <e2>involvement</e2>
D002738_D018771 NONE <e1>chloroquine</e1> therapy started <e2>arthralgia</e2>
D002738_D018771 NONE <e1>cq</e1> chloroquine therapy started <e2>arthralgia</e2>
D013256_D009220 NONE <e1>steroids</e1> treated suspected <e2>myositis</e2>
3220106
D009538_D006948 CID <e1>nicotine-induced</e1> <e2>hyperactivity</e2>
D009538_D006948 CID <e1>nicotine-treated</e1> rats <e2>hyperactivity</e2>
D009538_D006948 CID <e1>nicotine-treated</e1> rats develop <e2>hyperactivity</e2>
D009538_D006948 CID <e1>nicotine</e1> response <e2>hyperactivity</e2>
D004298_D006948 NONE <e1>da</e1> concentration receptors density increases develop <e2>hyperactivity</e2>
D004298_D006948 NONE <e1>da</e1> supersensitivity inducing followed develop <e2>hyperactivity</e2>
2790457
D002220_D012640 NONE <e1>carbamazepine</e1> inhibits development <e2>seizures</e2>
D002220_D012640 NONE <e1>carbamazepine</e1> treatment <e2>seizures</e2>
D002220_D012640 NONE <e1>cbz</e1> carbamazepine treatment <e2>seizures</e2>
D002220_D012640 NONE <e1>cbz</e1> administration methods stages evaluated effects treatment <e2>seizures</e2>
D002220_D012640 NONE <e1>cbz</e1> inhibited development lidocaine- <e2>seizures</e2>
D002220_D012640 NONE <e1>cbz</e1> inhibited had <e2>seizures</e2>
D002220_D012640 NONE <e1>cbz</e1> decreased incidence mortality <e2>seizure-related</e2>
D002220_D012640 NONE <e1>cbz</e1> had <e2>seizures</e2>
D002220_D012640 NONE <e1>cbz</e1> injection effect development <e2>seizures</e2>
D002220_D012640 NONE <e1>cbz</e1> effects stage development <e2>seizure</e2>
D002220_D012640 NONE <e1>cbz</e1> effects suggest underlie development <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine</e1> kindled <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine-induced</e1> lidocaine- <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine-induced</e1> lidocaine- development inhibited had <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine-injected</e1> rats incidence mortality <e2>seizure-related</e2>
D003042_D012640 CID <e1>cocaine-induced</e1> lidocaine-kindled <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine-kindled</e1> lidocaine- <e2>seizures</e2>
D008012_D012640 CID <e1>lidocaine</e1> cocaine kindled <e2>seizures</e2>
D008012_D012640 CID <e1>lidocaine-</e1> <e2>seizures</e2>
D008012_D012640 CID <e1>lidocaine-</e1> development inhibited had <e2>seizures</e2>
D008012_D012640 CID <e1>lidocaine-kindled</e1> <e2>seizures</e2>
D008012_D012640 CID <e1>lidocaine-</e1> <e2>seizures</e2>
16116131
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesia</e2>
D001058_D010300 NONE <e1>apomorphine</e1> infusion induced state modification result investigated using stimulation area group patients <e2>disease</e2>
D001058_D004409 NONE <e1>apomorphine</e1> infusion induced state <e2>dyskinetic</e2>
9867728
D005277_D006349 NONE <e1>fenfluramine</e1> users <e2>disease</e2>
D005277_D006349 NONE <e1>fenfluramine</e1> users % % had <e2>disease</e2>
D005277_D006349 NONE <e1>fenfluramine</e1> users <e2>abnormalities</e2>
D005277_D006349 NONE <e1>fenfluramine-phentermine</e1> receiving patients developed <e2>disease</e2>
D020372_D006349 NONE <e1>dexfenfluramine</e1> fenfluramine users <e2>disease</e2>
D020372_D006349 NONE <e1>dexfenfluramine</e1> fenfluramine users % % had <e2>disease</e2>
D020372_D006349 NONE <e1>dexfenfluramine</e1> fenfluramine users <e2>abnormalities</e2>
D010645_D006349 NONE <e1>fenfluramine-phentermine</e1> receiving patients developed <e2>disease</e2>
804391
D012293_D011507 CID <e1>rifampin</e1> patients immunity <e2>proteinuria</e2>
D012293_D011507 CID <e1>rifampin</e1> treated patients found <e2>proteinuria</e2>
D012293_D014376 NONE <e1>rifampin</e1> patients <e2>tuberculosis</e2>
D012293_D014376 NONE <e1>rifampin</e1> treated patients <e2>tuberculosis</e2>
9523850
D008775_D018771 NONE <e1>methylprednisolone</e1> value prevention syndrome <e2>arthralgia-myalgia</e2>
D008775_D018771 NONE <e1>mp</e1> administration reduces frequency syndrome <e2>arthralgia-myalgia</e2>
D008775_D063806 NONE <e1>methylprednisolone</e1> value prevention syndrome <e2>arthralgia-myalgia</e2>
D008775_D063806 NONE <e1>mp</e1> administration reduces frequency syndrome <e2>arthralgia-myalgia</e2>
D007505_D018771 CID <e1>dextran</e1> infusion associated syndrome <e2>arthralgia-myalgia</e2>
D007505_D063806 NONE <e1>dextran</e1> infusion associated syndrome <e2>arthralgia-myalgia</e2>
2569282
D020927_D009127 NONE <e1>dexmedetomidine</e1> prevents <e2>rigidity</e2>
D020927_D009127 NONE <e1>d-med</e1> treatment prevents <e2>rigidity</e2>
D020927_D009127 NONE <e1>d-med</e1> prevented <e2>rigidity</e2>
D020927_D009123 NONE <e1>dexmedetomidine</e1> capable inducing <e2>flaccidity</e2>
D020927_D009123 NONE <e1>d-med</e1> dexmedetomidine capable inducing <e2>flaccidity</e2>
D015760_D009127 CID <e1>alfentanil</e1> anesthesia caused <e2>rigidity</e2>
D015760_D009127 CID <e1>alfentanil-induced</e1> <e2>rigidity</e2>
D020927_D018476 NONE <e1>d-med</e1> animals flaccid <e2>akinetic</e2>
D020927_D012021 NONE <e1>d-med</e1> animals flaccid lacked response <e2>startle</e2>
12481039
D012964_D012640 NONE <e1>sodium</e1> channel density increased susceptibility <e2>seizures</e2>
D012964_D012640 NONE <e1>sodium</e1> beta 2-subunits lacking mice susceptibility <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine-induced</e1> seizures latency indicated displayed susceptibility <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine-induced</e1> <e2>seizures</e2>
20195852
D003287_D007674 CID <e1>media</e1> consumption risk <e2>nephropathy</e2>
D003287_D007674 CID <e1>media-induced</e1> <e2>nephropathy</e2>
D003287_D007674 CID <e1>media-induced</e1> nephropathy <e2>cin</e2>
D003287_D007674 CID <e1>media</e1> incidence <e2>cin</e2>
D003287_D007674 CID <e1>cm</e1> media incidence <e2>cin</e2>
D003287_D007674 CID <e1>cm</e1> type relation compared determined incidence <e2>cin</e2>
D003287_D007674 CID <e1>cm</e1> dosage received those whereas % patients <e2>cin</e2>
D003287_D007674 CID <e1>cm</e1> dosage received those whereas increased difference incidence <e2>cin</e2>
D003287_D007674 CID <e1>cm</e1> dosages related cin incidence difference increased whereas % patients <e2>cin</e2>
D003287_D007674 CID <e1>cm</e1> dosages related <e2>cin</e2>
D003287_D007674 CID <e1>cm</e1> type dosage depends needed reversible <e2>cin</e2>
D003287_D003490 NONE <e1>media</e1> incidence determined compared relation type presence <e2>cyanosis</e2>
D003287_D003490 NONE <e1>cm</e1> media incidence determined compared relation type presence <e2>cyanosis</e2>
D003287_D003490 NONE <e1>cm</e1> type presence <e2>cyanosis</e2>
D003287_D003490 NONE <e1>cm</e1> type dosage depends nor presence <e2>cyanosis</e2>
C038192_D007674 CID <e1>iopromide</e1> determined incidence <e2>cin</e2>
C038192_D003490 NONE <e1>iopromide</e1> determined compared relation type presence <e2>cyanosis</e2>
D007472_D007674 CID <e1>iohexol</e1> iopromide determined incidence <e2>cin</e2>
D007472_D003490 NONE <e1>iohexol</e1> iopromide determined compared relation type presence <e2>cyanosis</e2>
15673851
D016202_D020760 NONE <e1>n-methyl-d-aspartate</e1> receptors activation contribute degeneration neurons induced interval <e2>ischemia</e2>
D016202_D020760 NONE <e1>nmda</e1> activation setting <e2>ischemia</e2>
D009020_D020760 NONE <e1>morphine</e1> induced interval <e2>ischemia</e2>
D016202_D001157 NONE <e1>n-methyl-d-aspartate</e1> receptors activation degeneration interval <e2>occlusion</e2>
D016202_D001157 NONE <e1>nmda</e1> n-methyl-d-aspartate receptors activation degeneration interval <e2>occlusion</e2>
D009020_D001157 NONE <e1>morphine</e1> degeneration interval <e2>occlusion</e2>
D016291_D020336 NONE <e1>mk-801</e1> effect <e2>paraparesis</e2>
D016291_D020336 NONE <e1>mk-801</e1> reduced <e2>paraparesis</e2>
D009020_D020336 CID <e1>morphine-induced</e1> <e2>paraparesis</e2>
D009020_D020336 CID <e1>morphine-induced</e1> <e2>paraparesis</e2>
D009020_D020336 CID <e1>morphine</e1> induces <e2>paraparesis</e2>
D018698_D020336 NONE <e1>glutamate</e1> increase <e2>paraparesis</e2>
D016202_D020336 NONE <e1>nmda</e1> activation involved <e2>paraparesis</e2>
D016202_D020258 NONE <e1>nmda</e1> activation setting <e2>neurotoxic</e2>
7647582
D004737_D056486 CID <e1>enflurane</e1> anesthetics associated <e2>injury</e2>
D004737_D056486 CID <e1>enflurane</e1> produce condition similar that <e2>hepatitis</e2>
D007530_D056486 CID <e1>isoflurane</e1> enflurane anesthetics associated <e2>injury</e2>
D007530_D056486 CID <e1>isoflurane</e1> enflurane produce condition similar that <e2>hepatitis</e2>
D006221_D056486 CID <e1>halothane</e1> exposure associated <e2>injury</e2>
D006221_D056486 CID <e1>halothane</e1> <e2>hepatitis</e2>
D006221_D056486 CID <e1>halothane</e1> patients <e2>hepatitis</e2>
D006221_D056486 CID <e1>halothane</e1> <e2>hepatitis</e2>
D006221_D056486 CID <e1>halothane</e1> administration subsequent produce condition similar that <e2>hepatitis</e2>
D014269_D056486 NONE <e1>trifluoroacetyl</e1> adduct product response detected patients <e2>hepatitis</e2>
D004737_D004342 NONE <e1>enflurane</e1> isoflurane <e2>hypersensitivity</e2>
D004737_D004342 NONE <e1>enflurane</e1> produce condition <e2>hypersensitivity</e2>
D007530_D004342 NONE <e1>isoflurane</e1> <e2>hypersensitivity</e2>
D007530_D004342 NONE <e1>isoflurane</e1> enflurane produce condition <e2>hypersensitivity</e2>
D006221_D004342 NONE <e1>halothane</e1> induced <e2>hypersensitivity</e2>
D006221_D004342 NONE <e1>halothane</e1> hepatitis that similar condition <e2>hypersensitivity</e2>
D006221_D004342 NONE <e1>halothane</e1> administration subsequent produce condition <e2>hypersensitivity</e2>
7059267
D002747_D009901 CID <e1>chlorpropamide-induced</e1> optic <e2>neuropathy</e2>
D002747_D009901 CID <e1>chlorpropamide</e1> treated diabetes woman had optic <e2>neuropathy</e2>
D002747_D009901 CID <e1>diabenese</e1> chlorpropamide treated diabetes woman had optic <e2>neuropathy</e2>
D002747_D009901 CID <e1>chlorpropamide</e1> therapy discontinuation resolved optic <e2>neuropathy</e2>
D002747_D003924 NONE <e1>chlorpropamide</e1> treated <e2>diabetes</e2>
D002747_D003924 NONE <e1>diabenese</e1> chlorpropamide treated <e2>diabetes</e2>
D002747_D003924 NONE <e1>chlorpropamide</e1> therapy discontinuation resolved optic had woman <e2>diabetes</e2>
2528969
11208990
D009569_D007674 NONE <e1>oxide</e1> production association model <e2>nephropathy</e2>
D009569_D009404 NONE <e1>no</e1> role association model <e2>syndrome</e2>
D004317_D009404 CID <e1>adriamycin</e1> injection induced <e2>syndrome</e2>
D004317_D009404 CID <e1>adr</e1> adriamycin injection induced <e2>syndrome</e2>
D004317_D007674 NONE <e1>adr-induced</e1> groups <e2>nephropathy</e2>
D004317_D007674 NONE <e2><e1>adr-nephropathy</e1></e2>
D004317_D007674 NONE <e2><e1>adr-nephropathy</e1></e2>
D004317_D007674 NONE <e2><e1>adr-nephropathy</e1></e2>
D004317_C537346 NONE <e1>adr</e1> treated rats kidneys examination revealed areas <e2>proliferation</e2>
D004317_D009395 NONE <e1>adr</e1> treated rats kidneys examination revealed areas proliferation <e2>inflammation</e2>
D009573_D007674 NONE <e1>nitrite</e1> levels increased group <e2>adr-nephropathy</e2>
D010656_D007674 NONE <e1>phenylephrine</e1> impaired group <e2>adr-nephropathy</e2>
D000109_D007674 NONE <e1>acetylcholine</e1> related phenylephrine impaired group <e2>adr-nephropathy</e2>
D009569_D009401 NONE <e1>no</e1> interactions important pathogenesis <e2>nephrosis</e2>
D004317_D009401 NONE <e1>adr-induced</e1> <e2>nephrosis</e2>
16634859
D000431_D006130 CID <e1>alcohol-related</e1> <e2>impairment</e2>
D000431_D006130 CID <e1>alcohol</e1> recognition resulted <e2>growth</e2>
D000431_D006130 CID <e1>alcohol</e1> recognition resulted decreased cranial <e2>growth</e2>
16428827
C004742_D000647 NONE <e1>daidzein</e1> activates improves <e2>amnesia</e2>
C004742_D000647 NONE <e1>daidzein</e1> administration shown reverse <e2>amnesia</e2>
C004742_D000647 NONE <e1>daidzein</e1> play ameliorates <e2>amnesia</e2>
D002794_D000647 NONE <e1>choline</e1> acetyltransferase activates improves <e2>amnesia</e2>
D002794_D000544 NONE <e1>choline</e1> acetyltransferase factor treatment <e2>disease</e2>
D002794_D000544 NONE <e1>choline</e1> acetyltransferase factor treatment disease <e2>ad</e2>
D000109_D000544 NONE <e1>acetylcholine</e1> production augmentation enhances acetyltransferase factor treatment <e2>disease</e2>
D000109_D000544 NONE <e1>acetylcholine</e1> production augmentation enhances acetyltransferase factor treatment disease <e2>ad</e2>
D000109_D000544 NONE <e1>ach</e1> acetylcholine production augmentation enhances acetyltransferase factor treatment <e2>disease</e2>
D000109_D000544 NONE <e1>ach</e1> acetylcholine production augmentation enhances acetyltransferase factor treatment disease <e2>ad</e2>
C004742_D007859 NONE <e1>daidzein</e1> effects impairments learning <e2>memory</e2>
C004742_D008569 NONE <e1>daidzein</e1> effects impairments learning <e2>memory</e2>
D012601_D007859 NONE <e1>scopolamine-induced</e1> impairments learning <e2>memory</e2>
D012601_D008569 NONE <e1>scopolamine-induced</e1> impairments learning <e2>memory</e2>
D012601_D000647 CID <e1>scopolamine-induced</e1> <e2>amnesia</e2>
D012601_D000647 CID <e1>scopolamine-induced</e1> <e2>amnesia</e2>
D000109_D000647 NONE <e1>acetylcholine</e1> biosynthesis play ameliorates <e2>amnesia</e2>
7910951
D003473_D010243 NONE <e1>agents</e1> nondepolarizing <e2>paralysis</e2>
D000305_D010243 NONE <e1>corticosteroids</e1> agents nondepolarizing <e2>paralysis</e2>
D003473_D018908 CID <e1>agents</e1> use implicated cause <e2>weakness</e2>
D003473_D018908 CID <e1>nd-nmba</e1> use implicated cause <e2>weakness</e2>
D003473_D018908 CID <e1>nd-nmbas</e1> discontinuation developed <e2>weakness</e2>
D003473_D018908 CID <e1>nd-nmba</e1> junction due <e2>weakness</e2>
D003473_D012131 NONE <e1>nd-nmbas</e1> discontinuation developed patients <e2>insufficiency</e2>
D014673_D009135 NONE <e1>vecuronium</e1> level discontinued showed loss <e2>filaments</e2>
D003473_D009468 CID <e1>nd-nmba</e1> <e2>junction</e2>
D000305_D018908 NONE <e1>corticosteroids</e1> junction due <e2>weakness</e2>
D000305_D009468 NONE <e1>corticosteroids</e1> <e2>junction</e2>
7437994
6127992
D014700_D017202 NONE <e1>verapamil</e1> therapy failure developed patients <e2>disease</e2>
D014700_D006333 CID <e1>verapamil</e1> therapy <e2>failure</e2>
D014700_D007022 CID <e1>verapamil</e1> therapy failure <e2>hypotension</e2>
D014700_D001919 CID <e1>verapamil</e1> therapy failure hypotension <e2>bradycardia</e2>
D000319_D017202 NONE <e1>drugs</e1> verapamil therapy failure developed patients <e2>disease</e2>
D000319_D006333 CID <e1>drugs</e1> verapamil therapy <e2>failure</e2>
D000319_D007022 CID <e1>drugs</e1> verapamil therapy failure <e2>hypotension</e2>
D000319_D001919 CID <e1>drugs</e1> verapamil therapy failure hypotension <e2>bradycardia</e2>
15764424
D002395_D011605 NONE <e1>catecholamines</e1> severity relationship levels <e2>psychosis</e2>
D002395_D011605 NONE <e1>catecholamines</e1> levels <e2>symptoms</e2>
D002395_D011605 NONE <e1>catecholamines</e1> levels relationship diagnosis <e2>psychosis</e2>
D002395_D011605 NONE <e1>catecholamine</e1> metabolite levels drug assays collected interviewed examine relationship levels <e2>symptoms</e2>
D002395_D011605 NONE <e1>catecholamine</e1> metabolite levels drug assays collected interviewed examine relationship diagnosis <e2>psychosis</e2>
D002395_D006948 NONE <e1>catecholamines</e1> <e2>hyperkinesia</e2>
D002395_D001523 NONE <e1>catecholamines</e1> levels patients service <e2>psychiatric</e2>
D002395_D001523 NONE <e1>catecholamine</e1> metabolite levels drug assays collected interviewed examine relationship levels patients service <e2>psychiatric</e2>
D000661_D011605 CID <e1>amphetamine-</e1> diagnosis relationship levels <e2>symptoms</e2>
D000661_D011605 CID <e1>amphetamine-</e1> diagnosis <e2>psychosis</e2>
D000661_D001523 NONE <e1>amphetamine-</e1> diagnosis relationship levels patients service <e2>psychiatric</e2>
D003042_D011605 CID <e1>cocaine-induced</e1> amphetamine- diagnosis relationship levels <e2>symptoms</e2>
D003042_D011605 CID <e1>cocaine-induced</e1> amphetamine- diagnosis <e2>psychosis</e2>
D003042_D001523 NONE <e1>cocaine-induced</e1> amphetamine- diagnosis relationship levels patients service <e2>psychiatric</e2>
D008694_D006948 CID <e1>methamphetamine</e1> levels related scores rating <e2>hyperkinesia</e2>
D000661_D006948 CID <e1>amphetamine</e1> methamphetamine levels related scores rating <e2>hyperkinesia</e2>
2343592
D015378_D012640 NONE <e1>imipenem</e1> therapy activity <e2>seizure</e2>
C044650_D020521 NONE <e1>imipenem/cilastatin</e1> doses receiving developed patients history <e2>accident</e2>
C044650_D020521 NONE <e1>imipenem/cilastatin</e1> doses receiving developed patients history accident <e2>cva</e2>
C044650_D006259 NONE <e1>imipenem/cilastatin</e1> doses receiving developed patients history accident <e2>trauma</e2>
C044650_D007674 NONE <e1>imipenem/cilastatin</e1> doses receiving developed patients evidence <e2>disease</e2>
C044650_D012640 CID <e1>imipenem/cilastatin</e1> doses receiving developed <e2>seizures</e2>
D010672_D012640 NONE <e1>phenytoin</e1> doses controlled <e2>seizures</e2>
D047090_D012640 NONE <e1>beta-lactam</e1> antibiotics doses received evidence activity <e2>seizure</e2>
18161408
D002996_D009203 CID <e1>citrate</e1> associated pregnancy <e2>infarction</e2>
D002996_D009203 CID <e1>cc</e1> <e2>infarction</e2>
D002996_D013923 CID <e1>cc</e1> induction reported complication <e2>thromboembolism</e2>
D002996_D002637 NONE <e1>cc</e1> received presented <e2>pain</e2>
D002996_D013927 NONE <e1>cc</e1> complication <e2>thrombosis</e2>
16960342
D019259_D006509 NONE <e1>lamivudine</e1> monotherapy treatment improvement patient cirrhosis virus-related <e2>b</e2>
D019259_D005355 NONE <e1>lamivudine</e1> monotherapy treatment improvement patient <e2>cirrhosis</e2>
D019259_D005355 NONE <e1>lamivudine</e1> administration patients <e2>cirrhosis</e2>
3300918
D008784_D014652 CID <e1>methysergide</e1> ingestion secondary described case <e2>vasospasm</e2>
D004876_D005734 NONE <e1>ergot</e1> history discussion includes epidemics <e2>gangrene</e2>
D004876_D008881 CID <e1>ergot</e1> history discussion includes epidemics caused ages management <e2>headache</e2>
D004876_D008881 CID <e1>ergot</e1> preparations continue play therapy <e2>migraine</e2>
D002118_D008881 NONE <e1>calcium</e1> channel blockers advent continue play therapy <e2>migraine</e2>
D002118_D004881 NONE <e1>calcium</e1> channel blockers advent continue danger persists <e2>fire</e2>
D004876_D004881 NONE <e1>ergot</e1> preparations continue danger persists <e2>fire</e2>
19642243
C096918_D058186 NONE <e1>tenofovir</e1> patients <e2>failure</e2>
C096918_D000163 NONE <e1>tenofovir</e1> patients <e2>aids</e2>
C096918_D010019 NONE <e1>tenofovir</e1> patients failure receiving course <e2>osteomyelitis</e2>
D014640_D058186 CID <e1>vancomycin</e1> course receiving <e2>failure</e2>
D014640_D000163 NONE <e1>vancomycin</e1> course receiving failure patients <e2>aids</e2>
D014640_D010019 NONE <e1>vancomycin</e1> course <e2>osteomyelitis</e2>
D014640_D051437 NONE <e1>vancomycin</e1> therapy course developed <e2>failure</e2>
D014640_D051437 NONE <e1>vancomycin</e1> administration <e2>failure</e2>
C418563_D051437 NONE <e1>fumarate</e1> receiving patients therapy course developed <e2>failure</e2>
C096918_D005198 NONE <e1>tenofovir</e1> implicated development <e2>syndrome</e2>
C096918_D051437 NONE <e1>tenofovir</e1> implicated development syndrome <e2>insufficiency</e2>
C096918_D051437 NONE <e1>tenofovir</e1> raise risk <e2>failure</e2>
D014640_D007674 NONE <e1>vancomycin</e1> <e2>nephrotoxicity</e2>
D014640_D007674 NONE <e1>vancomycin</e1> nephrotoxicity infrequent result coadministration agent <e2>nephrotoxic</e2>
6454943
D002216_D011507 NONE <e1>captopril</e1> effect <e2>proteinuria</e2>
D002216_D011507 NONE <e1>captopril</e1> treatment effect <e2>proteinuria</e2>
D002216_D011507 NONE <e1>captopril</e1> administration failed <e2>proteinuria</e2>
D002216_D011507 NONE <e1>captopril</e1> treatment failed potentiate facilitate development <e2>proteinuria</e2>
D002216_D006973 NONE <e1>captopril</e1> effect rats <e2>hypertensive</e2>
D002216_D006973 NONE <e1>captopril</e1> treatment effect patients <e2>hypertensive</e2>
D011692_D011507 CID <e1>aminonucleoside-induced</e1> pre-existing <e2>proteinuria</e2>
D011692_D011507 CID <e1>aminonucleoside</e1> invoked <e2>proteinuria</e2>
D011692_D006973 NONE <e1>aminonucleoside-induced</e1> pre-existing proteinuria effect rats <e2>hypertensive</e2>
D002216_D007674 NONE <e1>captopril</e1> <e2>abnormality</e2>
10328196
D020123_D064420 NONE <e1>sirolimus</e1> administration <e2>toxicity</e2>
D020123_D064420 NONE <e1>rapamycin</e1> administration <e2>toxicity</e2>
D020123_D011565 NONE <e1>sirolimus</e1> administration <e2>psoriasis</e2>
D020123_D011565 NONE <e1>rapamycin</e1> administration <e2>psoriasis</e2>
D020123_D011565 NONE <e1>sirolimus</e1> cells treatment developed individuals <e2>psoriasis</e2>
D020123_D011565 NONE <e1>sirolimus-induced</e1> syndrome patient specimen had observations patient <e2>psoriasis</e2>
D020123_D011565 NONE <e1>sirolimus-treated</e1> patient <e2>psoriasis</e2>
D020123_D011565 NONE <e1>sirolimus</e1> presence tended cells patients <e2>psoriasis</e2>
D020123_D019559 CID <e1>sirolimus</e1> administration toxicity association <e2>syndrome</e2>
D020123_D019559 CID <e1>rapamycin</e1> administration toxicity association <e2>syndrome</e2>
D020123_D019559 CID <e1>sirolimus</e1> cells treatment developed <e2>syndrome</e2>
D020123_D019559 CID <e1>sirolimus-induced</e1> <e2>syndrome</e2>
D020123_D019559 CID <e1>sirolimus-treated</e1> patient observations had specimen patient <e2>syndrome</e2>
D020123_D019559 CID <e1>sirolimus</e1> effects include fever <e2>syndrome</e2>
D003907_D011565 NONE <e1>dexamethasone-induced</e1> spontaneous greater apoptosis exhibit tended cells patients <e2>psoriasis</e2>
D020123_D005334 NONE <e1>sirolimus</e1> effects include <e2>fever</e2>
D020123_D000740 NONE <e1>sirolimus</e1> effects include fever <e2>anemia</e2>
2716967
D007649_D002375 CID <e1>ketamine</e1> combinations induced <e2>catalepsy</e2>
D007649_D002375 CID <e1>ketamine</e1> induced analgesia <e2>catalepsy</e2>
D007649_D002375 CID <e1>ketamine</e1> pre-treatment produced induce augmented response <e2>cataleptic</e2>
D007649_D002375 CID <e1>ketamine</e1> cross-tolerance induce augmented response <e2>cataleptic</e2>
D009020_D002375 CID <e1>morphine</e1> ketamine combinations induced <e2>catalepsy</e2>
D009020_D002375 CID <e1>morphine</e1> ketamine induced analgesia <e2>catalepsy</e2>
D009020_D002375 CID <e1>morphine</e1> cross-tolerance produced induce augmented response <e2>cataleptic</e2>
D009020_D002375 CID <e1>morphine</e1> pretreatment induce augmented response <e2>cataleptic</e2>
D009020_D002375 CID <e1>morphine</e1> attributed produced induce augmented response <e2>cataleptic</e2>
D007649_D000699 NONE <e1>ketamine</e1> induced <e2>analgesia</e2>
D009020_D000699 NONE <e1>morphine</e1> ketamine induced <e2>analgesia</e2>
D007649_D009127 NONE <e1>ketamine</e1> predominance reflected latency loss righting reflex <e2>rigidity</e2>
D009020_D009127 NONE <e1>morphine</e1> ketamine predominance reflected latency loss righting reflex <e2>rigidity</e2>
D009270_D002375 NONE <e1>naloxone</e1> inhibited effects <e2>cataleptic</e2>
D009270_D002375 NONE <e1>naloxone</e1> differences mechanisms <e2>catalepsy</e2>
D009270_D009127 NONE <e1>naloxone</e1> differences latency <e2>rigidity</e2>
11861791
D011064_D006333 NONE <e1>)</e1> polymerase activation contributes development <e2>failure</e2>
D004317_D006333 CID <e1>doxorubicin-induced</e1> <e2>failure</e2>
D004317_D066126 NONE <e1>doxorubicin</e1> <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>dox</e1> doxorubicin <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>dox-induced</e1> <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>dox</e1> <e2>cardiotoxicity</e2>
D018943_D066126 NONE <e1>anthracycline</e1> antibiotic <e2>cardiotoxicity</e2>
C434926_D006331 NONE <e1>pj34</e1> deletion using demonstrate role development <e2>dysfunction</e2>
C434926_D006331 NONE <e1>pj34</e1> treatment improved <e2>dysfunction</e2>
D004317_D006331 NONE <e1>dox</e1> induced <e2>dysfunction</e2>
D004317_D005117 NONE <e1>dox</e1> treatment associated <e2>complications</e2>
12109865
3131282
C009166_D063646 NONE <e1>acetate</e1> effect <e2>co-carcinogenic</e2>
C009166_D013274 NONE <e1>acetate</e1> effect <e2>carcinogenesis</e2>
C009166_D013274 NONE <e1>acetate</e1> effect examined <e2>tumorigenesis</e2>
C009166_D013274 NONE <e1>ra</e1> acetate effect examined <e2>tumorigenesis</e2>
C009166_D013274 NONE <e1>ra</e1> co-administration observed given increased incidence <e2>tumors</e2>
C009166_D013274 NONE <e1>ra-free</e1> water group increased incidence <e2>tumors</e2>
C009166_D013274 NONE <e1>ra</e1> acted co-carcinogen <e2>carcinogenesis</e2>
D002083_D063646 NONE <e1>hydroxyanisole</e1> induced rats carcinogenesis effect <e2>co-carcinogenic</e2>
D002083_D013274 CID <e1>hydroxyanisole</e1> induced rats <e2>carcinogenesis</e2>
D002083_D013274 CID <e1>hydroxyanisole</e1> effect examined <e2>tumorigenesis</e2>
D002083_D013274 CID <e1>(bha)-induced</e1> <e2>tumorigenesis</e2>
D002083_D013274 CID <e1>bha</e1> given increased incidence <e2>tumors</e2>
D002083_D013274 CID <e1>bha</e1> <e2>carcinogenesis</e2>
D002083_D010212 NONE <e1>bha</e1> given increased incidence tumors <e2>papilloma</e2>
D002083_D002277 NONE <e1>bha</e1> given increased incidence tumors papilloma <e2>carcinoma</e2>
D002083_D002277 NONE <e1>bha</e1> given increased rats <e2>carcinoma</e2>
D002083_D002277 NONE <e1>bha</e1> given increased % 3/20 rat <e2>carcinoma</e2>
C009166_D010212 NONE <e1>ra</e1> co-administration observed given increased incidence tumors <e2>papilloma</e2>
C009166_D010212 NONE <e1>ra-free</e1> water group increased incidence tumors <e2>papilloma</e2>
C009166_D010212 NONE <e1>ra</e1> induced tumors <e2>papillomas</e2>
C009166_D010212 NONE <e1>ra</e1> co-administration induced tumors <e2>papillomas</e2>
C009166_D002277 NONE <e1>ra</e1> co-administration observed given increased incidence tumors papilloma <e2>carcinoma</e2>
C009166_D002277 NONE <e1>ra</e1> co-administration observed given increased rats <e2>carcinoma</e2>
C009166_D002277 NONE <e1>ra</e1> co-administration observed given increased % 3/20 rat <e2>carcinoma</e2>
C009166_D002277 NONE <e1>ra-free</e1> water group increased incidence tumors papilloma <e2>carcinoma</e2>
C009166_D002277 NONE <e1>ra-free</e1> water group increased rats <e2>carcinoma</e2>
C009166_D002277 NONE <e1>ra-free</e1> water group increased % 3/20 rat <e2>carcinoma</e2>
D002083_D017573 NONE <e1>bha</e1> rats co-administered showed effect development <e2>hyperplasia</e2>
D002083_D017573 NONE <e1>bha-induced</e1> <e2>hyperplasia</e2>
C009166_D017573 NONE <e1>ra</e1> co-administered showed effect development <e2>hyperplasia</e2>
C009166_D009369 NONE <e1>ra</e1> induced <e2>tumors</e2>
C009166_D009369 NONE <e1>ra</e1> co-administration induced <e2>tumors</e2>
19234905
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D014635_D006423 NONE <e1>valproate</e1> month improved subthalamotomy had <e2>hemianopsia</e2>
8600333
C053519_D001859 NONE <e1>protocol</e1> treated survivors <e2>tumors</e2>
D004317_D001859 NONE <e1>doxorubicin</e1> both protocol treated survivors <e2>tumors</e2>
D004317_D066126 NONE <e1>doxorubicin-induced</e1> <e2>cardiotoxicity</e2>
6308526
C024224_D000699 NONE <e1>naloxazone</e1> pretreatment blocked <e2>analgesia</e2>
C024224_D002375 NONE <e1>naloxazone</e1> pretreatment blocked analgesia <e2>catalepsy</e2>
C024224_D007035 NONE <e1>naloxazone</e1> pretreatment blocked analgesia catalepsy <e2>hypothermia</e2>
D009020_D000699 NONE <e1>morphine</e1> <e2>analgesia</e2>
D009020_D002375 CID <e1>morphine</e1> analgesia <e2>catalepsy</e2>
D009020_D007035 CID <e1>morphine</e1> analgesia catalepsy <e2>hypothermia</e2>
C024224_D007022 NONE <e1>naloxazone</e1> attenuated <e2>hypotension</e2>
C024224_D012131 NONE <e1>naloxazone</e1> attenuated hypotension <e2>depression</e2>
C024224_D001919 NONE <e1>naloxazone</e1> attenuated affected <e2>bradycardia</e2>
D009020_D007022 CID <e1>morphine-induced</e1> <e2>hypotension</e2>
D009020_D007022 CID <e1>morphine-induced</e1> bradycardia affected attenuated <e2>hypotension</e2>
D009020_D012131 NONE <e1>morphine-induced</e1> hypotension <e2>depression</e2>
D009020_D012131 NONE <e1>morphine-induced</e1> bradycardia affected attenuated hypotension <e2>depression</e2>
D009020_D001919 CID <e1>morphine-induced</e1> hypotension attenuated affected <e2>bradycardia</e2>
D009020_D001919 CID <e1>morphine-induced</e1> <e2>bradycardia</e2>
9326871
D017291_D017180 CID <e1>clarithromycin-induced</e1> <e2>tachycardia</e2>
D004917_D005759 CID <e1>erythromycin</e1> profile established <e2>gastroenteritis</e2>
D018942_D005759 NONE <e1>macrolides</e1> experience recorded established <e2>gastroenteritis</e2>
D004917_D066126 NONE <e1>erythromycin</e1> administration demonstrated <e2>cardiotoxicity</e2>
D018942_D066126 NONE <e1>macrolides</e1> reported demonstrated <e2>cardiotoxicity</e2>
D017291_D001145 NONE <e1>clarithromycin</e1> doses occurred <e2>dysrhythmias</e2>
2594614
C045856_D002318 NONE <e1>52021</e1> bn antagonist effect <e2>impairments</e2>
C045856_D002318 NONE <e1>52021</e1> bn administration studied alter demonstrate action <e2>toxicity</e2>
C045856_D002318 NONE <e1>52021</e1> bn action <e2>toxicity</e2>
D002045_D002318 NONE <e1>bupivacaine-induced</e1> <e2>impairments</e2>
D002045_D002318 NONE <e1>bupivacaine-induced</e1> <e2>toxicity</e2>
D002045_D007022 CID <e1>bupivacaine</e1> administration elicited decrease pressure rate hr <e2>)</e2>
D002045_D007022 CID <e1>bupivacaine</e1> administration min injection suppressed decrease mbp <e2>hr</e2>
D002045_D007022 CID <e1>bupivacaine</e1> reversion decrease mbp <e2>hr</e2>
D002045_D001919 CID <e1>bupivacaine</e1> administration elicited decrease pressure rate hr <e2>)</e2>
D002045_D001919 CID <e1>bupivacaine</e1> administration min injection suppressed decrease mbp <e2>hr</e2>
D002045_D001919 CID <e1>bupivacaine</e1> reversion decrease mbp <e2>hr</e2>
C045856_D007022 NONE <e1>52021</e1> bn factor injection suppressed decrease mbp <e2>hr</e2>
C045856_D007022 NONE <e1>52021</e1> bn i.v. injected bupivacaine reversion decrease mbp <e2>hr</e2>
C045856_D001919 NONE <e1>52021</e1> bn factor injection suppressed decrease mbp <e2>hr</e2>
C045856_D001919 NONE <e1>52021</e1> bn i.v. injected bupivacaine reversion decrease mbp <e2>hr</e2>
D002045_D018376 NONE <e1>bupivacaine-induced</e1> <e2>alterations</e2>
9061311
D013481_D017114 NONE <e1>superoxide</e1> production patients <e2>failure</e2>
D013481_D017114 NONE <e1>superoxide</e1> defects implicated incidence infections patients <e2>failure</e2>
D013481_D017114 NONE <e1>superoxide</e1> defects implicated incidence infections patients failure <e2>alf</e2>
D013481_D017114 NONE <e1>superoxide</e1> production neutrophils <e2>alf</e2>
D013481_D017114 NONE <e1>superoxide</e1> production neutrophils stimulated zymosan opsonized serum <e2>alf</e2>
D013481_D017114 NONE <e1>superoxide</e1> production neutrophils stimulated patients <e2>alf</e2>
D006861_D017114 NONE <e1>peroxide</e1> production patients <e2>failure</e2>
D006861_D017114 NONE <e1>peroxide</e1> superoxide defects implicated incidence infections patients <e2>failure</e2>
D006861_D017114 NONE <e1>peroxide</e1> superoxide defects implicated incidence infections patients failure <e2>alf</e2>
D006861_D017114 NONE <e1>peroxide</e1> superoxide production neutrophils <e2>alf</e2>
D006861_D017114 NONE <e1>peroxide</e1> superoxide production neutrophils stimulated zymosan opsonized serum <e2>alf</e2>
D006861_D017114 NONE <e1>peroxide</e1> superoxide production neutrophils stimulated patients <e2>alf</e2>
D013481_D001424 NONE <e1>superoxide</e1> defects implicated incidence <e2>infections</e2>
D006861_D001424 NONE <e1>peroxide</e1> superoxide defects implicated incidence <e2>infections</e2>
D010100_D017114 NONE <e1>oxygen</e1> radical production patients <e2>alf</e2>
D010100_D062787 NONE <e1>oxygen</e1> radical production <e2>overdose</e2>
D000082_D017114 CID <e1>paracetamol</e1> overdose production patients <e2>alf</e2>
D000082_D017114 CID <e1>paracetamol</e1> overdose demonstrate defect <e2>alf</e2>
D000082_D062787 NONE <e1>paracetamol</e1> <e2>overdose</e2>
D000082_D062787 NONE <e1>paracetamol</e1> <e2>overdose</e2>
D009240_D017114 NONE <e1>formyl-methionyl-leucyl-phenylalanine</e1> stimulated patients <e2>alf</e2>
D009240_D017114 NONE <e1>fmlp</e1> formyl-methionyl-leucyl-phenylalanine stimulated patients <e2>alf</e2>
18483878
D003520_D003556 CID <e1>cyclophosphamide</e1> <e2>cystitis</e2>
D003520_D003556 CID <e1>(cyp)-induced</e1> <e2>cystitis</e2>
D003520_D003556 CID <e1>cyclophosphamide</e1> <e2>cystitis</e2>
D003520_D003556 CID <e1>(cyp)-induced</e1> <e2>cystitis</e2>
D003520_D003556 CID <e1>cyp-induced</e1> <e2>cystitis</e2>
D003520_D001745 NONE <e1>cyp</e1> wt observed that increased mice <e2>inflammation</e2>
19300240
D005472_D054549 CID <e1>flourouracil-induced</e1> <e2>syndrome</e2>
D005472_D015179 NONE <e1>fluorouracil</e1> <e2>cancer</e2>
D002395_D009369 NONE <e1>catecholamines</e1> levels neuropeptides caused diagnosis <e2>cancer</e2>
D002395_D054549 NONE <e1>catecholamines</e1> levels contributed development <e2>abs</e2>
11078231
D004280_D017202 NONE <e1>dobutamine</e1> echocardiography <e2>ischemia</e2>
D004280_D017202 NONE <e1>dobutamine</e1> echocardiography useful test <e2>ischemia</e2>
D004280_D017202 NONE <e1>dobutamine</e1> induced <e2>ischemia</e2>
D004280_D003329 CID <e1>dobutamine</e1> echocardiography ischemia <e2>spasm</e2>
D004280_D003329 CID <e1>dobutamine</e1> induced ischemia <e2>spasm</e2>
D004280_D003329 CID <e1>dobutamine</e1> provoke <e2>spasm</e2>
D000109_D023921 NONE <e1>acetylcholine</e1> injection induced documented <e2>stenosis</e2>
D004280_D000788 CID <e1>dobutamine</e1> provoke patients <e2>angina</e2>
9630698
D006220_D009127 CID <e1>haloperidol</e1> induced <e2>rigidity</e2>
D006220_D009127 CID <e1>haloperidol-induced</e1> <e2>rigidity</e2>
C066192_D009127 NONE <e1>acid</e1> decreased <e2>rigidity</e2>
C066192_D009127 NONE <e1>5,7-dcka</e1> acid decreased <e2>rigidity</e2>
D005998_D009127 NONE <e1>glycine</e1> site antagonist acid decreased <e2>rigidity</e2>
12139551
D008787_D006323 CID <e1>metoclopramide</e1> <e2>arrest</e2>
D008787_D006323 CID <e1>metoclopramide</e1> arrest causing episodes <e2>arrest</e2>
D008787_D006323 CID <e1>metoclopramide</e1> injections case metoclopramide <e2>arrest</e2>
D008787_D006323 CID <e1>metoclopramide</e1> injections case metoclopramide arrest causing episodes <e2>arrest</e2>
D008787_D006323 CID <e1>metoclopramide</e1> injection followed <e2>asystole</e2>
D008787_D006323 CID <e1>metoclopramide</e1> received is s followed <e2>asystole</e2>
D008787_D006323 CID <e1>metoclopramide</e1> administration s followed <e2>asystole</e2>
D008787_D006323 CID <e1>metoclopramide</e1> caused <e2>arrest</e2>
11022397
D014331_D008569 NONE <e1>tropicamide</e1> administration points size measures impairment <e2>recall</e2>
D010862_D008569 NONE <e1>pilocarpine</e1> tropicamide administration points size measures impairment <e2>recall</e2>
D012601_D008569 CID <e1>scopolamine-induced</e1> impairment <e2>recall</e2>
D012601_D008569 CID <e1>scopolamine-induced</e1> impairment had <e2>recall</e2>
16047871
D014859_C535509 NONE <e1>warfarin-induced</e1> <e2>vasculitis</e2>
D014859_C535509 NONE <e1>warfarin</e1> report patients <e2>lv</e2>
D014859_C535509 NONE <e1>warfarin</e1> therapy associated reaction <e2>lv</e2>
D014859_D012871 NONE <e1>warfarin</e1> receiving developed <e2>eruptions</e2>
D014859_D012871 NONE <e1>warfarin</e1> resolved lesions confirming available results biopsies <e2>lesion</e2>
D014859_D018366 CID <e1>warfarin</e1> resolved <e2>lesions</e2>
16364460
D016713_D000647 NONE <e1>ritanserin</e1> microinjection scopolamine-induced <e2>amnesia</e2>
D016713_D000647 NONE <e1>ritanserin</e1> effect scopolamine <e2>amnesia</e2>
D016713_D000647 NONE <e1>ritanserin</e1> microinjection improves <e2>amnesia</e2>
D012601_D000647 CID <e1>scopolamine-induced</e1> <e2>amnesia</e2>
D012601_D000647 CID <e1>scopolamine</e1> <e2>amnesia</e2>
D012601_D000647 CID <e1>scopolamine-induced</e1> <e2>amnesia</e2>
16418614
D011441_D014657 CID <e1>ptu-associated</e1> <e2>vasculitis</e2>
D011441_D014657 CID <e1>propylthiouracil</e1> <e2>vasculitis</e2>
D011441_D014657 CID <e1>(ptu)-associated</e1> <e2>vasculitis</e2>
D011441_D014657 CID <e1>ptu</e1> withdrawal resolution detection made diagnosis <e2>vasculitis</e2>
D011441_D014424 NONE <e1>ptu-associated</e1> vasculitis girl <e2>syndrome</e2>
D011441_D006111 NONE <e1>ptu-associated</e1> vasculitis girl syndrome <e2>disease</e2>
7263204
D007213_D000741 CID <e1>indomethacin</e1> <e2>anemia</e2>
D007213_D000741 CID <e1>indomethacin</e1> implicated cause <e2>anemia</e2>
D007213_D000741 CID <e1>indomethacin</e1> allopurinol drugs given described case <e2>anemia</e2>
D007213_D000741 CID <e1>indomethacin</e1> test substantiates causing <e2>anemia</e2>
D000493_D000741 NONE <e1>allopurinol</e1> drugs given described case <e2>anemia</e2>
9545159
D020117_D008133 CID <e1>cisapride-diltiazem</e1> interaction related <e2>interval</e2>
D004110_D008133 CID <e1>cisapride-diltiazem</e1> interaction related <e2>interval</e2>
D020117_D015835 NONE <e1>cisapride</e1> prescribed treatment <e2>disorders</e2>
D004917_D008133 CID <e1>erythromycin</e1> administration reported prolongation <e2>interval</e2>
D004917_D016171 CID <e1>erythromycin</e1> administration reported prolongation <e2>pointes</e2>
D004917_D016757 CID <e1>erythromycin</e1> administration reported prolongation pointes <e2>death</e2>
D001393_D008133 CID <e1>azole</e1> antifungal agents erythromycin administration reported prolongation <e2>interval</e2>
D001393_D016171 CID <e1>azole</e1> antifungal agents erythromycin administration reported prolongation <e2>pointes</e2>
D001393_D016757 CID <e1>azole</e1> antifungal agents erythromycin administration reported prolongation pointes <e2>death</e2>
D020117_D005764 NONE <e1>cisapride</e1> taking <e2>disorder</e2>
D020117_D006973 NONE <e1>cisapride</e1> taking woman occurred agent has effect <e2>hypertension</e2>
D004110_D005764 NONE <e1>diltiazem</e1> <e2>disorder</e2>
D004110_D006973 NONE <e1>diltiazem</e1> disorder taking woman occurred agent has effect <e2>hypertension</e2>
2320800
D007069_D001002 CID <e1>ifosfamide</e1> chemotherapy complicating <e2>anuria</e2>
D007069_D001002 CID <e1>ifosfamide</e1> day developed failure <e2>anuria</e2>
D007069_D001002 CID <e1>ifosfamide</e1> suspect due <e2>anuria</e2>
D007069_D001943 NONE <e1>ifosfamide</e1> chemotherapy complicating patient <e2>cancer</e2>
D007069_D001943 NONE <e1>ifosfamide</e1> day developed woman <e2>cancer</e2>
D007069_D007674 CID <e1>ifosfamide</e1> chemotherapy complicating patient <e2>function</e2>
D007069_D007674 CID <e1>ifosfamide</e1> drug <e2>nephrotoxic</e2>
D007069_D007674 CID <e1>ifosfamide</e1> drug <e2>tubulopathies</e2>
D007069_D007674 CID <e1>ifosfamide</e1> use patients pretreated chemotherapy <e2>nephrotoxic</e2>
D002945_D001943 NONE <e1>cisplatin</e1> treated woman <e2>cancer</e2>
D002945_D051437 NONE <e1>cisplatin</e1> treated woman developed <e2>failure</e2>
D002945_D001002 NONE <e1>cisplatin</e1> treated woman developed failure <e2>anuria</e2>
D002945_D001002 NONE <e1>cisplatin</e1> chemotherapy received patient occurring suspect due <e2>anuria</e2>
D007069_D051437 NONE <e1>ifosfamide</e1> day developed <e2>failure</e2>
D007069_D007022 NONE <e1>ifosfamide</e1> suspect occurring patient received <e2>hypotension</e2>
D002945_D007022 NONE <e1>cisplatin</e1> chemotherapy received <e2>hypotension</e2>
16586083
D016861_D009203 CID <e1>inhibitors</e1> treatment failure risk <e2>infarction</e2>
D016861_D020521 CID <e1>inhibitors</e1> treatment failure <e2>stroke</e2>
D016861_D006973 CID <e1>inhibitors</e1> treatment failure stroke <e2>hypertension</e2>
D016861_D006333 CID <e1>inhibitors</e1> treatment <e2>failure</e2>
C109794_D002318 NONE <e1>peptide</e1> markers help avoiding occurrence <e2>toxicity</e2>
C109794_D002318 NONE <e1>nt-probnp</e1> peptide markers help avoiding occurrence <e2>toxicity</e2>
6615052
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013927 NONE <e1>heparin-induced</e1> thrombocytopenia <e2>thrombosis</e2>
D006493_D006470 CID <e1>heparin-induced</e1> thrombocytopenia <e2>hemorrhage</e2>
D006493_D006470 CID <e1>heparin</e1> receiving patients include <e2>hemorrhage</e2>
D006493_D013923 CID <e1>heparin</e1> receiving patients include hemorrhage events <e2>thromboembolic</e2>
D006493_D001791 NONE <e1>heparin</e1> resistance <e2>count</e2>
D006493_D001791 NONE <e1>heparin</e1> added revealed <e2>count</e2>
D006493_D001791 NONE <e1>heparin</e1> testing <e2>aggregation</e2>
14648024
D014212_D004893 CID <e1>acid-induced</e1> <e2>nodosum</e2>
D014212_D004893 CID <e1>acid</e1> associated <e2>nodosum</e2>
D014212_D004893 CID <e1>atra</e1> acid associated <e2>nodosum</e2>
D014212_D004893 CID <e1>atra</e1> therapy developed <e2>nodosum</e2>
D014212_D004893 CID <e1>atra</e1> therapy developed fever <e2>nodules</e2>
D014212_D004893 CID <e1>atra</e1> seemed etiology <e2>nodosum</e2>
D014212_D004893 CID <e1>atra-induced</e1> <e2>nodosum</e2>
D014212_D015473 NONE <e1>acid-induced</e1> nodosum patients <e2>leukemia</e2>
D014212_D015473 NONE <e1>acid</e1> <e2>leukemia</e2>
D014212_D015473 NONE <e1>acid</e1> leukemia <e2>apl</e2>
D014212_D015473 NONE <e1>atra</e1> acid <e2>leukemia</e2>
D014212_D015473 NONE <e1>atra</e1> acid leukemia <e2>apl</e2>
D014212_D015473 NONE <e1>atra</e1> therapy developed patients <e2>apl</e2>
D014212_D005334 CID <e1>atra</e1> therapy developed <e2>fever</e2>
D014212_D010146 NONE <e1>atra</e1> therapy developed fever nodules <e2>painful</e2>
D013256_D004893 NONE <e1>steroid</e1> use effective <e2>nodosum</e2>
17490864
D000661_D006948 CID <e1>amphetamine-induced</e1> <e2>hyperactivity</e2>
21418164
D008130_D064420 NONE <e1>ccnu</e1> <e2>toxicity</e2>
D008130_D064420 NONE <e1>lomustine</e1> ccnu <e2>toxicity</e2>
D008130_D064420 NONE <e1>ccnu</e1> treated dogs met criteria class <e2>toxicity</e2>
D008130_D064420 NONE <e1>ccnu-associated</e1> <e2>toxicity</e2>
D008130_D006402 NONE <e1>1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea</e1> receiving dogs incidence <e2>toxicities</e2>
D008130_D006402 NONE <e1>ccnu</e1> incidence <e2>toxicities</e2>
D008130_D007674 NONE <e1>1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea</e1> receiving dogs incidence <e2>toxicities</e2>
D008130_D007674 NONE <e1>ccnu</e1> incidence <e2>toxicities</e2>
D008130_D056486 NONE <e1>1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea</e1> receiving dogs incidence <e2>toxicities</e2>
D008130_D056486 NONE <e1>ccnu</e1> incidence <e2>toxicities</e2>
D008130_D005767 NONE <e1>1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea</e1> receiving dogs incidence <e2>toxicities</e2>
D008130_D005767 NONE <e1>ccnu</e1> incidence <e2>toxicities</e2>
D008130_D008223 NONE <e1>ccnu</e1> used treatment <e2>lymphoma</e2>
D008130_D008223 NONE <e1>ccnu</e1> used tumours <e2>lymphoma</e2>
D008130_D034801 NONE <e1>ccnu</e1> used treatment lymphoma <e2>tumour</e2>
D008130_D001932 NONE <e1>ccnu</e1> used treatment lymphoma <e2>tumour</e2>
D008130_D015620 NONE <e1>ccnu</e1> used <e2>tumours</e2>
D000409_D064420 NONE <e1>alanine</e1> transaminase <e2>toxicity</e2>
9022662
D010389_D002819 CID <e1>pemoline</e1> induced <e2>choreoathetosis</e2>
D010389_D002819 CID <e1>pemoline</e1> experienced <e2>choreoathetosis</e2>
D010389_D002819 CID <e1>pemoline</e1> overdose presenting patients considered possibility movements <e2>choreoathetoid</e2>
D010389_D001264 CID <e1>pemoline</e1> induced <e2>choreoathetosis</e2>
D010389_D001264 CID <e1>pemoline</e1> experienced <e2>choreoathetosis</e2>
D010389_D001264 CID <e1>pemoline</e1> overdose presenting patients considered possibility movements <e2>choreoathetoid</e2>
D010389_D001289 NONE <e1>pemoline</e1> derivative different used treatment <e2>disorder</e2>
C064210_D001289 NONE <e1>oxazolidine</e1> derivative different used treatment <e2>disorder</e2>
D000662_D001289 NONE <e1>amphetamines</e1> different used treatment <e2>disorder</e2>
D010389_D009069 NONE <e1>pemoline</e1> associated cause <e2>disorders</e2>
D010389_D009069 NONE <e1>pemoline</e1> <e2>disorder</e2>
D008774_D001289 NONE <e1>methylphenidate</e1> treated <e2>disorder</e2>
D001569_D002819 NONE <e1>benzodiazepines</e1> decontamination received attempt control movements <e2>choreoathetoid</e2>
D001569_D001264 NONE <e1>benzodiazepines</e1> decontamination received attempt control movements <e2>choreoathetoid</e2>
D010389_D062787 CID <e1>pemoline</e1> <e2>overdose</e2>
839274
D003276_D000236 CID <e1>contraceptives</e1> women <e2>adenomas</e2>
D003276_D000236 CID <e1>contraceptives</e1> use associated cases <e2>adenoma</e2>
D003276_D020518 CID <e1>contraceptives</e1> women adenomas <e2>hyperplasia</e2>
D003276_D020518 CID <e1>contraceptives</e1> use associated cases one <e2>hyperplasia</e2>
18177388
D000661_D054549 CID <e1>amphetamine</e1> use setting woman <e2>syndrome</e2>
D000661_D054549 CID <e1>amphetamine</e1> use setting woman syndrome <e2>cardiomyopathy</e2>
D000661_D054549 CID <e1>amphetamine</e1> use occurring presented type <e2>syndrome</e2>
12851669
D017373_D054556 NONE <e1>acetate</e1> women <e2>thromboembolism</e2>
D017373_D054556 NONE <e1>acetate</e1> women <e2>thromboembolism</e2>
D017373_D054556 NONE <e1>acetate</e1> women thromboembolism <e2>vte</e2>
D017373_D054556 NONE <e1>cpa/ee</e1> ethinylestradiol acetate women <e2>thromboembolism</e2>
D017373_D054556 NONE <e1>cpa/ee</e1> ethinylestradiol acetate women thromboembolism <e2>vte</e2>
D017373_D054556 NONE <e1>cpa/ee</e1> women years years 3.4 risk <e2>vte</e2>
D017373_D054556 NONE <e1>cpa/ee</e1> taking women that similar suggest risk <e2>vte</e2>
D004997_D054556 NONE <e1>ethinylestradiol</e1> acetate women <e2>thromboembolism</e2>
D004997_D054556 NONE <e1>ethinylestradiol</e1> acetate women <e2>thromboembolism</e2>
D004997_D054556 NONE <e1>ethinylestradiol</e1> acetate women thromboembolism <e2>vte</e2>
D004997_D054556 NONE <e1>cpa/ee</e1> ethinylestradiol acetate women <e2>thromboembolism</e2>
D004997_D054556 NONE <e1>cpa/ee</e1> ethinylestradiol acetate women thromboembolism <e2>vte</e2>
D004997_D054556 NONE <e1>cpa/ee</e1> women years years 3.4 risk <e2>vte</e2>
D004997_D054556 NONE <e1>cpa/ee</e1> taking women that similar suggest risk <e2>vte</e2>
D003277_D054556 CID <e1>contraceptives</e1> women achieve estimates <e2>thromboembolism</e2>
D003277_D054556 CID <e1>contraceptives</e1> women achieve estimates thromboembolism <e2>vte</e2>
D003277_D054556 CID <e1>cocs</e1> contraceptives women achieve estimates <e2>thromboembolism</e2>
D003277_D054556 CID <e1>cocs</e1> contraceptives women achieve estimates thromboembolism <e2>vte</e2>
D003277_D054556 CID <e1>cocs</e1> found had <e2>vte</e2>
D003277_D054556 CID <e1>cocs</e1> women years 3.4 risk <e2>vte</e2>
D003277_D054556 CID <e1>cocs</e1> women years years 3.4 risk <e2>vte</e2>
D003277_D054556 CID <e1>cocs</e1> women <e2>vte</e2>
D016912_D054556 NONE <e1>levonorgestrel-containing</e1> cocs women years years 3.4 risk <e2>vte</e2>
3670965
D012459_D012202 NONE <e1>salicylates</e1> association lack disappearing <e2>syndrome</e2>
D001241_D012202 CID <e1>aspirin</e1> ingestion salicylates association lack disappearing <e2>syndrome</e2>
10692744
D000086_D005862 CID <e1>acetazolamide-induced</e1> <e2>syndrome</e2>
D000086_D005862 CID <e1>acetazolamide-induced</e1> <e2>syndrome</e2>
D000086_D003221 NONE <e1>acetazolamide</e1> induced <e2>confusion</e2>
D000086_D007674 NONE <e1>acetazolamide</e1> induced confusion reaction patients <e2>impairment</e2>
19940105
D018698_D010300 NONE <e1>glutamate</e1> subtype modulates models <e2>disease</e2>
D018698_D010300 NONE <e1>glutamate</e1> receptors modulate represent targets treatment <e2>disease</e2>
D018698_D010300 NONE <e1>glutamate</e1> receptors modulate represent targets treatment disease <e2>pd</e2>
C507346_D010300 NONE <e1>dihydrochloride</e1> effects tested models <e2>pd</e2>
C507346_D010300 NONE <e1>amn082</e1> dihydrochloride effects tested models <e2>pd</e2>
C507346_D010300 NONE <e1>amn082</e1> reverses task used evaluate symptoms patients <e2>pd</e2>
C507346_D010300 NONE <e1>amn082</e1> doses have models <e2>pd</e2>
C507346_D002375 NONE <e1>amn082</e1> administration oral reverses <e2>catalepsy</e2>
C507346_D002375 NONE <e1>amn082</e1> reduces duration <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol-induced</e1> <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol-induced</e1> <e2>catalepsy</e2>
C507346_D018476 NONE <e1>amn082</e1> reverses task used evaluate symptoms <e2>akinetic</e2>
D016627_D018476 NONE <e1>6-ohda-lesioned</e1> rats cue respond time reverses task used evaluate symptoms <e2>akinetic</e2>
D016627_D010300 NONE <e1>6-ohda-lesioned</e1> rats cue respond time reverses task used evaluate symptoms patients <e2>pd</e2>
2980315
C053571_D014693 NONE <e1>iopentol</e1> lower frequencies <e2>fibrillation</e2>
D007472_D014693 NONE <e1>iohexol</e1> iopentol lower frequencies <e2>fibrillation</e2>
D008794_D014693 CID <e1>metrizoate</e1> lower frequencies <e2>fibrillation</e2>
6433367
D011453_D012640 NONE <e1>prostaglandin</e1> synthetase inhibitors effect <e2>convulsions</e2>
D011453_D012640 NONE <e1>prostaglandins</e1> relationship <e2>seizure</e2>
D011453_D012640 NONE <e1>prostaglandins</e1> relationship investigate evaluated effects inhibitors <e2>convulsions</e2>
D011453_D012640 NONE <e1>pgs</e1> prostaglandins relationship <e2>seizure</e2>
D011453_D012640 NONE <e1>pgs</e1> prostaglandins relationship investigate evaluated effects inhibitors <e2>convulsions</e2>
D011453_D012640 NONE <e1>pgs</e1> involved underlying fluorthyl- <e2>convulsions</e2>
D011453_D012640 NONE <e1>pgs</e1> involved underlying fluorthyl- <e2>convulsions</e2>
D005481_D012640 CID <e1>flurothyl</e1> induced convulsions inhibitors effects evaluated investigate relationship <e2>seizure</e2>
D005481_D012640 CID <e1>flurothyl</e1> induced <e2>convulsions</e2>
D005481_D012640 CID <e1>fluorthyl-</e1> <e2>convulsions</e2>
D005481_D012640 CID <e1>fluorthyl-</e1> <e2>convulsions</e2>
D010852_D012640 CID <e1>picrotoxin</e1> flurothyl induced convulsions inhibitors effects evaluated investigate relationship <e2>seizure</e2>
D010852_D012640 CID <e1>picrotoxin</e1> flurothyl induced <e2>convulsions</e2>
D010852_D012640 CID <e1>picrotoxin-</e1> fluorthyl- <e2>convulsions</e2>
D010852_D012640 CID <e1>picrotoxin-</e1> fluorthyl- <e2>convulsions</e2>
D010433_D012640 CID <e1>pentetrazol</e1> flurothyl induced convulsions inhibitors effects evaluated investigate relationship <e2>seizure</e2>
D010433_D012640 CID <e1>pentetrazol</e1> flurothyl induced <e2>convulsions</e2>
D010433_D012640 CID <e1>ptz</e1> pentetrazol flurothyl induced convulsions inhibitors effects evaluated investigate relationship <e2>seizure</e2>
D010433_D012640 CID <e1>ptz</e1> pentetrazol flurothyl induced <e2>convulsions</e2>
D010433_D012640 CID <e1>ptz-induced</e1> fluorthyl- <e2>convulsions</e2>
D010433_D012640 CID <e1>ptz-induced</e1> fluorthyl- <e2>convulsions</e2>
D001640_D012640 CID <e1>bicuculline</e1> electroshock flurothyl induced convulsions inhibitors effects evaluated investigate relationship <e2>seizure</e2>
D001640_D012640 CID <e1>bicuculline</e1> electroshock flurothyl induced <e2>convulsions</e2>
D001640_D012640 CID <e1>bicuculline-induced</e1> picrotoxin- fluorthyl- <e2>convulsions</e2>
D001640_D012640 CID <e1>bicuculline-induced</e1> picrotoxin- fluorthyl- <e2>convulsions</e2>
16600756
D011453_D053201 NONE <e1>prostaglandins</e1> urine patients <e2>bladder</e2>
D011453_D053201 NONE <e1>pgs</e1> ngf changes women <e2>oab</e2>
D011453_D053201 NONE <e1>pg</e1> ngf correlations parameters patients <e2>oab</e2>
D011453_D053201 NONE <e1>pgs</e1> ngf have roles development symptoms <e2>oab</e2>
D015232_D053201 CID <e1>pge2</e1> ngf results increased patients <e2>oab</e2>
D015232_D053201 CID <e1>pge2</e1> <e2>oab</e2>
D015237_D053201 CID <e1>pgf2alpha</e1> pge2 ngf results increased patients <e2>oab</e2>
D015237_D053201 CID <e1>pgf2alpha</e1> ngf correlate parameters patients <e2>oab</e2>
D011464_D053201 NONE <e1>pgi2</e1> different controls patients <e2>oab</e2>
D011464_D053201 NONE <e1>pgi2</e1> ngf correlate parameters patients <e2>oab</e2>
8410199
D018698_D012640 NONE <e1>glutamate</e1> neurons loss <e2>seizures</e2>
D018698_D012640 NONE <e1>acid</e1> mrna-containing neurons vulnerable damage <e2>seizure-induced</e2>
D018698_D012640 NONE <e1>acid</e1> mrna-containing neurons vulnerable model <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine-induced</e1> <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine</e1> injected studied <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine-induced</e1> <e2>seizures</e2>
C028911_D009410 NONE <e1>violet</e1> staining methods <e2>degeneration</e2>
C028911_D009410 NONE <e1>violet</e1> staining studies suggested related <e2>loss</e2>
1636026
D013496_D058186 CID <e1>suprofen</e1> associated development <e2>failure</e2>
D013496_D058186 CID <e1>suprofen</e1> causes declines <e2>function</e2>
D013496_D007674 NONE <e1>suprofen</e1> mg dose effects <e2>nephrotoxic</e2>
D014527_D007674 NONE <e1>acid</e1> mg/dl addition perfused kidney compared effects <e2>nephrotoxic</e2>
D014527_D058186 NONE <e1>acid</e1> distribution altering causes declines <e2>function</e2>
6637851
D000638_D064420 NONE <e1>amiodarone</e1> therapy efficacy <e2>toxicity</e2>
D000638_D064420 NONE <e1>amiodarone</e1> effective causes <e2>toxicity</e2>
D000638_D017180 NONE <e1>amiodarone</e1> therapy <e2>tachycardia</e2>
D000638_D017180 NONE <e1>amiodarone</e1> administered patients sustained <e2>tachycardia</e2>
D000638_D017180 NONE <e1>amiodarone</e1> administered patients sustained tachycardia <e2>vt</e2>
D000638_D017180 NONE <e1>amiodarone</e1> treatment continued had recurrence <e2>vt</e2>
D000638_D017180 NONE <e1>amiodarone</e1> continuing managed had recurrence <e2>vt</e2>
D000638_D017180 NONE <e1>amiodarone</e1> effective treatment <e2>vt</e2>
D000638_D017180 NONE <e1>amiodarone</e1> managed % patients <e2>vt</e2>
D000638_D014693 NONE <e1>amiodarone</e1> therapy tachycardia <e2>fibrillation</e2>
D000638_D014693 NONE <e1>amiodarone</e1> treatment continued had recurrence vt <e2>fibrillation</e2>
D000638_D014693 NONE <e1>amiodarone</e1> treatment continued had recurrence vt fibrillation <e2>vf</e2>
D000638_D014693 NONE <e1>amiodarone</e1> effective treatment vt <e2>vf</e2>
D000638_D014693 NONE <e1>amiodarone</e1> managed % patients vt <e2>vf</e2>
D000638_D006323 NONE <e1>amiodarone</e1> administered patients sustained tachycardia <e2>arrest</e2>
12734532
D010665_D009203 CID <e1>dexatrim</e1> cause <e2>infarction</e2>
D010665_D009203 CID <e1>phenylpropanolamine</e1> dexatrim cause <e2>infarction</e2>
D010665_D009202 NONE <e1>ppa</e1> abuse <e2>injury</e2>
D010665_D009202 NONE <e1>dexatrim</e1> <e2>injury</e2>
D010665_D009202 NONE <e1>(ppa)-induced</e1> <e2>injury</e2>
D010665_D009202 NONE <e1>ppa</e1> <e2>injury</e2>
D010665_D062787 NONE <e1>ppa</e1> abuse linked involved <e2>overdose</e2>
3535719
D009428_D064420 NONE <e1>netilmicin</e1> efficacy <e2>toxicity</e2>
D014031_D064420 NONE <e1>tobramycin</e1> netilmicin efficacy <e2>toxicity</e2>
D009428_D007239 NONE <e1>sulfate</e1> efficacy compared patients <e2>infections</e2>
D014031_D007239 NONE <e1>sulfate</e1> efficacy compared patients <e2>infections</e2>
D010878_D007239 NONE <e1>sodium</e1> conjunction compared patients <e2>infections</e2>
D009428_D007674 CID <e1>netilmicin</e1> treated patients proportion occurred <e2>nephrotoxicity</e2>
D014031_D007674 CID <e1>tobramycin</e1> netilmicin treated patients proportion occurred <e2>nephrotoxicity</e2>
D009428_D006311 CID <e1>netilmicin</e1> occurred <e2>ototoxicity</e2>
D009428_D006311 CID <e1>netilmicin</e1> reversible severe <e2>ototoxicity</e2>
D010878_D006311 CID <e1>piperacillin</e1> netilmicin occurred <e2>ototoxicity</e2>
D010878_D006311 CID <e1>piperacillin-treated</e1> tobramycin netilmicin occurred <e2>ototoxicity</e2>
D014031_D006311 CID <e1>tobramycin</e1> netilmicin occurred <e2>ototoxicity</e2>
D014031_D006311 CID <e1>tobramycin</e1> reversible severe <e2>ototoxicity</e2>
D000617_D006311 NONE <e1>aminoglycoside-associated</e1> <e2>ototoxicity</e2>
6115999
D001539_D006973 NONE <e1>bendrofluazide</e1> treatment <e2>hypertension</e2>
D001539_D006973 NONE <e1>bendrofluazide</e1> one allocated participants trial <e2>hypertension</e2>
D011433_D006973 NONE <e1>propranolol</e1> bendrofluazide treatment <e2>hypertension</e2>
D011433_D006973 NONE <e1>propranolol</e1> bendrofluazide one allocated participants trial <e2>hypertension</e2>
D001539_D007172 CID <e1>bendrofluazide</e1> treatment <e2>impotence</e2>
D001539_D007172 CID <e1>bendrofluazide</e1> treatment association show occurred <e2>impotence</e2>
D011433_D007172 CID <e1>propranolol</e1> taking patients frequently occurred show association treatment <e2>impotence</e2>
D011433_D007172 CID <e1>propranolol</e1> taking patients frequently occurred <e2>impotence</e2>
D001539_D018149 CID <e1>bendrofluazide</e1> treatment associated <e2>tolerance</e2>
D001539_D006073 CID <e1>bendrofluazide</e1> treatment associated tolerance men women <e2>gout</e2>
D001539_D011928 NONE <e1>bendrofluazide</e1> treatment associated tolerance <e2>phenomenon</e2>
D001539_D004417 NONE <e1>bendrofluazide</e1> treatment associated tolerance phenomenon <e2>dyspnoea</e2>
D011433_D018149 NONE <e1>propranolol</e1> taking <e2>tolerance</e2>
D011433_D006073 NONE <e1>propranolol</e1> taking tolerance men women <e2>gout</e2>
D011433_D011928 CID <e1>propranolol</e1> taking tolerance <e2>phenomenon</e2>
D011433_D004417 CID <e1>propranolol</e1> taking tolerance phenomenon <e2>dyspnoea</e2>
D011433_D003316 NONE <e1>propranolol</e1> group occurred known <e2>disease</e2>
11847945
D007530_D002779 CID <e1>isoflurane</e1> exposure <e2>hepatitis</e2>
D007530_D002779 CID <e1>isoflurane</e1> exposure case <e2>hepatitis</e2>
D007530_D002779 CID <e1>isoflurane</e1> cause <e2>hepatitis</e2>
D007530_D056486 CID <e1>isoflurane</e1> exposure <e2>hepatitis</e2>
D007530_D056486 CID <e1>isoflurane</e1> exposure case <e2>hepatitis</e2>
D007530_D056486 CID <e1>isoflurane</e1> cause <e2>hepatitis</e2>
D004177_D000699 NONE <e1>dipyrone</e1> <e2>analgesia</e2>
12013711
D018967_D010468 CID <e1>risperidone-associated</e1> <e2>disturbances</e2>
D018967_D010468 CID <e1>risperidone</e1> treatment starting appeared episodes <e2>disturbances</e2>
D018967_D010468 CID <e1>risperidone</e1> administration continued wore <e2>disturbances</e2>
D018967_D012559 NONE <e1>risperidone-associated</e1> disturbances patients <e2>schizophrenic</e2>
D018967_D012559 NONE <e1>risperidone</e1> treated patients <e2>schizophrenic</e2>
D008238_D010468 NONE <e1>lsd</e1> abuse history patients <e2>disturbances</e2>
D008238_D010468 NONE <e1>lsd</e1> consumption related flashbacks experienced <e2>disturbances</e2>
D008238_D012559 NONE <e1>lsd</e1> abuse history patients <e2>schizophrenic</e2>
D008238_D012559 NONE <e1>lsd</e1> abuse history had patients <e2>schizophrenic</e2>
D008238_D001480 NONE <e1>lsd</e1> abuse history had developed <e2>eps</e2>
D018967_D001480 NONE <e1>risperidone</e1> treated patients had developed <e2>eps</e2>
19923525
D009553_D008569 NONE <e1>nimodipine</e1> prevents <e2>impairment</e2>
D009553_D007022 NONE <e1>nimodipine</e1> prevents impairment caused <e2>hypotension</e2>
D009553_D007022 NONE <e1>nimodipine</e1> administered onset <e2>hypotension</e2>
D009553_D007022 NONE <e1>nimo</e1> nimodipine administered onset <e2>hypotension</e2>
D009553_D007022 NONE <e1>nimo</e1> ntg saline injected those compared subjected episodes <e2>hypotensive</e2>
D009553_D007022 NONE <e1>nimo</e1> attenuated improve absence <e2>hypotension</e2>
D009553_D007022 NONE <e1>nimo</e1> effect attributable <e2>hypotension</e2>
D005996_D008569 CID <e1>nitroglycerin-induced</e1> hypotension caused <e2>impairment</e2>
D005996_D007022 CID <e1>nitroglycerin-induced</e1> <e2>hypotension</e2>
D005996_D007022 CID <e1>nitroglycerin</e1> (ntg)-induced <e2>hypotension</e2>
D005996_D007022 CID <e1>(ntg)-induced</e1> <e2>hypotension</e2>
D005996_D007022 CID <e1>ntg</e1> saline injected those compared subjected episodes <e2>hypotensive</e2>
D005996_D007022 CID <e1>ntg</e1> saline injected those compared subjected episodes <e2>hypotensive</e2>
D005996_D007022 CID <e1>ntg</e1> injection produced delayed <e2>hypotension</e2>
D005996_D007022 CID <e1>ntg</e1> caused consolidation disruption attenuated improve absence <e2>hypotension</e2>
D002118_D007022 NONE <e1>calcium</e1> homeostasis preservation attributable <e2>hypotension</e2>
6436733
D014635_D004827 NONE <e1>acid</e1> given patients <e2>epileptic</e2>
D014635_D004827 NONE <e1>vpa</e1> acid given patients <e2>epileptic</e2>
D000641_D006970 CID <e1>ammonia</e1> higher patients complained <e2>drowsiness</e2>
D000641_D006970 CID <e1>nh3</e1> ammonia higher patients complained <e2>drowsiness</e2>
D014635_D006970 CID <e1>vpa</e1> levels similar higher patients complained <e2>drowsiness</e2>
20533999
D004298_D020258 NONE <e1>dopamine</e1> essential development <e2>neurotoxicity</e2>
D004298_D020258 NONE <e1>da</e1> <e2>neurotoxicity</e2>
D004298_D020258 NONE <e1>da</e1> deficient engineered mice develop <e2>neurotoxicity</e2>
D004298_D020258 NONE <e1>da</e1> essential development <e2>neurotoxicity</e2>
D004298_D020258 NONE <e1>da</e1> independent mechanisms warrant suggest demonstrate essential development <e2>neurotoxicity</e2>
D008694_D020258 CID <e1>methamphetamine-induced</e1> <e2>neurotoxicity</e2>
D008694_D020258 CID <e1>meth-induced</e1> <e2>neurotoxicity</e2>
D008694_D020258 CID <e1>meth</e1> <e2>neurotoxicity</e2>
D008694_D020258 CID <e1>meth</e1> effects preserved long develop <e2>neurotoxicity</e2>
D008694_D020258 CID <e1>meth-induced</e1> <e2>neurotoxicity</e2>
D004298_D064420 NONE <e1>dopamine</e1> mediates <e2>toxicity</e2>
D004298_D064420 NONE <e1>dopamine</e1> mediates believed <e2>toxicity</e2>
D004298_D064420 NONE <e1>dopamine</e1> mediates believed enhance <e2>toxicity</e2>
D004298_D064420 NONE <e1>da</e1> dopamine mediates <e2>toxicity</e2>
D004298_D064420 NONE <e1>da</e1> dopamine mediates believed <e2>toxicity</e2>
D004298_D064420 NONE <e1>da</e1> dopamine mediates believed enhance <e2>toxicity</e2>
D004298_D064420 NONE <e1>da</e1> neurotransmission interfere drugs decrease toxicity believed mediates <e2>toxicity</e2>
D004298_D064420 NONE <e1>da</e1> neurotransmission interfere drugs decrease <e2>toxicity</e2>
D004298_D064420 NONE <e1>da</e1> neurotransmission interfere drugs decrease toxicity believed enhance <e2>toxicity</e2>
D004298_D064420 NONE <e1>da</e1> neurotransmission increase drugs enhance believed mediates <e2>toxicity</e2>
D004298_D064420 NONE <e1>da</e1> neurotransmission increase drugs enhance believed <e2>toxicity</e2>
D004298_D064420 NONE <e1>da</e1> neurotransmission increase drugs enhance <e2>toxicity</e2>
D008694_D064420 NONE <e1>methamphetamine</e1> <e2>toxicity</e2>
D008694_D064420 NONE <e1>methamphetamine</e1> toxicity mediates believed <e2>toxicity</e2>
D008694_D064420 NONE <e1>methamphetamine</e1> toxicity mediates believed enhance <e2>toxicity</e2>
D008694_D064420 NONE <e1>(meth)-induced</e1> <e2>toxicity</e2>
D008694_D064420 NONE <e1>(meth)-induced</e1> toxicity mediates believed <e2>toxicity</e2>
D008694_D064420 NONE <e1>(meth)-induced</e1> toxicity mediates believed enhance <e2>toxicity</e2>
D007980_D020258 NONE <e1>l-dihydroxyphenylalanine</e1> ability reverse effect <e2>neurotoxicity</e2>
D019805_D020258 NONE <e1>alpha-methyl-para-tyrosine</e1> effect <e2>neurotoxicity</e2>
D004298_D009461 NONE <e1>da</e1> deficits have engineered demonstrate develop <e2>deficits</e2>
D008694_D009461 NONE <e1>meth-induced</e1> <e2>deficits</e2>
15517007
D003520_D006331 CID <e1>cyclophosphamide</e1> used patients <e2>damage</e2>
D003520_D012595 NONE <e1>cyclophosphamide</e1> used patients <e2>sclerosis</e2>
D018943_D006331 NONE <e1>anthracyclines</e1> cyclophosphamide used patients <e2>damage</e2>
D018943_D012595 NONE <e1>anthracyclines</e1> cyclophosphamide used patients <e2>sclerosis</e2>
D008942_D006331 CID <e1>mitoxantrone</e1> cyclophosphamide used patients <e2>damage</e2>
D008942_D012595 NONE <e1>mitoxantrone</e1> cyclophosphamide used patients <e2>sclerosis</e2>
16157917
C047781_D009207 CID <e1>lamotrigine</e1> associated exacerbation <e2>myoclonus</e2>
C047781_D009207 CID <e1>lamotrigine</e1> treated epilepsies patients experienced exacerbation appearance <e2>jerks</e2>
C047781_D009207 CID <e1>lamotrigine</e1> treated epilepsies patients experienced exacerbation appearance jerks <e2>mj</e2>
C047781_D009207 CID <e1>ltg</e1> lamotrigine treated epilepsies patients experienced exacerbation appearance <e2>jerks</e2>
C047781_D009207 CID <e1>ltg</e1> lamotrigine treated epilepsies patients experienced exacerbation appearance jerks <e2>mj</e2>
C047781_D009207 CID <e1>ltg</e1> exacerbated <e2>mj</e2>
C047781_D009207 CID <e1>ltg</e1> dose decreased disappeared <e2>mj</e2>
C047781_D009207 CID <e1>ltg</e1> exacerbated <e2>mj</e2>
C047781_D009207 CID <e1>ltg</e1> exacerbated mj patients <e2>status</e2>
C047781_D009207 CID <e1>ltg</e1> withdrawal ceased status patients <e2>mj</e2>
C047781_D009207 CID <e1>ltg</e1> withdrawal ceased <e2>status</e2>
C047781_C562694 NONE <e1>lamotrigine</e1> associated exacerbation <e2>epilepsies</e2>
C047781_C562694 NONE <e1>lamotrigine</e1> treated <e2>epilepsies</e2>
C047781_C562694 NONE <e1>lamotrigine</e1> treated epilepsies <e2>ige</e2>
C047781_C562694 NONE <e1>ltg</e1> lamotrigine treated <e2>epilepsies</e2>
C047781_C562694 NONE <e1>ltg</e1> lamotrigine treated epilepsies <e2>ige</e2>
12911170
D002939_D009395 CID <e1>ciprofloxacin-induced</e1> <e2>nephritis</e2>
D002939_D009395 CID <e1>ciprofloxacin</e1> associated effects <e2>nephritis</e2>
D002939_D009395 CID <e1>ciprofloxacin-induced</e1> <e2>nephritis</e2>
D002939_D000744 NONE <e1>ciprofloxacin-induced</e1> nephritis <e2>anemia</e2>
D002939_D000744 NONE <e1>ciprofloxacin-induced</e1> nephritis <e2>anemia</e2>
D002939_D000743 CID <e1>ciprofloxacin</e1> associated effects nephritis <e2>anemia</e2>
D013256_D000743 NONE <e1>steroid</e1> therapy drug stopping improved <e2>anemia</e2>
2886572
D004837_D006973 CID <e1>epinephrine-induced</e1> rats <e2>hypertensive</e2>
2322844
D011453_D010146 NONE <e1>prostaglandins</e1> responses <e2>pain</e2>
D019342_D010146 NONE <e1>acid</e1> tests plate using evaluated effects administration prostaglandins responses <e2>pain</e2>
D015230_D006930 CID <e1>d2</e1> had action <e2>hyperalgesic</e2>
D015230_D006930 CID <e1>d2</e1> that showed effect <e2>hyperalgesic</e2>
D015230_D006930 CID <e1>d2</e1> effect <e2>hyperalgesic</e2>
D015230_D006930 CID <e1>d2</e1> exert <e2>hyperalgesia</e2>
D015232_D006930 CID <e1>e2</e1> showed effect <e2>hyperalgesic</e2>
D015232_D006930 CID <e1>e2-induced</e1> <e2>hyperalgesia</e2>
D015232_D006930 CID <e1>e2</e1> d2 exert <e2>hyperalgesia</e2>
D011453_D006930 NONE <e1>pg</e1> doses effect <e2>hyperalgesic</e2>
C053876_D006930 NONE <e1>ah6809</e1> antagonist injection blocked effect <e2>hyperalgesic</e2>
C053876_D006930 NONE <e1>ah6809</e1> blocked <e2>hyperalgesia</e2>
D015237_D010146 NONE <e1>alpha</e1> had responses <e2>pain</e2>
6150641
D002927_D007172 CID <e1>cimetidine</e1> taking developed changes <e2>impotence</e2>
D002927_D007172 CID <e1>cimetidine</e1> replaced disappeared developed changes <e2>impotence</e2>
D011899_D007172 NONE <e1>ranitidine</e1> replaced disappeared developed changes <e2>impotence</e2>
D002927_D056486 NONE <e1>cimetidine</e1> doses treatment associated <e2>toxicity</e2>
D002927_D056486 NONE <e1>cimetidine</e1> therapy seen associated associated <e2>toxicity</e2>
D002927_D006402 NONE <e1>cimetidine</e1> doses treatment associated <e2>toxicity</e2>
D002927_D006402 NONE <e1>cimetidine</e1> therapy seen associated associated <e2>toxicity</e2>
D011899_D056486 NONE <e1>ranitidine</e1> doses treatment associated <e2>toxicity</e2>
D011899_D056486 NONE <e1>ranitidine</e1> therapy associated associated <e2>toxicity</e2>
D011899_D006402 NONE <e1>ranitidine</e1> doses treatment associated <e2>toxicity</e2>
D011899_D006402 NONE <e1>ranitidine</e1> therapy associated associated <e2>toxicity</e2>
D003404_D056486 NONE <e1>creatinine</e1> level associated associated <e2>toxicity</e2>
D003404_D006402 NONE <e1>creatinine</e1> level associated associated <e2>toxicity</e2>
15075188
D011692_D009404 CID <e1>aminonucleoside-induced</e1> <e2>syndrome</e2>
D011692_D009404 CID <e1>pan-induced</e1> <e2>syndrome</e2>
D012964_D009404 NONE <e1>sodium</e1> retention accompanied <e2>syndrome</e2>
D012964_D009404 NONE <e1>sodium</e1> retention associated <e2>syndrome</e2>
D012964_D004487 NONE <e1>sodium</e1> retention <e2>edema</e2>
D011692_D011507 CID <e1>pan</e1> treatment induced <e2>proteinuria</e2>
D011692_D034141 CID <e1>pan</e1> treatment induced <e2>hypoalbuminemia</e2>
D011692_D001201 CID <e1>pan</e1> treatment induced decreased <e2>ascites</e2>
D012964_D011507 NONE <e1>sodium</e1> excretion decreased induced <e2>proteinuria</e2>
D012964_D034141 NONE <e1>sodium</e1> excretion decreased induced <e2>hypoalbuminemia</e2>
D012964_D001201 NONE <e1>sodium</e1> excretion decreased <e2>ascites</e2>
16006300
D002119_D064420 NONE <e1>carbonate</e1> <e2>toxicity</e2>
D002119_D006934 CID <e1>carbonate</e1> toxicity <e2>syndrome</e2>
D002119_D006934 CID <e1>carbonate-induced</e1> <e2>hypercalcemia</e2>
D002119_D006934 CID <e1>carbonate-induced</e1> hypercalcemia patients describe gain insights cause <e2>syndrome</e2>
D002119_D006934 CID <e1>carbonate</e1> amounts precipitated cause <e2>syndrome</e2>
D002119_D006934 CID <e1>carbonate</e1> amounts precipitated cause <e2>hypercalcemia</e2>
D002118_D006934 NONE <e1>calcium</e1> > <e2>hypercalcemia</e2>
D002118_D006934 NONE <e1>calcium</e1> > hypercalcemia presented review literature <e2>syndrome</e2>
C097949_D058186 NONE <e1>d</e1> concentrations had <e2>insufficiency</e2>
C097949_D000471 NONE <e1>d</e1> concentrations had insufficiency <e2>alkalosis</e2>
D002118_D006996 NONE <e1>calcium</e1> concentrations patients received caused <e2>hypocalcemia</e2>
C019248_D006996 CID <e1>pamidronate</e1> received caused <e2>hypocalcemia</e2>
C019248_D006996 CID <e1>pamidronate</e1> treatment associated risk <e2>hypocalcemia</e2>
C019248_D006934 NONE <e1>pamidronate</e1> treatment associated cases <e2>hypercalcemia</e2>
3115150
D007650_D009127 NONE <e1>ketanserin</e1> pretreatment reverses <e2>rigidity</e2>
D007650_D009127 NONE <e1>ketanserin</e1> pretreatment attenuated <e2>rigidity</e2>
D007650_D009127 NONE <e1>ketanserin</e1> received animals motionless absence <e2>rigidity</e2>
D015760_D009127 CID <e1>alfentanil-induced</e1> <e2>rigidity</e2>
D015760_D009127 CID <e1>alfentanil</e1> produced <e2>rigidity</e2>
D015760_D009127 CID <e1>alfentanil</e1> produced <e2>rigidity</e2>
D015760_D009127 CID <e1>alfentanil</e1> followed animals motionless absence <e2>rigidity</e2>
D015760_D009127 CID <e1>alfentanil</e1> receiving animals motionless absence <e2>rigidity</e2>
D012701_D009127 NONE <e1>serotonin</e1> receptor antagonist ketanserin pretreatment attenuated <e2>rigidity</e2>
D012701_D009127 NONE <e1>serotonin</e1> antagonists pretreatment useful attenuating <e2>rigidity</e2>
D002707_D009127 NONE <e1>chlordiazepoxide</e1> failed influence <e2>rigidity</e2>
D012701_D002318 NONE <e1>serotonin</e1> antagonists pretreatment useful necessary assess interaction cns <e2>depression</e2>
D012701_D012131 NONE <e1>serotonin</e1> antagonists pretreatment useful necessary assess interaction cns <e2>depression</e2>
18513945
D010121_D007022 CID <e1>oxytocin</e1> uterotonic cause <e2>hypotension</e2>
D010121_D007022 CID <e1>oxytocin-induced</e1> <e2>hypotension</e2>
D010121_D007022 CID <e1>oxytocin</e1> response <e2>hypotension</e2>
D010121_D006473 NONE <e1>oxytocin-induced</e1> hypotension attributed <e2>loss</e2>
D010121_D020521 NONE <e1>oxytocin</e1> response hypotension associated decrease increase volume <e2>stroke</e2>
2722224
D006854_D006973 CID <e1>hydrocortisone-induced</e1> <e2>hypertension</e2>
D006854_D006973 CID <e1>hydrocortisone</e1> <e2>pressure</e2>
D006854_D016534 NONE <e1>hydrocortisone</e1> pressure rise associated <e2>output</e2>
16720068
D017374_D009459 CID <e1>paroxetine</e1> treatment related <e2>syndrome</e2>
D017374_D009459 CID <e1>paroxetine</e1> occur demonstrating patient presented symptoms <e2>syndrome</e2>
D017374_D009459 CID <e1>paroxetine</e1> occur demonstrating patient presented symptoms syndrome <e2>nms</e2>
D017374_D009459 CID <e1>paroxetine</e1> occur symptoms <e2>nms-like</e2>
D000525_D009459 CID <e1>alprazolam</e1> paroxetine treatment related <e2>syndrome</e2>
D000525_D009459 CID <e1>alprazolam</e1> treatment paroxetine occur demonstrating patient presented symptoms <e2>syndrome</e2>
D000525_D009459 CID <e1>alprazolam</e1> treatment paroxetine occur demonstrating patient presented symptoms syndrome <e2>nms</e2>
D000525_D009459 CID <e1>alprazolam</e1> treatment paroxetine occur symptoms <e2>nms-like</e2>
D017374_D011596 NONE <e1>paroxetine</e1> day exhibited <e2>retardation</e2>
D017374_D009127 NONE <e1>paroxetine</e1> day exhibited retardation <e2>rigidity</e2>
D017374_D014202 NONE <e1>paroxetine</e1> day exhibited retardation <e2>tremors</e2>
D000525_D011596 NONE <e1>alprazolam</e1> paroxetine day exhibited <e2>retardation</e2>
D000525_D009127 NONE <e1>alprazolam</e1> paroxetine day exhibited retardation <e2>rigidity</e2>
D000525_D014202 NONE <e1>alprazolam</e1> paroxetine day exhibited retardation <e2>tremors</e2>
19721134
D010862_D001145 NONE <e1>pilocarpine</e1> effects evaluate designed using models <e2>arrhythmia</e2>
D010862_D001145 NONE <e1>pilocarpine</e1> delayed onset <e2>arrhythmias</e2>
D010862_D001145 NONE <e1>pilocarpine</e1> delayed showed decreased score <e2>arrhythmia</e2>
D010862_D001145 NONE <e1>pilocarpine</e1> delayed showed decreased increased time rats <e2>arrhythmic</e2>
D010862_D001145 NONE <e1>pilocarpine</e1> produced actions models rat <e2>arrhythmic</e2>
D000157_D001145 CID <e1>aconitine-induced</e1> rat models <e2>arrhythmia</e2>
D000157_D001145 CID <e1>aconitine</e1> induced models rat <e2>arrhythmic</e2>
D010042_D001145 CID <e1>ouabain-induced</e1> models <e2>arrhythmia</e2>
D010042_D001145 CID <e1>ouabain</e1> aconitine induced models rat <e2>arrhythmic</e2>
D010862_D017180 NONE <e1>pilocarpine</e1> delayed showed decreased course tachycardia <e2>fibrillation</e2>
D010862_D014693 NONE <e1>pilocarpine</e1> delayed showed decreased course tachycardia <e2>fibrillation</e2>
D002118_D001145 NONE <e1>ca(2</e1> of handling improvement related m(3)-machr. stimulating produced actions models rat <e2>arrhythmic</e2>
21294084
D010406_D004827 NONE <e1>penicillin</e1> induced model discharges <e2>epileptic</e2>
D010406_D004827 NONE <e1>penicillin</e1> induced model <e2>epilepsy</e2>
D010406_D004827 NONE <e1>penicillin-induced</e1> model activity <e2>epileptic</e2>
D010406_D004827 NONE <e1>penicillin-induced</e1> model <e2>epilepsy</e2>
D010406_D004827 NONE <e1>penicillin-induced</e1> activity <e2>epileptic</e2>
14742097
D004809_D020018 NONE <e1>ephedrine</e1> <e2>dysfunction</e2>
D004809_D020018 NONE <e1>ephedrine</e1> has reversing <e2>dysfunction</e2>
D004809_D020018 NONE <e1>ephedrine</e1> effects study participated women <e2>dysfunctional</e2>
D005473_D020018 CID <e1>fluoxetine</e1> receiving women <e2>dysfunctional</e2>
D020280_D020018 CID <e1>sertraline</e1> fluoxetine receiving women <e2>dysfunctional</e2>
D017374_D020018 CID <e1>paroxetine</e1> fluoxetine receiving women <e2>dysfunctional</e2>
11868798
D013148_D007008 NONE <e1>spironolactone</e1> drug prevention <e2>hypokalemia</e2>
D013148_D007008 NONE <e1>spironolactone</e1> ability reduce prevent <e2>hypokalemia</e2>
D013148_D007008 NONE <e1>spironolactone</e1> reduce prevent <e2>hypokalemia</e2>
D013148_D009369 NONE <e1>spironolactone</e1> drug prevention hypokalemia patients <e2>cancer</e2>
D000666_D007008 CID <e1>b-related</e1> <e2>hypokalemia</e2>
D000666_D007008 CID <e1>amb.</e1> depletion treatment effect seems designed assess ability reduce prevent <e2>hypokalemia</e2>
D000666_D007008 CID <e1>amb.</e1> toxicity potentiates seems designed assess ability reduce prevent <e2>hypokalemia</e2>
D000666_D007008 CID <e1>amb</e1> treatment patients <e2>hypokalemia</e2>
D000666_D007008 CID <e1>amb</e1> treatment patients reducing prevent <e2>hypokalemia</e2>
D000666_D009369 NONE <e1>b-related</e1> hypokalemia patients <e2>cancer</e2>
D000666_D007674 NONE <e1>b</e1> effect <e2>nephrotoxicity</e2>
D000666_D007674 NONE <e1>amb</e1> b effect <e2>nephrotoxicity</e2>
D011188_D064420 NONE <e1>potassium</e1> responsible seems <e2>toxicity</e2>
D011188_D064420 NONE <e1>potassium</e1> responsible seems potentiates <e2>toxicity</e2>
D011188_D064420 NONE <e1>potassium</e1> depletion treatment effect seems <e2>toxicity</e2>
D011188_D064420 NONE <e1>potassium</e1> depletion treatment effect seems potentiates <e2>toxicity</e2>
D011188_D064420 NONE <e1>potassium</e1> requirements reduce ability assess designed seems <e2>toxicity</e2>
D011188_D064420 NONE <e1>potassium</e1> requirements reduce ability assess designed seems potentiates <e2>toxicity</e2>
D011188_D007008 NONE <e1>potassium</e1> responsible seems designed assess ability reduce prevent <e2>hypokalemia</e2>
D011188_D007008 NONE <e1>potassium</e1> depletion treatment effect seems designed assess ability reduce prevent <e2>hypokalemia</e2>
D011188_D007008 NONE <e1>potassium</e1> requirements reduce prevent <e2>hypokalemia</e2>
D011188_D007008 NONE <e1>potassium</e1> requirements reduce prevent <e2>hypokalemia</e2>
D011188_D007008 NONE <e1>potassium</e1> loss reducing prevent <e2>hypokalemia</e2>
D011188_D009503 NONE <e1>potassium</e1> responsible seems designed assess ability reduce prevent hypokalemia patients <e2>neutropenic</e2>
D011188_D009503 NONE <e1>potassium</e1> depletion treatment effect seems designed assess ability reduce prevent hypokalemia patients <e2>neutropenic</e2>
D011188_D009503 NONE <e1>potassium</e1> requirements reduce prevent hypokalemia patients <e2>neutropenic</e2>
D011188_D009503 NONE <e1>potassium</e1> requirements reduce prevent reducing patients <e2>neutropenic</e2>
D011188_D009503 NONE <e1>potassium</e1> loss reducing patients <e2>neutropenic</e2>
D000666_D064420 NONE <e1>amb.</e1> depletion treatment effect seems <e2>toxicity</e2>
D000666_D064420 NONE <e1>amb.</e1> depletion treatment effect seems potentiates <e2>toxicity</e2>
D000666_D064420 NONE <e1>amb.</e1> toxicity potentiates seems <e2>toxicity</e2>
D000666_D064420 NONE <e1>amb.</e1> <e2>toxicity</e2>
D000666_D064420 NONE <e1>amb</e1> treatment patients hypokalemia prevent reduce ability assess designed seems <e2>toxicity</e2>
D000666_D064420 NONE <e1>amb</e1> treatment patients hypokalemia prevent reduce ability assess designed seems potentiates <e2>toxicity</e2>
D000666_D009503 NONE <e1>amb.</e1> depletion treatment effect seems designed assess ability reduce prevent hypokalemia patients <e2>neutropenic</e2>
D000666_D009503 NONE <e1>amb.</e1> toxicity potentiates seems designed assess ability reduce prevent hypokalemia patients <e2>neutropenic</e2>
D000666_D009503 NONE <e1>amb</e1> treatment patients <e2>neutropenic</e2>
D000666_D009503 NONE <e1>amb</e1> treatment patients <e2>neutropenic</e2>
D013148_D064420 NONE <e1>spironolactone</e1> ability assess designed seems <e2>toxicity</e2>
D013148_D064420 NONE <e1>spironolactone</e1> ability assess designed seems potentiates <e2>toxicity</e2>
D013148_D009503 NONE <e1>spironolactone</e1> ability reduce prevent hypokalemia patients <e2>neutropenic</e2>
D013148_D009503 NONE <e1>spironolactone</e1> reduce prevent reducing patients <e2>neutropenic</e2>
D000666_D006402 NONE <e1>amb</e1> receive randomized patients <e2>disorders</e2>
D000666_D006402 NONE <e1>amb</e1> amb receive randomized patients <e2>disorders</e2>
D000666_D009181 NONE <e1>amb</e1> receive developing <e2>infection</e2>
D000666_D009181 NONE <e1>amb</e1> amb receive developing <e2>infection</e2>
D013148_D006402 NONE <e1>spironolactone</e1> amb receive randomized patients <e2>disorders</e2>
D013148_D009181 NONE <e1>spironolactone</e1> amb receive developing <e2>infection</e2>
12549952
D016642_D017114 CID <e1>bupropion</e1> <e2>failure</e2>
D016642_D017114 CID <e1>bupropion</e1> induced hepatotoxicity evidence is case resulted <e2>failure</e2>
D016642_D017114 CID <e1>bupropion</e1> receiving patient <e2>failure</e2>
D016642_D017114 CID <e1>bupropion</e1> induced <e2>insult</e2>
D002231_D017114 CID <e1>carbimazole</e1> therapy bupropion <e2>failure</e2>
D002231_D017114 CID <e1>carbimazole</e1> treatment resulted <e2>failure</e2>
D016642_D017093 NONE <e1>bupropion</e1> use associated <e2>failure</e2>
D002231_D017093 NONE <e1>carbimazole</e1> bupropion use associated <e2>failure</e2>
D002231_D006980 NONE <e1>carbimazole</e1> treated summary man history <e2>hyperthyroidism</e2>
D011433_D006980 NONE <e1>propranolol</e1> carbimazole treated summary man history <e2>hyperthyroidism</e2>
D016642_D056486 CID <e1>bupropion</e1> induced <e2>hepatotoxicity</e2>
D016642_D056486 CID <e1>bupropion</e1> induced <e2>hepatotoxicity</e2>
D016642_D056486 CID <e1>bupropion</e1> receiving patient failure resulted case is evidence <e2>hepatotoxicity</e2>
D016642_D056486 CID <e1>bupropion</e1> induced drugs <e2>hepatotoxic</e2>
D002231_D056486 CID <e1>carbimazole</e1> treatment resulted case is evidence <e2>hepatotoxicity</e2>
7197363
D001058_D012892 NONE <e1>apomorphine-induced</e1> aggressiveness effects <e2>deprivation</e2>
D001058_D012892 NONE <e1>apomorphine-induced</e1> aggressiveness effects deprivation <e2>remd</e2>
D001058_D012892 NONE <e1>apomorphine-induced</e1> aggressiveness increased hr <e2>remd</e2>
D001058_D012892 NONE <e1>apomorphine-induced</e1> aggressiveness increased reduced completing <e2>remd</e2>
D001058_D012892 NONE <e1>apomorphine-induced</e1> aggressiveness increased reduced completing <e2>remd</e2>
D001058_D001523 CID <e1>apomorphine-induced</e1> <e2>aggressiveness</e2>
D001058_D001523 CID <e1>apomorphine-induced</e1> <e2>aggressiveness</e2>
D001058_D009069 NONE <e1>apomorphine-induced</e1> aggressiveness effects <e2>twitches</e2>
D001058_D009069 NONE <e1>apomorphine-induced</e1> aggressiveness increased reduced completing <e2>twitches</e2>
D011814_D012892 NONE <e1>quipazine-induced</e1> head aggressiveness effects <e2>deprivation</e2>
D011814_D012892 NONE <e1>quipazine-induced</e1> head aggressiveness effects deprivation <e2>remd</e2>
D011814_D012892 NONE <e1>quipazine-induced</e1> head twitches completing reduced increased hr <e2>remd</e2>
D011814_D012892 NONE <e1>quipazine-induced</e1> head twitches completing reduced completing <e2>remd</e2>
D011814_D012892 NONE <e1>quipazine-induced</e1> head twitches completing <e2>remd</e2>
D011814_D001523 NONE <e1>quipazine-induced</e1> head <e2>aggressiveness</e2>
D011814_D001523 NONE <e1>quipazine-induced</e1> head twitches completing reduced increased <e2>aggressiveness</e2>
D011814_D009069 CID <e1>quipazine-induced</e1> head aggressiveness effects <e2>twitches</e2>
D011814_D009069 CID <e1>quipazine-induced</e1> head <e2>twitches</e2>
8665051
D000305_D009135 NONE <e1>corticosteroids</e1> doses treated patients occur <e2>myopathy</e2>
D008775_D000855 CID <e1>methylprednisolone</e1> saline injection receive assigned showed reduction <e2>intake</e2>
D008775_D000855 CID <e1>m</e1> methylprednisolone saline injection receive assigned showed reduction <e2>intake</e2>
D008775_D000855 CID <e1>m</e1> % groups reduction <e2>intake</e2>
D014221_D000855 CID <e1>triamcinolone</e1> saline injection receive assigned showed reduction <e2>intake</e2>
D014221_D000855 CID <e1>t</e1> triamcinolone saline injection receive assigned showed reduction <e2>intake</e2>
D014221_D000855 CID <e1>t</e1> m % groups reduction <e2>intake</e2>
D013256_D000855 NONE <e1>steroid-treated</e1> groups reduction <e2>intake</e2>
D013256_D013746 NONE <e1>steroid</e1> groups prolonged similar tensions <e2>tetanic</e2>
D008775_D013746 NONE <e1>m</e1> longer prolonged similar tensions <e2>tetanic</e2>
D013256_D009133 NONE <e1>steroid</e1> groups showed <e2>atrophy</e2>
D013256_D009133 NONE <e1>steroid</e1> groups <e2>atrophy</e2>
D013256_D009133 NONE <e1>steroids</e1> doses treatment induced caused <e2>atrophy</e2>
D013256_D009133 NONE <e1>steroids</e1> types induced caused <e2>atrophy</e2>
D013256_D009133 NONE <e1>steroid</e1> caused induced caused <e2>atrophy</e2>
D013256_D009336 NONE <e1>steroid</e1> groups showed revealed pattern absence <e2>necrosis</e2>
D013256_D009336 NONE <e1>steroids</e1> doses treatment induced caused <e2>necrosis</e2>
D013256_D009336 NONE <e1>steroids</e1> types induced caused <e2>necrosis</e2>
D013256_D009336 NONE <e1>steroid</e1> caused <e2>necrosis</e2>
D014221_D009133 CID <e1>t</e1> atrophy groups showed <e2>atrophy</e2>
D014221_D009133 CID <e1>t</e1> <e2>atrophy</e2>
D014221_D009133 CID <e1>t</e1> c rats performed study showed pronounced <e2>atrophy</e2>
D014221_D009133 CID <e1>t-treated</e1> animals pronounced <e2>atrophy</e2>
D014221_D009336 NONE <e1>t</e1> atrophy groups showed revealed pattern absence <e2>necrosis</e2>
D013256_D001284 NONE <e1>steroids</e1> doses treatment induced types induced <e2>atrophy</e2>
D013256_D001284 NONE <e1>steroids</e1> types induced <e2>atrophy</e2>
D013256_D001284 NONE <e1>steroid</e1> caused induced types induced <e2>atrophy</e2>
2709684
D010695_D006029 NONE <e1>phlorizin-induced</e1> <e2>glycosuria</e2>
D010695_D006029 NONE <e1>p</e1> treated animals that degree similar rats <e2>glycosuria</e2>
D010695_D006029 NONE <e1>p</e1> induced <e2>glycosuria</e2>
D010695_D007674 NONE <e1>phlorizin-induced</e1> glycosuria prevent <e2>nephrotoxicity</e2>
D010695_D007674 NONE <e1>phlorizin</e1> reabsorption blockage induced diuresis rats studied protection <e2>nephrotoxicity</e2>
D010695_D007674 NONE <e1>p</e1> phlorizin reabsorption blockage induced diuresis rats studied protection <e2>nephrotoxicity</e2>
D010695_D007674 NONE <e1>p</e1> induced evidence <e2>dysfunction</e2>
D005839_D006029 NONE <e1>gentamicin</e1> nephrotoxicity prevent <e2>glycosuria</e2>
D005839_D006029 NONE <e1>gentamicin-induced</e1> failure resistance responsible suggested have diuresis <e2>glycosuria</e2>
D005839_D007674 NONE <e1>gentamicin</e1> <e2>nephrotoxicity</e2>
D005839_D007674 NONE <e1>gentamicin</e1> <e2>nephrotoxicity</e2>
D005839_D007674 NONE <e1>gentamicin</e1> doses <e2>nephrotoxic</e2>
D013311_D003920 CID <e1>streptozotocin-induced</e1> <e2>mellitus</e2>
D013311_D003920 CID <e1>streptozotocin-induced</e1> mellitus <e2>dm</e2>
D013311_D006029 NONE <e1>streptozotocin-induced</e1> mellitus rats have diuresis <e2>glycosuria</e2>
D013311_D058186 NONE <e1>streptozotocin-induced</e1> mellitus rats have suggested responsible resistance <e2>failure</e2>
D013311_D058186 NONE <e1>streptozotocin-induced</e1> mellitus rats have suggested responsible resistance failure <e2>arf</e2>
D005839_D003920 NONE <e1>gentamicin-induced</e1> failure resistance responsible suggested have rats <e2>mellitus</e2>
D005839_D003920 NONE <e1>gentamicin-induced</e1> failure resistance responsible suggested have rats mellitus <e2>dm</e2>
D005839_D003920 NONE <e1>gentamicin</e1> nephrotoxicity protection studied rats <e2>non-diabetic</e2>
D005839_D003920 NONE <e1>gentamicin</e1> p group group <e2>dm</e2>
D005839_D003920 NONE <e1>gentamicin</e1> group group group <e2>dm</e2>
D005839_D003920 NONE <e1>gentamicin</e1> <e2>dm</e2>
D005839_D058186 CID <e1>gentamicin-induced</e1> <e2>failure</e2>
D005839_D058186 CID <e1>gentamicin-induced</e1> failure <e2>arf</e2>
D005839_D058186 CID <e2><e1>gentamicin-arf</e1></e2>
D005947_D007674 NONE <e1>glucose</e1> reabsorption blockage induced diuresis rats studied protection <e2>nephrotoxicity</e2>
D005947_D003920 NONE <e1>glucose</e1> reabsorption blockage induced diuresis rats <e2>non-diabetic</e2>
D010695_D003920 NONE <e1>phlorizin</e1> reabsorption blockage induced diuresis rats <e2>non-diabetic</e2>
D010695_D003920 NONE <e1>p</e1> phlorizin reabsorption blockage induced diuresis rats <e2>non-diabetic</e2>
D010695_D003920 NONE <e1>p</e1> treated animals that degree similar rats <e2>dm</e2>
D010695_D003920 NONE <e1>p</e1> group received group group <e2>dm</e2>
D010695_D003920 NONE <e1>p</e1> received group group <e2>dm</e2>
D010695_D003920 NONE <e1>p</e1> group group <e2>dm</e2>
D010695_D009956 NONE <e1>p</e1> induced evidence score <e2>necrosis</e2>
D010695_D009956 NONE <e1>p</e1> prevent gentamicin-arf decrease lysozymuria score <e2>necrosis</e2>
D010695_D009956 NONE <e1>p</e1> % decrease lysozymuria score <e2>necrosis</e2>
D010695_D009956 NONE <e1>p</e1> % decrease different score <e2>necrosis</e2>
D010695_D058186 NONE <e1>p</e1> prevent <e2>gentamicin-arf</e2>
D010695_D058186 NONE <e1>p</e1> % decrease <e2>gentamicin-arf</e2>
D005839_D009956 NONE <e1>gentamicin-arf</e1> decrease lysozymuria score <e2>necrosis</e2>
15531665
D001205_D002318 CID <e1>c</e1> increase risk <e2>disease</e2>
D001205_D002318 CID <e1>c</e1> intake mortality <e2>disease</e2>
D001205_D002318 CID <e1>c</e1> intake <e2>disease</e2>
D001205_D002318 CID <e1>c</e1> intake quintiles intakes assessed adjustment factors <e2>disease</e2>
D001205_D002318 CID <e1>c</e1> intake quintiles intakes risks mortality <e2>disease</e2>
D001205_D002318 CID <e1>c</e1> intake unrelated mortality <e2>disease</e2>
D001205_D002318 CID <e1>c</e1> intake associated risk mortality <e2>disease</e2>
D001205_D003920 NONE <e1>c</e1> increase risk women <e2>diabetes</e2>
D001205_D003920 NONE <e1>c</e1> intake persons <e2>diabetic</e2>
D001205_D003920 NONE <e1>c</e1> intake relation stroke women reported <e2>diabetic</e2>
D001205_D003920 NONE <e1>c</e1> intake quintiles intakes assessed adjustment factors type medication <e2>diabetes</e2>
D001205_D003920 NONE <e1>c</e1> intake quintiles intakes assessed adjustment factors duration <e2>diabetes</e2>
D001205_D003920 NONE <e1>c</e1> intake associated risk mortality women <e2>diabetes</e2>
D001205_D050197 NONE <e1>c</e1> intake promote <e2>atherosclerosis</e2>
D001205_D003324 NONE <e1>c</e1> intake relation <e2>disease</e2>
D001205_D003324 NONE <e1>c</e1> intake quintiles intakes assessed followed subjects free <e2>disease</e2>
D001205_D020521 NONE <e1>c</e1> intake relation <e2>stroke</e2>
D005492_D003324 NONE <e1>folate</e1> intakes assessed followed subjects free <e2>disease</e2>
D005492_D002318 NONE <e1>folate</e1> intakes assessed adjustment factors <e2>disease</e2>
D005492_D002318 NONE <e1>folate</e1> intakes risks mortality <e2>disease</e2>
D005492_D003920 NONE <e1>folate</e1> intakes assessed adjustment factors type medication <e2>diabetes</e2>
D005492_D003920 NONE <e1>folate</e1> intakes assessed adjustment factors duration <e2>diabetes</e2>
D014810_D003324 NONE <e1>e</e1> folate intakes assessed followed subjects free <e2>disease</e2>
D014810_D002318 NONE <e1>e</e1> folate intakes assessed adjustment factors <e2>disease</e2>
D014810_D002318 NONE <e1>e</e1> folate intakes risks mortality <e2>disease</e2>
D014810_D003920 NONE <e1>e</e1> folate intakes assessed adjustment factors type medication <e2>diabetes</e2>
D014810_D003920 NONE <e1>e</e1> folate intakes assessed adjustment factors duration <e2>diabetes</e2>
D019207_D003324 NONE <e1>beta-carotene</e1> folate intakes assessed followed subjects free <e2>disease</e2>
D019207_D002318 NONE <e1>beta-carotene</e1> folate intakes assessed adjustment factors <e2>disease</e2>
D019207_D002318 NONE <e1>beta-carotene</e1> folate intakes risks mortality <e2>disease</e2>
D019207_D003920 NONE <e1>beta-carotene</e1> folate intakes assessed adjustment factors type medication <e2>diabetes</e2>
D019207_D003920 NONE <e1>beta-carotene</e1> folate intakes assessed adjustment factors duration <e2>diabetes</e2>
16563323
C071741_D009207 NONE <e1>remifentanil</e1> pretreatment reduces <e2>myoclonus</e2>
C071741_D009207 NONE <e1>remifentanil</e1> microg/kg pretreatment effect effect incidence <e2>myoclonus</e2>
C071741_D009207 NONE <e1>remifentanil</e1> group lower incidence <e2>myoclonus</e2>
C071741_D009207 NONE <e1>remifentanil</e1> pretreatment <e2>myoclonus</e2>
D005045_D009207 CID <e1>etomidate</e1> reduces <e2>myoclonus</e2>
D005045_D009207 CID <e1>etomidate</e1> induction effect incidence <e2>myoclonus</e2>
D005045_D009207 CID <e1>etomidate</e1> administration incidence <e2>myoclonus</e2>
D005045_D009207 CID <e1>etomidate</e1> induction pretreatment <e2>myoclonus</e2>
D005045_D009207 CID <e1>etomidate</e1> administration women increased incidence <e2>myoclonus</e2>
C071741_D001049 NONE <e1>remifentanil</e1> pretreatment induction effects sedation <e2>apnea</e2>
C071741_D009325 NONE <e1>remifentanil</e1> pretreatment induction effects sedation apnea <e2>nausea</e2>
C071741_D011537 NONE <e1>remifentanil</e1> pretreatment induction effects sedation apnea nausea <e2>pruritus</e2>
D005045_D001049 NONE <e1>etomidate</e1> induction effects sedation <e2>apnea</e2>
D005045_D009325 NONE <e1>etomidate</e1> induction effects sedation apnea <e2>nausea</e2>
D005045_D011537 NONE <e1>etomidate</e1> induction effects sedation apnea nausea <e2>pruritus</e2>
16584858
C013592_D009203 NONE <e1>mangiferin</e1> role <e2>infarction</e2>
C013592_D009203 NONE <e1>mangiferin</e1> role dealt <e2>infarction</e2>
C013592_D009203 NONE <e1>mangiferin</e1> role dealt infarction <e2>mi</e2>
C013592_D009203 NONE <e1>mangiferin</e1> given days rats <e2>mi</e2>
C013592_D009203 NONE <e1>mangiferin</e1> administration rose compared rats <e2>mi</e2>
C013592_D009203 NONE <e1>mangiferin</e1> exerts effect <e2>mi</e2>
D007545_D009203 CID <e1>isoproterenol-induced</e1> <e2>infarction</e2>
D007545_D009203 CID <e1>isoproterenol</e1> <e2>infarction</e2>
D007545_D009203 CID <e1>isoproterenol</e1> infarction <e2>mi</e2>
D007545_D009203 CID <e1>(isph)-induced</e1> <e2>infarction</e2>
D007545_D009203 CID <e1>(isph)-induced</e1> infarction <e2>mi</e2>
D007545_D009203 CID <e1>isph-induced</e1> rats <e2>mi</e2>
D007545_D009203 CID <e1>isph-induced</e1> <e2>mi</e2>
D059808_D009203 NONE <e1>polyphenol</e1> mangiferin role dealt <e2>infarction</e2>
D059808_D009203 NONE <e1>polyphenol</e1> mangiferin role dealt infarction <e2>mi</e2>
D007545_D009202 NONE <e1>isph</e1> injection caused <e2>damage</e2>
D019344_D009202 NONE <e1>lactate</e1> dehydrogenase activity determined <e2>damage</e2>
D003401_D009202 NONE <e1>creatine</e1> phosphokinase isoenzymes dehydrogenase activity determined <e2>damage</e2>
D014527_D009202 NONE <e1>acid</e1> level dehydrogenase activity determined <e2>damage</e2>
D007501_D009202 NONE <e1>iron</e1> capacity activity determined <e2>damage</e2>
C013592_D017202 NONE <e1>mangiferin</e1> role analyzed test assay <e2>myocardium</e2>
C009591_D017202 NONE <e1>chloride</e1> analyzed test assay <e2>myocardium</e2>
C009591_D017202 NONE <e1>ttc</e1> chloride analyzed test assay <e2>myocardium</e2>
D013481_D009203 NONE <e1>superoxide</e1> dismutase enzymes altered rats <e2>mi</e2>
D005978_D009203 NONE <e1>glutathione</e1> peroxidase dismutase enzymes altered rats <e2>mi</e2>
D005978_D009203 NONE <e1>glutathione</e1> transferase dismutase enzymes altered rats <e2>mi</e2>
D005978_D009203 NONE <e1>glutathione</e1> reductase activities dismutase enzymes altered rats <e2>mi</e2>
D005978_D009203 NONE <e1>glutathione</e1> levels cerruloplasmin antioxidants dismutase enzymes altered rats <e2>mi</e2>
D001205_D009203 NONE <e1>c</e1> cerruloplasmin antioxidants dismutase enzymes altered rats <e2>mi</e2>
D014810_D009203 NONE <e1>e</e1> cerruloplasmin antioxidants dismutase enzymes altered rats <e2>mi</e2>
D004121_D009203 NONE <e1>sulphoxide</e1> ml suspended weight mangiferin given days rats <e2>mi</e2>
C013592_D006331 NONE <e1>mangiferin</e1> exerts potential regulated system <e2>damage</e2>
D007545_D006331 NONE <e1>isph-induced</e1> mi effect exerts potential regulated system <e2>damage</e2>
2004
D013881_D017180 CID <e1>mellaril</e1> drugs receiving appeared responsible cases <e2>tachycardia</e2>
D013881_D017180 CID <e1>thioridazine</e1> mellaril drugs receiving appeared responsible cases <e2>tachycardia</e2>
D002746_D013617 NONE <e1>thorazine</e1> receiving patient developed <e2>tachycardia</e2>
D002746_D013617 NONE <e1>chlorpromazine</e1> thorazine receiving patient developed <e2>tachycardia</e2>
D009661_D002037 CID <e1>aventyl</e1> produced <e2>block</e2>
D009661_D002037 CID <e1>nortriptyline</e1> aventyl produced <e2>block</e2>
D000639_D002037 CID <e1>elavil</e1> aventyl produced <e2>block</e2>
D000639_D002037 CID <e1>amitriptyline</e1> elavil aventyl produced <e2>block</e2>
D008012_D001145 NONE <e1>lidocaine</e1> administration responded <e2>arrhythmias</e2>
D011433_D001145 NONE <e1>propranolol</e1> administration instances required responded <e2>arrhythmias</e2>
D010640_D005117 NONE <e1>phenothiazines</e1> receiving patients <e2>complications</e2>
12745515
D016642_D012640 CID <e1>bupropion</e1> deprivation associated <e2>seizure</e2>
D016642_D012640 CID <e1>bupropion</e1> use associated <e2>seizure</e2>
D016642_D012640 CID <e1>bupropion</e1> use weeks experienced <e2>seizure</e2>
D016642_D012640 CID <e1>bupropion-associated</e1> <e2>seizures</e2>
D016642_D012892 NONE <e1>bupropion</e1> <e2>deprivation</e2>
D016642_D012892 NONE <e1>bupropion</e1> use <e2>deprivation</e2>
D016642_D012892 NONE <e1>bupropion-associated</e1> seizures risk add <e2>deprivation</e2>
3708922
D016572_D007674 CID <e1>cyclosporine</e1> <e2>nephrotoxicity</e2>
D016572_D007674 CID <e1>cyclosporine</e1> of csa role combination development <e2>toxicity</e2>
D016572_D007674 CID <e1>csa</e1> role combination development <e2>toxicity</e2>
D016572_D007674 CID <e1>csa</e1> administration potential <e2>nephrotoxic</e2>
D016572_D007674 CID <e1>csa</e1> induced toxicity aggravate administration potential <e2>nephrotoxic</e2>
D016572_D007674 CID <e1>csa</e1> <e2>nephrotoxicity</e2>
D016572_D007674 CID <e1>csa</e1> induced <e2>nephrotoxicity</e2>
D016572_D064420 NONE <e1>csa</e1> administration aggravate <e2>toxicity</e2>
D016572_D064420 NONE <e1>csa</e1> induced <e2>toxicity</e2>
D005839_D007674 NONE <e1>gentamicin</e1> potential <e2>nephrotoxic</e2>
D005839_D007674 NONE <e1>gentamicin</e1> <e2>nephrotoxicity</e2>
D005839_D064420 NONE <e1>gentamicin</e1> potential administration aggravate <e2>toxicity</e2>
D000666_D007674 NONE <e1>b</e1> administration potential <e2>nephrotoxic</e2>
D000666_D064420 NONE <e1>b</e1> administration aggravate <e2>toxicity</e2>
D007654_D007674 NONE <e1>ketoconazole</e1> b administration potential <e2>nephrotoxic</e2>
D007654_D064420 NONE <e1>ketoconazole</e1> b administration aggravate <e2>toxicity</e2>
15266215
C406224_D013927 NONE <e1>valdecoxib</e1> effects agents placebo events <e2>thrombotic</e2>
C406224_D013927 NONE <e1>valdecoxib</e1> analyzing determined incidence events <e2>thrombotic</e2>
C406224_D013927 NONE <e1>valdecoxib</e1> analyzing determined incidence events cardiac <e2>thrombotic</e2>
C406224_D013927 NONE <e1>valdecoxib</e1> similar crude events <e2>thrombotic</e2>
C406224_D013927 NONE <e1>valdecoxib</e1> dose similar risk events <e2>thrombotic</e2>
C406224_D013927 NONE <e1>valdecoxib</e1> placebo nonusers users higher risk <e2>thrombotic</e2>
C406224_D013927 NONE <e1>valdecoxib</e1> doses associated incidence events <e2>thrombotic</e2>
C406224_D001168 NONE <e1>valdecoxib</e1> effects agents placebo events patients <e2>arthritis</e2>
C406224_D010003 NONE <e1>valdecoxib</e1> data evaluated inhibitor patients <e2>osteoarthritis</e2>
C406224_D010003 NONE <e1>valdecoxib</e1> analyzing nsaid diclofenac <e2>osteoarthritis</e2>
C406224_D010003 NONE <e1>valdecoxib</e1> doses associated incidence relative placebo <e2>osteoarthritis</e2>
C406224_D001172 NONE <e1>valdecoxib</e1> data evaluated inhibitor patients osteoarthritis <e2>arthritis</e2>
C406224_D001172 NONE <e1>valdecoxib</e1> analyzing nsaid diclofenac osteoarthritis trials <e2>arthritis</e2>
C406224_D001172 NONE <e1>valdecoxib</e1> doses associated incidence relative placebo osteoarthritis patients <e2>arthritis</e2>
D004008_D013927 NONE <e1>diclofenac</e1> nsaid analyzing determined incidence events <e2>thrombotic</e2>
D004008_D013927 NONE <e1>diclofenac</e1> nsaid analyzing determined incidence events cardiac <e2>thrombotic</e2>
D004008_D010003 NONE <e1>diclofenac</e1> <e2>osteoarthritis</e2>
D004008_D001172 NONE <e1>diclofenac</e1> osteoarthritis trials <e2>arthritis</e2>
D007052_D013927 NONE <e1>ibuprofen</e1> diclofenac nsaid analyzing determined incidence events <e2>thrombotic</e2>
D007052_D013927 NONE <e1>ibuprofen</e1> diclofenac nsaid analyzing determined incidence events cardiac <e2>thrombotic</e2>
D007052_D010003 NONE <e1>ibuprofen</e1> diclofenac <e2>osteoarthritis</e2>
D007052_D001172 NONE <e1>ibuprofen</e1> diclofenac osteoarthritis trials <e2>arthritis</e2>
D009288_D013927 NONE <e1>naproxen</e1> diclofenac nsaid analyzing determined incidence events <e2>thrombotic</e2>
D009288_D013927 NONE <e1>naproxen</e1> diclofenac nsaid analyzing determined incidence events cardiac <e2>thrombotic</e2>
D009288_D010003 NONE <e1>naproxen</e1> diclofenac <e2>osteoarthritis</e2>
D009288_D001172 NONE <e1>naproxen</e1> diclofenac osteoarthritis trials <e2>arthritis</e2>
D001241_D013927 CID <e1>aspirin</e1> users users higher risk <e2>thrombotic</e2>
D001241_D013927 CID <e1>aspirin</e1> nonusers users higher risk <e2>thrombotic</e2>
3311455
D016572_D007674 CID <e1>cyclosporine</e1> therapy secondary <e2>nephrotoxicity</e2>
D016572_D007674 CID <e1>cyclosporine</e1> dosages cause <e2>nephrotoxicity</e2>
20635749
D000638_D006333 NONE <e1>amiodarone</e1> presenting patient <e2>failure</e2>
D000638_D006333 NONE <e1>amiodarone-induced</e1> hypothyroidism patient <e2>failure</e2>
D000638_D006333 NONE <e1>amiodarone-induced</e1> hypothyroidism patient failure <e2>chf</e2>
D000638_D006333 NONE <e1>amiodarone</e1> patients <e2>chf</e2>
D000638_D006333 NONE <e1>amiodarone</e1> usage patients <e2>chf</e2>
D000638_D009230 CID <e1>amiodarone</e1> presenting <e2>coma</e2>
D000638_D009230 CID <e1>amiodarone-induced</e1> hypothyroidism secondary <e2>coma</e2>
D000638_D009230 CID <e1>amiodarone</e1> therapy report <e2>coma</e2>
D000638_D003128 CID <e1>amiodarone</e1> presenting <e2>coma</e2>
D000638_D003128 CID <e1>amiodarone-induced</e1> hypothyroidism secondary <e2>coma</e2>
D000638_D003128 CID <e1>amiodarone</e1> therapy report <e2>coma</e2>
D000638_D007037 CID <e1>amiodarone-induced</e1> <e2>hypothyroidism</e2>
D000638_D007037 CID <e1>amiodarone</e1> patients suffer morbidity <e2>hypothyroidism</e2>
17042884
C069541_D001480 NONE <e1>quetiapine</e1> incidence <e2>symptoms</e2>
C069541_D001480 NONE <e1>quetiapine</e1> incidence symptoms <e2>eps</e2>
C069541_D001480 NONE <e1>quetiapine</e1> akathisia <e2>symptoms</e2>
C069541_D001480 NONE <e1>quetiapine</e1> akathisia symptoms <e2>eps</e2>
C069541_D001480 NONE <e1>quetiapine</e1> monotherapy different incidence events <e2>eps-related</e2>
C069541_D001480 NONE <e1>qtp</e1> events <e2>eps-related</e2>
C069541_D001480 NONE <e1>quetiapine</e1> induced incidence <e2>syndrome</e2>
C069541_D001480 NONE <e1>quetiapine</e1> therapy incidence <e2>eps</e2>
C069541_D001714 NONE <e1>quetiapine</e1> incidence studies patients <e2>mania</e2>
C069541_D001714 NONE <e1>quetiapine</e1> patients <e2>mania</e2>
C069541_D001714 NONE <e1>quetiapine</e1> therapy incidence similar conclusions <e2>mania</e2>
C069541_D017109 NONE <e1>quetiapine</e1> <e2>akathisia</e2>
C069541_D017109 NONE <e1>quetiapine</e1> monotherapy different incidence events <e2>akathisia</e2>
C069541_D017109 NONE <e1>quetiapine</e1> monotherapy similar low incidence <e2>akathisia</e2>
C069541_D017109 NONE <e1>qtp</e1> low incidence <e2>akathisia</e2>
C069541_D017109 NONE <e1>quetiapine</e1> induced incidence <e2>akathisia</e2>
C069541_D017109 NONE <e1>quetiapine</e1> therapy incidence eps <e2>akathisia</e2>
D008094_D001480 CID <e1>li/dvp</e1> qtp events <e2>eps-related</e2>
D008094_D001480 CID <e1>li/dvp</e1> pbo different events <e2>eps-related</e2>
D008094_D001480 CID <e1>lithium</e1> treated patients % experienced occurred events related <e2>eps</e2>
D008094_D001480 CID <e1>lithium</e1> treated patients % experienced events related <e2>eps</e2>
D014635_D001480 NONE <e1>li/dvp</e1> qtp events <e2>eps-related</e2>
D014635_D001480 NONE <e1>li/dvp</e1> pbo different events <e2>eps-related</e2>
D006220_D001480 CID <e1>haloperidol</e1> treated patients % occurred events related <e2>eps</e2>
D006220_D001480 CID <e1>haloperidol</e1> treated patients % occurred experienced events related <e2>eps</e2>
D006220_D001480 CID <e1>haloperidol</e1> induced incidence <e2>syndrome</e2>
D008094_D017109 NONE <e1>li/dvp</e1> qtp low incidence <e2>akathisia</e2>
D008094_D017109 NONE <e1>li/dvp</e1> pbo qtp low incidence <e2>akathisia</e2>
D014635_D017109 NONE <e1>li/dvp</e1> qtp low incidence <e2>akathisia</e2>
D014635_D017109 NONE <e1>li/dvp</e1> pbo qtp low incidence <e2>akathisia</e2>
D008094_D014202 CID <e1>lithium</e1> associated incidence <e2>tremor</e2>
D008094_D014202 CID <e1>lithium</e1> associated incidence <e2>tremor</e2>
D008094_D014202 CID <e1>lithium</e1> associated contributed rate <e2>tremor</e2>
D008094_D014202 CID <e1>lithium</e1> effect tremor incidence <e2>tremor</e2>
D008094_D014202 CID <e1>lithium</e1> effect <e2>tremor</e2>
D008094_D014202 CID <e1>lithium</e1> effect tremor incidence associated contributed rate <e2>tremor</e2>
D008094_D014202 CID <e1>lithium</e1> therapy receiving patients tremor rate contributed associated incidence <e2>tremor</e2>
D008094_D014202 CID <e1>lithium</e1> therapy receiving patients tremor rate contributed associated incidence <e2>tremor</e2>
D008094_D014202 CID <e1>lithium</e1> therapy receiving patients <e2>tremor</e2>
C069541_D014202 NONE <e1>quetiapine</e1> incidence <e2>tremor</e2>
C069541_D014202 NONE <e1>quetiapine</e1> incidence <e2>tremor</e2>
C069541_D014202 NONE <e1>quetiapine</e1> incidence associated contributed rate <e2>tremor</e2>
C069541_D014202 NONE <e1>quetiapine</e1> induced incidence <e2>tremor</e2>
D006220_D017109 CID <e1>haloperidol</e1> induced incidence <e2>akathisia</e2>
D006220_D014202 CID <e1>haloperidol</e1> induced incidence <e2>tremor</e2>
85485
D001556_D006528 CID <e1>hexachloride</e1> induced mice <e2>hepatoma</e2>
D001556_D006528 CID <e1>hexachloride</e1> induced <e2>hepatomas</e2>
D001556_D017093 NONE <e1>hexachloride</e1> induced hepatomas <e2>lesions</e2>
C012282_D006528 NONE <e1>ethyl-alpha-p-chlorophenoxyisobutyrate</e1> respond tumors most <e2>hepatomas</e2>
C012282_D009369 NONE <e1>ethyl-alpha-p-chlorophenoxyisobutyrate</e1> respond <e2>tumors</e2>
C012282_D009369 NONE <e1>ethyl-alpha-p-chlorophenoxyisobutyrate</e1> respond cells <e2>tumor</e2>
14975762
D004317_D009369 NONE <e1>doxorubicin</e1> agent <e2>anti-tumor</e2>
D004317_D006333 CID <e1>doxorubicin-induced</e1> apoptosis protects reduces extent <e2>failure</e2>
15930398
D015742_D000647 CID <e1>propofol</e1> sedation persistence <e2>amnesia</e2>
18201582
C084178_D006973 NONE <e1>telmisartan</e1> combination monotherapy <e2>hypertension</e2>
C084178_D006973 NONE <e1>telmisartan</e1> mg efficacy evaluate was objective monotherapy patients <e2>hypertension</e2>
D017311_D006973 NONE <e1>amlodipine</e1> telmisartan combination monotherapy <e2>hypertension</e2>
D017311_D006973 NONE <e1>amlodipine</e1> telmisartan combination monotherapy <e2>hypertension</e2>
D017311_D006973 NONE <e1>amlodipine</e1> mg efficacy evaluate was objective monotherapy patients <e2>hypertension</e2>
D017311_D006973 NONE <e1>amlodipine</e1> monotherapy patients <e2>hypertension</e2>
19917396
D016559_D006332 CID <e1>tacrolimus</e1> induced <e2>hypertrophy</e2>
D016559_D006332 CID <e1>tacrolimus</e1> induced <e2>hypertrophy</e2>
D016559_D006332 CID <e1>tacrolimus</e1> concentration reducing resolved <e2>hypertrophy</e2>
D016559_D006332 CID <e1>tacrolimus</e1> induces <e2>hypertrophy</e2>
10074612
D008775_D007022 CID <e1>methylprednisolone</e1> <e2>hypotension</e2>
D008775_D007022 CID <e1>methylprednisolone</e1> administration case <e2>hypotension</e2>
D008775_D001919 CID <e1>methylprednisolone</e1> hypotension <e2>bradycardia</e2>
D008775_D001919 CID <e1>methylprednisolone</e1> administration case hypotension <e2>bradycardia</e2>
D008775_D006323 CID <e1>methylprednisolone</e1> hypotension <e2>asystole</e2>
D008775_D006323 CID <e1>methylprednisolone</e1> administration case hypotension <e2>asystole</e2>
D008775_D003645 NONE <e1>methylprednisolone</e1> dose reviews mechanisms <e2>death</e2>
D008775_D003645 NONE <e1>ivmp</e1> methylprednisolone dose reviews mechanisms <e2>death</e2>
11704023
D013999_D005901 NONE <e1>timolol</e1> placebo response patients treatment <e2>glaucoma</e2>
D013999_D005901 NONE <e1>timolol</e1> placebo effect suspension forms gel rate patients treated <e2>glaucoma</e2>
D013999_D005901 NONE <e1>timolol</e1> solution timolol placebo effect suspension forms gel rate patients treated <e2>glaucoma</e2>
D013999_D005901 NONE <e1>timolol</e1> suspension forms gel rate patients treated <e2>glaucoma</e2>
D013999_D005901 NONE <e1>timolol</e1> gellan conjunctiva application gel rate patients treated <e2>glaucoma</e2>
D013999_D005902 NONE <e1>timolol</e1> randomized patients <e2>glaucoma</e2>
D013999_D005902 NONE <e1>timolol</e1> randomized patients <e2>glaucoma</e2>
D013999_D009798 NONE <e1>timolol</e1> randomized patients glaucoma <e2>hypertension</e2>
D013999_D009798 NONE <e1>timolol</e1> randomized patients glaucoma <e2>hypertension</e2>
19135948
C107135_D006086 NONE <e1>everolimus</e1> prophylaxis <e2>disease</e2>
C107135_D006504 CID <e1>everolimus</e1> prophylaxis associated incidence <e2>syndrome</e2>
C107135_D014652 CID <e1>everolimus</e1> prophylaxis associated incidence syndrome <e2>microangiopathy</e2>
D016559_D006086 NONE <e1>tacrolimus</e1> everolimus prophylaxis <e2>disease</e2>
D016559_D006504 CID <e1>tacrolimus</e1> everolimus prophylaxis associated incidence <e2>syndrome</e2>
D016559_D014652 CID <e1>tacrolimus</e1> everolimus prophylaxis associated incidence syndrome <e2>microangiopathy</e2>
D008727_D006086 NONE <e1>methotrexate</e1> combined inhibitor prophylaxis <e2>disease</e2>
D008727_D006086 NONE <e1>methotrexate</e1> combined inhibitor prophylaxis disease <e2>gvhd</e2>
C107135_D009190 NONE <e1>everolimus</e1> combination patients <e2>syndrome</e2>
C107135_D009190 NONE <e1>everolimus</e1> combination patients syndrome <e2>mds</e2>
C107135_D015470 NONE <e1>everolimus</e1> combination patients syndrome <e2>leukemia</e2>
C107135_D015470 NONE <e1>everolimus</e1> combination patients syndrome <e2>aml</e2>
D016559_D009190 NONE <e1>tacrolimus</e1> everolimus combination patients <e2>syndrome</e2>
D016559_D009190 NONE <e1>tacrolimus</e1> everolimus combination patients syndrome <e2>mds</e2>
D016559_D015470 NONE <e1>tacrolimus</e1> everolimus combination patients syndrome <e2>leukemia</e2>
D016559_D015470 NONE <e1>tacrolimus</e1> everolimus combination patients syndrome <e2>aml</e2>
10091616
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D001058_D010300 NONE <e1>apomorphine</e1> dose administration worsening tasks included patients had <e2>disease</e2>
D001058_D004409 CID <e1>apomorphine</e1> dose administration worsening tasks included patients had <e2>dyskinesia</e2>
D001058_D004409 CID <e1>apomorphine</e1> dose administration worsening <e2>dyskinesia</e2>
950631
D010396_D007674 CID <e1>penicillamine-induced</e1> <e2>disease</e2>
D010396_D001172 NONE <e1>d-penicillamine</e1> treatment months developed patients <e2>arthritis</e2>
D010396_D011507 CID <e1>d-penicillamine</e1> treatment months developed <e2>proteinuria</e2>
7803371
D003915_D003072 CID <e1>dextromethorphan</e1> abuse <e2>deterioration</e2>
D003915_D003072 CID <e1>dm</e1> use resulting case <e2>deterioration</e2>
9105126
D013256_D018658 CID <e1>steroid</e1> therapy associated <e2>defect</e2>
D013256_D018658 CID <e1>steroid</e1> therapy patients <e2>rupture</e2>
D013256_D018658 CID <e1>steroid</e1> therapy <e2>rupture</e2>
15276120
D014859_D006470 CID <e1>warfarin-associated</e1> <e2>hemorrhage</e2>
D014859_D006470 CID <e1>warfarin-related</e1> <e2>bleeding</e2>
11694026
C012655_D014581 NONE <e1>nimesulide</e1> tolerability paracetamol patients <e2>urticaria/angioedema</e2>
C012655_D014581 NONE <e1>nimesulide</e1> tolerability investigated number patients history <e2>urticaria/angioedema</e2>
C012655_D014581 NONE <e1>nimesulide</e1> procedure applied patients history <e2>urticaria/angioedema</e2>
C012655_D014581 NONE <e1>nimesulide</e1> tolerability paracetamol patients experienced <e2>urticaria/angioedema</e2>
C012655_D000799 CID <e1>nimesulide</e1> tolerability paracetamol patients <e2>urticaria/angioedema</e2>
C012655_D000799 CID <e1>nimesulide</e1> tolerability investigated number patients history <e2>urticaria/angioedema</e2>
C012655_D000799 CID <e1>nimesulide</e1> procedure applied patients history <e2>urticaria/angioedema</e2>
C012655_D000799 CID <e1>nimesulide</e1> tolerability paracetamol patients experienced <e2>urticaria/angioedema</e2>
D000082_D014581 NONE <e1>paracetamol</e1> patients <e2>urticaria/angioedema</e2>
D000082_D014581 NONE <e1>paracetamol</e1> tolerability investigated number patients history <e2>urticaria/angioedema</e2>
D000082_D014581 NONE <e1>paracetamol</e1> nimesulide procedure applied patients history <e2>urticaria/angioedema</e2>
D000082_D014581 NONE <e1>paracetamol</e1> patients experienced <e2>urticaria/angioedema</e2>
D000082_D000799 CID <e1>paracetamol</e1> patients <e2>urticaria/angioedema</e2>
D000082_D000799 CID <e1>paracetamol</e1> tolerability investigated number patients history <e2>urticaria/angioedema</e2>
D000082_D000799 CID <e1>paracetamol</e1> nimesulide procedure applied patients history <e2>urticaria/angioedema</e2>
D000082_D000799 CID <e1>paracetamol</e1> patients experienced <e2>urticaria/angioedema</e2>
D000894_D014581 NONE <e1>nsaid-induced</e1> <e2>urticaria/angioedema</e2>
D000894_D014581 NONE <e1>nsaid-induced</e1> <e2>urticaria/angioedema</e2>
D000894_D014581 NONE <e1>nsaid-induced</e1> <e2>urticaria/angioedema</e2>
D000894_D014581 NONE <e1>nsaid-induced</e1> urticaria/angioedema history subjects % % patients history <e2>urticaria</e2>
D000894_D014581 NONE <e1>nsaid-induced</e1> <e2>urticaria/angioedema</e2>
D000894_D014581 NONE <e1>nsaid-induced</e1> urticaria/angioedema history subjects % % <e2>urticaria</e2>
D000894_D014581 NONE <e1>nsaids</e1> caused <e2>urticaria/angioedema</e2>
D000894_D014581 NONE <e1>nsaid-induced</e1> angioedema history increased history <e2>urticaria</e2>
D000894_D000799 CID <e1>nsaid-induced</e1> <e2>urticaria/angioedema</e2>
D000894_D000799 CID <e1>nsaid-induced</e1> <e2>urticaria/angioedema</e2>
D000894_D000799 CID <e1>nsaid-induced</e1> <e2>urticaria/angioedema</e2>
D000894_D000799 CID <e1>nsaid-induced</e1> <e2>urticaria/angioedema</e2>
D000894_D000799 CID <e1>nsaid-induced</e1> urticaria/angioedema <e2>angioedema</e2>
D000894_D000799 CID <e1>nsaids</e1> caused <e2>urticaria/angioedema</e2>
D000894_D000799 CID <e1>nsaid-induced</e1> <e2>angioedema</e2>
19707748
D064704_D012640 CID <e1>levofloxacin</e1> associated <e2>seizures</e2>
D064704_D012640 CID <e1>levofloxacin</e1> treatment initiating developed <e2>seizures</e2>
D064704_D012640 CID <e1>levofloxacin</e1> treatment initiating developed patient case <e2>seizures</e2>
D064704_D012640 CID <e1>levofloxacin-induced</e1> seizures case patient developed <e2>seizures</e2>
D064704_D012640 CID <e1>levofloxacin-induced</e1> <e2>seizures</e2>
D064704_D012640 CID <e1>levofloxacin-induced</e1> <e2>seizures</e2>
15811908
C012052_D010673 NONE <e1>amisulpride</e1> unmasked <e2>pheochromocytoma</e2>
C012052_D010673 NONE <e1>amisulpride</e1> treated patient <e2>pheochromocytoma</e2>
C012052_D010673 NONE <e1>amisulpride-</e1> crisis patient <e2>pheochromocytoma</e2>
D063325_D010673 NONE <e1>tiapride</e1> amisulpride unmasked <e2>pheochromocytoma</e2>
D063325_D010673 NONE <e1>tiapride</e1> amisulpride treated patient <e2>pheochromocytoma</e2>
D063325_D010673 NONE <e1>tiapride-induced</e1> amisulpride- crisis patient <e2>pheochromocytoma</e2>
C012052_D006973 CID <e1>amisulpride</e1> of mg. doses vomiting developed <e2>hypertension</e2>
C012052_D006973 CID <e1>amisulpride</e1> therapy crisis <e2>hypertensive</e2>
C012052_D006973 CID <e1>amisulpride-</e1> crisis <e2>hypertensive</e2>
C012052_D006261 CID <e1>amisulpride</e1> of mg. doses vomiting developed hypertension <e2>headache</e2>
C012052_D014839 CID <e1>amisulpride</e1> of mg. doses <e2>vomiting</e2>
D063325_D006973 CID <e1>tiapride</e1> mg amisulpride of mg. doses vomiting developed <e2>hypertension</e2>
D063325_D006973 CID <e1>tiapride</e1> amisulpride therapy crisis <e2>hypertensive</e2>
D063325_D006973 CID <e1>tiapride-induced</e1> amisulpride- crisis <e2>hypertensive</e2>
D063325_D006261 CID <e1>tiapride</e1> mg amisulpride of mg. doses vomiting developed hypertension <e2>headache</e2>
D063325_D014839 CID <e1>tiapride</e1> mg amisulpride of mg. doses <e2>vomiting</e2>
D009529_D006973 NONE <e1>nicardipine</e1> recovered patient summary developed <e2>hypertension</e2>
D009529_D006261 NONE <e1>nicardipine</e1> recovered patient summary developed hypertension <e2>headache</e2>
D009529_D014839 NONE <e1>nicardipine</e1> recovered patient summary developed <e2>vomiting</e2>
D014700_D006973 NONE <e1>verapamil</e1> treatment nicardipine recovered patient summary developed <e2>hypertension</e2>
D014700_D006261 NONE <e1>verapamil</e1> treatment nicardipine recovered patient summary developed hypertension <e2>headache</e2>
D014700_D014839 NONE <e1>verapamil</e1> treatment nicardipine recovered patient summary developed <e2>vomiting</e2>
C037689_D010673 NONE <e1>benzamide</e1> drugs use associated symptoms <e2>pheochromocytoma</e2>
19719056
D019342_D010146 NONE <e1>acid</e1> model <e2>writhing</e2>
D019342_D004487 NONE <e1>acid</e1> model model <e2>edema</e2>
D002351_D010146 CID <e1>carrageenan-induced</e1> model model <e2>writhing</e2>
D002351_D004487 CID <e1>carrageenan-induced</e1> model <e2>edema</e2>
7707116
D015474_D009447 NONE <e1>acid</e1> trial children <e2>neuroblastoma</e2>
D015474_D009447 NONE <e1>acid</e1> treatment lines <e2>neuroblastoma</e2>
D015474_D009447 NONE <e1>cis-ra</e1> acid treatment lines <e2>neuroblastoma</e2>
D015474_D009447 NONE <e1>cis-ra</e1> demonstrated responses patients <e2>neuroblastoma</e2>
D015474_D009447 NONE <e1>cis-ra</e1> pharmacokinetics administered schedule children <e2>neuroblastoma</e2>
D015474_D064420 NONE <e1>cis-ra</e1> pharmacokinetics dosage <e2>toxicities</e2>
D015474_D064420 NONE <e1>cis-ra</e1> resolved <e2>toxicities</e2>
D015474_D006934 CID <e1>cis-ra</e1> levels predicted included <e2>hypercalcemia</e2>
11858397
D008787_D016171 CID <e1>metoclopramide</e1> induced <e2>pointes</e2>
D008787_D016171 CID <e1>metoclopramide</e1> administration developed torsade <e2>pointes</e2>
D008787_D016171 CID <e1>metoclopramide</e1> provokes torsade <e2>pointes</e2>
D008787_D016171 CID <e1>metoclopramide</e1> used patients risk torsade <e2>pointes</e2>
D008787_D002037 NONE <e1>metoclopramide</e1> induced woman <e2>block</e2>
D008787_D002037 NONE <e1>metoclopramide</e1> administration developed <e2>block</e2>
D020117_D016171 CID <e1>cisapride</e1> given developed torsade <e2>pointes</e2>
D004917_D016171 CID <e1>erythromycin</e1> cisapride given developed torsade <e2>pointes</e2>
7007443
D000082_D017114 CID <e1>paracetamol</e1> overdose survived <e2>failure</e2>
D000082_D017114 CID <e1>paracetamol</e1> overdose survived those fourfold died patients increased increased patients <e2>failure</e2>
D000082_D062787 NONE <e1>paracetamol</e1> <e2>overdose</e2>
D000082_D006525 NONE <e1>paracetamol</e1> overdose survived those fourfold died patients increased increased patients failure <e2>hepatitis</e2>
3653576
C001335_D058186 CID <e1>hexachloro-1:3-butadiene</e1> administration produced models <e2>damage</e2>
C001335_D058186 CID <e1>hcbd</e1> hexachloro-1:3-butadiene administration produced models <e2>damage</e2>
D011692_D058186 CID <e1>aminonucleoside</e1> hexachloro-1:3-butadiene administration produced models <e2>damage</e2>
D011692_D058186 CID <e1>pan</e1> aminonucleoside hexachloro-1:3-butadiene administration produced models <e2>damage</e2>
C004504_D058186 CID <e1>2-bromoethylamine</e1> produced models <e2>damage</e2>
C004504_D058186 CID <e1>bea</e1> 2-bromoethylamine produced models <e2>damage</e2>
C001335_D007674 NONE <e1>hcbd</e1> produced damage discriminated <e2>damage</e2>
C004504_D007674 NONE <e1>bea</e1> hcbd produced damage discriminated <e2>damage</e2>
D011692_D007674 NONE <e1>pan</e1> produced <e2>damage</e2>
3084782
D008625_D009393 CID <e1>tiopronin</e1> found <e2>nephritis</e2>
D008625_D009393 CID <e1>tiopronin</e1> group <e2>nephritis</e2>
D008625_D003872 CID <e1>tiopronin</e1> found nephritis <e2>dermatitis</e2>
D008625_D003872 CID <e1>tiopronin</e1> <e2>dermatitis</e2>
D010396_D009393 NONE <e1>d-penicillamine</e1> compound tiopronin found <e2>nephritis</e2>
D010396_D003872 NONE <e1>d-penicillamine</e1> compound tiopronin found nephritis <e2>dermatitis</e2>
D010396_D003872 NONE <e1>d-penicillamine</e1> compound tiopronin <e2>dermatitis</e2>
D006046_D009393 NONE <e1>gold</e1> thiosulphate dermatitis tiopronin found <e2>nephritis</e2>
D006046_D003872 CID <e1>gold</e1> thiosulphate dermatitis tiopronin found nephritis <e2>dermatitis</e2>
D006046_D003872 CID <e1>gold</e1> thiosulphate <e2>dermatitis</e2>
-1_D009393 NONE <e1>thiosulphate</e1> dermatitis tiopronin found <e2>nephritis</e2>
-1_D003872 NONE <e1>thiosulphate</e1> dermatitis tiopronin found nephritis <e2>dermatitis</e2>
-1_D003872 NONE <e1>thiosulphate</e1> <e2>dermatitis</e2>
D008625_D001172 NONE <e1>tiopronin</e1> group observed patients <e2>ra</e2>
3703509
D011241_D053609 NONE <e1>prednisone</e1> exposure developed <e2>lethargy</e2>
D011241_D006970 NONE <e1>prednisone</e1> exposure developed increasing <e2>somnolence</e2>
D011241_D059606 NONE <e1>prednisone</e1> exposure developed increasing somnolence <e2>polydipsia</e2>
D011241_D006963 NONE <e1>prednisone</e1> exposure developed increasing somnolence polydipsia <e2>polyphagia</e2>
D011241_D011141 NONE <e1>prednisone</e1> exposure developed increasing somnolence polydipsia polyphagia <e2>polyuria</e2>
D019344_D000140 NONE <e1>lactate</e1> level present <e2>acidosis</e2>
D019344_D007662 NONE <e1>lactate</e1> level present one <e2>ketosis</e2>
1687392
D004298_D002375 NONE <e1>dopamine</e1> receptors d-1 blockade induce <e2>catalepsy</e2>
D004298_D002375 NONE <e1>dopamine</e1> antagonists induced <e2>catalepsy</e2>
D004298_D002375 NONE <e1>dopamine</e1> antagonists induced catalepsy tested determined subtypes involved <e2>catalepsy</e2>
D004298_D002375 NONE <e1>dopamine</e1> subtypes determined tested <e2>catalepsy</e2>
D004298_D002375 NONE <e1>dopamine</e1> subtypes involved <e2>catalepsy</e2>
D004298_D002375 NONE <e1>dopamine</e1> fluphenazine <e2>catalepsy</e2>
D004298_D002375 NONE <e1>dopamine</e1> antagonists induced <e2>catalepsy</e2>
D005476_D002375 CID <e1>fluphenazine</e1> <e2>catalepsy</e2>
D005476_D002375 CID <e1>fluphenazine</e1> induced <e2>catalepsy</e2>
C534628_D002375 CID <e1>23390</e1> sch fluphenazine <e2>catalepsy</e2>
C534628_D002375 CID <e1>23390</e1> sch combination induce potentiation <e2>catalepsy</e2>
C534628_D002375 CID <e1>23390</e1> sch <e2>catalepsy</e2>
D013469_D002375 CID <e1>sulpiride</e1> fluphenazine <e2>catalepsy</e2>
D013469_D002375 CID <e1>sulpiride</e1> combination induce potentiation <e2>catalepsy</e2>
D013469_D002375 CID <e1>sulpiride</e1> sch <e2>catalepsy</e2>
D015647_D002375 NONE <e1>38393</e1> skf quinpirole decreased <e2>catalepsy</e2>
D015647_D002375 NONE <e1>38393</e1> skf combination cause effect <e2>catalepsy</e2>
D019257_D002375 NONE <e1>quinpirole</e1> decreased <e2>catalepsy</e2>
D019257_D002375 NONE <e1>quinpirole</e1> combination cause effect <e2>catalepsy</e2>
4090988
D000082_D001749 CID <e1>paracetamol</e1> <e2>tumours</e2>
D000082_D001749 CID <e1>paracetamol-treated</e1> groups developed bore <e2>carcinomas</e2>
D000082_D008113 CID <e1>paracetamol</e1> <e2>tumours</e2>
D000082_D008113 CID <e1>paracetamol-treated</e1> rats livers study revealed changes hepatocytes resemble those result exposure variety <e2>hepatocarcinogens</e2>
D000082_D010212 NONE <e1>paracetamol-treated</e1> groups developed <e2>papillomas</e2>
D000082_D006965 CID <e1>paracetamol-treated</e1> rats % developed <e2>hyperplasia</e2>
D000082_D001744 NONE <e1>paracetamol-treated</e1> rats % developed coincident presence <e2>calculi</e2>
D000082_D009369 NONE <e1>paracetamol</e1> feeding arose yield <e2>tumours</e2>
11524350
D002045_D064420 NONE <e1>bupivacaine-</e1> <e2>toxicity</e2>
D002045_D064420 NONE <e1>bupivacaine</e1> <e2>toxicity</e2>
D002045_D064420 NONE <e1>bupivacaine</e1> ropivacaine that intermediate <e2>toxicity</e2>
D002045_D064420 NONE <e1>bupivacaine</e1> induced that treatment susceptible appears administered that intermediate <e2>toxicity</e2>
C476513_D064420 NONE <e1>levobupivacaine-</e1> bupivacaine- <e2>toxicity</e2>
C476513_D064420 NONE <e1>levobupivacaine</e1> bupivacaine <e2>toxicity</e2>
C476513_D064420 NONE <e1>levobupivacaine</e1> <e2>toxicity</e2>
C476513_D064420 NONE <e1>levobupivacaine</e1> bupivacaine induced that treatment susceptible appears administered that intermediate <e2>toxicity</e2>
C037663_D064420 NONE <e1>ropivacaine-infused</e1> bupivacaine- <e2>toxicity</e2>
C037663_D064420 NONE <e1>ropivacaine</e1> bupivacaine <e2>toxicity</e2>
C037663_D064420 NONE <e1>ropivacaine</e1> that intermediate <e2>toxicity</e2>
C037663_D064420 NONE <e1>ropivacaine-induced</e1> arrest appears administered that intermediate <e2>toxicity</e2>
C476513_D012640 CID <e1>levobupivacaine</e1> doses produced <e2>seizures</e2>
C037663_D012640 CID <e1>ropivacaine</e1> levobupivacaine doses produced <e2>seizures</e2>
D002045_D012640 NONE <e1>bupivacaine</e1> those larger similar doses produced <e2>seizures</e2>
C476513_D001145 CID <e1>levobupivacaine</e1> doses produced <e2>dysrhythmias</e2>
C476513_D006323 CID <e1>levobupivacaine</e1> doses produced dysrhythmias <e2>asystole</e2>
C476513_D006323 CID <e1>levobupivacaine</e1> toxicity intermediate that administered appears <e2>arrest</e2>
C476513_D006323 CID <e1>levobupivacaine</e1> bupivacaine induced that treatment susceptible appears <e2>arrest</e2>
C037663_D001145 CID <e1>ropivacaine</e1> doses smaller doses produced <e2>dysrhythmias</e2>
C037663_D006323 CID <e1>ropivacaine</e1> doses smaller doses produced dysrhythmias <e2>asystole</e2>
C037663_D006323 CID <e1>ropivacaine</e1> that administered appears <e2>arrest</e2>
C037663_D006323 CID <e1>ropivacaine-induced</e1> <e2>arrest</e2>
D002045_D001145 NONE <e1>bupivacaine</e1> those larger smaller doses produced <e2>dysrhythmias</e2>
D002045_D006323 NONE <e1>bupivacaine</e1> those larger smaller doses produced dysrhythmias <e2>asystole</e2>
D002045_D006323 NONE <e1>bupivacaine</e1> ropivacaine that administered appears <e2>arrest</e2>
D002045_D006323 NONE <e1>bupivacaine</e1> induced that treatment susceptible appears <e2>arrest</e2>
8106150
D007980_D004409 NONE <e1>l-dopa-induced</e1> <e2>dyskinesias</e2>
D007980_D004409 NONE <e1>l-dopa</e1> combination tested see modified movements <e2>dyskinetic</e2>
D015632_D004409 NONE <e1>mptp-treated</e1> monkeys <e2>dyskinesias</e2>
D015632_D020734 CID <e1>mptp</e1> <e2>parkinsonian</e2>
D004298_D004409 NONE <e1>dopamine</e1> other neurotransmitters acting agents series tested see modified movements <e2>dyskinetic</e2>
D003000_D004409 NONE <e1>clonidine</e1> drugs reduced movements <e2>dyskinetic</e2>
D003000_D020734 NONE <e1>clonidine</e1> drugs reduced cost return symptomatology <e2>parkinsonian</e2>
D010830_D004409 NONE <e1>physostigmine</e1> clonidine drugs reduced movements <e2>dyskinetic</e2>
D010830_D020734 NONE <e1>physostigmine</e1> clonidine drugs reduced cost return symptomatology <e2>parkinsonian</e2>
D008784_D004409 NONE <e1>methysergide</e1> clonidine drugs reduced movements <e2>dyskinetic</e2>
D008784_D020734 NONE <e1>methysergide</e1> clonidine drugs reduced cost return symptomatology <e2>parkinsonian</e2>
-1_D004409 NONE <e1>5-mdot</e1> clonidine drugs reduced movements <e2>dyskinetic</e2>
-1_D020734 NONE <e1>5-mdot</e1> clonidine drugs reduced cost return symptomatology <e2>parkinsonian</e2>
D011433_D004409 NONE <e1>propranolol</e1> clonidine drugs reduced movements <e2>dyskinetic</e2>
D011433_D020734 NONE <e1>propranolol</e1> clonidine drugs reduced cost return symptomatology <e2>parkinsonian</e2>
D016291_D004409 NONE <e1>mk-801</e1> clonidine drugs reduced movements <e2>dyskinetic</e2>
D016291_D020734 NONE <e1>mk-801</e1> clonidine drugs reduced cost return symptomatology <e2>parkinsonian</e2>
D015016_D004409 NONE <e1>yohimbine</e1> reduced movements <e2>dyskinetic</e2>
D008614_D004409 NONE <e1>meperidine</e1> yohimbine reduced movements <e2>dyskinetic</e2>
D001418_D020821 NONE <e1>baclofen</e1> useful monkey form <e2>dystonic</e2>
D001418_D004409 NONE <e1>baclofen</e1> useful monkey form <e2>dyskinesia</e2>
D001285_D020821 NONE <e1>atropine</e1> converted movements <e2>dystonic</e2>
D001285_D002819 NONE <e1>atropine</e1> converted <e2>chorea</e2>
3431591
C031662_D064420 NONE <e1>3717</e1> cb inhibitor mediated <e2>cytotoxicity</e2>
C031662_D064420 NONE <e1>acid</e1> cb inhibitor mediated <e2>cytotoxicity</e2>
C031662_D064420 NONE <e1>3717</e1> cb potent di- determinant <e2>cytotoxicity</e2>
C031662_D064420 NONE <e1>3717</e1> <e2>cytotoxicity</e2>
C031662_D001943 NONE <e1>3717</e1> cb studies seen <e2>cancer</e2>
C031662_D010051 NONE <e1>3717</e1> cb studies seen cancer <e2>cancer</e2>
C031662_D006528 NONE <e1>3717</e1> cb studies seen cancer <e2>hepatoma</e2>
C031662_D008654 NONE <e1>3717</e1> cb studies seen cancer <e2>mesothelioma</e2>
18589141
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-induced</e1> thrombocytopenia <e2>hit</e2>
D006493_D013921 CID <e1>heparin</e1> reaction <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin</e1> reaction thrombocytopenia <e2>hit</e2>
D006493_D013921 CID <e1>4/heparin-reactive</e1> antibody transplantation frequencies <e2>hit</e2>
D006493_D013921 CID <e1>4/heparin-reactive</e1> antibody antibody <e2>hit</e2>
D006493_D013921 CID <e1>ufh-related</e1> <e2>hit</e2>
D006493_D013927 NONE <e1>sodium</e1> used prevent <e2>thrombosis</e2>
D006493_D013927 NONE <e1>ufh</e1> sodium used prevent <e2>thrombosis</e2>
D006495_D013927 NONE <e1>heparin</e1> sodium used prevent <e2>thrombosis</e2>
D006493_D001791 NONE <e1>heparin-induced</e1> test <e2>aggregation</e2>
7337133
D000082_D001929 CID <e1>acetaminophen</e1> overdose failure associated <e2>edema</e2>
D000082_D001929 CID <e1>acetaminophen-induced</e1> fatal failure patient signs symptoms <e2>edema</e2>
D000082_D017093 CID <e1>acetaminophen</e1> overdose <e2>failure</e2>
D000082_D017093 CID <e1>acetaminophen-induced</e1> fatal <e2>failure</e2>
D000082_D062787 NONE <e1>acetaminophen</e1> <e2>overdose</e2>
10539815
D000809_D051437 NONE <e1>angiotensin-converting</e1> therapy predictors <e2>function</e2>
D000809_D051437 NONE <e1>angiotensin-converting</e1> therapy reduces cause <e2>function</e2>
D000809_D051437 NONE <e1>angiotensin-converting</e1> therapy prescribed patients <e2>function</e2>
D000809_D006333 NONE <e1>angiotensin-converting</e1> therapy predictors function patients <e2>failure</e2>
D000809_D006333 NONE <e1>angiotensin-converting</e1> therapy reduces rates patients <e2>failure</e2>
D000809_D006333 NONE <e1>angiotensin-converting</e1> therapy reduces rates patients failure <e2>chf</e2>
D000809_D006333 NONE <e1>angiotensin-converting</e1> therapy prescribed patients <e2>chf</e2>
D000809_D018487 NONE <e1>angiotensin-converting</e1> therapy predictors results studies <e2>dysfunction</e2>
D004656_D018487 NONE <e1>enalapril</e1> trial data studies <e2>dysfunction</e2>
D004656_D006333 NONE <e1>enalapril</e1> trial treatment <e2>chf</e2>
D004656_D006333 NONE <e1>enalapril</e1> use caused increase risk function patients <e2>chf</e2>
D004656_D006333 NONE <e1>enalapril</e1> group reduced associated risk impairment patients <e2>chf</e2>
D003404_D051437 NONE <e1>creatinine</e1> rise defined <e2>function</e2>
D003404_D006973 NONE <e1>creatinine</e1> age function decrease predictors identify history <e2>hypertension</e2>
D003404_D003920 NONE <e1>creatinine</e1> age function decrease predictors identify history hypertension <e2>diabetes</e2>
D004232_D006973 NONE <e1>diuretic</e1> antiplatelet use identify history <e2>hypertension</e2>
D004232_D003920 NONE <e1>diuretic</e1> antiplatelet use identify history hypertension <e2>diabetes</e2>
D004232_D003920 NONE <e1>diuretic</e1> therapy groups <e2>diabetes</e2>
D004656_D051437 CID <e1>enalapril</e1> assigned patients had likelihood <e2>function</e2>
D004656_D051437 CID <e1>enalapril</e1> placebo groups associated <e2>function</e2>
D004656_D051437 CID <e1>enalapril</e1> group so associated risk developing <e2>function</e2>
D004656_D051437 CID <e1>enalapril</e1> group so associated risk developing <e2>function</e2>
D004656_D051437 CID <e1>enalapril</e1> 1.52 interval associated risk developing <e2>function</e2>
D004656_D051437 CID <e1>enalapril</e1> group <e2>function</e2>
D004656_D051437 CID <e1>enalapril</e1> use caused increase risk <e2>function</e2>
D004656_D051437 CID <e1>enalapril</e1> group reduced associated risk <e2>impairment</e2>
D004656_D003920 NONE <e1>enalapril</e1> placebo groups <e2>diabetes</e2>
D004656_D003920 NONE <e1>enalapril</e1> had placebo patients <e2>diabetes</e2>
D004656_D003920 NONE <e1>enalapril</e1> group reduced associated <e2>diabetes</e2>
D004232_D051437 CID <e1>diuretic</e1> therapy groups associated <e2>function</e2>
D004232_D051437 CID <e1>diuretic</e1> therapy associated risk <e2>function</e2>
18441470
D008094_D054537 CID <e1>lithium</e1> therapy secondary <e2>block</e2>
D008094_D054537 CID <e1>lithium</e1> therapy secondary developed case complete <e2>block</e2>
D008094_D012804 CID <e1>lithium</e1> effects reported <e2>dysfunction</e2>
D008094_D013575 NONE <e1>lithium</e1> therapy secondary developed case complete block <e2>attacks</e2>
D008094_D013575 NONE <e1>lithium</e1> levels remained <e2>attacks</e2>
3973521
11230490
D004317_D066126 NONE <e1>doxorubicin</e1> efficacy preserved <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>doxorubicin</e1> <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>myocet</e1> reduces <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>doxorubicin</e1> myocet reduces <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>doxorubicin</e1> <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>myocet</e1> improves reducing <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>doxorubicin</e1> index improves reducing <e2>cardiotoxicity</e2>
D004317_D001943 NONE <e1>doxorubicin</e1> efficacy preserved cardiotoxicity trial <e2>cancer</e2>
D004317_D001943 NONE <e1>doxorubicin</e1> cardiotoxicity trial <e2>cancer</e2>
D004317_D001943 NONE <e1>myocet</e1> reduces providing efficacy treatment <e2>cancer</e2>
D004317_D001943 NONE <e1>myocet</e1> reduces providing efficacy treatment cancer <e2>mbc</e2>
D004317_D001943 NONE <e1>doxorubicin</e1> myocet reduces providing efficacy treatment <e2>cancer</e2>
D004317_D001943 NONE <e1>doxorubicin</e1> myocet reduces providing efficacy treatment cancer <e2>mbc</e2>
D004317_D001943 NONE <e1>doxorubicin</e1> cardiotoxicity reduces providing efficacy treatment <e2>cancer</e2>
D004317_D001943 NONE <e1>doxorubicin</e1> cardiotoxicity reduces providing efficacy treatment cancer <e2>mbc</e2>
D004317_D001943 NONE <e1>myocet</e1> receive randomized patients patients <e2>mbc</e2>
D004317_D001943 NONE <e1>doxorubicin</e1> myocet receive randomized patients patients <e2>mbc</e2>
D004317_D001943 NONE <e1>myocet</e1> improves used combination therapy <e2>mbc</e2>
D004317_D001943 NONE <e1>doxorubicin</e1> index improves used combination therapy <e2>mbc</e2>
D003520_D066126 NONE <e1>cyclophosphamide</e1> doxorubicin efficacy preserved <e2>cardiotoxicity</e2>
D003520_D066126 NONE <e1>cyclophosphamide</e1> doxorubicin <e2>cardiotoxicity</e2>
D003520_D066126 NONE <e1>cyclophosphamide</e1> combination myocet reduces <e2>cardiotoxicity</e2>
D003520_D066126 NONE <e1>cyclophosphamide</e1> combination used improves reducing <e2>cardiotoxicity</e2>
D003520_D001943 NONE <e1>cyclophosphamide</e1> doxorubicin efficacy preserved cardiotoxicity trial <e2>cancer</e2>
D003520_D001943 NONE <e1>cyclophosphamide</e1> doxorubicin cardiotoxicity trial <e2>cancer</e2>
D003520_D001943 NONE <e1>cyclophosphamide</e1> combination myocet reduces providing efficacy treatment <e2>cancer</e2>
D003520_D001943 NONE <e1>cyclophosphamide</e1> combination myocet reduces providing efficacy treatment cancer <e2>mbc</e2>
D003520_D001943 NONE <e1>cyclophosphamide</e1> combination receive randomized patients patients <e2>mbc</e2>
D003520_D001943 NONE <e1>cyclophosphamide</e1> combination therapy <e2>mbc</e2>
D004317_D064420 NONE <e1>myocet</e1> receive randomized weeks progression <e2>toxicity</e2>
D004317_D064420 NONE <e1>doxorubicin</e1> myocet receive randomized weeks progression <e2>toxicity</e2>
D003520_D064420 NONE <e1>cyclophosphamide</e1> combination receive randomized weeks progression <e2>toxicity</e2>
D004317_D009503 CID <e1>myocet</e1> improves reducing <e2>neutropenia</e2>
D004317_D009503 CID <e1>doxorubicin</e1> index improves reducing <e2>neutropenia</e2>
D003520_D009503 CID <e1>cyclophosphamide</e1> combination used improves reducing <e2>neutropenia</e2>
11467664
D008687_D041781 CID <e1>metformin</e1> use associated <e2>jaundice</e2>
D008687_D041781 CID <e1>hydrochloride</e1> treatment initiation developed <e2>jaundice</e2>
D008687_D007565 NONE <e1>hydrochloride</e1> discontinued resolved <e2>jaundice</e2>
D008687_D007565 NONE <e1>metformin</e1> initiation wk onset <e2>jaundice</e2>
D008687_D007565 NONE <e1>metformin-associated</e1> hepatotoxicity example represents believe onset <e2>jaundice</e2>
D008687_D056486 NONE <e1>metformin</e1> initiation wk onset believe represents example <e2>hepatotoxicity</e2>
D008687_D056486 NONE <e1>metformin-associated</e1> <e2>hepatotoxicity</e2>
19319147
D014859_D006470 NONE <e1>warfarin-associated</e1> hemorrhage model reduces volume <e2>hemorrhage</e2>
D014859_D002543 CID <e1>warfarin-associated</e1> <e2>hemorrhage</e2>
D014859_D002543 CID <e1>warfarin-associated</e1> <e2>hemorrhage</e2>
D014859_D002543 CID <e1>warfarin-associated</e1> hemorrhage <e2>w-ich</e2>
D014859_D020521 NONE <e1>warfarin-associated</e1> hemorrhage type <e2>stroke</e2>
C025667_D002543 NONE <e1>pcc</e1> suggesting treatment <e2>w-ich</e2>
2557556
D015232_D006930 CID <e1>e2-induced</e1> <e2>hyperalgesia</e2>
D009020_D006930 NONE <e1>morphine</e1> alter <e2>hyperalgesia</e2>
D015124_D006930 CID <e1>monophosphate</e1> induced <e2>hyperalgesia</e2>
4069770
D005839_D007674 NONE <e1>gentamicin</e1> <e2>nephropathy</e2>
D005839_D058186 CID <e1>gentamicin</e1> therapy died <e2>failure</e2>
D010406_D058186 NONE <e1>penicillin</e1> presented findings baby died <e2>failure</e2>
D005839_D001002 NONE <e1>gentamicin</e1> concentration reached developed <e2>anuria</e2>
2840807
D009074_D004421 CID <e1>msh/acth</e1> neuropeptide stimulation syndrome <e2>dystonia-like</e2>
D000324_D004421 CID <e1>msh/acth</e1> neuropeptide stimulation syndrome <e2>dystonia-like</e2>
D000324_D003866 NONE <e1>acth</e1> fragments stimulated cause <e2>depression</e2>
D000324_D009069 NONE <e1>acth</e1> fragments stimulated cause depression resulted duration <e2>disorder</e2>
2533791
D017325_D006509 NONE <e1>vaccine</e1> injections injections globulin <e2>b</e2>
18808529
D007545_D009202 CID <e1>isoproterenol</e1> induces correlation <e2>injury</e2>
D007545_D009202 CID <e1>isoproterenol-induced</e1> <e2>damage</e2>
D007545_D009202 CID <e1>isoproterenol-induced</e1> damage mechanism unknown explanation mismatch demand hypotension <e2>hyperactivity</e2>
D007545_D007022 NONE <e1>isoproterenol-induced</e1> damage mechanism unknown explanation mismatch demand <e2>hypotension</e2>
D010100_D009202 NONE <e1>oxygen</e1> supply mismatch explanation unknown mechanism <e2>damage</e2>
D010100_D009202 NONE <e1>oxygen</e1> supply mismatch demand hypotension <e2>hyperactivity</e2>
D010100_D007022 NONE <e1>oxygen</e1> supply mismatch demand <e2>hypotension</e2>
D007545_D007511 CID <e1>isoproterenol</e1> induced injury sarcolemma integrity explain changes related <e2>injury</e2>
9952311
D004317_D028361 CID <e1>adriamycin-induced</e1> cardiomyopathy impairment <e2>mitochondria</e2>
D004317_D028361 CID <e1>adr</e1> effects involve structural <e2>impairment</e2>
D004317_D009202 NONE <e1>adriamycin-induced</e1> <e2>cardiomyopathy</e2>
D004317_D009369 NONE <e1>adriamycin</e1> use chemotherapy <e2>cancer</e2>
D004317_D009369 NONE <e1>adr</e1> adriamycin use chemotherapy <e2>cancer</e2>
D004317_D002318 NONE <e1>adriamycin</e1> use limited <e2>toxicity</e2>
D004317_D002318 NONE <e1>adr</e1> adriamycin use limited <e2>toxicity</e2>
D004317_D001145 NONE <e1>adr</e1> mice treatment caused <e2>arrhythmias</e2>
D004317_D001919 CID <e1>adr</e1> mice treatment caused arrhythmias characterized <e2>bradycardia</e2>
D004317_D004487 NONE <e1>adr</e1> mice treatment caused underwent <e2>swelling</e2>
10523326
D009569_D006973 NONE <e1>oxide</e1> synthase expression course <e2>hypertension</e2>
D009569_D006973 NONE <e1>no</e1> metabolites excretion species showed increased sequestration nitrotyrosine tissues rats <e2>hypertension</e2>
D009569_D006973 NONE <e1>no</e1> sequestration nitrotyrosine tissues rats <e2>hypertension</e2>
D009569_D006973 NONE <e1>no</e1> synthase expression depressed whether reduction nox <e2>hypertension</e2>
D009569_D006973 NONE <e1>no</e1> inactivation actions associated <e2>hypertension</e2>
D007854_D006973 CID <e1>lead-induced</e1> <e2>hypertension</e2>
D007854_D006973 CID <e1>lead-induced</e1> <e2>hypertension</e2>
D007854_D006973 CID <e1>lead-induced</e1> <e2>hypertension</e2>
D007854_D006973 CID <e1>lead-induced</e1> <e2>hypertension</e2>
D007854_D006973 CID <e1>lead-associated</e1> inhibition inactivation actions associated <e2>hypertension</e2>
D010100_D006973 NONE <e1>oxygen</e1> species showed increased sequestration nitrotyrosine tissues rats <e2>hypertension</e2>
C002744_D006973 NONE <e1>nitrotyrosine</e1> tissues rats <e2>hypertension</e2>
D014810_D006973 NONE <e1>e</e1> supplementation ameliorated <e2>hypertension</e2>
D008315_D006973 NONE <e1>mda</e1> concentration <e2>hypertension</e2>
1610717
D003042_D012640 CID <e1>cocaine-induced</e1> <e2>seizures</e2>
783197
D010042_D003324 NONE <e1>ouabain</e1> effects supply demand patients <e2>disease</e2>
D010042_D003324 NONE <e1>ouabain</e1> effects parameters patients <e2>disease</e2>
D010042_D003324 NONE <e1>ouabain</e1> administration falls conclude left patients <e2>disease</e2>
D010100_D003324 NONE <e1>oxygen</e1> supply demand patients <e2>disease</e2>
D010100_D003324 NONE <e1>oxygen</e1> supply effects interest presence <e2>disease</e2>
D004071_D003324 NONE <e1>glycosides</e1> effects interest presence <e2>disease</e2>
D010042_D006333 NONE <e1>ouabain</e1> effects <e2>failure</e2>
D010042_D006333 NONE <e1>ouabain</e1> administration falls conclude left patients <e2>failure</e2>
D010042_D002303 CID <e1>ouabain</e1> administration <e2>falls</e2>
2893236
D005680_D012133 NONE <e1>gaba</e1> involvement naloxone reversal <e2>paralysis</e2>
D005680_D012133 NONE <e1>gaba</e1> glutamate naloxone <e2>paralysis</e2>
D005680_D012133 NONE <e1>gaba</e1> involves suggest reverses <e2>paralysis</e2>
D009270_D012133 NONE <e1>naloxone</e1> reversal <e2>paralysis</e2>
D009270_D012133 NONE <e1>naloxone</e1> reversed <e2>paralysis</e2>
D009270_D012133 NONE <e1>naloxone</e1> <e2>paralysis</e2>
D009270_D012133 NONE <e1>naloxone</e1> reverses <e2>paralysis</e2>
D013874_D012133 CID <e1>thiopental</e1> produced <e2>paralysis</e2>
D013874_D012133 CID <e1>thiopental</e1> induced <e2>paralysis</e2>
D013874_D012133 CID <e1>thiopental</e1> produced <e2>paralysis</e2>
D013874_D012131 NONE <e1>thiopental</e1> produced <e2>arrest</e2>
D005680_D012131 NONE <e1>gaba</e1> increase <e2>arrest</e2>
D018698_D012131 NONE <e1>glutamate</e1> decrease mg/kg <e2>arrest</e2>
D000596_D012131 NONE <e1>acids</e1> any affecting decrease mg/kg <e2>arrest</e2>
D018698_D012133 NONE <e1>glutamate</e1> naloxone <e2>paralysis</e2>
8677458
D015080_D006470 CID <e1>mesna</e1> administration prevent <e2>cystitis</e2>
D015080_D006470 CID <e1>mesna</e1> administering prevented toxicity <e2>cystitis</e2>
D015080_D003556 CID <e1>mesna</e1> administration prevent <e2>cystitis</e2>
D015080_D003556 CID <e1>mesna</e1> administering prevented toxicity <e2>cystitis</e2>
D007069_D006470 CID <e1>ifosfamide-induced</e1> <e2>cystitis</e2>
D007069_D006470 CID <e1>ifosfamide</e1> toxicity <e2>cystitis</e2>
D007069_D003556 CID <e1>ifosfamide-induced</e1> <e2>cystitis</e2>
D007069_D003556 CID <e1>ifosfamide</e1> toxicity <e2>cystitis</e2>
D007069_D064420 NONE <e1>ifosfamide</e1> <e2>toxicity</e2>
D015080_D064420 NONE <e1>mesna</e1> administering prevented <e2>toxicity</e2>
D015080_D014839 NONE <e1>mesna</e1> concentrations patient taking mesna experiences <e2>emesis</e2>
D015080_D014839 NONE <e1>mesna</e1> experiences <e2>emesis</e2>
D007069_D014839 NONE <e1>ifosfamide-induced</e1> <e2>emesis</e2>
3411101
C033457_D056486 CID <e1>phenylethylbarbiturate-induced</e1> <e2>hepatitis</e2>
C033457_D056486 CID <e1>phenylethylbarbiturate</e1> administration affected <e2>hepatitis</e2>
C033457_D056486 CID <e1>phenylethylbarbiturate</e1> quinidine responsible <e2>hepatitis</e2>
D011802_D056486 NONE <e1>quinidine</e1> responsible <e2>hepatitis</e2>
17943461
D015215_D009202 CID <e1>azt-induced</e1> <e2>cardiomyopathy</e2>
D015215_D002311 CID <e1>zidovudine</e1> triggers cause disruption model <e2>dcm</e2>
D015215_D002311 CID <e1>3'-azido-2',3'-deoxythymidine</e1> zidovudine triggers cause disruption model <e2>dcm</e2>
D015215_D002311 CID <e1>azt</e1> 3'-azido-2',3'-deoxythymidine zidovudine triggers cause disruption model <e2>dcm</e2>
D015215_D002311 CID <e1>azt</e1> concentrations containing libitum received investigate triggers cause disruption model <e2>dcm</e2>
D015215_D002311 CID <e1>azt-treated</e1> mice developed <e2>dilation</e2>
11027904
D008691_D010146 NONE <e1>methadone-maintained</e1> abusers responses <e2>pain</e2>
D008691_D010146 NONE <e1>methadone-maintenance</e1> treatment stabilized tolerance <e2>pain</e2>
D008691_D009293 NONE <e1>methadone-maintenance</e1> treatment stabilized tolerance sample <e2>addicts</e2>
D004091_D010146 NONE <e1>hydromorphone</e1> administration examined tolerance <e2>pain</e2>
D020910_D010146 NONE <e1>ketorolac</e1> anti-inflammatory administration examined tolerance <e2>pain</e2>
11705128
D012254_D000743 CID <e1>ribavirin-induced</e1> <e2>anemia</e2>
D012254_D000743 CID <e1>ribavirin-induced</e1> <e2>anemia</e2>
D012254_D000743 CID <e1>ribavirin-induced</e1> anemia <e2>riha</e2>
D012254_D000743 CID <e1>ribavirin</e1> dosage reduction standard management <e2>riha</e2>
D012254_D000743 CID <e1>ribavirin</e1> dose incidence <e2>riha</e2>
D012254_D006526 NONE <e1>ribavirin-induced</e1> anemia strategies treatment <e2>c</e2>
D012254_D019698 NONE <e1>alpha-2b/ribavirin</e1> interferon therapy efficacy demonstrated monotherapy treatment <e2>c</e2>
D012254_D019698 NONE <e1>alpha-2b/ribavirin</e1> interferon therapy efficacy demonstrated monotherapy treatment c <e2>chc</e2>
D016898_D019698 NONE <e1>interferon-alpha</e1> monotherapy treatment <e2>c</e2>
D016898_D019698 NONE <e1>interferon-alpha</e1> monotherapy treatment c <e2>chc</e2>
17975693
D002939_D001008 CID <e1>ciprofloxacin-</e1> rats showed <e2>behaviour</e2>
D009643_D001008 CID <e1>norfloxacin-treated</e1> ciprofloxacin- rats showed <e2>behaviour</e2>
18627295
D004317_D009202 CID <e1>doxorubicin</e1> <e2>cardiomyopathy-induced</e2>
D004317_D009202 CID <e1>dox</e1> <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>dox</e1> cardiomyopathy development role elucidate studied investigating induction <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>dox-induced</e1> cardiomyopathy induction investigating studied elucidate role development <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>dox-induced</e1> <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>dox</e1> <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>dox</e1> <e2>cardiomyopathy</e2>
D004317_D007249 NONE <e1>doxorubicin</e1> cardiomyopathy-induced <e2>inflammation</e2>
D004317_D007249 NONE <e1>dox</e1> cardiomyopathy development role elucidate studied investigating <e2>inflammation</e2>
D004317_D007249 NONE <e1>dox-induced</e1> cardiomyopathy induction investigating <e2>inflammation</e2>
D018943_D066126 NONE <e1>anthracycline</e1> doxorubicin use limited effects <e2>cardiotoxic</e2>
D004317_D066126 NONE <e1>doxorubicin</e1> use limited effects <e2>cardiotoxic</e2>
D004317_D066126 NONE <e1>dox</e1> doxorubicin use limited effects <e2>cardiotoxic</e2>
D004317_D006331 NONE <e1>dox</e1> mice showed <e2>dysfunction</e2>
D004317_D006331 NONE <e1>dox</e1> b1r(-/- mice improved <e2>dysfunction</e2>
D004317_D006331 NONE <e1>dox</e1> mice improved <e2>dysfunction</e2>
2564649
D005283_D009127 CID <e1>fentanyl-induced</e1> <e2>rigidity</e2>
D005283_D009127 CID <e1>fentanyl</e1> anesthesia associated effect <e2>rigidity</e2>
D005283_D009127 CID <e1>fentanyl</e1> induction <e2>rigidity</e2>
D011224_D009127 NONE <e1>prazosin</e1> pretreatment lesions reduced antagonized <e2>rigidity</e2>
7542793
D016572_D007674 CID <e1>a</e1> <e2>nephrotoxicity</e2>
D016572_D007674 CID <e1>csa</e1> effects <e2>nephrotoxic</e2>
D016559_D007674 CID <e1>fk506</e1> a <e2>nephrotoxicity</e2>
D016559_D007674 CID <e1>fk506</e1> csa effects <e2>nephrotoxic</e2>
D016572_D006984 NONE <e1>a</e1> caused <e2>hypertrophy</e2>
D016572_D006984 NONE <e1>csa</e1> a caused <e2>hypertrophy</e2>
D016559_D006984 NONE <e1>fujimycine</e1> a caused <e2>hypertrophy</e2>
D016559_D006984 NONE <e1>fk506</e1> fujimycine a caused <e2>hypertrophy</e2>
D018942_D006984 NONE <e1>macrolide</e1> rapamycin a caused <e2>hypertrophy</e2>
D020123_D006984 NONE <e1>rapamycin</e1> a caused <e2>hypertrophy</e2>
D016572_D064420 NONE <e1>csa</e1> <e2>toxicity</e2>
D016559_D064420 NONE <e1>fk506</e1> csa <e2>toxicity</e2>
1300436
D005665_D007674 NONE <e1>furosemide</e1> effect <e2>nephropathy</e2>
D005665_D007674 NONE <e1>furosemide</e1> efficacy determine <e2>nephropathy</e2>
D005665_D007674 NONE <e1>furosemide</e1> deleterious <e2>nephropathy</e2>
D005665_D058186 CID <e1>furosemide</e1> pretreated group <e2>deteriorated</e2>
D003404_D058186 NONE <e1>creatinine</e1> rise angiographies <e2>deteriorated</e2>
D005665_D051437 NONE <e1>furosemide-treated</e1> group loss associated <e2>failure</e2>
D005665_D015431 NONE <e1>furosemide-treated</e1> group <e2>loss</e2>
12101159
D004110_D006323 CID <e1>diltiazem</e1> overdose arrest cardiac <e2>asystolic</e2>
D004110_D006323 CID <e1>diltiazem</e1> overdose <e2>arrest</e2>
D004110_D006323 CID <e1>diltiazem</e1> overdose role onset <e2>asystole</e2>
D004110_D006323 CID <e1>diltiazem</e1> overdose considered cases <e2>arrest</e2>
D004110_D062787 CID <e1>diltiazem</e1> <e2>overdose</e2>
D004110_D062787 CID <e1>diltiazem</e1> g took <e2>overdose</e2>
D004110_D062787 CID <e1>diltiazem</e1> <e2>overdose</e2>
D004110_D062787 CID <e1>diltiazem</e1> <e2>overdose</e2>
D002118_D006323 NONE <e1>calcium</e1> resuscitation arrest cardiac <e2>asystolic</e2>
D002118_D006323 NONE <e1>calcium</e1> resuscitation <e2>arrest</e2>
D002118_D006323 NONE <e1>calcium</e1> therapy role onset <e2>asystole</e2>
D002118_D062787 NONE <e1>calcium</e1> resuscitation arrest <e2>overdose</e2>
D002118_D062787 NONE <e1>calcium</e1> therapy role <e2>overdose</e2>
D000082_D062787 NONE <e1>paracetamol</e1> diltiazem g took <e2>overdose</e2>
D001241_D062787 NONE <e1>aspirin</e1> diltiazem g took <e2>overdose</e2>
D007547_D062787 NONE <e1>isosorbide</e1> nitrate took <e2>overdose</e2>
D009566_D062787 NONE <e1>nitrate</e1> took <e2>overdose</e2>
D000431_D062787 NONE <e1>alcohol</e1> nitrate took <e2>overdose</e2>
11099450
D007980_D010300 NONE <e1>levodopa-induced</e1> dyskinesias signs <e2>parkinsonian</e2>
D007980_D010300 NONE <e1>levodopa</e1> responsiveness outcome signs <e2>parkinsonian</e2>
D007980_D010300 NONE <e1>levodopa</e1> responsiveness correlations volume dyskinesias <e2>parkinsonian</e2>
D007980_D010300 NONE <e1>levodopa</e1> responsiveness value indicate responsible generation signs <e2>parkinsonian</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> dyskinesias <e2>lid</e2>
D007980_D004409 CID <e1>levodopa</e1> responsiveness correlations found was correlation improvement <e2>lid</e2>
D007980_D004409 CID <e1>levodopa</e1> responsiveness responsiveness correlations found was correlation improvement <e2>lid</e2>
D007980_D004409 CID <e1>levodopa</e1> responsiveness outcome signs <e2>lid</e2>
D007980_D004409 CID <e1>levodopa</e1> responsiveness correlations volume <e2>dyskinesias</e2>
D007980_D004409 CID <e1>levodopa</e1> responsiveness value indicate responsible generation signs <e2>dyskinesias</e2>
1079693
D000305_D014605 NONE <e1>corticosteroids</e1> treatment months respond % cases <e2>uveitis</e2>
D002738_D012164 NONE <e1>chloroquine</e1> used found case attributable <e2>chorioretinopathy</e2>
D006886_D012164 CID <e1>hydroxychloroquine</e1> chloroquine used found case attributable <e2>chorioretinopathy</e2>
D000305_D002386 NONE <e1>corticosteroids</e1> used found number <e2>cataracts</e2>
11195262
D014635_D007177 CID <e1>valproate</e1> contribution syndrome secretion <e2>hormone</e2>
D014635_D007177 CID <e1>valproate</e1> administered developed syndrome secretion <e2>hormone</e2>
D014635_D007177 CID <e1>valproate</e1> administered developed syndrome secretion hormone <e2>siadh</e2>
D014635_D007177 CID <e1>vpa</e1> valproate administered developed syndrome secretion <e2>hormone</e2>
D014635_D007177 CID <e1>vpa</e1> valproate administered developed syndrome secretion hormone <e2>siadh</e2>
D014635_D007177 CID <e1>vpa</e1> administration weakness factors combination result consider episode <e2>siadh</e2>
D014635_D004830 NONE <e1>vpa</e1> taking treatment <e2>convulsions</e2>
D014635_D002493 NONE <e1>vpa</e1> administration weakness <e2>system</e2>
2334179
D010396_D012594 NONE <e1>d-penicillamine</e1> treatment <e2>scleroderma</e2>
D010396_D012594 NONE <e1>d-penicillamine</e1> treated <e2>scleroderma</e2>
D010396_D012594 NONE <e1>d-penicillamine</e1> effective cases <e2>scleroderma</e2>
D010396_D009404 CID <e1>d-penicillamine</e1> caused <e2>syndrome</e2>
D010396_D011507 CID <e1>d-penicillamine</e1> caused patient <e2>proteinuria</e2>
D010396_D051437 NONE <e1>d-penicillamine</e1> caused developed <e2>insufficiency</e2>
18657397
D010406_D004827 NONE <e1>penicillin-induced</e1> <e2>activity</e2>
D010406_D004827 NONE <e1>penicillin</e1> model model research <e2>epilepsy</e2>
D010406_D004827 NONE <e1>penicillin-induced</e1> <e2>activity</e2>
D010406_D004827 NONE <e1>penicillin-induced</e1> periods <e2>activity</e2>
D010400_D004827 CID <e1>potassium</e1> injecting induced focus <e2>epileptic</e2>
9270571
D004298_D020734 NONE <e1>dopamine</e1> agonist use study monkeys <e2>parkinsonian</e2>
C095427_D020734 NONE <e1>a-86929</e1> use study monkeys <e2>parkinsonian</e2>
C095427_D020734 NONE <e1>a-86929</e1> administration efficacious alleviating <e2>parkinsonism</e2>
D007980_D020734 NONE <e1>levodopa-primed</e1> monkeys <e2>parkinsonian</e2>
D007980_D020734 NONE <e1>levodopa</e1> alleviating <e2>parkinsonism</e2>
D007980_D020734 NONE <e1>levodopa-induced</e1> dyskinesias reproduce likely efficacious alleviating <e2>parkinsonism</e2>
D007980_D020734 NONE <e1>levodopa</e1> challenge ly-171555 reproduce likely efficacious alleviating <e2>parkinsonism</e2>
D004298_D010300 NONE <e1>dopamine</e1> agonists utility treatment <e2>disease</e2>
D004298_D010300 NONE <e1>dopamine</e1> agonists utility treatment disease <e2>pd</e2>
D004298_D010300 NONE <e1>da</e1> agonists utility treatment <e2>disease</e2>
D004298_D010300 NONE <e1>da</e1> agonists utility treatment disease <e2>pd</e2>
D004298_D010300 NONE <e1>da</e1> agents tools <e2>pd</e2>
D015632_D004409 NONE <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1> monkeys study primed exhibit <e2>dyskinesias</e2>
D015632_D004409 NONE <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1> monkeys study primed exhibit evaluate effects locomotor <e2>dyskinetic</e2>
D015632_D004409 NONE <e1>(mptp)-exposed</e1> monkeys study primed exhibit <e2>dyskinesias</e2>
D015632_D004409 NONE <e1>(mptp)-exposed</e1> monkeys study primed exhibit evaluate effects locomotor <e2>dyskinetic</e2>
D015632_D004409 NONE <e1>mptp-induced</e1> parkinsonism alleviating efficacious likely reproduce <e2>dyskinesias</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> dyskinesias exhibit evaluate effects locomotor <e2>dyskinetic</e2>
D007980_D004409 CID <e1>levodopa</e1> alleviating efficacious likely reproduce <e2>dyskinesias</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D007980_D004409 CID <e1>levodopa</e1> challenge ly-171555 reproduce <e2>dyskinesias</e2>
C095427_D004409 NONE <e1>a-86929</e1> doses challenge effects evaluate exhibit <e2>dyskinesias</e2>
C095427_D004409 NONE <e1>a-86929</e1> doses challenge effects locomotor <e2>dyskinetic</e2>
C095427_D004409 NONE <e1>10-diol</e1> doses challenge effects evaluate exhibit <e2>dyskinesias</e2>
C095427_D004409 NONE <e1>10-diol</e1> doses challenge effects locomotor <e2>dyskinetic</e2>
C095427_D004409 NONE <e1>a-86929</e1> administration efficacious likely reproduce <e2>dyskinesias</e2>
D004298_D004409 NONE <e1>da</e1> agonist doses challenge effects evaluate exhibit <e2>dyskinesias</e2>
D004298_D004409 NONE <e1>da</e1> agonist doses challenge effects locomotor <e2>dyskinetic</e2>
D015632_D020734 CID <e1>mptp-induced</e1> <e2>parkinsonism</e2>
C416545_D020734 NONE <e1>ly-171555</e1> levodopa alleviating <e2>parkinsonism</e2>
C416545_D020734 NONE <e1>ly-171555</e1> reproduce likely efficacious alleviating <e2>parkinsonism</e2>
C416545_D004409 NONE <e1>ly-171555</e1> levodopa alleviating efficacious likely reproduce <e2>dyskinesias</e2>
C416545_D004409 NONE <e1>ly-171555</e1> reproduce <e2>dyskinesias</e2>
C095427_D010300 NONE <e1>a-86929</e1> efficacy duration agents tools <e2>pd</e2>
8305357
D003630_D012514 NONE <e1>daunorubicin</e1> <e2>sarcoma</e2>
D003630_D012514 NONE <e1>daunorubicin</e1> efficacy treatment <e2>sarcoma</e2>
D003630_D012514 NONE <e1>daunorubicin</e1> agent treatment <e2>sarcoma</e2>
D003630_D000163 NONE <e1>daunorubicin</e1> efficacy treatment sarcoma <e2>aids</e2>
15985056
D017963_D006606 CID <e1>azithromycin-associated</e1> <e2>hiccups</e2>
D017963_D006606 CID <e1>azithromycin</e1> therapy associated <e2>hiccups</e2>
D017963_D006606 CID <e1>azithromycin</e1> beginning presented <e2>hiccups</e2>
D017963_D006606 CID <e1>azithromycin</e1> discontinuation resolved <e2>hiccups</e2>
D017963_D006606 CID <e1>azithromycin</e1> mediated mechanism pathogenesis <e2>hiccups</e2>
D017963_D010612 NONE <e1>azithromycin</e1> beginning treatment <e2>pharyngitis</e2>
D001418_D006606 CID <e1>baclofen</e1> discontinuation resolved <e2>hiccups</e2>
D003907_D006606 NONE <e1>dexamethasone</e1> corticosteroids agents mentioned associated development <e2>hiccups</e2>
D008775_D006606 NONE <e1>methylprednisolone</e1> dexamethasone corticosteroids agents mentioned associated development <e2>hiccups</e2>
D001569_D006606 NONE <e1>benzodiazepines</e1> corticosteroids agents mentioned associated development <e2>hiccups</e2>
D008874_D006606 NONE <e1>midazolam</e1> benzodiazepines corticosteroids agents mentioned associated development <e2>hiccups</e2>
D018942_D006606 NONE <e1>macrolide</e1> antimicrobials related reported cases <e2>hiccups</e2>
D018942_D006606 NONE <e1>macrolides</e1> reaction reports sequence absence explanation <e2>hiccups</e2>
D018942_D006606 NONE <e1>macrolide</e1> antimicrobials reported associated <e2>hiccups</e2>
6794356
D016651_D014262 NONE <e1>carbonate</e1> <e2>regurgitation</e2>
D016651_D064420 NONE <e1>carbonate</e1> regurgitation valve <e2>toxicity</e2>
D008094_D014262 NONE <e1>lithium</e1> level described newborn <e2>regurgitation</e2>
D008094_D014262 NONE <e1>lithium</e1> compounds exposed infants disease patient patient manifest <e2>regurgitation</e2>
D008094_D001282 NONE <e1>lithium</e1> level described newborn regurgitation <e2>flutter</e2>
D008094_D001282 NONE <e1>lithium</e1> compounds exposed infants disease patient patient manifest regurgitation <e2>flutter</e2>
D008094_D006333 NONE <e1>lithium</e1> level described newborn regurgitation <e2>failure</e2>
D008094_D006331 NONE <e1>lithium</e1> compounds exposed infants <e2>disease</e2>
D016651_D006331 NONE <e1>carbonate</e1> factor incidence <e2>disease</e2>
11999899
D012110_D009069 NONE <e1>reserpine</e1> produced increases <e2>dyskinesia</e2>
D012110_D009069 NONE <e1>reserpine</e1> administered produce <e2>dyskinesia</e2>
D012110_D004409 CID <e1>reserpine</e1> produced increases signs indicative <e2>dyskinesia</e2>
D012110_D004409 CID <e1>reserpine</e1> produces <e2>movements</e2>
D012110_D004409 CID <e1>reserpine</e1> produces movements related considered parkinsonian-like signs <e2>dsykinesia</e2>
D012110_D014202 CID <e1>reserpine</e1> produced <e2>tremor</e2>
D012110_D014202 CID <e1>reserpine-treated</e1> mice increase <e2>tremor</e2>
D012110_D014202 CID <e1>reserpine</e1> induced increases <e2>tremor</e2>
D012110_D014202 CID <e1>reserpine</e1> induced <e2>tremor</e2>
D012110_D014202 CID <e1>reserpine</e1> pretreatment increases <e2>tremor</e2>
D012110_D014202 CID <e1>reserpine</e1> effects reversed pretreatment increases <e2>tremor</e2>
D012110_D002375 CID <e1>reserpine</e1> produced tremor <e2>catalepsy</e2>
D012110_D002375 CID <e1>reserpine</e1> induced protrusions <e2>catalepsy</e2>
D012110_D002375 CID <e1>reserpine</e1> induced increases tremor <e2>catalepsy</e2>
D012110_D002375 CID <e1>reserpine</e1> induced tremor <e2>catalepsy</e2>
D012110_D002375 CID <e1>reserpine</e1> pretreatment increases tremor <e2>catalepsy</e2>
D012110_D002375 CID <e1>reserpine</e1> effects reversed pretreatment increases tremor <e2>catalepsy</e2>
D012110_D010300 NONE <e1>reserpine</e1> produced signs suggestive <e2>disease</e2>
D012110_D010300 NONE <e1>reserpine</e1> produces movements related considered <e2>parkinsonian-like</e2>
D016291_D002375 NONE <e1>mk-801</e1> administered prevented movements protrusions <e2>catalepsy</e2>
D016291_D002375 NONE <e1>mk-801</e1> administration attenuated <e2>catalepsy</e2>
D016291_D002375 NONE <e1>mk-801</e1> injection pretreatment increases tremor <e2>catalepsy</e2>
D016291_D014202 NONE <e1>mk-801</e1> injection produced increase <e2>tremor</e2>
D016291_D014202 NONE <e1>mk-801</e1> administration attenuated catalepsy <e2>tremor</e2>
D016291_D014202 NONE <e1>mk-801</e1> injection pretreatment increases <e2>tremor</e2>
D001058_D009069 NONE <e1>apomophine</e1> injection followed administered produce <e2>dyskinesia</e2>
D016202_D002375 NONE <e1>nmda</e1> produced blockage restore movements protrusions <e2>catalepsy</e2>
D016202_D014202 NONE <e1>nmda</e1> produced blockage restore movements protrusions catalepsy <e2>tremor</e2>
9205462
D013629_C537296 CID <e1>tamoxifen</e1> use associated <e2>ovary</e2>
D013629_D009369 NONE <e1>tamoxifen</e1> use <e2>tumors</e2>
D013629_D001943 NONE <e1>tamoxifen</e1> <e2>carcinoma</e2>
D004967_D001943 NONE <e1>estrogen</e1> <e2>carcinoma</e2>
D013629_D017093 CID <e1>tamoxifen-induced</e1> <e2>dysfunction</e2>
D013629_D017093 CID <e1>tamoxifen</e1> metabolism alterations risk patients <e2>dysfunction</e2>
D013629_D006106 NONE <e1>tamoxifen-induced</e1> dysfunction patients risk <e2>tumors</e2>
D013629_D006106 NONE <e1>tamoxifen</e1> metabolism alterations risk <e2>tumors</e2>
19105845
D016642_D012640 CID <e1>hydrochloride-induced</e1> <e2>seizures</e2>
D016642_D012640 CID <e1>bupropion-induced</e1> <e2>seizures</e2>
D016642_D012640 CID <e1>hcl</e1> mg/kg dose <e2>convulsive</e2>
D016642_D012640 CID <e1>hcl</e1> mg/kg effect investigated incidence <e2>convulsions</e2>
D016642_D012640 CID <e1>bupropion-induced</e1> convulsions incidence investigated effect mg/kg dose <e2>convulsive</e2>
D016642_D012640 CID <e1>bupropion-induced</e1> <e2>convulsions</e2>
D016642_D012640 CID <e1>hcl</e1> administration induced <e2>convulsions</e2>
D016642_D012640 CID <e1>hcl</e1> time increasing significant revealed associated odds <e2>convulsions</e2>
D016642_D012640 CID <e1>bupropion</e1> dose fixed <e2>convulsive</e2>
D016642_D012640 CID <e1>bupropion</e1> dose time risk <e2>convulsions</e2>
9067481
C013440_D056486 NONE <e1>hemisuccinate</e1> stabilizer/rigidifier use addition shown protect effects <e2>hepatotoxic</e2>
-1_D056486 NONE <e1>salt</e1> administration shown protect effects <e2>hepatotoxic</e2>
-1_D056486 NONE <e1>cs</e1> ( administration shown protect effects <e2>hepatotoxic</e2>
-1_D056486 NONE <e1>cs</e1> dose pretreatment resulted protection effects <e2>hepatotoxic</e2>
-1_D056486 NONE <e1>cs</e1> protection mechanism appear dependent inhibition intermediate light protection observed <e2>hepatotoxicity</e2>
D002251_D056486 CID <e1>tetrachloride</e1> effects <e2>hepatotoxic</e2>
D002251_D056486 CID <e1>ccl4</e1> tetrachloride effects <e2>hepatotoxic</e2>
D002251_D056486 CID <e1>ccl4</e1> effects <e2>hepatotoxic</e2>
-1_D064420 NONE <e1>cs</e1> cytoprotection mechanism understanding further examined mice <e2>toxicity</e2>
-1_D064420 NONE <e1>cs</e1> abilities mice <e2>toxicity</e2>
-1_D064420 NONE <e1>cs</e1> form abilities mice <e2>toxicity</e2>
-1_D064420 NONE <e1>salt</e1> cs form abilities mice <e2>toxicity</e2>
-1_D064420 NONE <e1>cse</e1> salt cs form abilities mice <e2>toxicity</e2>
C103872_D064420 NONE <e1>acid</e1> cs form abilities mice <e2>toxicity</e2>
D000082_D064420 NONE <e1>acetaminophen-</e1> form abilities mice <e2>toxicity</e2>
D004317_D064420 NONE <e1>adriamycin-</e1> <e2>toxicity</e2>
D002251_D064420 NONE <e1>tetrachloride-</e1> adriamycin- <e2>toxicity</e2>
D002725_D064420 NONE <e1>chloroform-</e1> tetrachloride- adriamycin- <e2>toxicity</e2>
D005688_D064420 NONE <e1>galactosamine-induced</e1> chloroform- tetrachloride- adriamycin- <e2>toxicity</e2>
-1_D066126 NONE <e1>cs</e1> dose pretreatment resulted protection effects ccl4 <e2>cardiotoxic</e2>
D002251_D066126 NONE <e1>ccl4</e1> <e2>cardiotoxic</e2>
D002725_D056486 CID <e1>chcl3</e1> ccl4 effects <e2>hepatotoxic</e2>
D002725_D066126 NONE <e1>chcl3</e1> ccl4 <e2>cardiotoxic</e2>
D000082_D056486 CID <e1>acetaminophen</e1> ccl4 effects <e2>hepatotoxic</e2>
D000082_D066126 NONE <e1>acetaminophen</e1> ccl4 <e2>cardiotoxic</e2>
D005688_D056486 CID <e1>galactosamine</e1> ccl4 effects <e2>hepatotoxic</e2>
D005688_D056486 CID <e1>galactosamine</e1> <e2>hepatotoxicity</e2>
D005688_D066126 NONE <e1>galactosamine</e1> ccl4 <e2>cardiotoxic</e2>
D004317_D056486 NONE <e1>adriamycin</e1> administration effect protection effects <e2>hepatotoxic</e2>
D004317_D066126 CID <e1>adriamycin</e1> administration effect protection effects ccl4 <e2>cardiotoxic</e2>
2422478
D012701_D007022 NONE <e1>serotonin</e1> nerves involved effect <e2>hypotensive</e2>
D012701_D007022 NONE <e1>serotonin</e1> neurons cells microinjection elicits response <e2>hypotensive</e2>
D012701_D007022 NONE <e1>serotonin</e1> group area microinjection caused <e2>hypotension</e2>
D012701_D007022 NONE <e1>serotonin</e1> 5,7-dihydroxytryptamine abolished maximal mm <e2>hypotension</e2>
D012701_D007022 NONE <e1>serotonin</e1> projections descending lesion produce injection affect <e2>hypotension</e2>
D012701_D007022 NONE <e1>serotonin</e1> cells contribute cells mediate <e2>hypotension</e2>
D012701_D007022 NONE <e1>serotonin</e1> cells contribute action <e2>hypotensive</e2>
D008750_D007022 CID <e1>methyldopa</e1> effect <e2>hypotensive</e2>
D008750_D007022 CID <e1>methyldopa</e1> microinjection elicits response <e2>hypotensive</e2>
D008750_D007022 CID <e1>methyldopa</e1> microinjection caused <e2>hypotension</e2>
D008750_D007022 CID <e1>methyldopa-induced</e1> <e2>hypotension</e2>
D008750_D007022 CID <e1>methyldopa-induced</e1> hypotension mediate cells contribute action <e2>hypotensive</e2>
D008750_D007022 CID <e1>methyldopa</e1> action contribute cells mediate <e2>hypotension</e2>
D008750_D007022 CID <e1>methyldopa</e1> action <e2>hypotensive</e2>
D008750_D006973 NONE <e1>methyldopa</e1> microinjection caused <e2>hypertensive</e2>
D008750_D020521 NONE <e1>methyldopa</e1> microinjection caused hypertensive rats <e2>stroke-prone</e2>
D012701_D006973 NONE <e1>serotonin</e1> group area microinjection caused <e2>hypertensive</e2>
D012701_D006973 NONE <e1>serotonin</e1> 5,7-dihydroxytryptamine abolished maximal mm hypotension caused <e2>hypertensive</e2>
D012701_D020521 NONE <e1>serotonin</e1> group area microinjection caused hypertensive rats <e2>stroke-prone</e2>
D012701_D020521 NONE <e1>serotonin</e1> 5,7-dihydroxytryptamine abolished maximal mm hypotension caused hypertensive rats <e2>stroke-prone</e2>
D015116_D006973 NONE <e1>5,7-dihydroxytryptamine</e1> abolished maximal mm hypotension caused <e2>hypertensive</e2>
D015116_D006973 NONE <e1>5,7-dht</e1> 5,7-dihydroxytryptamine abolished maximal mm hypotension caused <e2>hypertensive</e2>
D015116_D020521 NONE <e1>5,7-dihydroxytryptamine</e1> abolished maximal mm hypotension caused hypertensive rats <e2>stroke-prone</e2>
D015116_D020521 NONE <e1>5,7-dht</e1> 5,7-dihydroxytryptamine abolished maximal mm hypotension caused hypertensive rats <e2>stroke-prone</e2>
D015116_D007022 NONE <e1>5,7-dihydroxytryptamine</e1> abolished maximal mm <e2>hypotension</e2>
D015116_D007022 NONE <e1>5,7-dht</e1> 5,7-dihydroxytryptamine abolished maximal mm <e2>hypotension</e2>
D015116_D007022 NONE <e1>5,7-dht</e1> injection affect <e2>hypotension</e2>
7421734
D004967_D010049 NONE <e1>estrogens</e1> received had <e2>failure</e2>
D004967_D010049 NONE <e1>estrogens</e1> <e2>failure</e2>
D004967_D006689 NONE <e1>estrogens</e1> received had irradiation <e2>disease</e2>
D004967_D016889 CID <e1>estrogens</e1> received had treatment implicated development <e2>cancer</e2>
D004967_D016889 CID <e1>estrogens</e1> women increased risk <e2>carcinoma</e2>
D004967_D009369 NONE <e1>estrogens</e1> failure therapy <e2>cancer</e2>
7843916
D003907_D009798 CID <e1>dexamethasone-induced</e1> <e2>hypertension</e2>
D003907_D009798 CID <e1>dexamethasone-treated</e1> <e2>eyes</e2>
D003907_D009798 CID <e1>dexamethasone</e1> treatment led generation <e2>hypertension</e2>
D003907_D009798 CID <e1>dexamethasone-treated</e1> eyes % generation <e2>hypertension</e2>
D013256_D005901 NONE <e1>steroid</e1> treatment resulted changes meshwork similar those reported <e2>glaucoma</e2>
D013256_D005902 NONE <e1>steroid</e1> treatment resulted changes meshwork similar those reported glaucoma <e2>glaucoma</e2>
6415512
D002220_D004831 CID <e1>carbamazepine</e1> therapy institution myoclonic <e2>seizures</e2>
D002220_D004831 CID <e1>carbamazepine</e1> treated children had absence <e2>seizures</e2>
D002220_D004832 CID <e1>carbamazepine</e1> therapy institution myoclonic <e2>seizures</e2>
D002220_D004832 CID <e1>carbamazepine</e1> treated children had absence <e2>seizures</e2>
D002220_D004827 NONE <e1>carbamazepine</e1> <e2>epilepsy</e2>
D002220_D012640 NONE <e1>carbamazepine</e1> discontinued returned had resolve <e2>seizures</e2>
D002220_D012640 NONE <e1>carbamazepine</e1> discontinued returned had resolve had persist <e2>seizures</e2>
1969772
D018818_D007022 CID <e1>fenoldopam</e1> induced <e2>hypotension</e2>
D018818_D007022 CID <e1>fenoldopam</e1> used induce <e2>hypotension</e2>
D018818_D007022 CID <e1>fenoldopam-induced</e1> <e2>hypotension</e2>
D018818_D007022 CID <e1>fenoldopam-induced</e1> hypotension increased decreased <e2>hypotension</e2>
D012964_D007022 NONE <e1>sodium</e1> nitroprusside-induced hypotension decreased increased <e2>hypotension</e2>
D012964_D007022 NONE <e1>sodium</e1> nitroprusside-induced <e2>hypotension</e2>
D009599_D007022 CID <e1>nitroprusside-induced</e1> hypotension decreased increased <e2>hypotension</e2>
D009599_D007022 CID <e1>nitroprusside-induced</e1> <e2>hypotension</e2>
D009599_D007022 CID <e1>nitroprusside</e1> vasodilator produce <e2>hypotension</e2>
D004298_D007022 NONE <e1>dopamine-1</e1> agonist causes preserves <e2>hypotension</e2>
3686155
D001971_D011605 CID <e1>bromocriptine</e1> induced <e2>psychosis</e2>
D001971_D011605 CID <e1>bromocriptine</e1> received seen <e2>psychosis</e2>
D001971_D011605 CID <e1>bromocriptine</e1> associated <e2>psychosis</e2>
D001971_D011605 CID <e1>bromocriptine</e1> cause <e2>psychosis</e2>
D001971_D001523 NONE <e1>bromocriptine</e1> received seen patients history <e2>psychiatric</e2>
D001971_D007775 NONE <e1>bromocriptine</e1> received inhibition <e2>lactation</e2>
D001971_D010300 NONE <e1>bromocriptine</e1> associated psychosis patients receiving drug <e2>disease</e2>
3120485
982002
D012293_D058186 CID <e1>rifampicin</e1> administration subsequent <e2>failure</e2>
D012293_D051437 NONE <e1>rifampicin</e1> administration <e2>failure</e2>
3950060
D000583_D007674 CID <e1>amikacin</e1> receiving patients <e2>nephrotoxicity</e2>
D000583_D007674 CID <e1>amikacin</e1> treated patients data analyzed factors associated <e2>nephrotoxicity</e2>
16574713
D018817_D020258 NONE <e1>3,4-methylenedioxymethamphetamine</e1> shown neurons known consequences <e2>lesions</e2>
D018817_D020258 NONE <e1>mdma</e1> 3,4-methylenedioxymethamphetamine shown neurons known consequences <e2>lesions</e2>
D018817_D020258 NONE <e1>ecstasy</e1> mdma 3,4-methylenedioxymethamphetamine shown neurons known consequences <e2>lesions</e2>
D018817_D020258 NONE <e1>mdma-induced</e1> <e2>lesions</e2>
D012701_D020258 NONE <e1>serotonin</e1> shown neurons known consequences <e2>lesions</e2>
D012701_D020258 NONE <e1>5-ht</e1> serotonin shown neurons known consequences <e2>lesions</e2>
D012701_D020258 NONE <e1>5-ht</e1> <e2>lesions</e2>
D012701_D020258 NONE <e1>5-ht</e1> involved functions <e2>lesions</e2>
D018817_D008569 CID <e1>mdma</e1> users observed evidence <e2>impairment</e2>
D018817_D008569 CID <e1>mdma</e1> use associated memory <e2>functioning</e2>
D018817_D008569 CID <e1>mdma</e1> use associated lead <e2>impairments</e2>
D018817_D008569 CID <e1>mdma</e1> use use lead associated memory <e2>functioning</e2>
D018817_D008569 CID <e1>mdma</e1> use use lead <e2>impairments</e2>
4038130
D008619_D009135 CID <e1>mepivacaine</e1> exposure seen addition <e2>damage</e2>
D008012_D009135 CID <e1>lidocaine</e1> mepivacaine exposure seen addition <e2>damage</e2>
D004837_D009135 NONE <e1>epinephrine</e1> mepivacaine exposure seen addition <e2>damage</e2>
8800187
D002122_D064420 NONE <e1>chloride</e1> effect <e2>toxicity</e2>
D015761_D064420 NONE <e1>4-aminopyridine</e1> therapy effect <e2>toxicity</e2>
D003891_D064420 NONE <e1>desipramine</e1> <e2>toxicity</e2>
D002118_D007022 NONE <e1>calcium</e1> channel blockade <e2>hypotension</e2>
D002118_D007022 NONE <e1>calcium</e1> channel inhibition pathogenesis <e2>hypotension</e2>
D002118_D062787 NONE <e1>calcium</e1> channel <e2>overdose</e2>
D003891_D007022 CID <e1>desipramine</e1> ip received produce <e2>hypotension</e2>
D003891_D001919 CID <e1>desipramine</e1> ip received produce hypotension <e2>bradycardia</e2>
D017693_D007022 NONE <e1>nahco3</e1> briefly reversed <e2>hypotension</e2>
D002122_D001145 CID <e1>cacl2</e1> group incidence <e2>arrhythmias</e2>
D002122_D012640 NONE <e1>cacl2</e1> group incidence <e2>seizures</e2>
D002122_D007022 NONE <e1>cacl2</e1> administration reverse <e2>hypotension</e2>
D015761_D007022 NONE <e1>4-aminopyridine</e1> cacl2 administration reverse <e2>hypotension</e2>
D002122_D002318 NONE <e1>cacl2</e1> therapy worsen <e2>toxicity</e2>
D002122_D002493 NONE <e1>cacl2</e1> therapy worsen <e2>toxicity</e2>
8546130
D017291_D006212 CID <e1>clarithromycin-associated</e1> <e2>hallucinations</e2>
D017291_D006212 CID <e1>clarithromycin</e1> antibiotic macrolide association occurring <e2>hallucinations</e2>
D017291_D007676 NONE <e1>clarithromycin-associated</e1> hallucinations patient <e2>failure</e2>
D017291_D007676 NONE <e1>clarithromycin</e1> dose combination face <e2>failure</e2>
D018942_D006212 NONE <e1>macrolide</e1> association occurring <e2>hallucinations</e2>
D017291_D020258 NONE <e1>clarithromycin</e1> dose combination facilitated appearance effect <e2>neurotoxic</e2>
D000535_D007676 NONE <e1>aluminum</e1> intoxication combination face <e2>failure</e2>
D000535_D020258 NONE <e1>aluminum</e1> intoxication combination facilitated appearance effect <e2>neurotoxic</e2>
9121607
D013256_D012640 NONE <e1>steroids</e1> protect pilocarpine- <e2>seizures</e2>
D013256_D012640 NONE <e1>steroids</e1> effective mg/kg <e2>seizures</e2>
D013256_D012640 NONE <e1>steroids</e1> potent protecting <e2>seizures</e2>
D013256_D012640 NONE <e1>steroids</e1> potent had values divided ed50 protection <e2>seizure</e2>
D013256_D012640 NONE <e1>steroids</e1> had potent protecting <e2>seizures</e2>
D013256_D012640 NONE <e1>steroids</e1> had values divided ed50 protection <e2>seizure</e2>
D013256_D012640 NONE <e1>steroids</e1> have indicating had potent protecting <e2>seizures</e2>
D013256_D012640 NONE <e1>steroids</e1> have indicating had values divided ed50 protection <e2>seizure</e2>
D013256_D012640 NONE <e1>steroids</e1> produced delay onset <e2>seizures</e2>
D013256_D012640 NONE <e1>steroids</e1> produced protect <e2>seizures</e2>
D013256_D012640 NONE <e1>steroid</e1> dose administered complete <e2>seizures</e2>
D013256_D012640 NONE <e1>steroids</e1> caused protect <e2>seizures</e2>
D013256_D012640 NONE <e1>steroids</e1> effective protecting <e2>seizures</e2>
D013256_D013226 NONE <e1>steroids</e1> protect pilocarpine- seizures <e2>epilepticus</e2>
D013256_D013226 NONE <e1>steroids</e1> effective mg/kg <e2>epilepticus</e2>
D013256_D013226 NONE <e1>steroid</e1> dose administered complete obtained <e2>epilepticus</e2>
D013256_D013226 NONE <e1>steroids</e1> effective protecting seizures <e2>epilepticus</e2>
D013256_D013226 NONE <e1>steroids</e1> effective utility treatment forms <e2>epilepticus</e2>
D010862_D012640 CID <e1>pilocarpine-</e1> <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine-</e1> activity <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine</e1> protecting effective mg/kg <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine</e1> <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine</e1> seizures protecting potent had values divided ed50 protection <e2>seizure</e2>
D010862_D012640 CID <e1>pilocarpine-</e1> protecting <e2>seizures</e2>
D010862_D013226 CID <e1>pilocarpine-</e1> seizures <e2>epilepticus</e2>
D010862_D013226 CID <e1>pilocarpine</e1> protecting effective mg/kg <e2>epilepticus</e2>
D010862_D013226 CID <e1>pilocarpine-</e1> protecting seizures <e2>epilepticus</e2>
D010862_D013226 CID <e1>pilocarpine-</e1> protecting effective utility treatment forms <e2>epilepticus</e2>
D007608_D012640 CID <e1>acid-induced</e1> kainic pilocarpine- <e2>seizures</e2>
D007608_D012640 CID <e1>acid-</e1> activity <e2>seizures</e2>
D007608_D012640 CID <e1>acid</e1> induced <e2>seizures</e2>
D007608_D012640 CID <e1>acid</e1> induced seizures onset delay produced protect <e2>seizures</e2>
D007608_D012640 CID <e1>acid-induced</e1> kainic <e2>seizures</e2>
D007608_D012640 CID <e1>acid-induced</e1> <e2>seizures</e2>
D007608_D013226 CID <e1>acid-induced</e1> kainic pilocarpine- seizures <e2>epilepticus</e2>
D007608_D013226 CID <e1>acid-induced</e1> kainic seizures complete obtained <e2>epilepticus</e2>
D007608_D013226 CID <e1>acid-induced</e1> seizures <e2>epilepticus</e2>
D007608_D013226 CID <e1>acid-induced</e1> seizures protecting effective utility treatment forms <e2>epilepticus</e2>
D011374_D012640 NONE <e1>progesterone</e1> metabolites evaluated activity <e2>seizures</e2>
D011374_D012640 NONE <e1>pregnane-20-ones</e1> progesterone metabolites evaluated activity <e2>seizures</e2>
D003900_D012640 NONE <e1>deoxycorticosterone</e1> progesterone metabolites evaluated activity <e2>seizures</e2>
D003900_D012640 NONE <e1>pregnane-21-diol-20-ones</e1> deoxycorticosterone progesterone metabolites evaluated activity <e2>seizures</e2>
D016202_D012640 NONE <e1>n-methyl-d-aspartate</e1> acid- activity <e2>seizures</e2>
D016202_D012640 NONE <e1>(nmda)-induced</e1> acid- activity <e2>seizures</e2>
D016202_D012640 NONE <e1>nmda</e1> delay caused protect <e2>seizures</e2>
D016202_D012640 NONE <e1>nmda</e1> <e2>seizures</e2>
D013256_D064420 NONE <e1>steroids</e1> potent had indicating have <e2>toxicity</e2>
D013256_D064420 NONE <e1>steroids</e1> had indicating have <e2>toxicity</e2>
D013256_D064420 NONE <e1>steroids</e1> have <e2>toxicity</e2>
D001569_D012640 NONE <e1>benzodiazepine</e1> clonazepam potent protecting <e2>seizures</e2>
D001569_D012640 NONE <e1>benzodiazepine</e1> clonazepam potent had values divided ed50 protection <e2>seizure</e2>
D001569_D064420 NONE <e1>benzodiazepine</e1> clonazepam potent had indicating have <e2>toxicity</e2>
D002998_D012640 NONE <e1>clonazepam</e1> potent protecting <e2>seizures</e2>
D002998_D012640 NONE <e1>clonazepam</e1> potent had values divided ed50 protection <e2>seizure</e2>
D002998_D012640 NONE <e1>clonazepam</e1> had potent protecting <e2>seizures</e2>
D002998_D012640 NONE <e1>clonazepam</e1> had values divided ed50 protection <e2>seizure</e2>
D002998_D064420 NONE <e1>clonazepam</e1> potent had indicating have <e2>toxicity</e2>
D002998_D064420 NONE <e1>clonazepam</e1> had indicating have <e2>toxicity</e2>
D010862_D064420 NONE <e1>pilocarpine</e1> seizures protecting potent had indicating have <e2>toxicity</e2>
9226773
D008094_D018500 CID <e1>lithium</e1> therapy <e2>insipidus</e2>
D008094_D018500 CID <e1>lithium-induced</e1> <e2>insipidus</e2>
D008094_D018500 CID <e1>lithium</e1> therapy discontinued diagnosed have <e2>insipidus</e2>
D008094_D018500 CID <e1>lithium</e1> cessation polyuric thirsty remained showed evidence <e2>insipidus</e2>
D008094_D018500 CID <e1>lithium</e1> induced <e2>insipidus</e2>
D008094_D018500 CID <e1>lithium</e1> stopped persisted considered <e2>insipidus</e2>
D008094_D018500 CID <e1>lithium-induced</e1> <e2>insipidus</e2>
D008094_D011141 CID <e1>lithium</e1> cessation <e2>polyuric</e2>
D008094_D011141 CID <e1>lithium</e1> induced insipidus considered persisted <e2>polyuria</e2>
D008094_D011141 CID <e1>lithium</e1> stopped persisted <e2>polyuria</e2>
D014667_D011141 NONE <e1>vasopressin</e1> thirst have showed remained thirsty <e2>polyuric</e2>
D014667_D018500 NONE <e1>vasopressin</e1> thirst have showed evidence <e2>insipidus</e2>
3780697
D005283_D009127 CID <e1>fentanyl</e1> administration <e2>rigidity</e2>
D005283_D009127 CID <e1>fentanyl</e1> dose received patient period described case <e2>rigidity</e2>
D005283_D012131 NONE <e1>fentanyl</e1> dose received patient period described case rigidity leading <e2>failure</e2>
19203554
D012460_D005921 NONE <e1>sulphasalazine</e1> treatment restarting <e2>glomerulonephritis</e2>
D012460_D005921 NONE <e1>sulphasalazine</e1> induce <e2>glomerulonephritis</e2>
D012460_D003093 NONE <e1>sulphasalazine</e1> treatment restarting developed woman <e2>colitis</e2>
D012460_D005128 NONE <e1>sulphasalazine</e1> treatment restarting developed <e2>eyes</e2>
D012460_D005128 NONE <e1>sulphasalazine</e1> treatment cessation resulted improvements fever <e2>eyes</e2>
D012460_D010996 CID <e1>sulphasalazine</e1> treatment restarting developed eyes <e2>effusion</e2>
D012460_D010996 CID <e1>sulphasalazine</e1> treatment cessation resulted titer volume <e2>effusions</e2>
D012460_D010996 CID <e1>sulphasalazine</e1> treatment cessation resulted initiated increased remained <e2>effusion</e2>
D012460_D004802 NONE <e1>sulphasalazine</e1> treatment restarting developed eyes effusion <e2>eosinophilia</e2>
D012460_D001745 NONE <e1>sulphasalazine</e1> treatment restarting developed eyes effusion <e2>abnormalities</e2>
D012460_D005334 CID <e1>sulphasalazine</e1> treatment cessation resulted improvements <e2>fever</e2>
D012460_D002637 NONE <e1>sulphasalazine</e1> treatment cessation resulted <e2>pain</e2>
D013256_D005334 NONE <e1>steroid</e1> therapy initiated resulted improvements <e2>fever</e2>
D013256_D005128 NONE <e1>steroid</e1> therapy initiated resulted improvements fever <e2>eyes</e2>
D013256_D002637 NONE <e1>steroid</e1> therapy initiated resulted <e2>pain</e2>
D013256_D010996 NONE <e1>steroid</e1> therapy initiated resulted titer volume <e2>effusions</e2>
D013256_D010996 NONE <e1>steroid</e1> therapy initiated increased remained <e2>effusion</e2>
D013256_D010996 NONE <e1>steroid</e1> therapy month disappeared <e2>effusion</e2>
12842176
D001556_D020258 NONE <e1>lindane</e1> effect influence modulation <e2>neurotoxicity</e2>
D001556_D020258 NONE <e1>lindane</e1> <e2>neurotoxicity</e2>
D008748_D012640 NONE <e1>3-methylcholanthrene</e1> pretreatment produce effect incidence <e2>convulsions</e2>
D008748_D012640 NONE <e1>3-methylcholanthrene</e1> pretreatment produce increased incidence <e2>convulsions</e2>
D008748_D012640 NONE <e1>mc</e1> 3-methylcholanthrene pretreatment produce effect incidence <e2>convulsions</e2>
D008748_D012640 NONE <e1>mc</e1> 3-methylcholanthrene pretreatment produce increased incidence <e2>convulsions</e2>
D001556_D012640 CID <e1>lindane</e1> induced <e2>convulsions</e2>
D001556_D012640 CID <e1>lindane</e1> induced convulsions incidence effect produce increased incidence <e2>convulsions</e2>
D001556_D012640 CID <e1>lindane</e1> convulsions incidence increased produce effect incidence <e2>convulsions</e2>
D001556_D012640 CID <e1>lindane</e1> <e2>convulsions</e2>
D001556_D012640 CID <e1>lindane</e1> metabolism blocked incidence <e2>convulsions</e2>
D001556_D012640 CID <e1>lindane</e1> treated animals increased blocked incidence <e2>convulsions</e2>
D001556_D012640 CID <e1>lindane</e1> involved indicating increased blocked incidence <e2>convulsions</e2>
D010634_D012640 NONE <e1>phenobarbital</e1> pretreatment increased produce effect incidence <e2>convulsions</e2>
D010634_D012640 NONE <e1>phenobarbital</e1> pretreatment increased incidence <e2>convulsions</e2>
D000431_D012640 NONE <e1>ethanol</e1> p450 inducer pretreatment increased produce effect incidence <e2>convulsions</e2>
D000431_D012640 NONE <e1>ethanol</e1> p450 inducer pretreatment increased incidence <e2>convulsions</e2>
D000431_D012640 NONE <e1>ethanol</e1> pb formed metabolites lindane involved indicating increased blocked incidence <e2>convulsions</e2>
D001556_D064420 NONE <e1>lindane</e1> metabolism blocked increased indicating involved <e2>toxicity</e2>
D001556_D064420 NONE <e1>lindane</e1> treated animals increased indicating involved <e2>toxicity</e2>
D001556_D064420 NONE <e1>lindane</e1> involved <e2>toxicity</e2>
C018021_D012640 NONE <e1>chloride</e1> incidence <e2>convulsions</e2>
C018021_D064420 NONE <e1>chloride</e1> incidence blocked increased indicating involved <e2>toxicity</e2>
D000431_D064420 NONE <e1>ethanol</e1> pb formed metabolites lindane involved <e2>toxicity</e2>
6699841
D009288_D007681 CID <e1>naproxen</e1> <e2>necrosis</e2>
D009288_D007681 CID <e1>naproxen</e1> therapy institution developed <e2>necrosis</e2>
D009288_D007681 CID <e1>naproxen</e1> therapy institution developed necrosis <e2>rpn</e2>
D013467_D001172 NONE <e1>sulindac</e1> treated <e2>arthritis</e2>
D013467_D007681 NONE <e1>sulindac</e1> treated arthritis man developed <e2>necrosis</e2>
D013467_D007681 NONE <e1>sulindac</e1> treated arthritis man developed necrosis <e2>rpn</e2>
D013467_D007681 NONE <e1>sulindac</e1> advantages discuss linking <e2>rpn</e2>
D005279_D001172 NONE <e1>calcium</e1> <e2>arthritis</e2>
D005279_D007681 NONE <e1>calcium</e1> arthritis man developed <e2>necrosis</e2>
D005279_D007681 NONE <e1>calcium</e1> arthritis man developed necrosis <e2>rpn</e2>
D012459_D001172 NONE <e1>salicylates</e1> calcium <e2>arthritis</e2>
D012459_D007681 NONE <e1>salicylates</e1> calcium arthritis man developed <e2>necrosis</e2>
D012459_D007681 NONE <e1>salicylates</e1> calcium arthritis man developed necrosis <e2>rpn</e2>
D006046_D001172 NONE <e1>gold</e1> salts salicylates calcium <e2>arthritis</e2>
D006046_D007681 NONE <e1>gold</e1> salts salicylates calcium arthritis man developed <e2>necrosis</e2>
D006046_D007681 NONE <e1>gold</e1> salts salicylates calcium arthritis man developed necrosis <e2>rpn</e2>
D009288_D001172 NONE <e1>naproxen</e1> therapy institution developed man <e2>arthritis</e2>
D013467_D007674 NONE <e1>sulindac</e1> advantages patients experienced <e2>toxicity</e2>
1545575
D003520_D006470 CID <e1>cyclophosphamide</e1> therapy complication <e2>cystitis</e2>
D003520_D006470 CID <e1>cyclophosphamide</e1> metabolite causes <e2>cystitis</e2>
D003520_D003556 CID <e1>cyclophosphamide</e1> therapy complication <e2>cystitis</e2>
D003520_D003556 CID <e1>cyclophosphamide</e1> metabolite causes <e2>cystitis</e2>
D015080_D006470 NONE <e1>mesna</e1> uroprophylaxis trial neutralizes metabolite causes <e2>cystitis</e2>
D015080_D006470 NONE <e1>mesna</e1> uroprophylaxis received had <e2>cystitis</e2>
D015080_D003556 NONE <e1>mesna</e1> uroprophylaxis trial neutralizes metabolite causes <e2>cystitis</e2>
D015080_D003556 NONE <e1>mesna</e1> uroprophylaxis received had <e2>cystitis</e2>
12452237
D008012_D010149 NONE <e1>lidocaine</e1> reduce <e2>myalgia</e2>
D008012_D010149 NONE <e1>lidocaine</e1> proven agent reduction <e2>myalgia</e2>
D013390_D010149 CID <e1>succinylcholine</e1> induced <e2>myalgia</e2>
D013390_D010149 CID <e1>succinylcholine</e1> used proven agent reduction <e2>myalgia</e2>
D008012_D063806 NONE <e1>lidocaine</e1> pretreatment effect reduction <e2>myalgia</e2>
D013390_D063806 NONE <e1>succinylcholine-induced</e1> <e2>myalgia</e2>
16826348
D003561_D010523 CID <e1>arabinoside</e1> treatment caused <e2>neuropathy</e2>
D003561_D010523 CID <e1>arabinoside</e1> therapy unclear mechanisms <e2>neuropathy</e2>
D003561_D015470 NONE <e1>arabinoside</e1> treatment patient <e2>leukemia</e2>
D003561_D064420 NONE <e1>arabinoside</e1> <e2>toxicity</e2>
D003561_D064420 NONE <e1>arabinoside</e1> toxicity recognized reported <e2>toxicity</e2>
D003561_D064420 NONE <e1>arabinoside</e1> toxicity reported recognized <e2>toxicity</e2>
D003561_D064420 NONE <e1>arabinoside</e1> <e2>toxicity</e2>
D003561_D006987 NONE <e1>arabinoside</e1> course resulted complained <e2>numbness</e2>
D008775_D009422 NONE <e1>methylprednisolone</e1> responded worsened resolving <e2>neuropathy</e2>
D008775_D006086 NONE <e1>methylprednisolone</e1> responded worsened development <e2>disease</e2>
3123611
D003276_D002819 CID <e1>contraception</e1> associated <e2>chorea</e2>
D003276_D002819 CID <e1>contraceptives</e1> receiving developed <e2>chorea</e2>
D003276_D002819 CID <e1>contraception</e1> had <e2>chorea</e2>
D000661_D002819 CID <e1>amphetamine-induced</e1> <e2>chorea</e2>
10411803
D015313_D000743 CID <e1>cefotetan</e1> use associated <e2>anemia</e2>
D015313_D000743 CID <e1>cefotetan</e1> cephalosporins associated <e2>anemia</e2>
D015313_D000743 CID <e1>cefotetan-induced</e1> <e2>anemias</e2>
D015313_D000743 CID <e1>cefotetan</e1> received patients that 10 cases <e2>anemias</e2>
D002511_D000743 NONE <e1>cephalosporins</e1> associated <e2>anemia</e2>
16596970
D010862_D012640 NONE <e1>pilocarpine</e1> <e2>seizures</e2>
D010862_D012640 NONE <e1>pilocarpine</e1> resulted loss <e2>seizures</e2>
D010862_D012640 NONE <e1>pilocarpine</e1> resulted had loss <e2>seizures</e2>
D010862_D001308 CID <e1>pilocarpine</e1> seizures cause impairment <e2>discrimination</e2>
D010862_D013226 CID <e1>pilocarpine</e1> <e2>epilepticus</e2>
D010862_D013226 CID <e1>pilocarpine</e1> resulted <e2>epilepticus</e2>
2576810
D016666_D006948 CID <e1>fluvoxamine</e1> treatment potentiated <e2>hyperactivity</e2>
D016666_D006948 CID <e1>fluvoxamine</e1> unaffected remained <e2>hyperactivity</e2>
D000661_D006948 CID <e1>amphetamine-induced</e1> <e2>hyperactivity</e2>
D009627_D006948 CID <e1>nomifensine</e1> induced <e2>hyperactivity</e2>
12091028
D003975_D006212 NONE <e1>diazepam</e1> remains decreases duration <e2>hallucinations</e2>
D007649_D006212 CID <e1>ketamine</e1> drug remains decreases duration <e2>hallucinations</e2>
11245434
D003520_D000740 NONE <e1>cyclophosphamide</e1> cytotoxicity reduction <e2>anemia-induced</e2>
D003520_D000740 NONE <e1>cyclophosphamide</e1> cytotoxicity treatment impact prevention <e2>anemia</e2>
D003520_D000740 NONE <e1>cyclophosphamide</e1> cytotoxicity reduces <e2>anemia</e2>
D003520_D000740 NONE <e1>cyclophosphamide</e1> cytotoxicity reduces increases correction <e2>anemia</e2>
D003520_D064420 NONE <e1>cyclophosphamide</e1> <e2>cytotoxicity</e2>
D003520_D064420 NONE <e1>cyclophosphamide</e1> <e2>cytotoxicity</e2>
D003520_D064420 NONE <e1>cyclophosphamide</e1> <e2>cytotoxicity</e2>
D003520_D009369 NONE <e1>cyclophosphamide</e1> cytotoxicity <e2>tumors</e2>
D003520_D009369 NONE <e1>cyclophosphamide</e1> cytotoxicity <e2>tumors</e2>
D003520_D009369 NONE <e1>cyclophosphamide</e1> dose treated <e2>tumors</e2>
D003520_D009369 NONE <e1>cyclophosphamide</e1> dose treated observed days delay regrowth <e2>tumors</e2>
D003520_D009369 NONE <e1>cyclophosphamide</e1> cytotoxicity <e2>tumors</e2>
D003520_D009369 NONE <e1>cyclophosphamide</e1> cytotoxicity reduces result supply tissue <e2>tumor</e2>
D016190_D000740 CID <e1>carboplatin</e1> dose using induced <e2>anemia</e2>
D016190_D000740 CID <e1>carboplatin</e1> application administered prevented development <e2>anemia</e2>
D016190_D009369 NONE <e1>carboplatin</e1> treatment days <e2>tumors</e2>
D016190_D009369 NONE <e1>carboplatin</e1> influenced rate <e2>tumor</e2>
D016190_D012509 NONE <e1>carboplatin</e1> treatment days tumors <e2>ds-sarcoma</e2>
D010100_D000740 NONE <e1>oxygen</e1> supply result reduces <e2>anemia</e2>
D010100_D000740 NONE <e1>oxygen</e1> supply result reduces increases correction <e2>anemia</e2>
D010100_D064420 NONE <e1>oxygen</e1> supply result reduces <e2>cytotoxicity</e2>
D010100_D009369 NONE <e1>oxygen</e1> supply result reduces cytotoxicity <e2>tumors</e2>
D010100_D009369 NONE <e1>oxygen</e1> supply tissue <e2>tumor</e2>
6203632
D007545_D006332 CID <e1>isoproterenol-induced</e1> <e2>hypertrophy</e2>
D007545_D006332 CID <e1>isoproterenol</e1> injections studied development <e2>hypertrophy</e2>
D007545_D006332 CID <e1>iso</e1> isoproterenol injections studied development <e2>hypertrophy</e2>
D007545_D006984 NONE <e1>iso</e1> response shows phase <e2>hypertrophic</e2>
8607407
D002110_D006973 CID <e1>caffeine</e1> men <e2>hypertension</e2>
D002110_D006973 CID <e1>caffeine</e1> actions enhanced persons <e2>hypertensive</e2>
D002110_D006973 CID <e1>caffeine</e1> ingestion achieved levels <e2>hypertensive</e2>
D002110_D006973 CID <e1>caffeine</e1> responses selective men <e2>hypertensive</e2>
D002110_D006973 CID <e1>caffeine</e1> responses selective replicated representative <e2>hypertensives</e2>
8473723
D008728_D012640 CID <e1>levomepromazine-fluvoxamine</e1> treatment induced <e2>seizures</e2>
D008728_D012640 CID <e1>levomepromazine-fluvoxamine</e1> <e2>seizures</e2>
D016666_D012640 CID <e1>levomepromazine-fluvoxamine</e1> treatment induced <e2>seizures</e2>
D016666_D012640 CID <e1>levomepromazine-fluvoxamine</e1> <e2>seizures</e2>
17194457
-1_D001523 NONE <e1>pcpa</e1> exposure decreased increased <e2>irritability</e2>
-1_D001523 NONE <e1>pcpa</e1> exposure decreased increased had behavior preference <e2>aggression</e2>
D013739_D001523 CID <e1>t</e1> had locomotion <e2>irritability</e2>
D013739_D001523 CID <e1>t</e1> had increased preference <e2>aggression</e2>
D012701_D001523 NONE <e1>5-ht</e1> users prone exhibit <e2>behavior</e2>
20394767
D015016_D012021 CID <e1>yohimbine</e1> increased <e2>startle</e2>
D015016_D012021 CID <e1>yohimbine</e1> increased startle suppressed <e2>startle</e2>
D015016_D012021 CID <e1>yohimbine</e1> increased startle suppressed suppressed <e2>startle</e2>
C015068_D012021 CID <e1>mcpp</e1> suppressed <e2>startle</e2>
C015068_D012021 CID <e1>mcpp</e1> suppressed <e2>startle</e2>
C015068_D012021 CID <e1>mcpp</e1> suppressed suppressed <e2>startle</e2>
D010433_D012021 CID <e1>ptz</e1> les startle suppressed <e2>startle</e2>
D010433_D012021 CID <e1>ptz</e1> les <e2>startle</e2>
D010433_D012021 CID <e1>ptz</e1> les startle suppressed suppressed <e2>startle</e2>
9228650
C049860_D000647 CID <e1>nik-247</e1> effects scopolamine-induced <e2>amnesia</e2>
C049860_D000647 CID <e1>nik-247</e1> effects cholinesterase <e2>amnesia</e2>
C049860_D000647 CID <e1>nik-247</e1> improves <e2>amnesia</e2>
D012601_D000647 CID <e1>scopolamine-induced</e1> <e2>amnesia</e2>
D012601_D000647 CID <e1>scopolamine-induced</e1> cholinesterase <e2>amnesia</e2>
D012601_D000647 CID <e1>scopolamine</e1> induced <e2>amnesia</e2>
D012601_D000647 CID <e1>scopolamine-induced</e1> improves <e2>amnesia</e2>
D013619_D000647 CID <e1>tacrine</e1> inhibitors those compared examined effects cholinesterase <e2>amnesia</e2>
C076946_D000647 CID <e1>e-2020</e1> tacrine inhibitors those compared examined effects cholinesterase <e2>amnesia</e2>
C049860_D000544 NONE <e1>nik-247</e1> drug treatment <e2>disease</e2>
17702969
D005473_D005315 CID <e1>fluoxetine</e1> exposure induces <e2>hypertension</e2>
D005473_D005315 CID <e1>fluoxetine</e1> exposure resulted <e2>hypertension</e2>
D005473_D006976 CID <e1>fluoxetine</e1> exposure induces <e2>hypertension</e2>
D005473_D006976 CID <e1>fluoxetine</e1> exposure increases prevalence <e2>syndrome</e2>
D005473_D006976 CID <e1>fluoxetine</e1> effect <e2>hypertension</e2>
D005473_D006976 CID <e1>fluoxetine</e1> exposure resulted <e2>hypertension</e2>
D005473_D006976 CID <e1>fluoxetine</e1> exposure induces <e2>hypertension</e2>
17490790
D007505_D009410 CID <e1>dextran</e1> induced degeneration <e2>neurons</e2>
D007505_D009410 CID <e1>dextran</e1> animals content increased study degeneration <e2>neurons</e2>
D007505_D009410 CID <e1>dextran</e1> increase sn causes degeneration <e2>neurons</e2>
D007501_D010300 NONE <e1>iron</e1> accumulation considered involved pathogenesis <e2>disease</e2>
D007501_D009410 NONE <e1>iron</e1> overload relationship demonstrate used study degeneration <e2>neurons</e2>
D007501_D009410 NONE <e1>iron</e1> staining voltammetry used study degeneration <e2>neurons</e2>
D007501_D009410 NONE <e1>iron</e1> content increased study degeneration <e2>neurons</e2>
D007501_D009410 NONE <e1>iron</e1> level increase sn causes degeneration <e2>neurons</e2>
D007501_D009410 NONE <e1>iron</e1> causes degeneration <e2>neurons</e2>
D014443_D009410 NONE <e1>tyrosine</e1> hydroxylase voltammetry used study degeneration <e2>neurons</e2>
11752998
D000241_D059787 NONE <e1>adenosine</e1> studies suggest effective treatment <e2>pain</e2>
D000241_D059787 NONE <e1>adenosine</e1> formulation volunteers studies suggests suggest effective treatment <e2>pain</e2>
D000241_D059350 NONE <e1>adenosine</e1> studies suggest effective treatment <e2>pain</e2>
D000241_D059350 NONE <e1>adenosine</e1> formulation volunteers studies suggests suggest effective treatment <e2>pain</e2>
D000241_D004342 NONE <e1>adenosine</e1> studies suggest suggests effective states <e2>hypersensitivity</e2>
D000241_D004342 NONE <e1>adenosine</e1> formulation volunteers studies suggests effective states <e2>hypersensitivity</e2>
D000241_D004342 NONE <e1>adenosine</e1> formulation efficacy screen was using stimulation <e2>hypersensitivity</e2>
D000241_D004342 NONE <e1>adenosine</e1> <e2>hypersensitivity</e2>
D002211_D004342 NONE <e1>capsaicin-evoked</e1> <e2>hypersensitivity</e2>
D002211_D004342 NONE <e1>capsaicin</e1> injection reflect presumed adenosine <e2>hypersensitivity</e2>
D000241_D010146 NONE <e1>adenosine</e1> doses trial trials studied obtained ratings <e2>pain</e2>
D000241_D010146 NONE <e1>adenosine</e1> trial doses trial trials studied obtained ratings <e2>pain</e2>
D000241_D010146 NONE <e1>adenosine</e1> produced effect report <e2>pain</e2>
D000241_D010146 NONE <e1>adenosine</e1> time short produced effect report <e2>pain</e2>
D000241_D006930 NONE <e1>adenosine</e1> doses trial trials studied obtained ratings response stimuli areas <e2>hyperalgesia</e2>
D000241_D006930 NONE <e1>adenosine</e1> doses trial trials studied obtained ratings response <e2>allodynia</e2>
D000241_D006930 NONE <e1>adenosine</e1> trial doses trial trials studied obtained ratings response stimuli areas <e2>hyperalgesia</e2>
D000241_D006930 NONE <e1>adenosine</e1> trial doses trial trials studied obtained ratings response <e2>allodynia</e2>
D000241_D006930 NONE <e1>adenosine</e1> produced reduced <e2>hyperalgesia</e2>
D000241_D006930 NONE <e1>adenosine</e1> produced reduced hyperalgesia <e2>allodynia</e2>
D000241_D006930 NONE <e1>adenosine</e1> time short produced reduced <e2>hyperalgesia</e2>
D000241_D006930 NONE <e1>adenosine</e1> time short produced reduced hyperalgesia <e2>allodynia</e2>
D002211_D010146 NONE <e1>capsaicin</e1> injection ratings <e2>pain</e2>
D002211_D010146 NONE <e1>capsaicin</e1> injection allodynia hyperalgesia reduced produced effect report <e2>pain</e2>
D002211_D006930 CID <e1>capsaicin</e1> injection ratings response stimuli areas <e2>hyperalgesia</e2>
D002211_D006930 CID <e1>capsaicin</e1> injection ratings response <e2>allodynia</e2>
D002211_D006930 CID <e1>capsaicin</e1> injection allodynia <e2>hyperalgesia</e2>
D002211_D006930 CID <e1>capsaicin</e1> injection <e2>allodynia</e2>
D000241_D009437 NONE <e1>adenosine</e1> residence due consistent that observed reports patients <e2>pain</e2>
11079278
D008790_D017202 NONE <e1>metoprolol</e1> effect glucagon <e2>ischemia</e2>
D008790_D017202 NONE <e1>metoprolol</e1> metoprolol effect glucagon <e2>ischemia</e2>
D008790_D017202 NONE <e1>metoprolol</e1> attenuates eliminates evidence <e2>ischemia</e2>
D004280_D017202 CID <e1>dobutamine-induced</e1> <e2>ischemia</e2>
D004280_D017202 CID <e1>dobutamine</e1> testing attenuates eliminates evidence <e2>ischemia</e2>
7416947
D004077_D020018 CID <e1>digoxin</e1> administration patients <e2>dysfunction</e2>
D004077_D012214 NONE <e1>digoxin</e1> patients capacity selected patients <e2>disease</e2>
19761039
D010936_D004409 NONE <e1>sinensis</e1> extract effect studied <e2>dyskinesia</e2>
D010936_D004409 NONE <e1>sinensis</e1> had <e2>dyskinesia</e2>
D012110_D004409 CID <e1>reserpine-induced</e1> <e2>dyskinesia</e2>
D012110_D004409 CID <e1>reserpine-induced</e1> <e2>dyskinesia</e2>
12852481
D001241_D000014 CID <e1>aspirin</e1> induces <e2>anomalies</e2>
D001241_D000014 CID <e1>acid</e1> aspirin induces <e2>anomalies</e2>
D001241_D000014 CID <e1>asa</e1> acid aspirin induces <e2>anomalies</e2>
D001241_D000014 CID <e1>asa</e1> administered compare test hypothesis confounds detection <e2>malformations</e2>
D001241_D000014 CID <e1>asa</e1> <e2>malformations</e2>
D001241_D000014 CID <e1>asa</e1> induces focused <e2>malformations</e2>
D001241_D000014 CID <e1>asa</e1> induces <e2>malformations</e2>
D001241_D000014 CID <e1>asa</e1> administered similar variations <e2>malformations</e2>
D001241_D000014 CID <e1>asa</e1> induced titrating achieve dose <e2>malformations</e2>
D001241_D005767 NONE <e1>asa</e1> administered compare test hypothesis confounds <e2>toxicity</e2>
D001241_D005767 NONE <e1>asa</e1> malformations detection confounds <e2>toxicity</e2>
D001241_D006345 CID <e1>asa</e1> induces focused results suggested induce <e2>defects</e2>
D001241_D006345 CID <e1>asa</e1> induces focused results suggested induce defects <e2>vsds</e2>
D001241_D006345 CID <e1>asa</e1> induces focused results suggested induce <e2>vsds</e2>
D001241_D009436 NONE <e1>asa</e1> induces focused results suggested induce defects <e2>defects</e2>
D001241_D009436 NONE <e1>asa</e1> induces focused results suggested induce defects defects <e2>mds</e2>
D001241_D009436 NONE <e1>asa</e1> induces focused results suggested induce rats <e2>mds</e2>
D001241_D065630 CID <e1>asa</e1> induces focused results suggested induce rats <e2>hernia</e2>
D001241_D065630 CID <e1>asa</e1> induces focused results suggested induce rats hernia <e2>dh</e2>
19058474
D014859_D010490 NONE <e1>warfarin</e1> interaction <e2>haemopericardium</e2>
D014859_D006471 CID <e1>warfarin</e1> interaction haemopericardium <e2>haemorrhage</e2>
D014859_D006470 NONE <e1>warfarin</e1> dosage maintaining consumed <e2>haemorrhage</e2>
11009181
D001058_D010300 NONE <e1>apomorphine</e1> therapy <e2>disease</e2>
D001058_D010300 NONE <e1>apomorphine</e1> drug used treat symptoms <e2>disease</e2>
D001058_D010300 NONE <e1>apomorphine</e1> administration treating <e2>disease</e2>
D001058_D010300 NONE <e1>apomorphine</e1> treatment efficacy degree fluctuating <e2>disease</e2>
D001058_D004409 NONE <e1>apomorphine</e1> infusions monotherapy associated reductions <e2>dyskinesias</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D001058_D001523 NONE <e1>apomorphine</e1> treatment effects related play sedation complications <e2>psychiatric</e2>
15897593
D064730_D001855 NONE <e1>dexrazoxane</e1> protects <e2>myelosuppression</e2>
D064730_D001855 NONE <e1>dexrazoxane</e1> doses reduced <e2>myelosuppression</e2>
D064730_D001855 NONE <e1>dexrazoxane</e1> doses reduced myelosuppression results antagonized dexrazoxane <e2>myelosuppression</e2>
D064730_D001855 NONE <e1>dexrazoxane</e1> antagonized results <e2>myelosuppression</e2>
D064730_D001855 NONE <e1>dexrazoxane</e1> <e2>myelosuppression</e2>
D005047_D001855 NONE <e1>etoposide</e1> drugs protects <e2>myelosuppression</e2>
D005047_D001855 NONE <e1>etoposide</e1> anthracyclines drugs purpose limit <e2>myelosuppression</e2>
D005047_D001855 NONE <e1>etoposide</e1> daunorubicin <e2>myelosuppression</e2>
D005047_D001855 NONE <e1>etoposide</e1> daunorubicin myelosuppression results antagonized dexrazoxane <e2>myelosuppression</e2>
D003630_D001855 NONE <e1>daunorubicin</e1> etoposide drugs protects <e2>myelosuppression</e2>
D003630_D001855 NONE <e1>daunorubicin</e1> anthracyclines drugs purpose limit <e2>myelosuppression</e2>
D003630_D001855 NONE <e1>daunorubicin</e1> <e2>myelosuppression</e2>
D003630_D001855 NONE <e1>daunorubicin</e1> myelosuppression results antagonized dexrazoxane <e2>myelosuppression</e2>
D004317_D001855 NONE <e1>doxorubicin</e1> drugs protects <e2>myelosuppression</e2>
D004317_D001855 NONE <e1>doxorubicin</e1> daunorubicin anthracyclines drugs purpose limit <e2>myelosuppression</e2>
D004317_D001855 NONE <e1>doxorubicin</e1> cytotoxicity myelosuppression dexrazoxane antagonized results <e2>myelosuppression</e2>
D004317_D001855 NONE <e1>doxorubicin</e1> cytotoxicity <e2>myelosuppression</e2>
D018943_D001855 NONE <e1>anthracyclines</e1> drugs purpose limit <e2>myelosuppression</e2>
D018943_D066126 NONE <e1>anthracyclines</e1> drugs purpose limit myelosuppression <e2>toxicity</e2>
D018943_D066126 NONE <e1>anthracycline-induced</e1> <e2>cardiotoxicity</e2>
D003630_D066126 NONE <e1>daunorubicin</e1> anthracyclines drugs purpose limit myelosuppression <e2>toxicity</e2>
D004317_D066126 NONE <e1>doxorubicin</e1> daunorubicin anthracyclines drugs purpose limit myelosuppression <e2>toxicity</e2>
D011034_D001855 NONE <e1>epipodophyllotoxin</e1> etoposide anthracyclines drugs purpose limit <e2>myelosuppression</e2>
D011034_D066126 NONE <e1>epipodophyllotoxin</e1> etoposide anthracyclines drugs purpose limit myelosuppression <e2>toxicity</e2>
D005047_D066126 NONE <e1>etoposide</e1> anthracyclines drugs purpose limit myelosuppression <e2>toxicity</e2>
D064730_D066126 NONE <e1>dexrazoxane</e1> recommended protection <e2>cardiotoxicity</e2>
D064730_D066126 NONE <e1>icrf-187</e1> dexrazoxane recommended protection <e2>cardiotoxicity</e2>
D064730_D006402 NONE <e1>dexrazoxane</e1> coadministration <e2>toxicity</e2>
D064730_D006402 NONE <e1>dexrazoxane</e1> doxorubicin sensitivity determined investigated <e2>toxicity</e2>
D064730_D006402 NONE <e1>dexrazoxane</e1> combining metastases patients trials ongoing aim improving <e2>toxicity</e2>
D005047_D006402 CID <e1>etoposide</e1> sensitivity determined investigated <e2>toxicity</e2>
D005047_D006402 CID <e1>etoposide</e1> doses dexrazoxane combining metastases patients trials ongoing aim improving <e2>toxicity</e2>
D003630_D006402 CID <e1>daunorubicin</e1> etoposide sensitivity determined investigated <e2>toxicity</e2>
D004317_D006402 CID <e1>doxorubicin</e1> sensitivity determined investigated <e2>toxicity</e2>
D064730_D015431 NONE <e1>dexrazoxane</e1> doses reduced myelosuppression <e2>loss</e2>
D064730_D015431 NONE <e1>dexrazoxane</e1> doses reduced myelosuppression results antagonized dexrazoxane myelosuppression <e2>loss</e2>
D064730_D015431 NONE <e1>dexrazoxane</e1> antagonized results myelosuppression <e2>loss</e2>
D064730_D015431 NONE <e1>dexrazoxane</e1> myelosuppression <e2>loss</e2>
D064730_D064420 NONE <e1>dexrazoxane</e1> doses reduced myelosuppression results antagonized dexrazoxane myelosuppression <e2>cytotoxicity</e2>
D064730_D064420 NONE <e1>dexrazoxane</e1> myelosuppression <e2>cytotoxicity</e2>
D003630_D015431 CID <e1>daunorubicin</e1> myelosuppression <e2>loss</e2>
D003630_D015431 CID <e1>daunorubicin</e1> myelosuppression results antagonized dexrazoxane myelosuppression <e2>loss</e2>
D003630_D064420 NONE <e1>daunorubicin</e1> myelosuppression results antagonized dexrazoxane myelosuppression <e2>cytotoxicity</e2>
D005047_D015431 CID <e1>etoposide</e1> daunorubicin myelosuppression <e2>loss</e2>
D005047_D015431 CID <e1>etoposide</e1> daunorubicin myelosuppression results antagonized dexrazoxane myelosuppression <e2>loss</e2>
D005047_D064420 NONE <e1>etoposide</e1> daunorubicin myelosuppression results antagonized dexrazoxane myelosuppression <e2>cytotoxicity</e2>
D004317_D015431 CID <e1>doxorubicin</e1> cytotoxicity myelosuppression dexrazoxane antagonized results myelosuppression <e2>loss</e2>
D004317_D015431 CID <e1>doxorubicin</e1> cytotoxicity myelosuppression <e2>loss</e2>
D004317_D064420 NONE <e1>doxorubicin</e1> <e2>cytotoxicity</e2>
D064730_D009362 NONE <e1>dexrazoxane</e1> combining <e2>metastases</e2>
D005047_D009362 NONE <e1>etoposide</e1> doses dexrazoxane combining <e2>metastases</e2>
1595783
D000638_D008171 NONE <e1>amiodarone</e1> <e2>toxicity</e2>
D000638_D008171 NONE <e1>amiodarone</e1> <e2>toxicity</e2>
D000638_D008171 NONE <e1>amiodarone-induced</e1> <e2>toxicity</e2>
D000638_D011014 CID <e1>amiodarone</e1> agent <e2>pneumonitis</e2>
D000638_D004342 NONE <e1>amiodarone</e1> toxicity thought result injury related accumulation <e2>pneumonitis</e2>
D000638_D000542 NONE <e1>amiodarone</e1> toxicity thought result injury related accumulation <e2>pneumonitis</e2>
3952818
D005472_D066126 NONE <e1>5-fluorouracil</e1> <e2>toxicity</e2>
D005472_D066126 NONE <e1>5-fu</e1> cause <e2>cardiotoxicity</e2>
D005472_D066126 NONE <e1>5-fu</e1> cause used prevention <e2>cardiotoxicity</e2>
D005472_D066126 NONE <e1>5-fu</e1> cardiotoxicity prevention used cause <e2>cardiotoxicity</e2>
D005472_D066126 NONE <e1>5-fu</e1> <e2>cardiotoxicity</e2>
D005472_D003110 NONE <e1>5-fluorouracil</e1> administration presented patient <e2>carcinoma</e2>
D005472_D003110 NONE <e1>5-fu</e1> 5-fluorouracil administration presented patient <e2>carcinoma</e2>
D005472_D009362 NONE <e1>5-fluorouracil</e1> administration presented patient carcinoma <e2>metastasis</e2>
D005472_D009362 NONE <e1>5-fu</e1> 5-fluorouracil administration presented patient carcinoma <e2>metastasis</e2>
D005472_D002637 CID <e1>5-fluorouracil</e1> administration presented <e2>pain</e2>
D005472_D002637 CID <e1>5-fu</e1> 5-fluorouracil administration presented <e2>pain</e2>
D009543_D000788 NONE <e1>nifedipine</e1> resolved pain similar that observed <e2>angina</e2>
D009543_D002637 NONE <e1>nifedipine</e1> resolved <e2>pain</e2>
D005472_D003329 NONE <e1>5-fu</e1> cause <e2>spasm</e2>
D005472_D003329 NONE <e1>5-fu</e1> cardiotoxicity prevention used cause <e2>spasm</e2>
D002118_D003329 NONE <e1>calcium</e1> antagonists used cause <e2>spasm</e2>
D002118_D066126 NONE <e1>calcium</e1> antagonists used cause <e2>cardiotoxicity</e2>
D002118_D066126 NONE <e1>calcium</e1> antagonists used prevention <e2>cardiotoxicity</e2>
8475949
D010419_D017180 NONE <e1>pentamidine</e1> <e2>tachycardia</e2>
D010419_D017180 NONE <e1>isethionate</e1> associated <e2>tachyarrhythmias</e2>
D010419_D016171 CID <e1>isethionate</e1> associated tachyarrhythmias <e2>pointes</e2>
D010419_D016171 CID <e1>pentamidine-induced</e1> torsade <e2>pointes</e2>
D010419_D016171 CID <e1>pentamidine</e1> treatment days average occurred <e2>pointes</e2>
D010419_D016171 CID <e1>pentamidine</e1> discontinuation treated <e2>pointes</e2>
D010419_C537153 NONE <e1>pentamidine-induced</e1> torsade pointes related induce <e2>hypomagnesemia</e2>
D008274_D016171 NONE <e1>magnesium</e1> levels related <e2>pointes</e2>
D008274_C537153 NONE <e1>magnesium</e1> levels related induce <e2>hypomagnesemia</e2>
D008274_D008133 NONE <e1>magnesium</e1> supplementation advocated observed <e2>prolongation</e2>
11860495
D013256_D000647 NONE <e1>steroid</e1> structure determine effects <e2>anti-amnesic</e2>
C018370_D000647 NONE <e1>sulphate</e1> effects <e2>anti-amnesic</e2>
C018370_D000647 NONE <e1>pregs</e1> able reverse effects <e2>amnesic-like</e2>
C018370_D000647 NONE <e1>pregs</e1> effects tested using model <e2>amnesia</e2>
C018370_D000647 NONE <e1>pregs</e1> ability demonstrated effective reversing <e2>amnesia</e2>
D005680_D000647 NONE <e1>gaba(a)r</e1> nmdar effects <e2>amnesic-like</e2>
D012601_D000647 CID <e1>scopolamine-induced</e1> <e2>amnesia</e2>
D012601_D000647 CID <e1>scopolamine-induced</e1> <e2>amnesia</e2>
2257294
C034753_D001855 NONE <e1>benzylacyclouridine</e1> reverses <e2>suppression</e2>
C034753_D001855 NONE <e1>bau</e1> reduced <e2>toxicity</e2>
C034753_D007153 NONE <e1>benzylacyclouridine</e1> reverses suppression impairment activity <e2>immunodeficiency</e2>
D015215_D001855 CID <e1>azidothymidine-induced</e1> <e2>suppression</e2>
D015215_D001855 CID <e1>azt</e1> coadministered reduced <e2>toxicity</e2>
D015215_D001855 CID <e1>azt-induced</e1> <e2>toxicity</e2>
D015215_D007153 NONE <e1>azidothymidine-induced</e1> suppression impairment activity <e2>immunodeficiency</e2>
D015215_D007153 NONE <e1>azidothymidine</e1> inhibition impairment activity antihuman virus <e2>immunodeficiency</e2>
D015215_D007153 NONE <e1>(azt)-induced</e1> inhibition impairment activity antihuman virus <e2>immunodeficiency</e2>
D014529_D007153 NONE <e1>uridine</e1> concentrations reported reduce inhibition impairment activity antihuman virus <e2>immunodeficiency</e2>
D014529_D007153 NONE <e1>urd</e1> uridine concentrations reported reduce inhibition impairment activity antihuman virus <e2>immunodeficiency</e2>
D014529_D064420 NONE <e1>urd</e1> administration associated <e2>toxicities</e2>
D014529_D064420 NONE <e1>urd</e1> catabolism inhibits increases <e2>toxicity</e2>
D014529_D064420 NONE <e1>urd</e1> concentration increases <e2>toxicity</e2>
D014529_D064420 NONE <e1>urd-related</e1> <e2>toxicity</e2>
D014529_D000740 NONE <e1>urd</e1> administration associated toxicities <e2>anemia</e2>
D014529_D007970 NONE <e1>urd</e1> administration associated toxicities anemia <e2>leukopenia</e2>
C034753_D064420 NONE <e1>benzylacyclouridine</e1> ability <e2>toxicities</e2>
C034753_D064420 NONE <e1>bau</e1> benzylacyclouridine ability <e2>toxicities</e2>
C034753_D000740 NONE <e1>benzylacyclouridine</e1> ability toxicities <e2>anemia</e2>
C034753_D000740 NONE <e1>bau</e1> benzylacyclouridine ability toxicities <e2>anemia</e2>
C034753_D000740 NONE <e1>bau</e1> azt administration reversed mice rendered <e2>anemic</e2>
C034753_D000740 NONE <e1>bau</e1> azt administration reversed <e2>anemia</e2>
C034753_D007970 NONE <e1>benzylacyclouridine</e1> ability toxicities anemia <e2>leukopenia</e2>
C034753_D007970 NONE <e1>bau</e1> benzylacyclouridine ability toxicities anemia <e2>leukopenia</e2>
C034753_D007970 NONE <e1>bau</e1> azt administration reversed mice rendered anemic <e2>leukopenic</e2>
C034753_D007970 NONE <e1>bau</e1> azt administration reversed anemia <e2>leukopenia</e2>
D015215_D064420 NONE <e1>azt-induced</e1> anemia <e2>toxicities</e2>
D015215_D000740 CID <e1>azt-induced</e1> <e2>anemia</e2>
D015215_D000740 CID <e1>azt</e1> administration rendered <e2>anemic</e2>
D015215_D000740 CID <e1>azt</e1> administration rendered mice reversed <e2>anemia</e2>
D015215_D000740 CID <e1>azt</e1> administration reversed mice rendered <e2>anemic</e2>
D015215_D000740 CID <e1>azt</e1> administration reversed <e2>anemia</e2>
D015215_D000740 CID <e1>azt-induced</e1> anemia reversed mice rendered <e2>anemic</e2>
D015215_D000740 CID <e1>azt-induced</e1> <e2>anemia</e2>
D015215_D007970 CID <e1>azt-induced</e1> anemia <e2>leukopenia</e2>
D015215_D007970 CID <e1>azt</e1> administration rendered anemic <e2>leukopenic</e2>
D015215_D007970 CID <e1>azt</e1> administration rendered mice reversed anemia <e2>leukopenia</e2>
D015215_D007970 CID <e1>azt</e1> administration reversed mice rendered anemic <e2>leukopenic</e2>
D015215_D007970 CID <e1>azt</e1> administration reversed anemia <e2>leukopenia</e2>
D015215_D007970 CID <e1>azt-induced</e1> anemia reversed mice rendered anemic <e2>leukopenic</e2>
D015215_D007970 CID <e1>azt-induced</e1> anemia <e2>leukopenia</e2>
D015215_-1 NONE <e1>azt</e1> administration rendered mice reversed cellularity <e2>megaloblastosis</e2>
D015215_-1 NONE <e1>azt</e1> administration reversed cellularity <e2>megaloblastosis</e2>
D015215_-1 NONE <e1>azt-induced</e1> anemia reversed cellularity <e2>megaloblastosis</e2>
C034753_-1 NONE <e1>bau</e1> azt administration reversed cellularity <e2>megaloblastosis</e2>
20103708
D013311_D003928 CID <e1>streptozotocin-induced</e1> <e2>nephropathy</e2>
D013311_D003928 CID <e1>streptozotocin-induced</e1> model patients using explore role <e2>nephropathy</e2>
D013311_D003928 CID <e1>streptozotocin-induced</e1> model patients <e2>nephropathy</e2>
D013311_D003928 CID <e1>streptozotocin-induced</e1> model <e2>nephropathy</e2>
D010100_D003928 NONE <e1>oxygen</e1> species production accompanied one <e2>nephropathy</e2>
D010100_D051437 NONE <e1>oxygen</e1> species production accompanied one causes <e2>failure</e2>
D013311_D058186 NONE <e1>streptozotocin-induced</e1> <e2>damage</e2>
18997632
D002110_D017180 CID <e1>caffeine</e1> pretreatment related <e2>tachycardia</e2>
D002110_D017180 CID <e1>caffeine</e1> administration developed bigeminy runs <e2>tachycardia</e2>
D002110_D012640 CID <e1>caffeine</e1> used improve duration <e2>seizure</e2>
D002110_D018879 CID <e1>caffeine</e1> used improve tolerated reports <e2>ectopy</e2>
D002110_D006331 NONE <e1>caffeine</e1> administration developed <e2>disease</e2>
D002110_D001145 NONE <e1>caffeine</e1> administration developed disease <e2>arrhythmia</e2>
D002110_D001145 NONE <e1>caffeine</e1> tolerated aware potential <e2>arrhythmias</e2>
14633084
D003907_D006470 NONE <e1>dexamethasone</e1> use prevention <e2>cystitis</e2>
D003907_D006470 NONE <e1>dexamethasone</e1> use combination prevention <e2>hc</e2>
D003907_D006470 NONE <e1>dexamethasone</e1> efficient blocking <e2>hc</e2>
D003907_D006470 NONE <e1>dexamethasone</e1> replacement prevent <e2>hc</e2>
D003907_D003556 NONE <e1>dexamethasone</e1> use prevention <e2>cystitis</e2>
D003907_D003556 NONE <e1>dexamethasone</e1> use combination prevention <e2>hc</e2>
D003907_D003556 NONE <e1>dexamethasone</e1> efficient blocking <e2>hc</e2>
D003907_D003556 NONE <e1>dexamethasone</e1> replacement prevent <e2>hc</e2>
D015080_D006470 NONE <e1>mesna</e1> use prevention <e2>cystitis</e2>
D015080_D006470 NONE <e1>mesna</e1> combination prevention <e2>hc</e2>
D015080_D006470 NONE <e1>mesna</e1> combination dexamethasone efficient blocking <e2>hc</e2>
D015080_D006470 NONE <e1>mesna</e1> doses replacement prevent <e2>hc</e2>
D015080_D006470 NONE <e1>mesna</e1> doses saline doses replacement prevent <e2>hc</e2>
D015080_D003556 NONE <e1>mesna</e1> use prevention <e2>cystitis</e2>
D015080_D003556 NONE <e1>mesna</e1> combination prevention <e2>hc</e2>
D015080_D003556 NONE <e1>mesna</e1> combination dexamethasone efficient blocking <e2>hc</e2>
D015080_D003556 NONE <e1>mesna</e1> doses replacement prevent <e2>hc</e2>
D015080_D003556 NONE <e1>mesna</e1> doses saline doses replacement prevent <e2>hc</e2>
D007069_D006470 CID <e1>ifosfamide-induced</e1> <e2>cystitis</e2>
D007069_D006470 CID <e1>ifosfamide</e1> chemotherapy side-effect <e2>cystitis</e2>
D007069_D006470 CID <e1>ifosfamide</e1> chemotherapy side-effect cystitis <e2>hc</e2>
D007069_D006470 CID <e1>ifs</e1> ifosfamide chemotherapy side-effect <e2>cystitis</e2>
D007069_D006470 CID <e1>ifs</e1> ifosfamide chemotherapy side-effect cystitis <e2>hc</e2>
D007069_D006470 CID <e1>ifs-induced</e1> <e2>hc</e2>
D007069_D006470 CID <e1>ifs-induced</e1> <e2>hc</e2>
D007069_D003556 CID <e1>ifosfamide-induced</e1> <e2>cystitis</e2>
D007069_D003556 CID <e1>ifosfamide</e1> chemotherapy side-effect <e2>cystitis</e2>
D007069_D003556 CID <e1>ifosfamide</e1> chemotherapy side-effect cystitis <e2>hc</e2>
D007069_D003556 CID <e1>ifs</e1> ifosfamide chemotherapy side-effect <e2>cystitis</e2>
D007069_D003556 CID <e1>ifs</e1> ifosfamide chemotherapy side-effect cystitis <e2>hc</e2>
D007069_D003556 CID <e1>ifs-induced</e1> <e2>hc</e2>
D007069_D003556 CID <e1>ifs-induced</e1> <e2>hc</e2>
19274460
D003520_D009101 NONE <e1>cyclophosphamide</e1> definition combination bortezomib/dexamethasone induction patients <e2>myeloma</e2>
D003520_D009101 NONE <e1>cyclophosphamide</e1> dose evaluate treatment transplantation patients <e2>myeloma</e2>
D003520_D009101 NONE <e1>cyclophosphamide</e1> dose evaluate treatment transplantation patients myeloma <e2>mm</e2>
D003520_D009101 NONE <e1>cyclophosphamide</e1> combination bortezomib treatment patients <e2>mm</e2>
C400082_D009101 NONE <e1>bortezomib/dexamethasone</e1> induction patients <e2>myeloma</e2>
C400082_D009101 NONE <e1>bortezomib</e1> combination dose evaluate treatment transplantation patients <e2>myeloma</e2>
C400082_D009101 NONE <e1>bortezomib</e1> combination dose evaluate treatment transplantation patients myeloma <e2>mm</e2>
C400082_D009101 NONE <e1>bortezomib</e1> treatment patients <e2>mm</e2>
D003907_D009101 NONE <e1>bortezomib/dexamethasone</e1> induction patients <e2>myeloma</e2>
D003907_D009101 NONE <e1>dexamethasone</e1> bortezomib combination dose evaluate treatment transplantation patients <e2>myeloma</e2>
D003907_D009101 NONE <e1>dexamethasone</e1> bortezomib combination dose evaluate treatment transplantation patients myeloma <e2>mm</e2>
D003907_D009101 NONE <e1>dexamethasone</e1> bortezomib treatment patients <e2>mm</e2>
6769133
D004317_D066126 NONE <e1>adriamycin</e1> effects <e2>cardiotoxic</e2>
D004317_D006333 CID <e1>adriamycin</e1> dose developed <e2>failure</e2>
D018943_D001768 NONE <e1>anthracycline-induced</e1> human cardiomyopathy found those resembled <e2>lesions</e2>
D018943_D009202 NONE <e1>anthracycline-induced</e1> human <e2>cardiomyopathy</e2>
D004317_D015470 CID <e1>adriamycin</e1> mg/m2 receiving developed <e2>leukemia</e2>
D004317_D007938 NONE <e1>adriamycin</e1> cardiotoxin consequence <e2>leukemia</e2>
3762968
D014042_D014899 CID <e1>tolazamide-induced</e1> wernicke <e2>encephalopathy</e2>
D014042_D014899 CID <e1>tolazamide</e1> treated developed <e2>encephalopathy</e2>
D014042_D014899 CID <e1>tolazamide-induced</e1> wernicke <e2>encephalopathy</e2>
D013831_D003920 NONE <e1>thiamine-dependent</e1> enzyme fibroblasts patient <e2>diabetic</e2>
D013831_D014899 NONE <e1>thiamine-dependent</e1> enzyme fibroblasts patient developed <e2>encephalopathy</e2>
D013831_D020915 NONE <e1>thiamine-dependent</e1> enzyme studied reported <e2>syndrome</e2>
D014042_D003920 NONE <e1>tolazamide</e1> treated developed patient <e2>diabetic</e2>
D014042_D020915 NONE <e1>tolazamide</e1> treated developed patient fibroblasts enzyme studied reported <e2>syndrome</e2>
D014042_D020915 NONE <e1>tolazamide-induced</e1> wernicke encephalopathy patient <e2>syndrome</e2>
D013835_D003920 NONE <e1>pyrophosphate</e1> km abnormality had delineate order studied enzyme fibroblasts patient <e2>diabetic</e2>
D013835_D003920 NONE <e1>tpp</e1> pyrophosphate km abnormality had delineate order studied enzyme fibroblasts patient <e2>diabetic</e2>
D013835_D003920 NONE <e1>tpp</e1> km determined had patient one kindreds <e2>diabetic</e2>
D013835_D014899 NONE <e1>pyrophosphate</e1> km abnormality had delineate order studied enzyme fibroblasts patient developed <e2>encephalopathy</e2>
D013835_D014899 NONE <e1>tpp</e1> pyrophosphate km abnormality had delineate order studied enzyme fibroblasts patient developed <e2>encephalopathy</e2>
D013835_D014899 NONE <e1>tpp</e1> km determined had patient one kindreds history <e2>encephalopathy</e2>
D013835_D020915 NONE <e1>pyrophosphate</e1> km abnormality had delineate order studied reported <e2>syndrome</e2>
D013835_D020915 NONE <e1>tpp</e1> pyrophosphate km abnormality had delineate order studied reported <e2>syndrome</e2>
3732088
D011188_D001145 NONE <e1>potassium</e1> diuretics <e2>arrhythmias</e2>
D011188_D001145 NONE <e1>potassium</e1> changes alter tendency <e2>arrhythmias</e2>
D011188_D006973 NONE <e1>potassium</e1> diuretics arrhythmias disease <e2>hypertensive</e2>
D011188_D006973 NONE <e1>potassium-conserving</e1> diuretic treatment weeks measured patients <e2>hypertension</e2>
D011188_D006973 NONE <e1>potassium-losing</e1> diuretic period weeks measured patients <e2>hypertension</e2>
D011188_D003327 NONE <e1>potassium</e1> diuretics arrhythmias <e2>disease</e2>
D011188_D003324 NONE <e1>potassium-conserving</e1> diuretic treatment weeks measured patients hypertension <e2>disease</e2>
D011188_D003324 NONE <e1>potassium-losing</e1> diuretic period weeks measured patients hypertension <e2>disease</e2>
D000584_D006973 NONE <e1>amiloride</e1> diuretic treatment weeks measured patients <e2>hypertension</e2>
D000584_D003324 NONE <e1>amiloride</e1> diuretic treatment weeks measured patients hypertension <e2>disease</e2>
D002752_D006973 NONE <e1>chlorthalidone</e1> diuretic period weeks measured patients <e2>hypertension</e2>
D002752_D003324 NONE <e1>chlorthalidone</e1> diuretic period weeks measured patients hypertension <e2>disease</e2>
D000584_D018879 NONE <e1>amiloride</e1> treatment associated frequency <e2>beats</e2>
D002752_D018879 CID <e1>chlorthalidone</e1> phase associated frequency <e2>beats</e2>
D011188_D017202 NONE <e1>potassium-losing</e1> therapy increase excitability patients <e2>disease</e2>
D011188_D017202 NONE <e1>potassium</e1> concentrations falls increase excitability patients <e2>disease</e2>
3137399
D016685_D066126 NONE <e1>c.</e1> induced <e2>cardiotoxicity</e2>
D016685_D066126 NONE <e1>c</e1> suggested <e2>cardiotoxic</e2>
D016685_D066126 NONE <e1>mmc</e1> c suggested <e2>cardiotoxic</e2>
D016685_D066126 NONE <e1>mmc-related</e1> <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>doxorubicin</e1> given with combined suggested <e2>cardiotoxic</e2>
D004317_D066126 NONE <e1>doxorubicin</e1> treated dependent <e2>cardiotoxicity</e2>
D016685_D006333 CID <e1>mmc</e1> mg developed <e2>failure</e2>
D004317_D006333 CID <e1>doxorubicin</e1> developed <e2>failure</e2>
761833
D000641_D003128 NONE <e1>ammonia</e1> <e2>coma</e2>
D000641_D003128 NONE <e1>ammonia</e1> <e2>coma</e2>
D000641_D003128 NONE <e1>ammonia</e1> <e2>coma</e2>
D000641_D003128 NONE <e1>ammonia</e1> blood concentrations affect prevent <e2>coma</e2>
D000641_D003128 NONE <e1>ammonia</e1> <e2>coma</e2>
D000641_D003128 NONE <e1>ammonia</e1> <e2>coma</e2>
D000641_D003128 NONE <e1>ammonia</e1> blood reduction prevention <e2>coma</e2>
D000641_D003128 NONE <e1>ammonia</e1> <e2>coma</e2>
D007980_D003128 NONE <e1>l-dopa</e1> reversal <e2>coma</e2>
D007980_D003128 NONE <e1>l-dopa</e1> prevented <e2>coma</e2>
D007980_D003128 NONE <e1>l-dopa</e1> effect ammonia <e2>coma</e2>
D007980_D003128 NONE <e1>l-dopa</e1> reduction prevention <e2>coma</e2>
D000643_D003128 CID <e1>nh4cl</e1> intraperitonealinjection minutes rats produced <e2>coma</e2>
D064751_D003128 NONE <e1>salt</e1> injection prevented <e2>coma</e2>
D004298_D003128 NONE <e1>dopamine</e1> sufficient infusion prevent <e2>coma</e2>
D004298_D003128 NONE <e1>dopamine</e1> raise infusion prevent <e2>coma</e2>
D004298_D003128 NONE <e1>dopamine</e1> effect accounted reduction prevention <e2>coma</e2>
D007980_D001927 NONE <e1>l-dopa</e1> receiving patients <e2>encephalopathic</e2>
8278214
D009020_D006930 CID <e1>morphine</e1> treated patients <e2>hyperalgesia</e2>
D009020_D006930 CID <e1>morphine</e1> doses treated disease stages patients developed <e2>hyperalgesia</e2>
D009020_D006930 CID <e1>morphine</e1> doses <e2>hyperalgesia/myoclonus</e2>
D009020_D006930 CID <e1>morphine</e1> plays indicates available descriptions relationship <e2>hyperalgesia/myoclonus</e2>
D009020_D009207 CID <e1>morphine</e1> treated patients hyperalgesia <e2>myoclonus</e2>
D009020_D009207 CID <e1>morphine</e1> doses <e2>hyperalgesia/myoclonus</e2>
D009020_D009207 CID <e1>morphine</e1> plays indicates available descriptions relationship <e2>hyperalgesia/myoclonus</e2>
D009020_D009369 NONE <e1>morphine</e1> treated patients <e2>cancer</e2>
D009020_D009369 NONE <e1>morphine</e1> doses treated disease stages patients <e2>cancer</e2>
10728962
D014667_D007022 CID <e1>vasopressin</e1> treatment <e2>hypotension</e2>
D014667_D007022 CID <e1>vasopressin</e1> doses restored patients failure <e2>hypotension</e2>
D014667_D006333 NONE <e1>vasopressin</e1> treatment hypotension <e2>failure</e2>
D014667_D006333 NONE <e1>vasopressin</e1> doses restored patients <e2>failure</e2>
D020105_D007022 CID <e1>milrinone-induced</e1> <e2>hypotension</e2>
D020105_D007022 CID <e1>milrinone</e1> inhibitors use restricted cause vasodilation <e2>hypotension</e2>
D020105_D007022 CID <e1>milrinone</e1> treatment <e2>hypotension</e2>
D020105_D007022 CID <e1>milrinone</e1> effect inhibiting restored patients failure <e2>hypotension</e2>
D020105_D006333 NONE <e1>milrinone-induced</e1> hypotension <e2>failure</e2>
D020105_D006333 NONE <e1>milrinone</e1> treatment <e2>failure</e2>
D020105_D006333 NONE <e1>milrinone</e1> treatment hypotension <e2>failure</e2>
D020105_D006333 NONE <e1>milrinone</e1> effect inhibiting restored patients <e2>failure</e2>
343678
D006514_D006509 NONE <e1>antigen</e1> donors preventing assess examined globulin <e2>b</e2>
D006514_D006509 NONE <e1>antigen</e1> donors preventing <e2>hepatitis</e2>
D006514_D006509 NONE <e1>(hbsag)-positive</e1> donors preventing assess examined globulin <e2>b</e2>
D006514_D006509 NONE <e1>(hbsag)-positive</e1> donors preventing <e2>hepatitis</e2>
430165
D010672_D010291 CID <e1>diphenylhydantoin</e1> toxicity manifestation <e2>hemiparesis</e2>
D010672_D010291 CID <e1>dph</e1> overdose suffered <e2>hemiparesis</e2>
D010672_D064420 NONE <e1>diphenylhydantoin</e1> <e2>toxicity</e2>
D010672_D064420 NONE <e1>dph</e1> <e2>toxicity</e2>
D010672_D062787 CID <e1>diphenylhydantoin</e1> <e2>overdose</e2>
D010672_D062787 CID <e1>dph</e1> <e2>overdose</e2>
D010672_D062787 CID <e1>dph</e1> <e2>overdose</e2>
D010672_D002526 CID <e1>diphenylhydantoin</e1> overdose effects those <e2>dysfunction</e2>
D010672_D002526 CID <e1>dph</e1> overdose effects those <e2>dysfunction</e2>
D010672_D001927 NONE <e1>dph</e1> toxicity manifest liable patients <e2>damage</e2>
1628552
D002738_D006327 NONE <e1>chloroquine</e1> related <e2>block</e2>
D002738_D006327 NONE <e1>chloroquine</e1> retinopathy features revealed revealed features <e2>block</e2>
D002738_D006327 NONE <e1>chloroquine</e1> discontinuation resolved treated <e2>block</e2>
D002738_D001766 CID <e1>chloroquine</e1> related block <e2>blindness</e2>
D002738_D015354 NONE <e1>chloroquine</e1> ingestion history woman presented deterioration <e2>vision</e2>
D002738_D005221 CID <e1>chloroquine</e1> ingestion history woman presented deterioration vision <e2>fatiguability</e2>
D002738_D004417 CID <e1>chloroquine</e1> ingestion history woman presented deterioration vision fatiguability <e2>dyspnoea</e2>
D002738_D004244 CID <e1>chloroquine</e1> ingestion history woman <e2>dizziness</e2>
D002738_D013575 CID <e1>chloroquine</e1> ingestion history woman dizziness progressing <e2>attacks</e2>
D002738_D012164 CID <e1>chloroquine</e1> <e2>retinopathy</e2>
D002738_D006333 CID <e1>chloroquine</e1> retinopathy features revealed revealed features <e2>failure</e2>
D002738_D006333 CID <e1>chloroquine</e1> discontinuation resolved treated insertion <e2>failure</e2>
D002738_D002037 CID <e1>chloroquine</e1> retinopathy features revealed revealed features block pattern <e2>block</e2>
1445986
D015313_D000743 CID <e1>cefotetan-induced</e1> <e2>anemia</e2>
D010406_D000743 NONE <e1>penicillins</e1> receiving patients described <e2>anemia</e2>
D002511_D000743 NONE <e1>cephalosporins</e1> penicillins receiving patients described <e2>anemia</e2>
D015313_D000740 NONE <e1>cefotetan</e1> receiving developed <e2>anemia</e2>
20042557
D015742_D003693 CID <e1>propofol</e1> sedation anesthesia repair underwent <e2>delirium</e2>
D015742_D003693 CID <e1>propofol</e1> sedation use decreased prevalence <e2>delirium</e2>
D015742_D003704 NONE <e1>propofol</e1> sedation anesthesia repair underwent delirium <e2>dementia</e2>
D015742_D006620 NONE <e1>propofol</e1> sedation anesthesia repair underwent <e2>fracture</e2>
D015742_D011183 CID <e1>propofol</e1> sedation use decreased prevalence <e2>delirium</e2>
10840460
D003520_D003556 CID <e1>cyclophosphamide-induced</e1> <e2>cystitis</e2>
D003520_D003556 CID <e1>cyclophosphamide</e1> used induce <e2>cystitis</e2>
D003520_D003556 CID <e1>cp</e1> cyclophosphamide used induce <e2>cystitis</e2>
D003520_D003556 CID <e1>cp-induced</e1> <e2>cystitis</e2>
D003520_D059265 NONE <e1>cyclophosphamide-induced</e1> cystitis approach model <e2>pain</e2>
D003520_D059265 NONE <e1>cp-induced</e1> cystitis model model <e2>pain</e2>
D000171_D003556 NONE <e1>acrolein</e1> produce known agent cyclophosphamide used induce <e2>cystitis</e2>
D009020_D001523 NONE <e1>morphine</e1> reversed <e2>disorders</e2>
D009020_D004487 NONE <e1>morphine</e1> administration time observed , modifications wall <e2>edema</e2>
D003520_D010146 CID <e1>cp-induced</e1> cystitis model model indicate allowing understanding <e2>syndromes</e2>
11860278
D004298_D004827 NONE <e1>dopamine</e1> plays control <e2>seizures</e2>
D004298_D004827 NONE <e1>da</e1> dopamine plays control <e2>seizures</e2>
D004298_D004827 NONE <e1>da</e1> receptors role occurrence death <e2>epilepsy-induced</e2>
D010862_D012640 CID <e1>pilocarpine</e1> treated mice occurrence <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine-induced</e1> <e2>seizures</e2>
D010862_D020258 NONE <e1>pilocarpine</e1> treated mice occurrence seizures <e2>neurotoxicity</e2>
D007608_D012640 CID <e1>ka</e1> comparison result <e2>seizures</e2>
D018698_D012640 NONE <e1>glutamate</e1> induced <e2>seizures</e2>
D000109_D012640 NONE <e1>acetylcholine</e1> glutamate induced <e2>seizures</e2>
2819587
11302406
D015725_D016171 CID <e1>fluconazole-induced</e1> torsade <e2>pointes</e2>
D015725_D016171 CID <e1>fluconazole-associated</e1> torsade <e2>pointes</e2>
D015725_D016171 CID <e1>fluconazole-associated</e1> torsade pointes <e2>tdp</e2>
D015725_D016171 CID <e1>fluconazole-associated</e1> torsade pointes case present discuss role causing <e2>tdp</e2>
D015725_D016171 CID <e1>fluconazole</e1> role discuss present case <e2>pointes</e2>
D015725_D016171 CID <e1>fluconazole</e1> role discuss present case pointes <e2>tdp</e2>
D015725_D016171 CID <e1>fluconazole</e1> role causing <e2>tdp</e2>
D015725_D016171 CID <e1>fluconazole</e1> commencing developed days <e2>tdp</e2>
D015725_D016171 CID <e1>fluconazole</e1> commencing developed had factors <e2>tdp</e2>
D015725_D016171 CID <e1>fluconazole</e1> commencing developed was association initiation fluconazole <e2>tdp</e2>
D015725_D016171 CID <e1>fluconazole</e1> initiation association was developed days <e2>tdp</e2>
D015725_D016171 CID <e1>fluconazole</e1> initiation association was developed had factors <e2>tdp</e2>
D015725_D016171 CID <e1>fluconazole</e1> <e2>tdp</e2>
D015725_D016171 CID <e1>fluconazole</e1> discontinued resolved <e2>tdp</e2>
D015725_D016171 CID <e1>fluconazole</e1> discontinued resolved continued indicates relationship use development <e2>tdp</e2>
D015725_D016171 CID <e1>fluconazole</e1> use relationship indicates continued resolved <e2>tdp</e2>
D015725_D016171 CID <e1>fluconazole</e1> use development <e2>tdp</e2>
D015725_D016171 CID <e1>fluconazole</e1> suggests etiology explain prolongation <e2>tdp</e2>
D015725_D016171 CID <e1>fluconazole</e1> aware cause leading <e2>tdp</e2>
D015725_D003324 NONE <e1>fluconazole</e1> commencing developed had factors <e2>disease</e2>
D015725_D003324 NONE <e1>fluconazole</e1> initiation association was developed had factors <e2>disease</e2>
D015725_D009202 NONE <e1>fluconazole</e1> commencing developed had factors disease <e2>cardiomyopathy</e2>
D015725_D009202 NONE <e1>fluconazole</e1> initiation association was developed had factors disease <e2>cardiomyopathy</e2>
D015725_D006333 NONE <e1>fluconazole</e1> commencing developed had factors disease <e2>failure</e2>
D015725_D006333 NONE <e1>fluconazole</e1> initiation association was developed had factors disease <e2>failure</e2>
D015725_D018879 NONE <e1>fluconazole</e1> discontinued resolved continued have <e2>contractions</e2>
D015725_D018879 NONE <e1>fluconazole</e1> use relationship indicates continued have <e2>contractions</e2>
D015725_D018879 NONE <e1>fluconazole</e1> suggests etiology explain disappearance nsvt <e2>contractions</e2>
D015725_D017180 NONE <e1>fluconazole</e1> discontinued resolved continued have contractions <e2>tachycardia</e2>
D015725_D017180 NONE <e1>fluconazole</e1> discontinued resolved continued have contractions tachycardia <e2>nsvt</e2>
D015725_D017180 NONE <e1>fluconazole</e1> use relationship indicates continued have contractions <e2>tachycardia</e2>
D015725_D017180 NONE <e1>fluconazole</e1> use relationship indicates continued have contractions tachycardia <e2>nsvt</e2>
D015725_D017180 NONE <e1>fluconazole</e1> suggests etiology explain disappearance <e2>nsvt</e2>
D011188_D003866 NONE <e1>potassium</e1> currents <e2>depression</e2>
D015725_D008133 NONE <e1>fluconazole</e1> suggests etiology explain <e2>prolongation</e2>
D015725_D008133 NONE <e1>fluconazole</e1> aware cause prolongation <e2>interval</e2>
D015725_D001145 NONE <e1>fluconazole</e1> administered patients risk <e2>arrhythmias</e2>
11271907
D003520_D006470 CID <e1>cyclophosphamide</e1> therapy secondary <e2>myocarditis</e2>
D003520_D006470 CID <e1>cyclophosphamide</e1> therapy complication <e2>myocarditis</e2>
D003520_D009205 CID <e1>cyclophosphamide</e1> therapy secondary <e2>myocarditis</e2>
D003520_D009205 CID <e1>cyclophosphamide</e1> therapy complication <e2>myocarditis</e2>
20304337
D003042_-1 NONE <e1>cocaine</e1> exposed infant <e2>dysgenesis</e2>
1255900
D006493_D013924 NONE <e1>heparin</e1> therapy <e2>thrombophlebitis</e2>
18405372
D012460_D056486 CID <e1>sulfasalazine</e1> associated <e2>hepatotoxicity</e2>
D012460_D056486 CID <e1>sulfasalazine</e1> <e2>hepatotoxicity</e2>
D012460_D056486 CID <e1>sulfasalazine</e1> <e2>hepatotoxicity</e2>
D012460_D056486 CID <e1>sulfasalazine</e1> <e2>hepatotoxicity</e2>
D012460_D056486 CID <e1>sulfasalazine</e1> associated <e2>hepatotoxicity</e2>
D012460_D001168 NONE <e1>sulfasalazine</e1> <e2>arthritis</e2>
7565311
D016190_D058186 CID <e1>carboplatin</e1> chemotherapy <e2>failure</e2>
D016190_D058186 CID <e1>carboplatin</e1> reported cause <e2>failure</e2>
D016190_D018233 NONE <e1>carboplatin</e1> <e2>rhabdomyosarcoma</e2>
6695415
D010665_D002543 CID <e1>phenylpropanolamine</e1> associated <e2>hemorrhage</e2>
D010665_D002543 CID <e1>ppa/caffeine</e1> lead <e2>hemorrhage</e2>
D002110_D002543 CID <e1>caffeine</e1> combination associated <e2>hemorrhage</e2>
D002110_D002543 CID <e1>ppa/caffeine</e1> lead <e2>hemorrhage</e2>
D010665_D020521 CID <e1>phenylpropanolamine</e1> drug associated effects <e2>stroke</e2>
D010665_D020521 CID <e1>ppa</e1> phenylpropanolamine drug associated effects <e2>stroke</e2>
D010665_D020521 CID <e1>ppa/caffeine</e1> lead <e2>stroke</e2>
D010665_D006973 CID <e1>ppa/caffeine</e1> lead stroke normotensive <e2>hypertensive</e2>
D010665_D006973 CID <e1>ppa/caffeine</e1> administration lead <e2>hypertension</e2>
D010665_D006973 CID <e1>ppa/caffeine</e1> administration lead hypertension normotensive animals <e2>hypertensive</e2>
D010665_D006973 CID <e1>ppa/caffeine</e1> lead animals <e2>hypertensive</e2>
D002110_D020521 NONE <e1>ppa/caffeine</e1> lead <e2>stroke</e2>
D002110_D006973 CID <e1>ppa/caffeine</e1> lead stroke normotensive <e2>hypertensive</e2>
D002110_D006973 CID <e1>ppa/caffeine</e1> administration lead <e2>hypertension</e2>
D002110_D006973 CID <e1>ppa/caffeine</e1> administration lead hypertension normotensive animals <e2>hypertensive</e2>
D002110_D006973 CID <e1>ppa/caffeine</e1> lead animals <e2>hypertensive</e2>
7596955
D000242_D001791 NONE <e1>camp</e1> <e2>aggregation</e2>
C045645_D006261 CID <e1>clz</e1> ingestion experienced <e2>headache</e2>
C045645_D005483 CID <e1>clz</e1> ingestion experienced headache duration accompanying <e2>flush</e2>
C045645_D009325 CID <e1>clz</e1> ingestion experienced headache one <e2>nausea</e2>
20510337
C024989_D007674 NONE <e1>q10</e1> treatment ameliorates <e2>nephrotoxicity</e2>
C024989_D007674 NONE <e1>q10</e1> treatment ameliorated <e2>damage</e2>
C024989_D007674 NONE <e1>q10</e1> represents option protect <e2>nephrotoxicity</e2>
D002945_D007674 NONE <e1>cisplatin</e1> <e2>nephrotoxicity</e2>
D002945_D007674 NONE <e1>cisplatin</e1> mediated <e2>damage</e2>
D002945_D007674 NONE <e1>cisplatin</e1> <e2>nephrotoxicity</e2>
C024989_D058186 NONE <e1>q10</e1> effect investigated mice <e2>injury</e2>
D002945_D058186 CID <e1>cisplatin</e1> injection induced <e2>injury</e2>
C024989_D009369 NONE <e1>q10</e1> compensated decreased elevations factor-alpha <e2>tumor</e2>
C024989_D009336 NONE <e1>q10</e1> compensated decreased elevations factor-alpha <e2>necrosis</e2>
D005978_D009369 NONE <e1>glutathione</e1> level deficits compensated decreased elevations factor-alpha <e2>tumor</e2>
D005978_D009336 NONE <e1>glutathione</e1> level deficits compensated decreased elevations factor-alpha <e2>necrosis</e2>
D013481_D009369 NONE <e1>superoxide</e1> activity level deficits compensated decreased elevations factor-alpha <e2>tumor</e2>
D013481_D009336 NONE <e1>superoxide</e1> activity level deficits compensated decreased elevations factor-alpha <e2>necrosis</e2>
D009569_D009369 NONE <e1>oxide</e1> factor-alpha <e2>tumor</e2>
D009569_D009336 NONE <e1>oxide</e1> factor-alpha <e2>necrosis</e2>
D010984_D009369 NONE <e1>platinum</e1> ion factor-alpha <e2>tumor</e2>
D010984_D009336 NONE <e1>platinum</e1> ion factor-alpha <e2>necrosis</e2>
D012643_D009369 NONE <e1>selenium</e1> ions reductions attenuated decreased elevations factor-alpha <e2>tumor</e2>
D012643_D009336 NONE <e1>selenium</e1> ions reductions attenuated decreased elevations factor-alpha <e2>necrosis</e2>
D015032_D009369 NONE <e1>zinc</e1> selenium ions reductions attenuated decreased elevations factor-alpha <e2>tumor</e2>
D015032_D009336 NONE <e1>zinc</e1> selenium ions reductions attenuated decreased elevations factor-alpha <e2>necrosis</e2>
D002945_D009369 NONE <e1>cisplatin</e1> administration resulted attenuated decreased elevations factor-alpha <e2>tumor</e2>
D002945_D009336 NONE <e1>cisplatin</e1> administration resulted attenuated decreased elevations factor-alpha <e2>necrosis</e2>
17511042
C417083_D063726 CID <e1>alpha-2b</e1> patient <e2>parasitosis</e2>
C417083_D063726 CID <e1>alpha-2b</e1> treatment developed <e2>parasitosis</e2>
C417083_D019698 NONE <e1>alpha-2b</e1> patient <e2>c</e2>
D012254_D063726 CID <e1>ribavirin</e1> alpha-2b patient <e2>parasitosis</e2>
D012254_D063726 CID <e1>ribavirin</e1> weekly alpha-2b treatment developed <e2>parasitosis</e2>
D012254_D019698 NONE <e1>ribavirin</e1> alpha-2b patient <e2>c</e2>
D012254_D019698 NONE <e1>ribavirin</e1> interferon patients <e2>c</e2>
1928887
D009270_D007022 NONE <e1>naloxone</e1> reversal <e2>hypotension</e2>
D009270_D007022 NONE <e1>naloxone</e1> shown block reverse actions <e2>hypotensive</e2>
D009270_D007022 NONE <e1>naloxone</e1> administration resolved case manifested <e2>hypotension</e2>
D009270_D007022 NONE <e1>naloxone</e1> treated <e2>hypotension</e2>
D009270_D007022 NONE <e1>naloxone</e1> role reversal <e2>hypotension</e2>
D009270_D062787 NONE <e1>naloxone</e1> reversal <e2>overdose</e2>
D009270_D062787 NONE <e1>naloxone</e1> administration resolved case <e2>overdose</e2>
D002216_D007022 NONE <e1>captopril</e1> overdose reversal <e2>hypotension</e2>
D002216_D007022 NONE <e1>captopril</e1> actions <e2>hypotensive</e2>
D002216_D007022 NONE <e1>captopril</e1> overdose case manifested <e2>hypotension</e2>
D002216_D007022 NONE <e1>captopril-induced</e1> <e2>hypotension</e2>
D002216_D007022 NONE <e1>captopril</e1> resulting reversal <e2>hypotension</e2>
D002216_D062787 NONE <e1>captopril</e1> <e2>overdose</e2>
D002216_D062787 NONE <e1>captopril</e1> <e2>overdose</e2>
10354657
D008094_D013959 NONE <e1>lithium</e1> therapy duration respect evaluated had relative <e2>disease</e2>
D008094_D013959 NONE <e1>lithium</e1> therapy onset years accelerated patients having relatives affected <e2>illness</e2>
D008094_D013959 NONE <e1>lithium</e1> therapy onset years patients accelerated patients having relatives affected <e2>illness</e2>
D008094_D013959 NONE <e1>lithium</e1> therapy factor <e2>illness</e2>
D008094_D001714 NONE <e1>lithium</e1> therapy receiving <e2>disorder</e2>
D008094_D007037 CID <e1>lithium</e1> therapy onset years accelerated onset <e2>hypothyroidism</e2>
D008094_D007037 CID <e1>lithium</e1> therapy onset years patients accelerated onset <e2>hypothyroidism</e2>
D008094_D007037 CID <e1>lithium</e1> therapy factor <e2>hypothyroidism</e2>
D008094_D006934 NONE <e1>lithium</e1> therapy factor hypothyroidism <e2>hypercalcemia</e2>
18086064
D020927_D009203 NONE <e1>dexmedetomidine</e1> associated mortality <e2>infarction</e2>
D020927_D017202 NONE <e1>dexmedetomidine</e1> associated <e2>ischaemia</e2>
1899352
D015080_D006417 NONE <e1>mesna</e1> adding essential precise frequency <e2>hematuria</e2>
D015080_D006417 NONE <e1>mesna</e1> adding infusate patients <e2>hematuria</e2>
16725121
D009638_D012640 NONE <e1>norepinephrine</e1> function induced administration desipramine linking alteration sensitivity <e2>convulsions</e2>
D009638_D012640 NONE <e1>norepinephrine</e1> transporter alterations relation sensitization <e2>seizures</e2>
D003891_D012640 NONE <e1>desipramine</e1> linking alteration sensitivity <e2>convulsions</e2>
D003891_D012640 NONE <e1>desipramine</e1> administration increased incidence appearance <e2>convulsions</e2>
D003891_D012640 NONE <e1>desipramine</e1> administration increased decreased that <e2>convulsions</e2>
D003891_D012640 NONE <e1>desipramine</e1> co-administration reversed changes activity <e2>convulsive</e2>
D003891_D012640 NONE <e1>desipramine</e1> administration induced lidocaine activity <e2>convulsive</e2>
D003891_D012640 NONE <e1>desipramine</e1> administration induced net down-regulation relevant sensitization <e2>convulsions</e2>
D003891_D012640 NONE <e1>desipramine-induced</e1> sensitization <e2>convulsions</e2>
D003891_D012640 NONE <e1>desipramine-induced</e1> sensitization <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine</e1> induce alterations relation sensitization <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine-induced</e1> convulsions that decreased increased incidence appearance <e2>convulsions</e2>
D003042_D012640 CID <e1>cocaine-induced</e1> <e2>convulsions</e2>
D003042_D012640 CID <e1>cocaine</e1> lidocaine activity <e2>convulsive</e2>
D003042_D012640 CID <e1>cocaine</e1> administration resulting kindling distinct mechanism have sensitization <e2>seizures</e2>
D008012_D012640 CID <e1>lidocaine-induced</e1> <e2>convulsions</e2>
D008012_D012640 CID <e1>lidocaine-induced</e1> convulsions appearance incidence increased decreased that <e2>convulsions</e2>
D008012_D012640 CID <e1>lidocaine</e1> co-administration reversed changes activity <e2>convulsive</e2>
D008012_D012640 CID <e1>lidocaine</e1> activity <e2>convulsive</e2>
D008012_D012640 CID <e1>lidocaine</e1> <e2>convulsions</e2>
D008012_D012640 CID <e1>lidocaine</e1> <e2>seizures</e2>
2917114
D006024_D001919 NONE <e1>glycopyrronium</e1> kg-1 use provided sufficient minimize <e2>bradycardias</e2>
D004491_D001919 CID <e1>edrophonium</e1> min provided sufficient minimize <e2>bradycardias</e2>
D004491_D001919 CID <e1>edrophonium-induced</e1> early <e2>bradycardias</e2>
19139001
D000518_D015179 NONE <e1>difluoromethylornithine</e1> trial prevention <e2>adenomas</e2>
D013467_D015179 NONE <e1>sulindac</e1> difluoromethylornithine trial prevention <e2>adenomas</e2>
D000518_D018256 NONE <e1>difluoromethylornithine</e1> months treatment recurrence <e2>polyps</e2>
D000518_D018256 NONE <e1>dfmo</e1> difluoromethylornithine months treatment recurrence <e2>polyps</e2>
D013467_D018256 NONE <e1>sulindac</e1> difluoromethylornithine months treatment recurrence <e2>polyps</e2>
D000518_D034381 NONE <e1>dfmo</e1> treatment toxicity <e2>loss</e2>
D000518_D034381 NONE <e1>dfmo</e1> group experienced <e2>loss</e2>
D000518_D064420 NONE <e1>dfmo</e1> treatment <e2>toxicity</e2>
D013467_D034381 CID <e1>sulindac</e1> group experienced <e2>loss</e2>
14745746
C090450_D001943 NONE <e1>anastrozole</e1> group women <e2>cancer</e2>
D013629_D001943 NONE <e1>tamoxifen</e1> anastrozole group women <e2>cancer</e2>
8854309
D003042_D011681 CID <e1>cocaine-induced</e1> paranoia marker measure <e2>oscillation</e2>
D003042_D010259 CID <e1>cocaine-induced</e1> <e2>paranoia</e2>
D003042_D010259 CID <e1>cocaine-induced</e1> <e2>paranoia</e2>
D003042_D010259 CID <e1>cocaine-induced</e1> paranoia <e2>cip</e2>
D003042_D010259 CID <e1>cocaine-induced</e1> paranoia remains model <e2>paranoia</e2>
D016578_D011681 NONE <e1>cocaine</e1> abusers group distinguish able measures <e2>oscillation</e2>
D016578_D011681 NONE <e1>crack</e1> addicts group distinguish able measures <e2>oscillation</e2>
D016578_D010259 NONE <e1>cocaine</e1> abusers group endorsing <e2>cip</e2>
D016578_D010259 NONE <e1>cocaine</e1> abusers group distinguish group addicts denied <e2>cip</e2>
D016578_D010259 NONE <e1>crack</e1> addicts group distinguish group endorsing <e2>cip</e2>
D016578_D010259 NONE <e1>crack</e1> addicts denied <e2>cip</e2>
9321531
D007980_D010300 NONE <e1>levodopa-induced</e1> dyskinesias reduces <e2>disease</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
8617710
D020280_D003072 NONE <e1>sertraline</e1> effect sensitization <e2>impairment</e2>
D020280_D003072 NONE <e1>sertraline</e1> administration worsened <e2>impairment</e2>
D006220_D003072 CID <e1>haloperidol</e1> <e2>impairment</e2>
D006220_D003072 CID <e1>haloperidol</e1> administration hours observed impairment <e2>function</e2>
D006220_D003072 CID <e1>haloperidol</e1> produced profile <e2>impairment</e2>
384871
D004977_D009901 CID <e1>ethambutol</e1> treatment <e2>neuropathy</e2>
D007538_D009901 CID <e1>isoniazid</e1> ethambutol treatment <e2>neuropathy</e2>
D004977_D064420 NONE <e1>ethambutol</e1> hazards <e2>toxicity</e2>
16629641
D007372_D006526 NONE <e1>interferon</e1> therapy treatment <e2>infection</e2>
D012254_D006526 NONE <e1>ribavirin</e1> interferon therapy treatment <e2>infection</e2>
D012254_D006526 NONE <e1>ribavirin-induced</e1> hemolysis result decrease problematic patients <e2>infection</e2>
D012254_D006461 NONE <e1>ribavirin-induced</e1> <e2>hemolysis</e2>
D012254_D000740 NONE <e1>ribavirin-induced</e1> hemolysis result decrease problematic <e2>anemia</e2>
D012254_D000740 NONE <e1>ribavirin-associated</e1> <e2>anemia</e2>
D012254_D000740 NONE <e1>ribavirin-associated</e1> <e2>anemia</e2>
D012254_D007674 NONE <e1>ribavirin-induced</e1> hemolysis result decrease problematic those have comorbid <e2>disorders</e2>
D012254_D002318 NONE <e1>ribavirin-induced</e1> hemolysis result decrease problematic those have comorbid <e2>disorders</e2>
C026956_D000743 NONE <e1>viramidine</e1> has potential maintain decreasing risk <e2>anemia</e2>
C026956_D019698 NONE <e1>viramidine</e1> has potential maintain decreasing risk anemia patients <e2>c.</e2>
D012254_D000743 CID <e1>ribavirin</e1> prodrug viramidine has potential maintain decreasing risk <e2>anemia</e2>
D012254_D000743 CID <e1>ribavirin</e1> efficacy maintain decreasing risk <e2>anemia</e2>
D012254_D019698 NONE <e1>ribavirin</e1> prodrug viramidine has potential maintain decreasing risk anemia patients <e2>c.</e2>
D012254_D019698 NONE <e1>ribavirin</e1> efficacy maintain decreasing risk anemia patients <e2>c.</e2>
16132524
D017239_D005909 NONE <e1>paclitaxel/carboplatin</e1> liquid phases chemotherapy <e2>glioblastoma</e2>
D017239_D005909 NONE <e1>paclitaxel</e1> application feasibility recurrences <e2>glioblastoma</e2>
D017239_D005909 NONE <e1>paclitaxel</e1> application received total patients recurrence re-resection multiforme <e2>glioblastoma</e2>
D016190_D005909 NONE <e1>paclitaxel/carboplatin</e1> liquid phases chemotherapy <e2>glioblastoma</e2>
D016190_D005909 NONE <e1>carboplatin</e1> paclitaxel application feasibility recurrences <e2>glioblastoma</e2>
D016190_D005909 NONE <e1>carboplatin</e1> phases paclitaxel application received total patients recurrence re-resection multiforme <e2>glioblastoma</e2>
D017239_D001929 CID <e1>paclitaxel</e1> received suffered moderate <e2>edema</e2>
D017239_D001929 CID <e1>paclitaxel</e1> total received received suffered moderate <e2>edema</e2>
8841157
C081489_D006973 NONE <e1>valsartan</e1> antagonist treatment <e2>hypertension</e2>
C081489_D006973 NONE <e1>valsartan</e1> receive allocated outpatients mild <e2>hypertension</e2>
C081489_D006973 NONE <e1>valsartan</e1> effective amlodipine treatment mild <e2>hypertension</e2>
D000804_D006973 NONE <e1>ii</e1> antagonist treatment <e2>hypertension</e2>
D017311_D006973 NONE <e1>amlodipine</e1> efficacy study valsartan antagonist treatment <e2>hypertension</e2>
D017311_D006973 NONE <e1>amlodipine</e1> valsartan receive allocated outpatients mild <e2>hypertension</e2>
D017311_D006973 NONE <e1>amlodipine</e1> treatment mild <e2>hypertension</e2>
D017311_D004487 CID <e1>amlodipine</e1> group higher incidence <e2>edema</e2>
D017311_D004487 CID <e1>amlodipine</e1> % % higher incidence <e2>edema</e2>
D017311_D004487 CID <e1>amlodipine</e1> valsartan % % % higher incidence <e2>edema</e2>
D017311_D004487 CID <e1>amlodipine</e1> % % higher incidence <e2>edema</e2>
C081489_D004487 CID <e1>valsartan</e1> % higher incidence <e2>edema</e2>
C081489_D004487 CID <e1>valsartan</e1> % % % higher incidence <e2>edema</e2>
12180796
D009569_D009369 NONE <e1>oxide</e1> type factor-beta1 <e2>tumor</e2>
D009569_D009369 NONE <e1>oxide</e1> synthase type factor-beta1 <e2>tumor</e2>
D009569_D001167 NONE <e1>oxide</e1> type <e2>arteritis</e2>
D009569_D001167 NONE <e1>oxide</e1> synthase type expressions examined <e2>arteritis</e2>
D018818_D009369 NONE <e1>fenoldopam</e1> induced arteritis type factor-beta1 <e2>tumor</e2>
D018818_D009369 NONE <e1>fenoldopam</e1> vasodilators induced arteritis examined expressions type factor-beta1 <e2>tumor</e2>
D018818_D001167 CID <e1>fenoldopam</e1> induced <e2>arteritis</e2>
D018818_D001167 CID <e1>fenoldopam</e1> vasodilators induced <e2>arteritis</e2>
D013806_D009369 NONE <e1>theophylline</e1> fenoldopam induced arteritis type factor-beta1 <e2>tumor</e2>
D013806_D009369 NONE <e1>theophylline</e1> fenoldopam vasodilators induced arteritis examined expressions type factor-beta1 <e2>tumor</e2>
D013806_D001167 CID <e1>theophylline</e1> fenoldopam induced <e2>arteritis</e2>
D013806_D001167 CID <e1>theophylline</e1> fenoldopam vasodilators induced <e2>arteritis</e2>
9431903
D005996_D046628 NONE <e1>trinitrate</e1> effect sphincter <e2>spasm</e2>
D005996_D046628 NONE <e1>trinitrate</e1> effect sphincter <e2>spasm</e2>
D005996_D046628 NONE <e1>trinitrate</e1> effect evaluated patients sphincter <e2>dyskinesia</e2>
D005996_D046628 NONE <e1>trinitrate</e1> effectiveness sphincter <e2>spasm</e2>
D005996_D046628 NONE <e1>trinitrate</e1> able relevance treatment sphincter <e2>dyskinesia</e2>
D005996_D013035 NONE <e1>trinitrate</e1> effect sphincter <e2>spasm</e2>
D005996_D013035 NONE <e1>trinitrate</e1> effect sphincter <e2>spasm</e2>
D005996_D013035 NONE <e1>trinitrate</e1> effectiveness sphincter <e2>spasm</e2>
D009388_D046628 CID <e1>prostigmine-morphine</e1> administration evoked sphincter <e2>spasm</e2>
D009388_D046628 CID <e1>prostigmine-morphine-induced</e1> sphincter <e2>spasm</e2>
D009388_D046628 CID <e1>prostigmine-morphine-induced</e1> sphincter effect evaluated patients sphincter <e2>dyskinesia</e2>
D009388_D046628 CID <e1>prostigmine-morphine</e1> administration induced sphincter <e2>spasm</e2>
D009388_D046628 CID <e1>prostigmine</e1> induced sphincter <e2>spasm</e2>
D009388_D013035 CID <e1>prostigmine-morphine</e1> administration evoked sphincter <e2>spasm</e2>
D009388_D013035 CID <e1>prostigmine-morphine-induced</e1> sphincter <e2>spasm</e2>
D009388_D013035 CID <e1>prostigmine-morphine</e1> administration induced sphincter <e2>spasm</e2>
D009388_D013035 CID <e1>prostigmine</e1> induced sphincter <e2>spasm</e2>
D009388_D013035 CID <e1>prostigmine-morphine</e1> provocation caused indicating <e2>spasm</e2>
D009020_D046628 CID <e1>prostigmine-morphine</e1> administration evoked sphincter <e2>spasm</e2>
D009020_D046628 CID <e1>prostigmine-morphine-induced</e1> sphincter <e2>spasm</e2>
D009020_D046628 CID <e1>prostigmine-morphine-induced</e1> sphincter effect evaluated patients sphincter <e2>dyskinesia</e2>
D009020_D046628 CID <e1>prostigmine-morphine</e1> administration induced sphincter <e2>spasm</e2>
D009020_D046628 CID <e1>morphine</e1> prostigmine induced sphincter <e2>spasm</e2>
D009020_D046628 CID <e1>morphine-induced</e1> sphincter <e2>spasm</e2>
D009020_D046628 CID <e1>morphine</e1> effect overcome able relevance treatment sphincter <e2>dyskinesia</e2>
D009020_D013035 CID <e1>prostigmine-morphine</e1> administration evoked sphincter <e2>spasm</e2>
D009020_D013035 CID <e1>prostigmine-morphine-induced</e1> sphincter <e2>spasm</e2>
D009020_D013035 CID <e1>prostigmine-morphine</e1> administration induced sphincter <e2>spasm</e2>
D009020_D013035 CID <e1>morphine</e1> prostigmine induced sphincter <e2>spasm</e2>
D009020_D013035 CID <e1>prostigmine-morphine</e1> provocation caused indicating <e2>spasm</e2>
D009020_D013035 CID <e1>morphine-induced</e1> sphincter <e2>spasm</e2>
3015327
D007538_D009422 CID <e1>isoniazid</e1> remodelling <e2>neuropathy</e2>
D007538_D009422 CID <e1>isoniazid</e1> dose caused <e2>neuropathy</e2>
9201797
D002354_D002375 NONE <e1>hydrochloride</e1> effect <e2>catalepsy</e2>
D002354_D002375 NONE <e1>carteolol</e1> effects <e2>catalepsy</e2>
D002354_D002375 NONE <e1>carteolol</e1> inhibited <e2>catalepsy</e2>
D002354_D002375 NONE <e1>carteolol</e1> improves <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol-induced</e1> <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol-induced</e1> <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol-induced</e1> <e2>catalepsy</e2>
D011433_D002375 NONE <e1>propranolol</e1> those compared studied effects <e2>catalepsy</e2>
D011433_D002375 NONE <e1>propranolol</e1> carteolol inhibited <e2>catalepsy</e2>
D001712_D002375 NONE <e1>biperiden</e1> propranolol those compared studied effects <e2>catalepsy</e2>
D001712_D002375 NONE <e1>biperiden</e1> propranolol carteolol inhibited <e2>catalepsy</e2>
D002354_D009069 NONE <e1>carteolol</e1> evoke signs stereotypy <e2>hyperlocomotion</e2>
D004298_D009069 NONE <e1>dopamine</e1> signs stereotypy <e2>hyperlocomotion</e2>
D002354_D017109 NONE <e1>carteolol</e1> improves expected effective treatment <e2>akathisia</e2>
D006220_D017109 NONE <e1>haloperidol-induced</e1> catalepsy improves expected effective treatment <e2>akathisia</e2>
D004298_D002375 NONE <e1>dopamine</e1> receptor activity attenuating expected improves <e2>catalepsy</e2>
D004298_D017109 NONE <e1>dopamine</e1> receptor activity attenuating expected effective treatment <e2>akathisia</e2>
15042318
D004317_C535648 NONE <e1>doxorubicin-based</e1> chemotherapy cycle fibrillation form association <e2>lymphoma</e2>
D004317_D009223 NONE <e1>doxorubicin-based</e1> chemotherapy cycle fibrillation form association lymphoma <e2>dystrophy</e2>
D004317_D009136 NONE <e1>doxorubicin-based</e1> chemotherapy cycle fibrillation form <e2>dystrophy</e2>
D004317_D001281 CID <e1>doxorubicin-based</e1> chemotherapy cycle <e2>fibrillation</e2>
8492347
D005665_D013746 CID <e1>furosemide</e1> <e2>tetany</e2>
D005665_D012206 CID <e1>furosemide</e1> tetany <e2>rhabdomyolysis</e2>
D008274_D013746 NONE <e1>magnesium</e1> supplementation importance <e2>tetany</e2>
D008274_D012206 NONE <e1>magnesium</e1> supplementation importance tetany <e2>rhabdomyolysis</e2>
D011188_D007008 NONE <e1>potassium</e1> corrected spasms associated cause <e2>hypokalemia</e2>
D011188_D018908 NONE <e1>potassium</e1> corrected spasms associated cause <e2>weakness</e2>
D011188_C537153 NONE <e1>potassium</e1> corrected spasms associated <e2>hypomagnesemia</e2>
D011188_D013035 NONE <e1>potassium</e1> corrected <e2>spasms</e2>
D011188_D013746 NONE <e1>potassium</e1> corrected spasms <e2>tetany</e2>
D002118_D007008 NONE <e1>calcium</e1> supplementation potassium corrected spasms associated cause <e2>hypokalemia</e2>
D002118_D018908 NONE <e1>calcium</e1> supplementation potassium corrected spasms associated cause <e2>weakness</e2>
D002118_C537153 NONE <e1>calcium</e1> supplementation potassium corrected spasms associated <e2>hypomagnesemia</e2>
D002118_D013035 NONE <e1>calcium</e1> supplementation potassium corrected <e2>spasms</e2>
D002118_D013746 NONE <e1>calcium</e1> supplementation potassium corrected spasms <e2>tetany</e2>
D008274_D007008 NONE <e1>magnesium</e1> depletion effects noted observed reported <e2>hypokalemia</e2>
D008274_D006996 NONE <e1>magnesium</e1> depletion effects noted observed <e2>hypocalcemia</e2>
10414674
D007660_D013345 NONE <e1>ketoprofen</e1> receive randomized patients <e2>hemorrhage</e2>
D007660_D013345 NONE <e1>ketoprofen</e1> receive randomized patients hemorrhage <e2>sah</e2>
D007660_D013345 NONE <e1>ketoprofen</e1> receive randomized starting diagnosis <e2>sah</e2>
D007660_D013345 NONE <e1>ketoprofen</e1> group day times receive randomized patients <e2>hemorrhage</e2>
D007660_D013345 NONE <e1>ketoprofen</e1> group day times receive randomized patients hemorrhage <e2>sah</e2>
D007660_D013345 NONE <e1>ketoprofen</e1> group day times receive randomized starting diagnosis <e2>sah</e2>
D007660_D013345 NONE <e1>ketoprofen</e1> function patients <e2>sah</e2>
D007660_D017542 NONE <e1>ketoprofen</e1> receive randomized starting diagnosis sah <e2>aneurysmal</e2>
D007660_D017542 NONE <e1>ketoprofen</e1> group day times receive randomized starting diagnosis sah <e2>aneurysmal</e2>
D000082_D013345 NONE <e1>acetaminophen</e1> nsaid times receive randomized patients <e2>hemorrhage</e2>
D000082_D013345 NONE <e1>acetaminophen</e1> nsaid times receive randomized patients hemorrhage <e2>sah</e2>
D000082_D013345 NONE <e1>acetaminophen</e1> nsaid times receive randomized starting diagnosis <e2>sah</e2>
D000082_D013345 NONE <e1>acetaminophen</e1> group day times receive randomized patients <e2>hemorrhage</e2>
D000082_D013345 NONE <e1>acetaminophen</e1> group day times receive randomized patients hemorrhage <e2>sah</e2>
D000082_D013345 NONE <e1>acetaminophen</e1> group day times receive randomized starting diagnosis <e2>sah</e2>
D000082_D013345 NONE <e1>acetaminophen</e1> impaired function patients <e2>sah</e2>
D000082_D017542 NONE <e1>acetaminophen</e1> nsaid times receive randomized starting diagnosis sah <e2>aneurysmal</e2>
D000082_D017542 NONE <e1>acetaminophen</e1> group day times receive randomized starting diagnosis sah <e2>aneurysmal</e2>
D000244_D001791 NONE <e1>diphosphate</e1> microm induced <e2>aggregation</e2>
D007660_D001791 CID <e1>ketoprofen</e1> administration decreased <e2>aggregation</e2>
D000082_D001791 NONE <e1>acetaminophen</e1> group increased <e2>aggregation</e2>
D000082_D001791 NONE <e1>acetaminophen</e1> group increased compared results <e2>aggregation</e2>
D007660_D006406 CID <e1>ketoprofen</e1> group patient developed <e2>hematoma</e2>
D007660_D002532 NONE <e1>ketoprofen</e1> used surgery <e2>aneurysms</e2>
D007660_D006470 NONE <e1>ketoprofen</e1> used pose factor <e2>hemorrhage</e2>
8643966
D017239_D002289 NONE <e1>paclitaxel</e1> chemotherapy <e2>cancer</e2>
D017239_D002289 NONE <e1>paclitaxel</e1> infusions patients iiib <e2>cancer</e2>
D017239_D002289 NONE <e1>paclitaxel</e1> infusions patients iiib cancer <e2>nsclc</e2>
D017239_D002289 NONE <e1>paclitaxel</e1> infusion efficacy trial patients iiib <e2>nsclc</e2>
D017239_D002289 NONE <e1>paclitaxel</e1> combined drugs active <e2>nsclc</e2>
D017239_D002289 NONE <e1>paclitaxel</e1> comparing studies remain indicated studies paclitaxel combined drugs active <e2>nsclc</e2>
D017239_D009369 NONE <e1>paclitaxel</e1> demonstrated activity types <e2>tumor</e2>
D017239_D009369 NONE <e1>taxol</e1> company paclitaxel demonstrated activity types <e2>tumor</e2>
D017239_D010051 NONE <e1>paclitaxel</e1> demonstrated activity <e2>carcinoma</e2>
D017239_D010051 NONE <e1>taxol</e1> company paclitaxel demonstrated activity <e2>carcinoma</e2>
D017239_D001943 NONE <e1>paclitaxel</e1> demonstrated activity <e2>carcinoma</e2>
D017239_D001943 NONE <e1>taxol</e1> company paclitaxel demonstrated activity <e2>carcinoma</e2>
D017239_D064420 NONE <e1>paclitaxel</e1> infusion efficacy <e2>toxicity</e2>
D017239_D064420 NONE <e1>paclitaxel</e1> agent infusion proving effective infusion superior terms incidence <e2>toxicity</e2>
9041081
D013256_D009798 NONE <e1>steroid-induced</e1> <e2>pressure</e2>
D013256_D009798 NONE <e1>steroid-induced</e1> transient <e2>rise</e2>
D000305_D009798 CID <e1>corticosteroid</e1> therapy resolved <e2>pressure</e2>
16710500
D004977_D009901 CID <e1>ethambutol-associated</e1> optic <e2>neuropathy</e2>
D004977_D009901 CID <e1>ethambutol-associated</e1> <e2>neuropathy</e2>
D004977_D014376 NONE <e1>ethambutol</e1> used treatment <e2>tuberculosis</e2>
D004977_D014786 CID <e1>ethambutol</e1> used associated <e2>loss</e2>
D004977_D014786 CID <e1>ethambutol</e1> usage associated <e2>loss</e2>
12093990
D012254_D000257 NONE <e1>ribavirin</e1> treatment <e2>disease</e2>
D012254_D000257 NONE <e1>ribavirin</e1> therapy <e2>disease</e2>
D012254_D000257 NONE <e1>ribavirin</e1> <e2>disease</e2>
D012254_D000257 NONE <e1>ribavirin</e1> effective children <e2>disease</e2>
D012254_D000257 NONE <e1>ribavirin</e1> treated <e2>disease</e2>
D012254_D000257 NONE <e1>ribavirin</e1> therapies trial prevalence <e2>disease</e2>
D012254_D018357 NONE <e1>ribavirin</e1> licensed form treatment <e2>infection</e2>
D012254_D018357 NONE <e1>ribavirin</e1> treat combination licensed form treatment <e2>infection</e2>
D012254_D006526 NONE <e1>ribavirin</e1> licensed combination treat ribavirin intravenous <e2>c.</e2>
D012254_D006526 NONE <e1>ribavirin</e1> intravenous <e2>c.</e2>
D012254_D006482 NONE <e1>ribavirin</e1> licensed treatment infection <e2>viruses</e2>
D012254_D006482 NONE <e1>ribavirin</e1> treat combination licensed treatment infection <e2>viruses</e2>
D012254_D000740 NONE <e1>ribavirin</e1> effect <e2>anemia</e2>
C059262_D000257 NONE <e1>cidofovir</e1> use <e2>infection</e2>
C059262_D007674 NONE <e1>cidofovir</e1> use limited <e2>nephrotoxicity</e2>
C059262_D058186 CID <e1>cidofovir</e1> use associated <e2>failure</e2>
C059262_D009503 CID <e1>cidofovir</e1> use associated failure <e2>neutropenia</e2>
D012254_D007239 NONE <e1>ribavirin</e1> effective unlikely begun course <e2>infection</e2>
17049862
D010672_D007035 NONE <e1>phenytoin</e1> administration safe child <e2>hypothermic</e2>
D010672_D007035 NONE <e1>phenytoin</e1> <e2>hypothermia</e2>
D010672_D007035 NONE <e1>phenytoin</e1> administration presence <e2>hypothermia</e2>
D010672_D012640 NONE <e1>phenytoin</e1> administered part prophylaxis <e2>seizure</e2>
D010672_D001919 CID <e1>phenytoin</e1> administration developed <e2>bradycardia</e2>
D001285_D001919 NONE <e1>atropine</e1> refractory developed <e2>bradycardia</e2>
D004837_D001919 NONE <e1>adrenaline</e1> atropine refractory developed <e2>bradycardia</e2>
11063349
D020123_D064420 NONE <e1>rapa</e1> conversion patients undergoing cyclosporine <e2>toxicity</e2>
D016572_D064420 NONE <e1>cyclosporine</e1> <e2>toxicity</e2>
D016572_D064420 NONE <e1>csa</e1> cyclosporine <e2>toxicity</e2>
D016572_D064420 NONE <e1>csa</e1> <e2>toxicity</e2>
D016572_D064420 NONE <e1>csa</e1> csa <e2>toxicity</e2>
D016559_D064420 NONE <e1>tacrolimus</e1> <e2>toxicity</e2>
D016559_D064420 NONE <e1>tac</e1> <e2>toxicity</e2>
D016559_D064420 NONE <e1>tac</e1> csa <e2>toxicity</e2>
D016559_D064420 NONE <e1>tac</e1> <e2>toxicity</e2>
D016572_D007674 CID <e1>csa</e1> <e2>nephrotoxicity</e2>
D016572_D007674 CID <e1>csa</e1> csa <e2>nephrotoxicity</e2>
D016572_-1 NONE <e1>csa</e1> toxicity <e2>dysmorphism</e2>
D016572_-1 NONE <e1>csa</e1> csa toxicity <e2>dysmorphism</e2>
D016572_D008232 NONE <e1>csa</e1> toxicity dysmorphism <e2>disorder</e2>
D016572_D008232 NONE <e1>csa</e1> toxicity dysmorphism disorder <e2>ptld</e2>
D016572_D008232 NONE <e1>csa</e1> csa toxicity dysmorphism <e2>disorder</e2>
D016572_D008232 NONE <e1>csa</e1> csa toxicity dysmorphism disorder <e2>ptld</e2>
D016572_D056486 NONE <e1>csa</e1> toxicity <e2>hepatotoxicity</e2>
D016572_D056486 NONE <e1>csa</e1> csa toxicity <e2>hepatotoxicity</e2>
D016559_D007674 CID <e1>tac</e1> csa <e2>nephrotoxicity</e2>
D016559_D007674 CID <e1>tac</e1> toxicity csa <e2>nephrotoxicity</e2>
D016559_-1 NONE <e1>tac</e1> csa toxicity <e2>dysmorphism</e2>
D016559_-1 NONE <e1>tac</e1> toxicity <e2>dysmorphism</e2>
D016559_D008232 NONE <e1>tac</e1> csa toxicity dysmorphism <e2>disorder</e2>
D016559_D008232 NONE <e1>tac</e1> csa toxicity dysmorphism disorder <e2>ptld</e2>
D016559_D008232 NONE <e1>tac</e1> toxicity dysmorphism <e2>disorder</e2>
D016559_D008232 NONE <e1>tac</e1> toxicity dysmorphism disorder <e2>ptld</e2>
D016559_D056486 NONE <e1>tac</e1> csa toxicity <e2>hepatotoxicity</e2>
D016559_D056486 NONE <e1>tac</e1> toxicity <e2>hepatotoxicity</e2>
D003404_D007674 NONE <e1>creatinine</e1> decrease was results switched <e2>nephrotoxicity</e2>
D020123_D011014 NONE <e1>rapa</e1> discontinued <e2>pneumonia</e2>
D020123_D008232 NONE <e1>rapa</e1> discontinued pneumonia <e2>ptld</e2>
D020123_D013281 NONE <e1>rapa</e1> discontinued pneumonia <e2>ulcers</e2>
D020123_D011020 NONE <e1>rapa</e1> levels patients converting monitored given prophylaxis <e2>pneumonia</e2>
11900788
D009538_D002375 CID <e1>nicotine</e1> potentiation <e2>catalepsy</e2>
D009538_D002375 CID <e1>nicotine</e1> effects <e2>catalepsy</e2>
D009538_D002375 CID <e1>nicotine</e1> morphine induced <e2>catalepsy</e2>
D009538_D002375 CID <e1>nicotine</e1> morphine combination induced <e2>catalepsy</e2>
D009538_D002375 CID <e1>nicotine</e1> morphine induced <e2>catalepsy</e2>
D009538_D002375 CID <e1>nicotine</e1> induced morphine potentiation mediated elicited <e2>catalepsy</e2>
D009020_D002375 CID <e1>morphine-induced</e1> <e2>catalepsy</e2>
D009020_D002375 CID <e1>morphine</e1> induced <e2>catalepsy</e2>
D009020_D002375 CID <e1>morphine</e1> induced <e2>catalepsy</e2>
D009020_D002375 CID <e1>morphine</e1> combination induced <e2>catalepsy</e2>
D009020_D002375 CID <e1>morphine</e1> induced <e2>catalepsy</e2>
D009020_D002375 CID <e1>morphine</e1> <e2>catalepsy</e2>
D009020_D002375 CID <e1>morphine</e1> potentiation mediated elicited <e2>catalepsy</e2>
D001285_D002375 NONE <e1>atropine</e1> administration reduced <e2>catalepsy</e2>
D001285_D002375 NONE <e1>atropine</e1> injection decreased <e2>catalepsy</e2>
D009270_D002375 NONE <e1>naloxone</e1> atropine administration reduced <e2>catalepsy</e2>
D009270_D002375 NONE <e1>naloxone</e1> atropine injection decreased <e2>catalepsy</e2>
D008464_D002375 NONE <e1>mecamylamine</e1> atropine administration reduced <e2>catalepsy</e2>
D018738_D002375 NONE <e1>hexamethonium</e1> atropine administration reduced <e2>catalepsy</e2>
D018738_D002375 NONE <e1>hexamethonium</e1> atropine injection decreased <e2>catalepsy</e2>
11583940
C063008_D007674 NONE <e1>mofetil</e1> agents have <e2>nephrotoxicity</e2>
D020123_D007674 NONE <e1>sirolimus</e1> mofetil agents have <e2>nephrotoxicity</e2>
D020123_D007674 NONE <e1>rapamycin</e1> sirolimus mofetil agents have <e2>nephrotoxicity</e2>
1700207
C032151_D001145 NONE <e1>cibenzoline</e1> isomers effects <e2>arrhythmias</e2>
C032151_D001145 NONE <e1>(+)-cibenzoline</e1> effects examined using models <e2>arrhythmia</e2>
C032151_D001145 NONE <e1>(-)-cibenzoline</e1> (+)-cibenzoline effects examined using models <e2>arrhythmia</e2>
C032151_D001145 NONE <e1>(+)-cibenzoline</e1> suppressed <e2>arrhythmias</e2>
C032151_D001145 NONE <e1>(+)-cibenzoline</e1> concentrations <e2>arrhythmias</e2>
C032151_D001145 NONE <e1>(-)-cibenzoline</e1> i.v. dose suppressed <e2>arrhythmia</e2>
C032151_D001145 NONE <e1>(-)-cibenzoline</e1> i.v. dose suppressed needed suppress <e2>arrhythmias</e2>
C032151_D001145 NONE <e1>(-)-cibenzoline</e1> <e2>arrhythmia</e2>
D004070_D001145 NONE <e1>digitalis</e1> <e2>arrhythmia</e2>
D004070_D001145 NONE <e1>digitalis-</e1> <e2>arrhythmias</e2>
D004070_D001145 NONE <e1>digitalis-</e1> <e2>arrhythmias</e2>
D004070_D001145 NONE <e1>digitalis-induced</e1> <e2>arrhythmia</e2>
D004070_D001145 NONE <e1>digitalis-induced</e1> arrhythmia suppressed needed suppress <e2>arrhythmias</e2>
D004070_D001145 NONE <e1>digitalis-</e1> <e2>arrhythmia</e2>
D012964_D001145 NONE <e1>na</e1> channel blockers suppressed <e2>arrhythmia</e2>
D010042_D001145 CID <e1>ouabain</e1> injection induced <e2>arrhythmia</e2>
D010424_D001145 NONE <e1>pentobarbital-anesthetized</e1> dogs injection induced <e2>arrhythmia</e2>
D002118_D001145 NONE <e1>ca</e1> blockers suppressed <e2>arrhythmia</e2>
D004837_D001145 CID <e1>adrenaline</e1> infusion induced <e2>arrhythmia</e2>
D004837_D001145 CID <e1>adrenaline-induced</e1> digitalis- <e2>arrhythmias</e2>
D004837_D001145 CID <e1>adrenaline-induced</e1> digitalis- <e2>arrhythmias</e2>
D004837_D001145 CID <e1>adrenaline-induced</e1> arrhythmias suppress needed suppressed <e2>arrhythmia</e2>
D004837_D001145 CID <e1>adrenaline-induced</e1> <e2>arrhythmias</e2>
D004837_D001145 CID <e1>adrenaline-induced</e1> digitalis- <e2>arrhythmia</e2>
D006221_D001145 NONE <e1>halothane-anesthetized</e1> dogs infusion induced <e2>arrhythmia</e2>
6118280
D001569_D009207 NONE <e1>benzodiazepines</e1> drugs baclofen <e2>jerks</e2>
D001569_D009207 NONE <e1>benzodiazepines</e1> found potent blocking <e2>jerks</e2>
D001569_D009207 NONE <e1>benzodiazepines</e1> 5-htp found beneficial management <e2>myoclonus</e2>
D001569_D009207 NONE <e1>benzodiazepines</e1> 5-htp found fact seems <e2>myoclonus</e2>
D001418_D009207 NONE <e1>baclofen</e1> <e2>jerks</e2>
D001418_D009207 NONE <e1>(-)-baclofen</e1> mk-212 value management <e2>myoclonus</e2>
D009118_D009207 CID <e1>muscimol-induced</e1> <e2>jerks</e2>
D009118_D009207 CID <e1>muscimol</e1> produced <e2>jerks</e2>
D009118_D009207 CID <e1>muscimol-induced</e1> myoclonus seems fact found beneficial management <e2>myoclonus</e2>
D009118_D009207 CID <e1>muscimol-induced</e1> <e2>myoclonus</e2>
D002998_D009207 NONE <e1>clonazepam</e1> benzodiazepines found potent blocking <e2>jerks</e2>
D003975_D009207 NONE <e1>diazepam</e1> potent blocking <e2>jerks</e2>
D006916_D009207 NONE <e1>5-htp</e1> found beneficial management <e2>myoclonus</e2>
D006916_D009207 NONE <e1>5-htp</e1> found fact seems <e2>myoclonus</e2>
C014896_D009207 NONE <e1>mk-212</e1> value management <e2>myoclonus</e2>
20552622
D000420_D013617 CID <e1>salbutamol</e1> triggered <e2>tachyarrhythmia</e2>
D000420_D013617 CID <e1>salbutamol</e1> presented trigger <e2>siat</e2>
D001262_D001145 NONE <e1>atenolol</e1> therapy resolved <e2>arrhythmia</e2>
D001262_D001145 NONE <e1>atenolol</e1> week disappeared <e2>arrhythmia</e2>
D000420_D013610 NONE <e1>salbutamol</e1> beta-agonist known induce <e2>tachycardia</e2>
D001262_D013610 NONE <e1>atenolol</e1> beta-blocker blocks swallowing originating reflexes trigger known induce <e2>tachycardia</e2>
11282081
D014700_D001281 CID <e1>verapamil</e1> effects <e2>fibrillation</e2>
D014700_D001281 CID <e1>verapamil</e1> administered methods evaluate mechanisms promotion <e2>af</e2>
D014700_D001281 CID <e1>verapamil</e1> caused promotion <e2>af</e2>
D014700_D001281 CID <e1>verapamil</e1> caused increasing duration <e2>af</e2>
D014700_D001281 CID <e1>verapamil</e1> shortened accelerated decreased length <e2>af</e2>
D014700_D001281 CID <e1>verapamil</e1> caused that similar acceleration produced affect erp length <e2>af</e2>
D014700_D001281 CID <e1>verapamil</e1> caused that similar acceleration produced affect erp duration <e2>af</e2>
D014700_D001281 CID <e1>verapamil</e1> failed promote <e2>af</e2>
D014700_D001281 CID <e1>verapamil</e1> promoted <e2>af</e2>
D014700_D001281 CID <e1>verapamil</e1> promotes <e2>af</e2>
D002118_D013617 NONE <e1>ca(2</e1> decreases promotes remodeling <e2>tachycardia-induced</e2>
D002118_D001281 NONE <e1>ca(2</e1> decreases promotes occurrence <e2>fibrillation</e2>
D002118_D001281 NONE <e1>ca(2</e1> decreases promotes occurrence fibrillation <e2>af</e2>
D002118_D001281 NONE <e1>ca(2</e1> blockade promote <e2>af</e2>
D002118_D001281 NONE <e1>ca(2</e1> blockade promote consistent effect <e2>af</e2>
D002118_D001281 NONE <e1>ca(2</e1> inhibition effect consistent promote <e2>af</e2>
D002118_D001281 NONE <e1>ca(2</e1> inhibition effect <e2>af</e2>
D002118_D001281 NONE <e1>ca(2</e1> blockers evaluate mechanisms promotion <e2>af</e2>
D009020_D001281 NONE <e1>morphine-chloralose</e1> dogs administered methods evaluate mechanisms promotion <e2>af</e2>
D002698_D001281 NONE <e1>morphine-chloralose</e1> dogs administered methods evaluate mechanisms promotion <e2>af</e2>
D004110_D001281 NONE <e1>diltiazem</e1> affect erp length <e2>af</e2>
D004110_D001281 NONE <e1>diltiazem</e1> affect erp duration <e2>af</e2>
D004110_D001281 NONE <e1>diltiazem</e1> shared promotes <e2>af</e2>
7650771
D004456_D064420 NONE <e1>iodide</e1> drops instillation resulting <e2>toxicity</e2>
D004456_D018908 CID <e1>iodide</e1> drops use developed presented <e2>weakness</e2>
D004456_D009157 NONE <e1>iodide</e1> drops use developed given diagnosis <e2>gravis</e2>
19893084
D005839_D058186 CID <e1>gentamicin</e1> induced <e2>failure</e2>
7066357
D011692_D009404 CID <e1>aminonucleoside</e1> induced <e2>syndrome</e2>
D011692_D009404 CID <e1>aminonucleoside</e1> induced <e2>syndrome</e2>
D011692_D009404 CID <e1>aminonucleoside</e1> induced syndrome found lipoproteins alterations <e2>syndrome</e2>
D011692_D009404 CID <e1>aminonucleoside</e1> ascertain syndrome alterations lipoproteins found <e2>syndrome</e2>
D011692_D009404 CID <e1>aminonucleoside</e1> ascertain <e2>syndrome</e2>
D011692_D009404 CID <e1>aminonucleoside</e1> administration development <e2>syndrome</e2>
D005227_D009404 NONE <e1>acids</e1> level decreased stage <e2>pre-nephrotic</e2>
D014280_D009404 NONE <e1>triacylglycerol</e1> acids level decreased stage <e2>pre-nephrotic</e2>
D002788_D009404 NONE <e1>esters</e1> phospholipid that decreased stage <e2>pre-nephrotic</e2>
3962737
D000638_D056486 CID <e1>amiodarone</e1> <e2>hepatotoxicity</e2>
D000638_D056486 CID <e1>amiodarone</e1> treatment patient <e2>hepatitis</e2>
D000638_D056486 CID <e1>amiodarone</e1> treatment patient presented review <e2>hepatotoxicity</e2>
D000638_D056486 CID <e1>amiodarone</e1> hepatotoxicity review presented patient <e2>hepatitis</e2>
D000638_D056486 CID <e1>amiodarone</e1> <e2>hepatotoxicity</e2>
D000638_D056486 CID <e1>amiodarone</e1> treatment exists <e2>injury</e2>
D000638_D056486 CID <e1>amiodarone</e1> treatment steatosis <e2>hepatitis</e2>
D000638_D013610 NONE <e1>amiodarone</e1> proved effective treatment <e2>tachyarrhythmias</e2>
D000638_D002779 CID <e1>amiodarone</e1> treatment patient <e2>hepatitis</e2>
D000638_D002779 CID <e1>amiodarone</e1> hepatotoxicity review presented patient <e2>hepatitis</e2>
D000638_D002779 CID <e1>amiodarone</e1> treatment steatosis <e2>hepatitis</e2>
D000638_D005234 CID <e1>amiodarone</e1> treatment <e2>steatosis</e2>
D000638_D006519 NONE <e1>amiodarone</e1> treatment steatosis <e2>hepatitis</e2>
D000638_D008103 CID <e1>amiodarone</e1> treatment steatosis <e2>liver</e2>
15096016
D007980_D018476 NONE <e1>levodopa-induced</e1> dyskinesias improving seems improves <e2>bradykinesia</e2>
D007980_D009127 NONE <e1>levodopa-induced</e1> dyskinesias improving seems improves bradykinesia <e2>rigidity</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
8586822
D002216_D006973 NONE <e1>captopril-treated</e1> rats <e2>hypertensive</e2>
D002216_D006973 NONE <e1>captopril-treated</e1> rats <e2>hypertensive</e2>
D002216_D006973 NONE <e1>captopril-treated</e1> rats contributes effect <e2>hypertensive</e2>
D017673_D006973 CID <e1>chloride</e1> supplementation effect contributes rats <e2>hypertensive</e2>
D017673_D006973 CID <e1>chloride</e1> supplementation effect <e2>hypertensive</e2>
D017673_D006973 CID <e1>chloride-induced</e1> increase <e2>map</e2>
D018738_D006973 NONE <e1>hexamethonium</e1> infusion resulted decline eliminated increase <e2>map</e2>
7651879
D005442_D012640 CID <e1>flumazenil</e1> administration <e2>seizure</e2>
D005442_D012640 CID <e1>flumazenil</e1> administration patient <e2>seizure</e2>
D005442_D012131 NONE <e1>flumazenil</e1> antagonist used reverse sedation <e2>depression</e2>
D001569_D012131 NONE <e1>benzodiazepine</e1> antagonist used reverse sedation <e2>depression</e2>
D001569_D012131 NONE <e1>benzodiazepines</e1> induced sedation <e2>depression</e2>
6402369
D007069_D001745 CID <e1>ifosfamide-induced</e1> <e2>toxicity</e2>
D007069_D001745 CID <e1>ifosfamide</e1> induced <e2>toxicity</e2>
D007069_D001745 CID <e1>if</e1> effect <e2>toxicity</e2>
D007069_D001745 CID <e1>if</e1> treatment group tested effect <e2>toxicity</e2>
D007069_D008175 NONE <e1>ifosfamide-induced</e1> toxicity treatment patients <e2>cancer</e2>
D007069_D008175 NONE <e1>ifosfamide</e1> induced toxicity effect tested group patients <e2>cancer</e2>
D007069_D008175 NONE <e1>if</e1> effect tested group patients <e2>cancer</e2>
D007069_D008175 NONE <e1>if</e1> treatment group patients <e2>cancer</e2>
D015080_D001745 NONE <e1>sulphonate</e1> treatment <e2>toxicity</e2>
D015080_D001745 NONE <e1>mesna</e1> sulphonate treatment <e2>toxicity</e2>
D015080_D001745 NONE <e1>sulphonate</e1> effect <e2>toxicity</e2>
D015080_D001745 NONE <e1>mesna</e1> sulphonate effect <e2>toxicity</e2>
D015080_D008175 NONE <e1>sulphonate</e1> treatment patients <e2>cancer</e2>
D015080_D008175 NONE <e1>mesna</e1> sulphonate treatment patients <e2>cancer</e2>
D015080_D008175 NONE <e1>sulphonate</e1> effect tested group patients <e2>cancer</e2>
D015080_D008175 NONE <e1>mesna</e1> sulphonate effect tested group patients <e2>cancer</e2>
D013438_D001745 NONE <e1>thiol</e1> 2-mercaptoethane administration effect <e2>toxicity</e2>
D013438_D008175 NONE <e1>thiol</e1> 2-mercaptoethane administration effect tested group patients <e2>cancer</e2>
D015080_D064420 NONE <e1>mesna</e1> series series respect haematological <e2>toxicity</e2>
8958188
C045894_D009369 NONE <e1>lometrexol</e1> has activity <e2>tumours</e2>
D008727_D009369 NONE <e1>methotrexate</e1> has activity <e2>tumours</e2>
C045894_D064420 NONE <e1>lometrexol</e1> development curtailed <e2>toxicities</e2>
C045894_D064420 NONE <e1>lometrexol</e1> <e2>toxicity</e2>
C045894_D064420 NONE <e1>lometrexol</e1> study confirmed reduced <e2>toxicity</e2>
C045894_D064420 NONE <e1>lometrexol</e1> <e2>toxicity</e2>
C045894_D064420 NONE <e1>lometrexol</e1> pharmacokinetics altered indicating unlikely reduce <e2>toxicity</e2>
C045894_D064420 NONE <e1>lometrexol</e1> clearance enhancing reduce <e2>toxicity</e2>
D005492_D064420 NONE <e1>acid</e1> administration prevented <e2>toxicity</e2>
D005492_D064420 NONE <e1>acid</e1> supplementation given lometrexol study confirmed reduced <e2>toxicity</e2>
D005492_D064420 NONE <e1>acid</e1> supplementation reduced <e2>toxicity</e2>
D005492_D064420 NONE <e1>folate</e1> elevation extent <e2>toxicity</e2>
D005492_D064420 NONE <e1>acid</e1> administration altered indicating unlikely reduce <e2>toxicity</e2>
10743694
1535072
D015016_D020018 NONE <e1>yohimbine</e1> treatment <e2>effects</e2>
D015016_D020018 NONE <e1>yohimbine</e1> used treat <e2>effects</e2>
D015016_D020018 NONE <e1>yohimbine</e1> evaluated treatment <e2>effects</e2>
D015016_D020018 NONE <e1>yohimbine</e1> given patients disorder disorders suffered <e2>effects</e2>
D015016_D020018 NONE <e1>yohimbine</e1> treatment <e2>effects</e2>
D012701_D020018 NONE <e1>serotonin</e1> blockers induced <e2>effects</e2>
D012701_D020018 NONE <e1>serotonin</e1> blockers caused <e2>effects</e2>
D012701_D020018 NONE <e1>serotonin</e1> blockers treatment suffered <e2>effects</e2>
D012701_D020018 NONE <e1>serotonin</e1> blockers caused <e2>effects</e2>
D015016_D007172 NONE <e1>yohimbine</e1> facilitates helpful treatment <e2>impotence</e2>
D002997_D020018 CID <e1>clomipramine</e1> <e2>effects</e2>
D012701_D009771 NONE <e1>serotonin</e1> blockers treatment suffered disorders <e2>disorder</e2>
D012701_D014256 NONE <e1>serotonin</e1> blockers treatment suffered disorders disorder <e2>trichotillomania</e2>
D012701_D001008 NONE <e1>serotonin</e1> blockers treatment suffered disorders disorder trichotillomania <e2>anxiety</e2>
D012701_D019964 NONE <e1>serotonin</e1> blockers treatment suffered <e2>disorders</e2>
D015016_D009771 NONE <e1>yohimbine</e1> given patients <e2>disorder</e2>
D015016_D014256 NONE <e1>yohimbine</e1> given patients disorder <e2>trichotillomania</e2>
D015016_D001008 NONE <e1>yohimbine</e1> given patients disorder trichotillomania <e2>anxiety</e2>
D015016_D001008 NONE <e1>yohimbine</e1> effects included sweating <e2>anxiety</e2>
D015016_D019964 NONE <e1>yohimbine</e1> given patients disorder <e2>disorders</e2>
7880714
7053705
D013866_D006504 CID <e1>6-thioguanine</e1> caused <e2>disease</e2>
D013866_D006504 CID <e1>6-thioguanine</e1> months developed disease <e2>liver</e2>
D013866_D006504 CID <e1>6-thioguanine</e1> related case presented opportunity observe features <e2>disease</e2>
D013866_D054198 NONE <e1>6-thioguanine</e1> months developed man <e2>leukemia</e2>
8384253
D014750_D008228 NONE <e1>vincristine</e1> treated patients <e2>lymphoma</e2>
D014750_D008228 NONE <e1>vincristine</e1> effects evaluate order investigated patients <e2>lymphoma</e2>
D014750_D009422 NONE <e1>vincristine</e1> signs symptoms <e2>neuropathy</e2>
D014750_D009422 NONE <e1>vincristine</e1> <e2>neuropathy</e2>
8111719
D007069_D006212 CID <e1>ifosfamide-induced</e1> neurotoxicity <e2>hallucinations</e2>
D007069_D006212 CID <e1>ifosfamide</e1> effect <e2>hallucinations</e2>
D007069_D006212 CID <e1>ifosfamide-induced</e1> <e2>hallucinations</e2>
D007069_D006212 CID <e1>ifosfamide-induced</e1> <e2>hallucinations</e2>
D007069_D006212 CID <e1>ifosfamide-induced</e1> <e2>hallucinations</e2>
D007069_D020258 NONE <e1>ifosfamide-induced</e1> <e2>neurotoxicity</e2>
D007069_D020258 NONE <e1>ifosfamide</e1> effect hallucinations symptom <e2>neurotoxicity</e2>
D007069_D020258 NONE <e1>ifosfamide-induced</e1> hallucinations occur signs <e2>neurotoxicity</e2>
D006220_D011595 NONE <e1>haloperidol</e1> neuroleptics marked becomes <e2>agitation</e2>
9579567
D013629_D001943 NONE <e1>tamoxifen</e1> used treatment <e2>cancer</e2>
D013629_D001943 NONE <e1>tamoxifen</e1> used proposed prevention <e2>cancer</e2>
D013629_D001943 NONE <e1>tamoxifen</e1> use cancer women treated <e2>cancer</e2>
D013629_D001943 NONE <e1>tamoxifen</e1> role cancer used proposed prevention <e2>cancer</e2>
D013629_D001943 NONE <e1>tamoxifen</e1> <e2>cancer</e2>
D013629_D001943 NONE <e1>tamoxifen</e1> ratio evaluation treatment <e2>cancer</e2>
D013629_D016889 CID <e1>tamoxifen</e1> use <e2>cancer</e2>
D013629_D016889 CID <e1>tamoxifen</e1> received women likely have <e2>cancer</e2>
D013629_D016889 CID <e1>tamoxifen</e1> had women had <e2>cancer</e2>
D013629_D016889 CID <e1>tamoxifen</e1> had disease prognosis those <e2>cancer</e2>
D013629_D016889 CID <e1>tamoxifen</e1> role <e2>cancer</e2>
D013629_D016889 CID <e1>tamoxifen</e1> treated women diagnosed <e2>cancers</e2>
D013629_D020178 NONE <e1>tamoxifen</e1> had <e2>disease</e2>
9669632
D020117_D043183 NONE <e1>cisapride</e1> effects patients <e2>syndrome</e2>
D020117_D043183 NONE <e1>cisapride</e1> agent treatment effects motility <e2>syndrome</e2>
D020117_D043183 NONE <e1>cisapride</e1> agent treatment effects motility syndrome <e2>ibs</e2>
D020117_D043183 NONE <e1>cisapride</e1> treatment underwent patients <e2>ibs</e2>
D020117_D043183 NONE <e1>cisapride-treated</e1> patients <e2>ibs</e2>
D020117_D043183 NONE <e1>cisapride</e1> patients <e2>ibs</e2>
D020117_D043183 NONE <e1>cisapride</e1> therapy score had patients <e2>ibs</e2>
D020117_D043183 NONE <e1>cisapride</e1> mm score score had patients <e2>ibs</e2>
D020117_D043183 NONE <e1>cisapride</e1> affects characteristics symptoms <e2>ibs</e2>
D020117_D003248 NONE <e1>cisapride</e1> treatment underwent patients <e2>constipation-predominant</e2>
D020117_D003248 NONE <e1>cisapride-treated</e1> patients lower scores relating severity <e2>constipation</e2>
D020117_D003248 NONE <e1>cisapride-treated</e1> patients <e2>constipation-predominant</e2>
D020117_D003248 NONE <e1>cisapride</e1> patients lower scores relating severity <e2>constipation</e2>
D020117_D003248 NONE <e1>cisapride</e1> patients <e2>constipation-predominant</e2>
D020117_D003967 NONE <e1>cisapride</e1> treatment underwent patients constipation-predominant <e2>diarrhoea-predominant</e2>
D020117_D003967 NONE <e1>cisapride</e1> observed patients <e2>diarrhoea-predominant</e2>
D020117_D003967 NONE <e1>cisapride-treated</e1> patients <e2>diarrhoea-predominant</e2>
D020117_D003967 NONE <e1>cisapride</e1> mm higher patients <e2>diarrhoea-predominant</e2>
D020117_D003967 NONE <e1>cisapride</e1> sec duration higher patients <e2>diarrhoea-predominant</e2>
D020117_D003967 NONE <e1>cisapride</e1> cont./min frequency duration higher patients <e2>diarrhoea-predominant</e2>
D020117_D003967 NONE <e1>cisapride</e1> therapy score had patients <e2>diarrhoea-predominant</e2>
D020117_D003967 NONE <e1>cisapride</e1> mm score score had patients <e2>diarrhoea-predominant</e2>
D020117_D010146 NONE <e1>cisapride</e1> therapy score <e2>pain</e2>
D020117_D010146 NONE <e1>cisapride</e1> mm score score <e2>pain</e2>
873132
D003840_D002779 NONE <e1>acid</e1> 7alpha-hydroxylation <e2>cholestasis</e2>
D004997_D002779 CID <e1>estradiol-induced</e1> <e2>cholestasis</e2>
20973483
D058915_D010300 NONE <e1>antagonist</e1> models <e2>disease</e2>
D058915_D010300 NONE <e1>antagonist</e1> models <e2>disease</e2>
D006220_D010300 NONE <e1>haloperidol-induced</e1> catalepsy models <e2>disease</e2>
D006220_D002375 CID <e1>haloperidol-induced</e1> <e2>catalepsy</e2>
D006220_D004409 NONE <e1>haloperidol-induced</e1> catalepsy models disease models number = model <e2>akinesia</e2>
D012110_D010300 NONE <e1>reserpine-induced</e1> akinesia model = number models <e2>disease</e2>
D012110_D002375 NONE <e1>reserpine-induced</e1> akinesia model = number models disease models <e2>catalepsy</e2>
D012110_D004409 CID <e1>reserpine-induced</e1> <e2>akinesia</e2>
D016627_D010300 NONE <e1>6-hydroxydopamine</e1> model = number models <e2>disease</e2>
D016627_D010300 NONE <e1>6-ohda</e1> 6-hydroxydopamine model = number models <e2>disease</e2>
D016627_D002375 NONE <e1>6-hydroxydopamine</e1> model = number models disease models <e2>catalepsy</e2>
D016627_D002375 NONE <e1>6-ohda</e1> 6-hydroxydopamine model = number models disease models <e2>catalepsy</e2>
D016627_D004409 NONE <e1>6-hydroxydopamine</e1> model = model <e2>akinesia</e2>
D016627_D004409 NONE <e1>6-ohda</e1> 6-hydroxydopamine model = model <e2>akinesia</e2>
D015632_D010300 NONE <e1>mptp-treated</e1> model model = number models <e2>disease</e2>
D015632_D002375 NONE <e1>mptp-treated</e1> model model = number models disease models <e2>catalepsy</e2>
D015632_D004409 NONE <e1>mptp-treated</e1> model model = model <e2>akinesia</e2>
3183120
C033706_D001927 CID <e1>tiazofurin</e1> usage associated <e2>lesions</e2>
9549528
D007980_D020734 NONE <e1>l-dopa-induced</e1> dyskinesia patients <e2>parkinsonian</e2>
D007980_D020734 NONE <e1>l-dopa</e1> medication patients <e2>parkinsonian</e2>
D007980_D020734 NONE <e1>l-dopa</e1> dyskinesia one changes induced supplementary groups patients <e2>parkinsonian</e2>
D007980_D004409 CID <e1>l-dopa-induced</e1> <e2>dyskinesia</e2>
D007980_D004409 CID <e1>l-dopa</e1> medication patients groups supplementary induced changes one <e2>dyskinesia</e2>
D007980_D004409 CID <e1>l-dopa</e1> medication patients groups supplementary induced changes one other <e2>dyskinesia</e2>
D007980_D004409 CID <e1>l-dopa</e1> <e2>dyskinesia</e2>
D007980_D004409 CID <e1>l-dopa</e1> dyskinesia one other <e2>dyskinesia</e2>
D007980_D004409 CID <e1>l-dopa-induced</e1> dyskinesia <e2>movement</e2>
D007980_D004409 CID <e1>l-dopa-induced</e1> <e2>dyskinesia</e2>
D007980_D006948 NONE <e1>l-dopa-induced</e1> dyskinesia movement <e2>hyperkinetic</e2>
18239197
D014282_D003072 CID <e1>trihexyphenidyl</e1> challenge associated <e2>slowing</e2>
D014282_D003072 CID <e1>trihexyphenidyl</e1> dose resulted ratings <e2>slowness</e2>
D014282_D003072 CID <e1>trihexyphenidyl</e1> placebo ratings <e2>slowness</e2>
D014282_D003072 CID <e1>trihexyphenidyl</e1> challenge <e2>slowing</e2>
D014282_D003221 NONE <e1>trihexyphenidyl</e1> effects relationship examine were reflecting sedation <e2>confusion</e2>
D014282_D003221 NONE <e1>trihexyphenidyl-induced</e1> effects relationship investigate reflecting sedation <e2>confusion</e2>
17241657
D003042_D012640 CID <e1>cocaine</e1> actions <e2>convulsive</e2>
D003042_D012640 CID <e1>cocaine-induced</e1> <e2>convulsions</e2>
C519696_D012640 NONE <e1>umb24</e1> pretreatment attenuated <e2>convulsions</e2>
C107044_D012640 NONE <e1>21</e1> (+/-)-sm umb24 pretreatment attenuated <e2>convulsions</e2>
20558148
D016202_D002375 NONE <e1>nmda</e1> receptors mediated neurotransmission modulate <e2>catalepsy</e2>
D016202_D002375 NONE <e1>nmda</e1> antagonists microinjections challenged <e2>catalepsy</e2>
D016202_D002375 NONE <e1>nmda</e1> n-methyl-d-aspartate antagonists microinjections challenged <e2>catalepsy</e2>
D016202_D002375 NONE <e1>n-methyl-d-aspartate</e1> antagonists microinjections challenged <e2>catalepsy</e2>
D016202_D002375 NONE <e1>nmda</e1> n-methyl-d-aspartate antagonists microinjections challenged <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol-induced</e1> <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol</e1> examined influence mechanisms ic <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol-induced</e1> <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol</e1> injections previous microinjection attenuated <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol-induced</e1> <e2>catalepsy</e2>
D000596_D002375 NONE <e1>acid-mediated</e1> mechanisms ic <e2>catalepsy</e2>
D004298_D002375 NONE <e1>dopamine</e1> blocker induced <e2>catalepsy</e2>
D018698_D002375 NONE <e1>glutamate</e1> antagonists microinjections challenged <e2>catalepsy</e2>
D018698_D002375 NONE <e1>glutamate-mediated</e1> mechanisms <e2>catalepsy</e2>
D016291_D002375 NONE <e1>mk-801</e1> antagonists microinjections challenged <e2>catalepsy</e2>
D016291_D002375 NONE <e1>mk-801</e1> microinjection attenuated <e2>catalepsy</e2>
C031231_D002375 NONE <e1>ap7</e1> antagonists microinjections challenged <e2>catalepsy</e2>
C031231_D002375 NONE <e1>ap7</e1> mk-801 microinjection attenuated <e2>catalepsy</e2>
10027919
C051883_D006962 NONE <e1>22-oxacalcitriol</e1> suppresses <e2>hyperparathyroidism</e2>
C051883_D006962 NONE <e1>oct</e1> <e2>hyperparathyroidism</e2>
C051883_D006962 NONE <e1>oct</e1> prevent indicate use management <e2>hyperparathyroidism</e2>
C051883_D001851 NONE <e1>22-oxacalcitriol</e1> suppresses inducing <e2>turnover</e2>
C051883_D001851 NONE <e1>oct</e1> prevent indicate use induce <e2>turnover</e2>
C051883_D001851 NONE <e1>oct</e1> prevent indicate use increase risk <e2>disease</e2>
C051883_D051437 NONE <e1>22-oxacalcitriol</e1> suppresses inducing turnover dogs <e2>failure</e2>
C051883_D051437 NONE <e1>oct</e1> decreased induction <e2>insufficiency</e2>
C051883_D051437 NONE <e1>oct</e1> prevent occurrence dogs <e2>insufficiency</e2>
D002117_D051437 NONE <e1>calcitriol</e1> therapy suppresses levels patients <e2>failure</e2>
D002117_D006934 CID <e1>calcitriol</e1> therapy suppresses has drawbacks <e2>hypercalcemia</e2>
D002117_D001851 CID <e1>calcitriol</e1> therapy suppresses has drawbacks hypercalcemia suppression <e2>turnover</e2>
D002117_D001851 CID <e1>calcitriol</e1> therapy suppresses has drawbacks lead <e2>disease</e2>
C051883_D007674 NONE <e1>oct</e1> effects levels states <e2>function</e2>
C051883_-1 NONE <e1>oct</e1> reversed formation <e2>osteoid</e2>
C051883_D005355 NONE <e1>oct</e1> reversed formation osteoid <e2>fibrosis</e2>
C051883_D006934 CID <e1>oct</e1> prevent occurrence <e2>hypercalcemia</e2>
7189975
D002045_D012640 CID <e1>bupivacaine-induced</e1> seizures % fatal dose causing <e2>convulsions</e2>
D002045_D012640 CID <e1>bupivacaine-induced</e1> <e2>seizures</e2>
C004616_D012640 CID <e1>chloroprocaine</e1> group % fatal dose causing <e2>convulsions</e2>
C004616_D012640 CID <e1>chloroprocaine</e1> group % fatal % <e2>seizures</e2>
D008012_D012640 CID <e1>lidocaine</e1> group % fatal dose causing <e2>convulsions</e2>
D008012_D012640 CID <e1>lidocaine</e1> group % fatal % <e2>seizures</e2>
7724492
D004317_D007674 NONE <e1>doxorubicin</e1> <e2>toxicity</e2>
D004317_D007674 NONE <e1>(adriamycin)-loaded</e1> nanoparticles <e2>toxicity</e2>
D004317_D007674 NONE <e1>doxorubicin-loaded</e1> nanoparticle <e2>toxicity</e2>
D004317_D007674 NONE <e1>dx</e1> animals killed <e2>toxicity</e2>
D003487_D007674 NONE <e1>cyanoacrylate</e1> nanoparticles <e2>toxicity</e2>
D004317_D005921 NONE <e1>doxorubicin-loaded</e1> nanoparticle toxicity explored rats rats <e2>glomerulonephritis</e2>
D004317_D005921 NONE <e1>dx</e1> rats died rats <e2>glomerulonephritis</e2>
D004317_D011507 CID <e1>dx</e1> treated those appeared <e2>proteinuria</e2>
D004317_D011507 CID <e1>doxorubicin</e1> treatment prolonged intense appeared <e2>proteinuria</e2>
D004317_D011507 CID <e1>dx</e1> dxnp difference appeared <e2>proteinuria</e2>
15565293
D004977_D009901 CID <e1>ethambutol-induced</e1> optic patients loss measure <e2>neuropathy</e2>
D004977_D009901 CID <e1>ethambutol-induced</e1> optic <e2>neuropathy</e2>
D004977_D009901 CID <e1>ethambutol</e1> complication optic <e2>neuropathy</e2>
D004977_D009901 CID <e1>ethambutol</e1> optic <e2>neuropathy</e2>
D004977_D009901 CID <e1>(emb)-induced</e1> optic <e2>neuropathy</e2>
D004977_D009901 CID <e1>emb-induced</e1> optic history subjects <e2>neuropathy</e2>
D004977_D009901 CID <e1>emb-induced</e1> optic patients results show <e2>neuropathy</e2>
D004977_D009901 CID <e1>emb-induced</e1> optic management terms <e2>neuropathy</e2>
D004977_D009901 CID <e1>ethambutol</e1> dosing manage important terms <e2>neuropathy</e2>
D004977_D009410 NONE <e1>ethambutol-induced</e1> optic neuropathy map <e2>degeneration</e2>
D004977_D014376 NONE <e1>ethambutol</e1> agent used treat <e2>tuberculosis</e2>
D004977_D014786 CID <e1>ethambutol</e1> optic neuropathy short- <e2>deficits</e2>
D004977_D014786 CID <e1>(emb)-induced</e1> optic neuropathy short- <e2>deficits</e2>
D004977_D014786 CID <e1>emb-induced</e1> optic history subjects was <e2>deficits</e2>
D004977_D014786 CID <e1>emb-induced</e1> optic history subjects was deficits <e2>deficits</e2>
D004977_D051437 NONE <e1>emb-induced</e1> optic management terms important manage dosing patients <e2>impairment</e2>
D004977_D051437 NONE <e1>ethambutol</e1> dosing patients <e2>impairment</e2>
17074608
D014635_D002819 CID <e1>valproate-induced</e1> <e2>chorea</e2>
D014635_D002819 CID <e1>valproate</e1> therapy initiation presentation encephalopathy <e2>chorea</e2>
D014635_D001927 CID <e1>valproate-induced</e1> chorea <e2>encephalopathy</e2>
D014635_D001927 CID <e1>valproate</e1> therapy initiation presentation <e2>encephalopathy</e2>
D014635_D020158 NONE <e1>valproate-induced</e1> chorea <e2>hyperglycinemia</e2>
D014635_D020158 NONE <e1>valproate</e1> therapy initiation presentation <e2>hyperglycinemia</e2>
D005998_D020158 NONE <e1>glycine</e1> system defect leads disorder <e2>hyperglycinemia</e2>
D005998_D020158 NONE <e1>glycine</e1> accumulation leads disorder <e2>hyperglycinemia</e2>
D005998_D000592 NONE <e1>glycine</e1> system defect leads disorder <e2>metabolism</e2>
D005998_D000592 NONE <e1>glycine</e1> accumulation leads disorder <e2>metabolism</e2>
D014635_D007805 NONE <e1>valproate</e1> therapy initiation presentation hyperglycinemia have found patient <e2>delay</e2>
D014635_D008607 NONE <e1>valproate</e1> therapy initiation presentation hyperglycinemia have found patient delay <e2>retardation</e2>
15580403
D012254_D006461 NONE <e1>ribavirin</e1> reduction patients <e2>hemolysis</e2>
D012254_D006461 NONE <e1>ribavirin</e1> interferon therapy timing reduction patients <e2>hemolysis</e2>
D012254_D006461 NONE <e1>ribavirin</e1> reduction patients <e2>hemolysis</e2>
D012254_D019698 NONE <e1>ribavirin</e1> reduction timing therapy <e2>c.</e2>
D012254_D019698 NONE <e1>ribavirin</e1> interferon therapy <e2>c.</e2>
D007372_D006461 NONE <e1>interferon</e1> therapy timing reduction patients <e2>hemolysis</e2>
D007372_D019698 NONE <e1>interferon</e1> therapy <e2>c.</e2>
D007372_D000743 CID <e1>interferon</e1> therapy events one <e2>anemia</e2>
D012254_D000743 CID <e1>ribavirin</e1> interferon therapy events one <e2>anemia</e2>
D012254_D000743 CID <e1>ribavirin-related</e1> <e2>anemia</e2>
D012254_D000740 NONE <e1>ribavirin</e1> reduction patients continue decreased to <e2>anemia-related</e2>
12600698
C005435_D015837 NONE <e1>edaravone</e1> effect <e2>vestibulotoxicity</e2>
C005435_D015837 NONE <e1>edaravone</e1> alleviation <e2>vestibulotoxicity</e2>
C005435_D015837 NONE <e1>edaravone</e1> suppresses <e2>vestibulotoxicity</e2>
D013307_D015837 CID <e1>streptomycin-induced</e1> <e2>vestibulotoxicity</e2>
D013307_D015837 CID <e1>streptomycin-induced</e1> <e2>vestibulotoxicity</e2>
D013307_D015837 CID <e1>streptomycin-induced</e1> <e2>vestibulotoxicity</e2>
C005435_D002544 NONE <e1>edaravone</e1> has used treat <e2>infarction</e2>
18541230
D011692_D009401 CID <e1>aminonucleoside</e1> <e2>nephrosis</e2>
D011692_D009401 CID <e1>aminonucleoside-induced</e1> <e2>nephrosis</e2>
D011692_D009404 NONE <e1>aminonucleoside-induced</e1> nephrosis rats effects model <e2>syndrome</e2>
D011692_D009404 NONE <e1>aminonucleoside-induced</e1> <e2>syndrome</e2>
D011692_D006402 NONE <e1>aminonucleoside-induced</e1> <e2>abnormalities</e2>
D011692_D007674 NONE <e1>aminonucleoside-induced</e1> <e2>dysfunction</e2>
D011692_D006949 NONE <e1>aminonucleoside-induced</e1> dysfunction <e2>hyperlipidemia</e2>
48362
D011802_D056486 CID <e1>quinidine</e1> <e2>hepatitis</e2>
D011802_D056486 CID <e1>quinidine</e1> <e2>hepatotoxicity</e2>
17263743
C009250_D006323 NONE <e1>sevoflurane</e1> induction undergoing palsy child <e2>arrest</e2>
C009250_D002547 NONE <e1>sevoflurane</e1> induction undergoing <e2>palsy</e2>
D003000_D006323 CID <e1>clonidine</e1> <e2>arrest</e2>
D003000_D006323 CID <e1>clonidine-associated</e1> <e2>arrest</e2>
D003000_D002547 NONE <e1>clonidine</e1> arrest child <e2>palsy</e2>
D003000_D002547 NONE <e1>clonidine</e1> receiving seizure present case child <e2>palsy</e2>
D003000_D004827 NONE <e1>clonidine</e1> receiving seizure <e2>disorder</e2>
D003000_D011595 NONE <e1>clonidine</e1> <e2>restlessness</e2>
D001418_D002547 NONE <e1>baclofen</e1> pump placement presented present case child <e2>palsy</e2>
D001418_D004827 NONE <e1>baclofen</e1> pump placement presented present seizure <e2>disorder</e2>
D001418_D011595 NONE <e1>baclofen</e1> pump placement presented present seizure receiving clonidine <e2>restlessness</e2>
D003000_D001008 NONE <e1>clonidine</e1> doses administered reduce <e2>anxiety</e2>
10910842
D011239_D018908 CID <e1>prednisolone-induced</e1> <e2>dysfunction</e2>
D011239_D001284 NONE <e1>prednisolone-induced</e1> dysfunction caused <e2>atrophy</e2>
D000109_D018908 NONE <e1>acetylcholine</e1> expression caused <e2>dysfunction</e2>
D000109_D001284 NONE <e1>acetylcholine</e1> expression caused <e2>atrophy</e2>
D014403_D013746 NONE <e1>d-tubocurarine</e1> curves tensions tensions <e2>tetanic</e2>
D011239_D009468 NONE <e1>prednisolone</e1> <e2>dysfunction</e2>
D011239_D009133 CID <e1>prednisolone</e1> dysfunction dose-dependent derives <e2>atrophy</e2>
D000109_D009133 NONE <e1>acetylcholine</e1> expression changes derive dose-dependent <e2>atrophy</e2>
2750819
D008278_D020879 CID <e1>sulfate</e1> <e2>blockade</e2>
D008278_D020879 CID <e1>sulfate</e1> mg developed <e2>blockade</e2>
D009543_D020879 CID <e1>nifedipine</e1> sulfate <e2>blockade</e2>
D009543_D020879 CID <e1>nifedipine</e1> tocolysis received patient developed <e2>blockade</e2>
D009543_D064420 NONE <e1>nifedipine</e1> potentiate <e2>toxicity</e2>
D008274_D064420 NONE <e1>magnesium</e1> <e2>toxicity</e2>
8494478
D002939_D007674 NONE <e1>ciprofloxacin-induced</e1> <e2>nephrotoxicity</e2>
D002939_D007674 NONE <e1>ciprofloxacin</e1> associated <e2>nephrotoxicity</e2>
D002939_D009369 NONE <e1>ciprofloxacin-induced</e1> nephrotoxicity patients <e2>cancer</e2>
D002939_D009369 NONE <e1>ciprofloxacin</e1> treatment followed failure developed patients <e2>cancer</e2>
D002939_D058186 CID <e1>ciprofloxacin</e1> treatment followed <e2>failure</e2>
D002939_D058186 CID <e1>ciprofloxacin-induced</e1> <e2>failure</e2>
10524660
D005996_D020326 CID <e1>trinitrate</e1> induces attacks <e2>aura</e2>
D005996_D020325 NONE <e1>trinitrate</e1> induces attacks sufferers <e2>aura</e2>
D005996_D020325 NONE <e1>trinitrate</e1> infusion response examined order clarify true migraine <e2>aura</e2>
D005996_D020325 NONE <e1>trinitrate</e1> infusion sufferers <e2>aura</e2>
D005996_D020325 NONE <e1>gtn</e1> trinitrate infusion response examined order clarify true migraine <e2>aura</e2>
D005996_D020325 NONE <e1>gtn</e1> trinitrate infusion sufferers <e2>aura</e2>
D009569_D010146 NONE <e1>oxide</e1> involved mechanisms <e2>pain</e2>
D009569_D010146 NONE <e1>no</e1> oxide involved mechanisms <e2>pain</e2>
D009569_D010146 NONE <e1>no</e1> involved mechanisms <e2>pain</e2>
D009569_D020326 CID <e1>oxide</e1> involved <e2>aura</e2>
D009569_D020326 CID <e1>no</e1> oxide involved <e2>aura</e2>
D005996_D006261 NONE <e1>trinitrate</e1> infusion response <e2>headache</e2>
D005996_D006261 NONE <e1>gtn</e1> trinitrate infusion response <e2>headache</e2>
D005996_D006261 NONE <e1>gtn</e1> infusion severe <e2>headache</e2>
D005996_D006261 NONE <e1>gtn-induced</e1> <e2>headache</e2>
D005996_D006261 NONE <e1>gtn-induced</e1> headache disappeared occurred intensity <e2>headache</e2>
D005996_D008881 NONE <e1>gtn</e1> infusion severe <e2>migraineurs</e2>
D005996_D008881 NONE <e1>gtn-induced</e1> headache disappeared occurred intensity <e2>migraineurs</e2>
D009569_D020325 NONE <e1>no</e1> involved mechanisms <e2>aura</e2>
D009569_D020325 NONE <e1>no</e1> liberate shown help understanding coupling depression headache <e2>aura</e2>
D009569_D003866 NONE <e1>no</e1> liberate shown <e2>depression</e2>
D009569_D003866 NONE <e1>no</e1> liberate shown help understanding coupling <e2>depression</e2>
D009569_D006261 NONE <e1>no</e1> liberate shown help understanding coupling depression <e2>headache</e2>
9154656
D000809_D009404 NONE <e1>renin-angiotensin</e1> proteins concentration altered rats <e2>syndrome</e2>
D000809_D009404 NONE <e1>renin-angiotensin</e1> proteins concentration altered rats syndrome <e2>ns</e2>
D011692_D009404 CID <e1>amino-nucleoside</e1> injection induced <e2>ns</e2>
D011692_D009404 CID <e1>pan</e1> amino-nucleoside injection induced <e2>ns</e2>
D011692_D009404 CID <e1>pan</e1> injection observed established <e2>ns</e2>
D011692_D009404 CID <e1>pan</e1> induced <e2>ns</e2>
7619765
D005047_D009203 CID <e1>etoposide-related</e1> <e2>infarction</e2>
D005047_D009203 CID <e1>etoposide</e1> containing chemotherapy reported occurrence <e2>infarction</e2>
D005047_D003327 NONE <e1>etoposide</e1> containing chemotherapy reported man factors <e2>disease</e2>
12571256
C044834_D007674 NONE <e1>iodixanol</e1> medium effects <e2>nephrotoxic</e2>
C044834_D007674 NONE <e1>iodixanol</e1> used likely <e2>nephropathy</e2>
D007472_D007674 CID <e1>iohexol</e1> those effects <e2>nephrotoxic</e2>
D003404_D003920 NONE <e1>creatinine</e1> concentrations <e2>diabetes</e2>
1848636
D008790_D007008 NONE <e1>metoprolol</e1> <e2>hypokalemia</e2>
D013726_D007008 CID <e1>terbutaline-induced</e1> <e2>hypokalemia</e2>
10225068
D008012_D011128 CID <e1>lignocaine</e1> <e2>syndrome</e2>
D008012_D011128 CID <e1>lignocaine</e1> syndrome review cases <e2>syndrome</e2>
D008012_D020258 NONE <e1>lignocaine</e1> dose ranged caused <e2>neurotoxicity</e2>
D008012_D020258 NONE <e1>lignocaine</e1> <e2>neurotoxicity</e2>
11284996
D009569_D006261 CID <e1>oxide-induced</e1> <e2>headache</e2>
D009569_D006261 CID <e1>oxide</e1> induced <e2>headache</e2>
D009569_D006261 CID <e1>no</e1> oxide induced <e2>headache</e2>
D009569_D006261 CID <e1>no</e1> trinitrate induced <e2>headache</e2>
D009569_D006261 CID <e1>no-induced</e1> <e2>headache</e2>
D009569_D018781 NONE <e1>oxide-induced</e1> headache patients <e2>headache</e2>
D009569_D018781 NONE <e1>no</e1> trinitrate induced patients <e2>headache</e2>
D009569_D051270 NONE <e1>oxide</e1> induced headache <e2>headaches</e2>
D009569_D051270 NONE <e1>no</e1> oxide induced headache <e2>headaches</e2>
D005996_D006261 CID <e1>trinitrate</e1> induced <e2>headache</e2>
D005996_D006261 CID <e1>gtn</e1> trinitrate induced <e2>headache</e2>
D005996_D006261 CID <e1>gtn</e1> receive placebo days <e2>headache-free</e2>
D005996_D006261 CID <e1>gtn</e1> day developed <e2>headache</e2>
D005996_D006261 CID <e1>gtn</e1> day developed pronounced <e2>headache</e2>
D005996_D018781 NONE <e1>trinitrate</e1> induced patients <e2>headache</e2>
D005996_D018781 NONE <e1>gtn</e1> trinitrate induced patients <e2>headache</e2>
921394
D007649_D003866 NONE <e1>ketamine</e1> injections produced <e2>depression</e2>
D007649_D013610 CID <e1>ketamine-induced</e1> <e2>tachycardia</e2>
6817363
C036466_D007859 NONE <e1>aniracetam</e1> effects learning <e2>memory</e2>
C036466_D007859 NONE <e1>5057</e1> ro aniracetam effects learning <e2>memory</e2>
C036466_D008569 NONE <e1>aniracetam</e1> effects learning <e2>memory</e2>
C036466_D008569 NONE <e1>5057</e1> ro aniracetam effects learning <e2>memory</e2>
C036466_D003072 NONE <e1>aniracetam</e1> effect studied forms <e2>functions</e2>
C036466_D003072 NONE <e1>5057</e1> ro effect studied forms <e2>functions</e2>
C036466_D003072 NONE <e1>1-anisoyl-2-pyrrolidinone</e1> ro effect studied forms <e2>functions</e2>
C036466_D003072 NONE <e1>aniracetam</e1> doses seen improvements <e2>functions</e2>
C036466_D006935 NONE <e1>aniracetam</e1> effect studied prevention complete prevention incapacity learn response rats exposed <e2>hypercapnia</e2>
C036466_D006935 NONE <e1>aniracetam</e1> effect studied prevention retrieval task induced electroshock <e2>hypercapnia</e2>
C036466_D006935 NONE <e1>5057</e1> ro effect studied prevention complete prevention incapacity learn response rats exposed <e2>hypercapnia</e2>
C036466_D006935 NONE <e1>5057</e1> ro effect studied prevention retrieval task induced electroshock <e2>hypercapnia</e2>
C036466_D006935 NONE <e1>1-anisoyl-2-pyrrolidinone</e1> ro effect studied prevention complete prevention incapacity learn response rats exposed <e2>hypercapnia</e2>
C036466_D006935 NONE <e1>1-anisoyl-2-pyrrolidinone</e1> ro effect studied prevention retrieval task induced electroshock <e2>hypercapnia</e2>
C036466_D000647 NONE <e1>aniracetam</e1> effect studied prevention complete prevention <e2>amnesia</e2>
C036466_D000647 NONE <e1>aniracetam</e1> effect studied prevention complete complete protection <e2>amnesia</e2>
C036466_D000647 NONE <e1>5057</e1> ro effect studied prevention complete prevention <e2>amnesia</e2>
C036466_D000647 NONE <e1>5057</e1> ro effect studied prevention complete complete protection <e2>amnesia</e2>
C036466_D000647 NONE <e1>1-anisoyl-2-pyrrolidinone</e1> ro effect studied prevention complete prevention <e2>amnesia</e2>
C036466_D000647 NONE <e1>1-anisoyl-2-pyrrolidinone</e1> ro effect studied prevention complete complete protection <e2>amnesia</e2>
D012601_D003072 NONE <e1>scopolamine-induced</e1> amnesia prevention complete prevention studied forms <e2>functions</e2>
D012601_D006935 NONE <e1>scopolamine-induced</e1> amnesia prevention complete prevention incapacity learn response rats exposed <e2>hypercapnia</e2>
D012601_D006935 NONE <e1>scopolamine-induced</e1> amnesia prevention complete prevention studied prevention retrieval task induced electroshock <e2>hypercapnia</e2>
D012601_D000647 CID <e1>scopolamine-induced</e1> <e2>amnesia</e2>
D012601_D000647 CID <e1>scopolamine-induced</e1> amnesia prevention complete complete protection <e2>amnesia</e2>
D002701_D003072 NONE <e1>chloramphenicol</e1> induced task retention- prevention studied forms <e2>functions</e2>
D002701_D006935 NONE <e1>chloramphenicol</e1> induced task retention- prevention complete prevention incapacity learn response rats exposed <e2>hypercapnia</e2>
D002701_D006935 NONE <e1>chloramphenicol</e1> induced task retention- prevention studied prevention retrieval task induced electroshock <e2>hypercapnia</e2>
D002701_D000647 NONE <e1>chloramphenicol</e1> induced task retention- prevention complete prevention <e2>amnesia</e2>
D002701_D000647 NONE <e1>chloramphenicol</e1> induced task retention- prevention complete complete protection <e2>amnesia</e2>
D003513_D003072 NONE <e1>cycloheximide</e1> chloramphenicol induced task retention- prevention studied forms <e2>functions</e2>
D003513_D003072 NONE <e1>cycloheximide</e1> induced task retention deficit test administered reversal studied forms <e2>functions</e2>
D003513_D006935 NONE <e1>cycloheximide</e1> chloramphenicol induced task retention- prevention complete prevention incapacity learn response rats exposed <e2>hypercapnia</e2>
D003513_D006935 NONE <e1>cycloheximide</e1> chloramphenicol induced task retention- prevention studied prevention retrieval task induced electroshock <e2>hypercapnia</e2>
D003513_D006935 NONE <e1>cycloheximide</e1> induced task retention deficit test administered reversal studied prevention complete prevention incapacity learn response rats exposed <e2>hypercapnia</e2>
D003513_D006935 NONE <e1>cycloheximide</e1> induced task retention deficit test administered reversal studied prevention retrieval task induced electroshock <e2>hypercapnia</e2>
D003513_D000647 NONE <e1>cycloheximide</e1> chloramphenicol induced task retention- prevention complete prevention <e2>amnesia</e2>
D003513_D000647 NONE <e1>cycloheximide</e1> chloramphenicol induced task retention- prevention complete complete protection <e2>amnesia</e2>
D003513_D000647 NONE <e1>cycloheximide</e1> induced task retention deficit test administered reversal studied prevention complete prevention <e2>amnesia</e2>
D003513_D000647 NONE <e1>cycloheximide</e1> induced task retention deficit test administered reversal studied prevention complete complete protection <e2>amnesia</e2>
8742498
D009243_D056486 NONE <e1>nad-precursors</e1> free influence <e2>hepatotoxicity</e2>
D009243_D056486 NONE <e1>nad</e1> precursors free diet effects substrate acts mice <e2>hepatitis</e2>
D009243_D056486 NONE <e1>nad</e1> depletion inhibition reduced <e2>hepatitis</e2>
D000082_D056486 CID <e1>acetaminophen</e1> <e2>hepatotoxicity</e2>
D000082_D056486 CID <e1>acetaminophen</e1> <e2>(aap)-hepatitis</e2>
D000082_D056486 CID <e1>acetaminophen</e1> (aap)-hepatitis suffering mice effects demonstrated suggesting involves <e2>injury</e2>
D000082_D056486 CID <e2><e1>(aap)-hepatitis</e1></e2>
D000082_D056486 CID <e1>(aap)-hepatitis</e1> suffering mice effects demonstrated suggesting involves <e2>injury</e2>
D000082_D056486 CID <e1>aap-induced</e1> injury involves suggesting demonstrated effects mice suffering <e2>(aap)-hepatitis</e2>
D000082_D056486 CID <e1>aap-induced</e1> <e2>injury</e2>
D000082_D056486 CID <e1>aap</e1> <e2>hepatitis</e2>
D000082_D056486 CID <e1>aap</e1> presence measured inhibited <e2>damage</e2>
D000082_D056486 CID <e1>ethanol/aap-mice</e1> given observed reduction <e2>hepatitis</e2>
D000082_D056486 CID <e1>aap-induced</e1> <e2>hepatitis</e2>
D000082_D056486 CID <e1>acetaminophen</e1> preparations use see order avoid <e2>damage</e2>
D009536_D056486 NONE <e1>amide</e1> effects mice suffering <e2>(aap)-hepatitis</e2>
D009536_D056486 NONE <e1>amide</e1> effects demonstrated suggesting involves <e2>injury</e2>
D009536_D056486 NONE <e1>naa</e1> given observed reduction <e2>hepatitis</e2>
D009536_D056486 NONE <e1>naa</e1> inhibition reduced <e2>hepatitis</e2>
D009536_D056486 NONE <e1>naa</e1> application see order avoid <e2>damage</e2>
D011064_D056486 NONE <e1>)</e1> polymerase inhibitor amide effects mice suffering <e2>(aap)-hepatitis</e2>
D011064_D056486 NONE <e1>)</e1> polymerase inhibitor amide effects demonstrated suggesting involves <e2>injury</e2>
D000431_D056486 CID <e1>ethanol</e1> consumption influence evaluates acts mice <e2>hepatitis</e2>
D000431_D056486 CID <e1>ethanol</e1> caused exacerbation inhibited <e2>damage</e2>
D000431_D056486 CID <e1>ethanol</e1> inhibited <e2>damage</e2>
D000431_D056486 CID <e1>ethanol/aap-mice</e1> given observed reduction <e2>hepatitis</e2>
D000431_D056486 CID <e1>ethanol</e1> exacerbation <e2>hepatitis</e2>
D018698_D056486 NONE <e1>glutamate-oxaloacetate</e1> transaminase activities quantified <e2>injuries</e2>
D018698_D056486 NONE <e1>glutamate-pyruvate</e1> transaminase transaminase activities quantified <e2>injuries</e2>
D062907_D056486 NONE <e1>glutamate-oxaloacetate</e1> transaminase activities quantified <e2>injuries</e2>
D019289_D056486 NONE <e1>glutamate-pyruvate</e1> transaminase transaminase activities quantified <e2>injuries</e2>
1415380
D011803_D006463 CID <e1>quinine</e1> ingestion associated <e2>syndrome</e2>
D011803_D006463 CID <e1>quinine</e1> ingestion phenomenon <e2>syndrome</e2>
D011803_D006463 CID <e1>quinine-associated</e1> <e2>syndrome</e2>
8480959
D008148_D006937 NONE <e1>lovastatin</e1> efficacy women <e2>hypercholesterolemia</e2>
D008148_D006937 NONE <e1>lovastatin</e1> efficacy women <e2>hypercholesterolemia</e2>
D008148_D006937 NONE <e1>lovastatin</e1> effective tolerated therapy <e2>hypercholesterolemia</e2>
D003401_D009135 NONE <e1>creatine</e1> elevations symptoms defined <e2>myopathy</e2>
D008148_D009135 CID <e1>lovastatin</e1> dose associated rare <e2>myopathy</e2>
17965424
C422649_D001172 NONE <e1>etoricoxib</e1> patients <e2>arthritis</e2>
C422649_D001172 NONE <e1>etoricoxib</e1> results tolerability etoricoxib patients <e2>arthritis</e2>
C422649_D001172 NONE <e1>etoricoxib</e1> tolerability compare diclofenac patients <e2>arthritis</e2>
C422649_D001172 NONE <e1>etoricoxib</e1> tolerability compare diclofenac patients arthritis <e2>ra</e2>
C422649_D001172 NONE <e1>etoricoxib</e1> received enrolled patients total diagnosed <e2>ra</e2>
D004008_D001172 NONE <e1>sodium</e1> tolerability diclofenac tolerability etoricoxib patients <e2>arthritis</e2>
D004008_D001172 NONE <e1>diclofenac</e1> patients <e2>arthritis</e2>
D004008_D001172 NONE <e1>diclofenac</e1> patients arthritis <e2>ra</e2>
D004008_D001172 NONE <e1>diclofenac</e1> enrolled patients total diagnosed <e2>ra</e2>
C422649_D005767 NONE <e1>etoricoxib</e1> lower rate <e2>aes</e2>
C422649_D005767 NONE <e1>etoricoxib</e1> demonstrated risk discontinuing <e2>aes</e2>
C422649_D005767 NONE <e1>etoricoxib</e1> demonstrated common discontinuations <e2>aes</e2>
C422649_D005767 NONE <e1>etoricoxib</e1> higher demonstrated risk discontinuing <e2>aes</e2>
C422649_D005767 NONE <e1>etoricoxib</e1> higher demonstrated common discontinuations <e2>aes</e2>
D004008_D005767 CID <e1>diclofenac</e1> lower rate <e2>aes</e2>
D004008_D005767 CID <e1>diclofenac</e1> discontinuations risk discontinuing <e2>aes</e2>
D004008_D005767 CID <e1>diclofenac</e1> discontinuations risk demonstrated common discontinuations <e2>aes</e2>
C422649_D006973 CID <e1>etoricoxib</e1> higher incidence discontinuations aes <e2>hypertension-related</e2>
C422649_D006973 CID <e1>etoricoxib</e1> higher diclofenac % p<0.001 <e2>hypertension</e2>
C422649_D004487 CID <e1>etoricoxib</e1> higher incidence discontinuations aes hypertension-related <e2>oedema-related</e2>
C422649_D004487 CID <e1>etoricoxib</e1> higher diclofenac % p<0.001 hypertension <e2>oedema</e2>
D004008_D006973 NONE <e1>diclofenac</e1> higher incidence discontinuations aes <e2>hypertension-related</e2>
D004008_D006973 NONE <e1>diclofenac</e1> % p<0.001 <e2>hypertension</e2>
D004008_D004487 NONE <e1>diclofenac</e1> higher incidence discontinuations aes hypertension-related <e2>oedema-related</e2>
D004008_D004487 NONE <e1>diclofenac</e1> % p<0.001 hypertension <e2>oedema</e2>
6381653
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesia</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesia</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D007980_D010302 NONE <e1>levodopa-induced</e1> dyskinesia cases <e2>parkinsonism</e2>
D007980_D010302 NONE <e1>levodopa-induced</e1> dyskinesias control course treatment <e2>parkinsonism</e2>
D007980_D020821 NONE <e1>levodopa-induced</e1> dyskinesia cases parkinsonism choreic ballistic <e2>dystonic</e2>
D007980_D013786 NONE <e1>levodopa-induced</e1> dyskinesias control <e2>lesions</e2>
12691807
D007980_D004421 CID <e1>levodopa-induced</e1> <e2>dystonia</e2>
D007980_D013494 NONE <e1>levodopa-induced</e1> dystonia supranuclear <e2>palsy</e2>
D007980_D013494 NONE <e1>levodopa-induced</e1> dystonia case patient <e2>psp</e2>
D007980_D013494 NONE <e1>levodopa-induced</e1> dystonia case describe highlight importance recognizing management <e2>psp</e2>
D007980_D004409 NONE <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D007980_D010300 NONE <e1>levodopa-induced</e1> dyskinesias reported <e2>disease</e2>
D007980_D019578 NONE <e1>levodopa-induced</e1> dyskinesias reported disease <e2>atrophy</e2>
D007980_D008538 NONE <e1>levodopa-induced</e1> <e2>dystonia</e2>
D007980_D008538 NONE <e1>levodopa-induced</e1> dystonia <e2>omd</e2>
2055425
D013311_D003920 CID <e1>streptozotocin-induced</e1> <e2>mellitus</e2>
D013311_D003920 CID <e2><e1>streptozotocin-diabetic</e1></e2>
D013311_D003920 CID <e1>streptozotocin-induced</e1> <e2>diabetes</e2>
D000255_D003920 NONE <e1>atp</e1> stimulation rats <e2>diabetic</e2>
D000255_D003920 NONE <e1>atp</e1> stimulation rats <e2>diabetic</e2>
D018723_D003920 NONE <e1>bethanechol</e1> stimulation rats <e2>diabetic</e2>
D018723_D003920 NONE <e1>bethanechol</e1> stimulation rats <e2>diabetic</e2>
3769769
D014282_D001919 CID <e1>hydrochloride</e1> <e2>bradycardia</e2>
D014282_D012559 NONE <e1>hydrochloride</e1> drug treated patient <e2>schizophrenic</e2>
6674249
D015119_D009135 CID <e1>acid</e1> induce <e2>myopathy</e2>
D015119_D009135 CID <e1>eaca</e1> acid induce <e2>myopathy</e2>
D015119_D009135 CID <e1>acid</e1> treatment necrotizing <e2>myopathy</e2>
D015119_D009135 CID <e1>eaca</e1> acid treatment necrotizing <e2>myopathy</e2>
D015119_D009336 CID <e1>acid</e1> treatment necrotizing <e2>myopathy</e2>
D015119_D009336 CID <e1>eaca</e1> acid treatment necrotizing <e2>myopathy</e2>
D015119_D013345 NONE <e1>acid</e1> treatment patient <e2>haemorrhage</e2>
D015119_D013345 NONE <e1>acid</e1> treatment patient haemorrhage <e2>sah</e2>
D015119_D013345 NONE <e1>eaca</e1> acid treatment patient <e2>haemorrhage</e2>
D015119_D013345 NONE <e1>eaca</e1> acid treatment patient haemorrhage <e2>sah</e2>
15686794
D000638_D017116 CID <e1>amiodarone</e1> administration <e2>pain</e2>
D000638_D017116 CID <e1>amiodarone</e1> loading initiation experienced devastating <e2>pain</e2>
D000638_D001281 NONE <e1>amiodarone</e1> represents drug cardioversion <e2>fibrillation</e2>
D000638_D001281 NONE <e1>amiodarone</e1> represents drug cardioversion fibrillation <e2>af</e2>
D000638_D001281 NONE <e1>amiodarone</e1> loading initiation experienced patients suffering <e2>fibrillation</e2>
3413271
D004837_D017202 CID <e1>epinephrine</e1> induced <e2>ischemia</e2>
D004837_D017202 CID <e1>epinephrine</e1> role eliciting <e2>ischemia</e2>
D004837_D017202 CID <e1>epinephrine</e1> produced <e2>ischemia</e2>
D004837_D017202 CID <e1>epinephrine</e1> induced <e2>ischemia</e2>
D004837_D017202 CID <e1>epinephrine-induced</e1> ischemia characterized marked <e2>ischemia</e2>
D004837_D007511 NONE <e1>epinephrine</e1> induced ischemia mechanisms comparison <e2>ischemia</e2>
D004837_D007511 NONE <e1>epinephrine</e1> infusion compared signs <e2>ischemia</e2>
D004837_D007511 NONE <e1>epinephrine-induced</e1> <e2>ischemia</e2>
D004837_D007511 NONE <e1>epinephrine</e1> produced <e2>ischemia</e2>
D004837_D003324 NONE <e1>epinephrine</e1> role examined patients <e2>disease</e2>
D010100_D007511 NONE <e1>oxygen</e1> consumption increasing signs <e2>ischemia</e2>
D004837_D003866 NONE <e1>epinephrine</e1> produced evidenced <e2>depression</e2>
D004837_D000787 NONE <e1>epinephrine</e1> produced evidenced depression <e2>angina</e2>
7161250
D006220_D010302 CID <e1>haloperidol</e1> doses higher incidence <e2>parkinsonism</e2>
D001569_D017109 NONE <e1>benzodiazepine</e1> lorazepam controlled <e2>akathisia</e2>
D008140_D017109 NONE <e1>lorazepam</e1> controlled <e2>akathisia</e2>
19996135
D014148_D012640 CID <e1>acid</e1> associated <e2>seizures</e2>
D014148_D012640 CID <e1>txa</e1> usage <e2>seizures</e2>
D014148_D012640 CID <e1>txa</e1> doses received patients <e2>seizures</e2>
D014148_D012640 CID <e1>txa</e1> use associated <e2>seizures</e2>
